	Page 1
1	IN THE UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF OHIO
3	EASTERN DIVISION
4	
	~~~~~~~~~~
5	
6	IN RE: NATIONAL PRESCRIPTION MDL No. 2804
	OPIATE LITIGATION
7	Case No. 17-md-2804
8	Judge Dan Aaron
	This document relates to: Polster
9	
	The County of Cuyahoga v. Purdue
10	Pharma L.P., et al.
	Case No. 18-0P-45090
11	
12	~~~~~~~~~
13	Videotaped deposition of
	THOMAS GILSON, M.D.
14	30(b)(6)
15	
16	January 14, 2019
	9:07 a.m.
17	
18	
19	Taken at:
20	Climaco, Wilcox, Peca & Garofoli
21	55 Public Square, Suite 1950
22	Cleveland, Ohio
23	
24	Dence I Dellevelve DDD GID
25	Renee L. Pellegrino, RPR, CLR

	age 2 Page
APPEARANCES:	1 APPEARANCES, CONT'D:
2 On behalf of Cuyahoga County: Napoli Shkolnik PLLC	2 On behalf of Teva Pharmaceuticals:
SALVATORE BADALA, ESQ.	(Via Telephone)  3 Morgan, Lewis & Bockius LLP
360 Lexington Avenue	ALYSE FISCHER, ESQ.
New York, New York 10017	4 77 West Wacker Drive
(844) 230-7676	Chicago, Illinois 60601-5094
sbadala@napolilaw.com - and -	5 (312) 324-1107
5 Plevin & Gallucci	alyse.fischer@morganlewis.com
FRANK GALLUCCI, ESQ.	6 On behalf of Discount Drug Mart:
55 Public Square	On behalf of Discount Drug Mart: 7 (Via Telephone)
Suite 2222	Cavitch Familo & Durkin
Cleveland, Ohio 44113-1901 (216) 861-0804	8 CHIP ERB, ESQ.
gallucci@pglawyer.com	1300 East Ninth Street, 20th Floor
On behalf the City of Cleveland:	9 Cleveland, Ohio 44114
Zashin & Rich	(216) 621-7860
AMI J. PATEL, ESQ.	10 lwerb@cavitch.com
950 Main Avenue, Fourth Floor Cleveland, Ohio 44113	11 On behalf of H.D. Smith: (Via Telephone)
(216) 696-4441	12 Barnes & Thornburg
ajp@zrlaw.com	WILLIAM PADGETT, ESQ.
On behalf of Walmart, Inc.:	13 11 South Meridian Street
Jones Day	Indianapolis, Indiana 46204-3535
EDWARD M. CARTER, ESQ.	14 (317) 231-7353
BRANDY H. RANJAN, ESQ. 325 John H. McConnell Boulevard	william.padgett@btlaw.com
Suite 600	On habelf of Endo Dharmacouticals Inc. Endo
Columbus, Ohio 43215-2673	On behalf of Endo Pharmaceuticals, Inc., Endo
(614) 469-3939	16 Health Solutions, Inc., Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc.:
ecarter@jonesday.com	17 Baker & Hostetler
branjan@jonesday.com	RUTH HARTMAN, ESQ.
On behalf of McKesson Corporation:	18 127 Public Square, Suite 2000
Covington & Burling LLP	Cleveland, Ohio 44114-1214
ASEEM PADUKONE, ESQ.	19 (216) 621-0200
One Front Street	rhartman@bakerlaw.com
San Francisco, California 94111-5356	20 21 ~~~~
(415) 591-6000	21 ~~~~ 22
apadukone@cov.com	22 23
~~~~	24
5	25
D.	
F2	age 3 Page
APPEARANCES, CONT'D:	age 3 Pag
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation:	1 APPEARANCES, CONT'D:
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ.	1 APPEARANCES, CONT'D:
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext	1 APPEARANCES, CONT'D:2 On behalf of Johnson & Johnson and Janssen
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: Tucker Ellis LLP
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: Tucker Ellis LLP ERICA M. JAMES, ESQ.
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: Tucker Ellis LLP ERICA M. JAMES, ESQ. 950 Main Avenue, Suite 1100
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: Tucker Ellis LLP ERICA M. JAMES, ESQ.
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: Tucker Ellis LLP ERICA M. JAMES, ESQ. 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com	 APPEARANCES, CONT'D: On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: Tucker Ellis LLP ERICA M. JAMES, ESQ. 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 (216) 592-5000
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and -	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ.	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and lackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.:	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ.	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415, 659-5980 sboranian@reedsmith.com lporter@reedsmith.com lporter@reedsmith.com - and aakson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and -	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ.	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ.	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and and Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health:	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18 19
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and and Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health: (Via Telephone)	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health: (Via Telephone) Williams & Connolly LLP	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18 19
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health: (Via Telephone) Williams & Connolly LLP J. ANDREW KEYES, ESQ.	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18 19 20 21
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and and Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussem@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health: (Via Telephone) Williams & Connolly LLP J. ANDREW KEYES, ESQ. 725 Twelfth Street NW Washington, D.C. 20005	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18 19 20 21 22
APPEARANCES, CONT'D: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com lporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health: (Via Telephone) Williams & Connolly LLP J. ANDREW KEYES, ESQ. 725 Twelfth Street NW Washington, D.C. 20005 (202) 434-5844	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
APPEARANCES, CONTD: On behalf of AmerisourceBergen Drug Corporation: Reed Smith LLP STEVEN J. BORANIAN, ESQ. LUKE PORTER, ESQ. (Via Telephone and Veritext Virtual Stream) 101 Second Street Suite 1800 San Francisco, California 94105 (415) 659-5980 sboranian@reedsmith.com Iporter@reedsmith.com - and - Jackson Kelly PLLC SANDRA K. ZERRUSEN, ESQ. 50 South Main Street Suite 201 Akron, Ohio 44308 (330) 252-9060 skzerussen@jacksonkelly.com On behalf of Purdue Pharma, L.P.: Dechert LLP MARK S. CHEFFO, ESQ. Three Bryant Park, 1095 Avenue of the Americas New York, New York 10036-6796 (212) 698-3814 mark.cheffo@dechert.com - and - Dechert LLP SARA D. ROITMAN, ESQ. 35 West Wacker Drive Suite 3400 Chicago, Illinois 20005 (312) 646-5857 sara.roitman@wc.com On behalf of Cardinal Health: (Via Telephone) Williams & Connolly LLP J. ANDREW KEYES, ESQ. 725 Twelfth Street NW Washington, D.C. 20005	1 APPEARANCES, CONT'D: 2 On behalf of Johnson & Johnson and Janssen Pharmaceuticals, Inc.: 3 Tucker Ellis LLP ERICA M. JAMES, ESQ. 4 950 Main Avenue, Suite 1100 Cleveland, Ohio 44113-7213 5 (216) 592-5000 erica.james@tuckerellis.com 6 7 ALSO PRESENT: Shaun Crum, Videographer 8 ~~~~~ 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Page 6	1 INDEX OF EXHIBITE CONTIN	Page 8
1 TRANSCRIPT INDEX	1 INDEX OF EXHIBITS, CONT'D	
2	2 3 Exhibit 12 Document Entitled "Opioid Crisis 248	
3 APPEARANCES2	Response: Examining Overdose	
4 INDEX OF EXHIBITS7	4 Deaths at Cuyahoga County	
	Medical Examiner's Office," with	
5 INDEX OF OBJECTIONS9	5 Attached Sheet Bates Numbered	
6	CUYAH_001684555 - Marked	
7 EXAMINATION OF THOMAS GILSON, M.D.:	6 Confidential	
8 BY MR. CHEFFO20	7 Exhibit 13 Document Entitled "Ohio 263	
	Department of Health, Ohio's	
9 BY MR. BORANIAN183	8 Prescription Drug Overdose	
10 BY MR. CARTER284	Epidemic: Epidemiology,	
11 BY MS. ROITMAN344	9 Contributing Factors and Ongoing	
12 BY MR. BADALA354	Prevention Efforts," Beginning 10 Bates Number CUYAH_001547662 -	
	Marked Confidential	
13	11	
14 AFTERNOON SESSION183	Exhibit 14 Binder 343	
15	12	
16 REPORTER'S CERTIFICATE358	13	
	14	
17	15	
18 EXHIBIT CUSTODY - RETAINED BY COURT REPORTER	16	
19	17	
20	18	
21	19	
	20	
22	21	
23	22	
24	23	
25	24 25	
Page 7		Page 9
1 INDEX OF EXHIBITS	1 INDEX OF OBJECTIONS 2	
2 3 Number Description Marked	3 Objection26	
4	Objection31 4 Objection32	
5 Exhibit 1 Third Amended Notice of 29 Videotaped 30(b)(6) Deposition	Objection33	
6 of the County of Cuyahoga	5 Objection34 Objection34	
7 Exhibit 2 Plaintiff's The County of 66	6 Objection35	
Cuyahoga, Ohio and State of Ohio 8. Ex Rel Prosecuting Attorney of	Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C.	Objection 36 7 Objection 37 Objection 37	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga,	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127 19 Exhibit 9 E-Mail String, Beginning Bates 234 Number CUYAH_001709118 - Marked	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127 19 Exhibit 9 E-Mail String, Beginning Bates 234 20 Number CUYAH_001709118 - Marked Confidential	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127 19 Exhibit 9 E-Mail String, Beginning Bates 234 Number CUYAH_001709118 - Marked	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127 19 Exhibit 9 E-Mail String, Beginning Bates 234 Number CUYAH_001709118 - Marked Confidential 11 Exhibit 10 Article Entitled "The Cuyahoga 240 County Heroin Epidemic"	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127 19 Exhibit 9 E-Mail String, Beginning Bates 234 Number CUYAH_001709118 - Marked Confidential 21 Exhibit 10 Article Entitled "The Cuyahoga 240 County Heroin Epidemic" 22 Exhibit 11 Document Entitled "Overdose 244	7 Objection	
8 Ex Rel, Prosecuting Attorney of Cuyahoga County, Michael C. 9 O'Malley's Amended Responses to the Manufacturer Defendants' and 10 National Retail Pharmacy Defendants' First Set of 11 Interrogatories, with Attached Spreadsheets 12 Exhibit 3 Plaintiffs The City of 84 13 Cleveland, County of Cuyahoga, County of Summit and City of 14 Akron's Supplemental Amended Responses and Objections to the 15 Manufacturer Defendants' First Set of Interrogatories, 16 Submitted Pursuant to Discovery Ruling No. 13 17 Exhibit 7 Handwritten Notes 127 18 Exhibit 8 Handwritten Notes 127 19 Exhibit 9 E-Mail String, Beginning Bates 234 Number CUYAH_001709118 - Marked Confidential 21 Exhibit 10 Article Entitled "The Cuyahoga 240 22 County Heroin Epidemic"	7 Objection	

1 INDEX OF OBJECTIONS,	Page 10	1 INDEX OF OBJECTIONS, CONT'D	Page 12
2		2	
3 Objection		3 Objection110 Objection111	
4 Objection	50	4 Objection112	
Objection		Objection112	
5 Objection		5 Objection113 Objection113	
6 Objection	33	6 Objection114	
Objection		Objection114 7 Objection116	
Objection		Objection117	
8 Objection		8 Objection117	
Objection		Objection	
Objection		Objection118	
10 Objection		10 Objection120	
Objection		Objection	
Objection		Objection122	
12 Objection		12 Objection	
Objection		Objection124 13 Objection124	
Objection	76	Objection124	
14 Objection		14 Objection125 Objection125	
15 Objection		15 Objection126	
Objection		Objection129	
16 Objection		16 Objection130 Objection130	
17 Objection		17 Objection	
Objection	30	Objection131	
18 Objection		18 Objection132 Objection132	
19 Objection	1	19 Objection	
Objection		Objection133	
20 Objection		20 Objection134 Objection134	
21 Objection	36	21 Objection135	
Objection		Objection	
22 Objection		22 Objection135 Objection136	
23 Objection	7	23 Objection136	
Objection		Objection137 24 Objection137	
Objection		Objection138	
25 Objection	38	25 Objection139	
	Page 11		Page 13
1 INDEX OF OBJECTIONS,	CONT'D	1 INDEX OF OBJECTIONS, CONT'D 2	
3 Objection	39	3 Objection139	
Objection	39		
		Objection141	
4 Objection	39	4 Objection142	
Objection	19 19 10	4 Objection	
Objection 8 5 Objection 9 Objection 9	19 19 10 11	4 Objection	
Objection	19 19 10 11	4 Objection	
Objection	19 19 10 10 11 11 12 13	4 Objection	
Objection 8 5 Objection 9 Objection 9 6 Objection 9 Objection 9 7 Objection 9 Objection 9	19 19 10 11 11 12 13 15	4 Objection	
Objection	199 190 191 191 192 133 155	4 Objection	
Objection 8 5 Objection 9 Objection 9 6 Objection 9 Objection 9 Objection 9 8 Objection 9 9 Objection 9	19 19 10 10 11 10 12 13 15 15 15 15	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 196	4 Objection	
Objection	199 190 101 101 102 103 105 105 106 106	4 Objection	
Objection 8 5 Objection 9 Objection 9 6 Objection 9 Objection 9 Objection 9 8 Objection 9 Ob	199 190 191 191 192 193 195 195 196 196 196 197	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 196 197 197	4 Objection	
Objection 8 5 Objection 9 Objection 9 6 Objection 9 Objection 9 Objection 9 8 Objection 9 Ob	199 190 191 191 192 193 195 195 196 196 197 197 197 198	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 196 197 197 197 198 198	4 Objection	
Objection 8 5 Objection 9 Objection 9 6 Objection 9 7 Objection 9 7 Objection 9 8 Objection 9 9 Objection 9 10 Objection 9 10 Objection 9 10 Objection 9 11 Objection 9 12 Objection 9 13 Objection 9 13 Objection 9 14 Objection 9 14 Objection 9	199 190 191 191 192 193 195 195 196 196 197 197 198 198 199	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 197 197 197 198 199 199	4 Objection	
Objection	199 101 101 101 101 102 103 105 105 106 106 107 107 107 108 108 108 108 109 109 109 109 109 100	4 Objection	
Objection	199 101 101 102 103 105 105 105 105 106 106 107 107 107 108 108 109 109 109 100 101	4 Objection	
Objection	199 190 191 191 192 193 195 196 197 197 197 198 198 198 199 199 199 199 199 199 199	4 Objection	
Objection	199 101 101 102 103 105 105 106 106 107 107 107 108 108 108 109 109 100 100 101 102 102	4 Objection	
Objection	199 190 191 191 192 193 195 196 197 197 197 198 198 198 199 199 199 199 199 190 190 190 190 190	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 197 197 197 198 198 198 199 199 199 190 190 190 190 190 190 190	4 Objection	
Objection	199 190 191 191 192 193 195 196 197 197 197 197 198 198 199 199 199 199 190 190 190 190 190 190	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 197 197 197 198 198 199 199 199 199 199 199 199 199	4 Objection	
Objection	199 190 191 191 192 193 195 196 197 197 197 198 198 199 199 199 199 199 199 199 199	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 197 197 197 197 198 198 198 199 199 199 199 199 199 199	4 Objection	
Objection	199 190 191 191 192 193 195 195 196 197 197 197 197 198 198 199 199 199 199 199 199 199 199	4 Objection	
Objection	199 190 191 191 192 193 195 195 195 196 196 197 197 197 198 198 198 198 199 199 199 199 190 100 100 101 101 102 102 103 103 104 104 104 105 105 105 105 105 105 105 105 105 105	4 Objection	
Objection	199 190 191 191 192 193 195 195 195 195 195 195 196 196 197 197 197 198 198 199 199 199 199 199 190 100 101 102 102 103 103 104 104 104 105 105 105 105 106 107 107 108	4 Objection	
Objection	199 190 191 191 192 193 195 195 195 195 195 195 196 196 196 197 197 197 198 198 199 199 190 190 190 190 190 190 190 190	4 Objection	

	Page 14		Page 16
1 INDEX OF OBJECTIONS, CONT'D	1 age 14	1 INDEX OF OBJECTIONS, CONT'D	rage ro
2 2 Objection 196		2 2 Objection 200	
3 Objection186 Objection186		3 Objection290 Objection294	
4 Objection187		4 Objection295	
Objection187 5 Objection188		Objection	
Objection189		Objection298	
6 Objection189		6 Objection298	
Objection191 7 Objection193		Objection299 7 Objection300	
Objection194		Objection301	
8 Objection194		8 Objection303	
Objection195 9 Objection195		Objection303 9 Objection304	
Objection195		Objection306	
10 Objection196		10 Objection306	
Objection196 11 Objection196		Objection307 11 Objection307	
Objection200		Objection308	
12 Objection200		12 Objection308	
Objection201 13 Objection202		Objection309 13 Objection312	
Objection205		Objection313	
14 Objection205		14 Objection313	
Objection209 15 Objection210		Objection316 15 Objection316	
Objection210		Objection316	
16 Objection211		16 Objection317	
Objection211 17 Objection212		Objection318 17 Objection318	
Objection216		Objection318	
18 Objection217		18 Objection319	
Objection		Objection	
Objection219		Objection320	
20 Objection		20 Objection	
Objection		Objection320 21 Objection323	
Objection221		Objection324	
22 Objection		22 Objection325 Objection325	
Objection224 23 Objection224		23 Objection326	
Objection225		Objection326	
24 Objection225 Objection226		24 Objection	
25 Objection228		25 Objection	
1 INDEX OF OBJECTIONS CONT'D	Page 15	1 INDEX OF OBJECTIONS CONT'D	Page 17
1 INDEX OF OBJECTIONS, CONT'D 2	Page 15	1 INDEX OF OBJECTIONS, CONT'D	Page 17
2 3 Objection236	Page 15	2	Page 17
2 3 Objection236 Objection236	Page 15	2 3 Objection336	Page 17
2 3 Objection	Page 15	2 3 Objection336 Objection336	Page 17
2 3 Objection	Page 15	2 3 Objection	Page 17
2 3 Objection	Page 15	2 3 Objection	Page 17
2 3 Objection	Page 15	2 3 Objection	Page 17
2 3 Objection	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 337 Objection 338	Page 17
2 3 Objection	Page 15	2 3 Objection	Page 17
2 3 Objection	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 338 6 Objection 338 Objection 339	Page 17
2 3 Objection	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339	Page 17
2 2 3 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 7 Objection 240 0bjection 245 8 Objection 257 7 Objection 259 9 Objection 264 0bjection 265 10 Objection 265	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 338 6 Objection 338 Objection 338 Objection 339 Objection 339 Objection 340	Page 17
2 3 Objection 236 Objection 237 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 259 9 Objection 264 Objection 265 10 Objection 265 10 Objection 266 Objection 267	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340	Page 17
2 3 Objection	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 340	Page 17
2 2 3 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 7 Objection 240 0bjection 245 8 Objection 257 0bjection 259 9 Objection 264 0bjection 265 10 Objection 267 11 Objection 267 0bjection 268 12 Objection 268 12 Objection 268	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340	Page 17
2 3 Objection	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 5 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 341	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 264 Objection 266 Objection 267 10 Objection 267 11 Objection 268 12 Objection 269 Objection 269 Objection 269 13 Objection 270	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 340 Objection 341 10 Objection 341	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 7 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 269 9 Objection 264 Objection 266 10 Objection 267 11 Objection 268 12 Objection 269 Objection 269 13 Objection 270 Objection 270 14 Objection 270 14 Objection 271	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 9 Objection 340 Objection 341 10 Objection 341 Objection 342	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 Objection 249 Objection 245 8 Objection 257 Objection 259 9 Objection 264 Objection 266 Objection 267 10 Objection 268 12 Objection 268 12 Objection 269 0bjection 269 13 Objection 270 Objection 270 Objection 270 Objection 271 Objection 271	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 9 Objection 340 Objection 341 10 Objection 341 Objection 342 11 Objection 349	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 Objection 238 6 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 259 9 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 268 12 Objection 269 Objection 269 Objection 270 Objection 270 Objection 270 14 Objection 271	Page 15	2 3 Objection 336 Objection 336 4 Objection 336 Objection 337 5 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 9 Objection 340 Objection 341 10 Objection 341 Objection 342 11 Objection 349 Objection 349 Objection 352	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 266 Objection 267 10 Objection 268 12 Objection 268 12 Objection 269 Objection 269 13 Objection 270 Objection 270 Objection 271 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 272 16 Objection 273	Page 15	2 3 Objection 336 Objection 336 4 Objection 336 Objection 337 5 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 341 10 Objection 341 Objection 342 11 Objection 342 11 Objection 349 Objection 352 12 Objection 353	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 259 9 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 267 Objection 269 12 Objection 269 13 Objection 270 14 Objection 271 Objection 271 Objection 271 Objection 271 Objection 272 Objection 272 Objection 272 Objection 273 Objection 273 Objection 275	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 338 6 Objection 338 6 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 341 Objection 341 Objection 342 10 Objection 342 11 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 353 Objection 47	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 266 Objection 267 10 Objection 268 12 Objection 268 12 Objection 269 0bjection 269 13 Objection 270 Objection 270 Objection 271 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 272 16 Objection 273	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 7 Objection 339 7 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 341 Objection 341 Objection 342 10 Objection 342 10 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 353 Objection 353 Objection 353	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 259 9 Objection 265 10 Objection 266 Objection 267 11 Objection 267 12 Objection 269 13 Objection 270 14 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 273 Objection 278 Objection 278 Objection 279 18 Objection 279	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 338 6 Objection 338 6 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 341 Objection 341 Objection 342 10 Objection 342 11 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 353 Objection 47	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 268 12 Objection 269 Objection 269 13 Objection 270 14 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 273 Objection 275 17 Objection 278 Objection 279 Objection 279 Objection 279 Objection 279	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 7 Objection 339 7 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 341 10 Objection 341 Objection 342 10 Objection 342 10 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 47	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 259 9 Objection 265 10 Objection 266 Objection 267 11 Objection 267 12 Objection 269 13 Objection 270 14 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 273 Objection 278 Objection 278 Objection 279 18 Objection 279	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 341 10 Objection 341 Objection 342 10 Objection 342 11 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 47 13 14 15 16	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 268 12 Objection 269 Objection 269 13 Objection 270 14 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 273 Objection 278 Objection 279 Objection 279 Objection 279 Objection 279 Objection 27	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 339 0 Objection 340 8 Objection 340 Objection 340 Objection 341 10 Objection 341 Objection 342 10 Objection 342 11 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 47 13 14 15 16 17	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 266 Objection 267 10 Objection 266 Objection 268 12 Objection 269 13 Objection 269 13 Objection 270 Objection 271 15 Objection 271 Objection 272 16 Objection 273 Objection 275 17 Objection 275 18 Objection 279 18 Objection 279 Objection 279 Objection 279 Objection 279 Objection <	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 5 Objection 337 Objection 338 6 Objection 338 Objection 339 7 Objection 340 8 Objection 340 9 Objection 340 9 Objection 340 Objection 341 10 Objection 341 10 Objection 341 Objection 342 11 Objection 342 12 Objection 352 12 Objection 353 Objection 353 Objection 47 13 14 15 16 17 18	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 268 12 Objection 269 Objection 269 13 Objection 270 14 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 273 Objection 278 Objection 279 Objection 279 Objection 279 Objection 279 Objection 27	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 5 Objection 338 6 Objection 338 7 Objection 339 7 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 341 10 Objection 341 10 Objection 341 10 Objection 342 11 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 47 13 44 15 16 17 18 19 19	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 266 Objection 266 Objection 267 11 Objection 268 12 Objection 269 13 Objection 270 Objection 270 Objection 271 15 Objection 271 Objection 272 16 Objection 273 Objection 275 17 Objection 275 18 Objection 279 19 Objection 279 19 Objection 279 10 Objection 279 10 Objection 280 Objection	Page 15	2 3 Objection 336 Objection 336 4 Objection 337 Objection 337 Objection 338 6 Objection 338 6 Objection 339 Objection 340 8 Objection 340 Objection 340 Objection 340 Objection 341 Objection 341 Objection 342 11 Objection 342 11 Objection 349 Objection 352 12 Objection 353 Objection 353 Objection 47 13 14 15 16 17 18 19 20	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 267 12 Objection 269 13 Objection 270 14 Objection 270 14 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 278 Objection 279 Objection 279 Objection 279 Objection 280 20 Objection 280 20 Objection <	Page 15	2 3 Objection	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 5 Objection 237 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 266 Objection 266 Objection 267 10 Objection 268 12 Objection 269 13 Objection 270 Objection 270 Objection 271 14 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 275 17 Objection 275 19 Objection 279 19 Objection 279 19 Objection 279 19 Objection 280 Objection	Page 15	2 3 Objection	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 5 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 257 Objection 259 9 Objection 264 Objection 265 10 Objection 266 Objection 267 11 Objection 267 12 Objection 269 13 Objection 270 14 Objection 270 15 Objection 271 Objection 271 Objection 271 Objection 272 16 Objection 273 Objection 278 Objection 278 Objection 279 Objection 279 Objection 279 Objection 280 20 Objection <t< td=""><td>Page 15</td><td>2 3 Objection</td><td>Page 17</td></t<>	Page 15	2 3 Objection	Page 17
2 3 Objection 236 Objection 236 4 Objection 237 Objection 237 Objection 238 6 Objection 239 Objection 239 7 Objection 240 Objection 245 8 Objection 257 Objection 264 Objection 266 Objection 266 Objection 267 10 Objection 268 12 Objection 269 13 Objection 270 Objection 270 Objection 271 14 Objection 271 15 Objection 271 Objection 272 16 Objection 273 Objection 275 17 Objection 275 19 Objection 279 19 Objection 279 19 Objection 279 19 Objection 280 Objection	Page 15	2 3 Objection	Page 17

Page 18 Page 20 THE VIDEOGRAPHER: The date is 1 MR. BADALA: I'm sorry. Before you 2 January 14th, 2019. We are on the record at 2 do that, is Ms. Rendon on the phone? I assume 3 9:07 a.m. This is the deposition of Thomas 3 not. We just have a standing objection to 4 Ms. Rendon's participation in this matter and 4 Gilson in the matter of In Re: National 5 Baker Hostetler as well. 5 Prescription Opiate Litigation, in the United 6 States District Court, Northern District of MS. HARTMAN: Just so you know, Endo 7 Ohio, Eastern Division. 7 Defendants want their client to have counsel Will counsel please state 8 here and we know your objection but we're here. 9 9 appearances for the record? MR. BADALA: That's fine. 10 MR. BADALA: Salvatore Badala for 10 THOMAS GILSON, M.D., of lawful 11 the Plaintiff, Cuyahoga County. 11 age, called for examination, as provided by 12 MR. GALLUCCI: Frank Gallucci for 12 the Federal Rules of Civil Procedure, being 13 Plaintiff, Cuyahoga County. 13 by me first duly sworn, as hereinafter 14 MS. PATEL: Ami Patel, for 14 certified, deposed and said as follows: 15 Plaintiff, City of Cleveland. 15 EXAMINATION OF THOMAS GILSON, M.D. MS. JAMES: Erica James, Tucker 16 BY MR. CHEFFO: 17 Ellis, for Janssen Pharmaceuticals and Johnson & 17 Q. Good morning, Doctor. 18 Johnson. 18 You understand you're under oath 19 MR. PADUKONE: Aseem Padukone, 19 today? 20 Covington & Burling, on behalf of McKesson 20 Yes, I do. 21 Corporation. 21 You've been deposed before? Ο. 22 MS. HARTMAN: Ruth Hartman, Baker 22 A. Yes, I have. 23 Hostetler, on behalf of the Endo Defendants. 23 Q. And you understand that you've been MS. RANJAN: Brandy Ranjan from 24 designated today as what we call a 30(b)(6) or a 25 Jones Day on behalf of Walmart. 25 corporate designee? Page 19 Page 21 1 MR. CARTER: Ed Carter for Walmart. A. Yes, I do. 1 2 MS. ZERRUSEN: Sandy Zerrusen, 2 Q. And you understand that that means 3 Jackson Kelly, on behalf of AmerisourceBergen. 3 that you're testifying on behalf of the county? 4 MR. BORANIAN: Steven Boranian from 4 A. Cuyahoga County, yes, I do. 5 Reed Smith for Defendant AmerisourceBergen. 5 Q. Great. Thank you. MS. ROITMAN: Sara Roitman from 6 Would you be good enough to tell us 7 Dechert on behalf of Purdue. 7 what you did in connection with your preparation 8 MR. CHEFFO: Mark Cheffo, also from 8 today? And I don't want you to tell me any 9 Dechert, for Purdue. 9 conversations you had with your lawyers, but you 10 THE VIDEOGRAPHER: Will counsel on 10 can tell me if you met with lawyers, what you 11 the phone please state appearances for the 11 reviewed and what else you may or may not have 12 record? 12 done. 13 MR. PADGETT: Bill Padgett on behalf 13 A. I did meet with attorneys today. 14 of Defendant H.D. Smith. 14 Pardon me. I met with attorneys prior to today. 15 MR. KEYES: Andrew Keyes on behalf 15 I reviewed case material in the medical 16 examiner's office. I also reviewed case 16 of Cardinal Health. 17 MS. FISCHER: Alyse Fischer, Morgan 17 material with regard to the Division of Child 18 Lewis, on behalf of the Teva Defendants. 18 and Family Services. I discussed information 19 MR. PORTER: Luke Porter with Reed 19 with the previous coroner. I also discussed 20 Smith on behalf of AmerisourceBergen. 20 information with other county officials with 21 MR. ERB: Chip Erb of Cavitch on 21 regard to the impact of the opioid crisis on 22 behalf of Discount Drug Mart. 22 their agencies. I would say in preparation, in MR. CHEFFO: Anybody else? 23 23 general, we've been dealing with the crisis now 24 THE VIDEOGRAPHER: Will the court 24 for a number of years and I've done a lot of 25 reporter please swear in the witness? 25 preparation in an indirect way ready for today.

6 (Pages 18 - 21)

Q. Well, about how many hours did you

- 2 spend preparing for the deposition and your 3 topics today?
- 4 A. All those seven years.
- 5 Q. Well, you didn't know that you were 6 going to be deposed today seven years ago, did
- 7 you?

1

- 8 A. I hope not. No.
- When did you first learn that you
- 10 were going to be a corporate designee in this 11 deposition?
- 12 A. It was a few months ago. I couldn't
- 13 give you an exact answer how many hours.
- 14 Several I can say.
- Q. Several? 15
- Several. 16 A.
- 17 Like five, ten? O.
- No. I'd say probably closer to 35 18
- 19 to 40.
- 20 Q. For all the topics?
- 21 For all those topics, yes. A.
- 22 And what specific documents did you
- 23 review from the case materials and the various
- 24 coroner information on the divisions in
- 25 connection with your preparing for the
- Page 23

- 1 deposition today?
- A. I reviewed materials in association
- 3 with the medical examiner's website, other
- 4 things that were available from task forces. I
- 5 also reviewed, as I mentioned, things from the
- 6 Division of Child and Family Services, medical
- 7 literature, internet searches.
- Q. And I guess what I'm trying to just
- 9 find -- if you can help us out, Doctor, a little
- 10 more specificity. Did you keep track of
- 11 anything? Did you make copies of anything you 11 county hospital, MetroHealth Medical Center.
- 12 reviewed?
- 13 A. I did not, no, not specifically.
- 14 Q. Was there anything that was reviewed
- 15 that was not publicly available?
- A. To the best of my knowledge,
- 17 everything that I reviewed was publicly
- 18 available.
- Q. Were they things that you reviewed
- 20 of your own volition or were they anything that
- 21 was provided to you?
- 22 A. Primarily things of my own volition.
- 23 I don't think anything was provided to me
- 24 separately.
- Q. And did you print anything out or 25

- 1 did you review everything online?
- A. More online. I mean, our website is

Page 24

- 3 online and I can access things through that.
- Q. And who else did you talk to in
- 5 connection with your preparation for the various
- 6 topics that you're going to testify about today?
- 7 A. I would have spoken to Dr. Elizabeth
- 8 Balraj, who was the previous coroner. I spoke
- 9 to Hugh Shannon, who was the administrator,
- 10 chief of operations, in my office. I spoke to
- 11 Tamara Chapman in the Department of Child and
- 12 Family Services, in addition to David Merriman,
- 13 who is the director of health and human
- 14 services. I spoke to Commander Gingell in the
- 15 Cleveland Police Department in preparation for
- 16 today. I spoke to Keith Martin, who is in the
- 17 Drug Enforcement Agency. I also spoke to Derek
- 18 Siegel, who is the director of the High
- 19 Intensity Drug Trafficking Area for Ohio.
- 20 Nobody else is coming to mind.
- 21 Q. Okay. And you probably know from
- 22 your experience and you have good lawyers -- I'm
- 23 sure they've told you as well -- but if during
- 24 the course of the deposition something pops up
- 25 into your mind, oh, I remember speaking to him,
- Page 25
- 1 it's perfectly appropriate for you to amend your
 - 3 A. Sure.
 - Oh, I'm sorry. I can add two
 - 5 people. I spoke to Vince Caraffi, who was the

2 response and let us know if that does happen.

- 6 injury prevention program head at the Board of
- 7 Health in Cuyahoga County and he was also the
- 8 head of the opiate task force for the County
- 9 Board of Health. And I also spoke to Dr. Joan
- 10 Papp, who is an emergency room physician at your
- 12 She is also the medical director of Project
- 13 DAWN, our Deaths Avoided With Naloxone program.
- 14 Q. Project --
- 15 A. DAWN.
- 16 Q. -- DAWN.
 - Did you take any notes during these
- 18 interviews or conversations?
- 19 A. Nothing I retained.
- 20 Q. Well, did you take notes during the
- 21 time?

- 22 A. I might have scribbled things on
- 23 pads, but I don't have them now.
- 24 Q. Where are they?
- 25 A. I threw them away.

Page 26 Page 28 1 O. You weren't asked to retain those? 1 Q. Is that a Linda Singer letter? 2 Nobody asked me to retain them, no. 2 A. Linda Singer, that's it. 3 3 Why would you throw them away? Q. Okay. Did I see some handwritten 4 They are just really things to 4 notes in the very beginning? 5 refresh my memory, but once I had gotten things 5 A. Yes, you did. 6 in my head, I didn't feel I needed them anymore. 6 Q. And are those your notes? 7 7 Q. And you're certain that all of your A. These are my notes, yes. 8 notes are -- have been destroyed? 8 Q. Okay. Well, we may come back to 9 MR. BADALA: Objection to form. 9 that, but let's -- so other than what you've A. I don't know where they would be. I 10 told us, Doctor -- you've spoken to the folks 10 11 mean, if they're in the Cleveland trash dump 11 that you've identified, you looked at some 12 somewhere I guess, but I don't have access to 12 publicly available information, you met with 13 them anymore. 13 your lawyers -- did you do anything else to 14 Q. And you took notes during each of 14 prepare for giving testimony here on behalf of 15 these calls? 15 Cuyahoga? A. I took notes I recall when I was 16 A. No. I think I reviewed my articles 17 talking to the folks at the Division of Child 17 that I've written on this as well and 18 and Family Services, Mr. Caraffi and Dr. Papp. 18 presentations and things like that, but I 19 They're the only ones I remember taking notes 19 believe those were made available already as 20 with. 20 well. 21 21 Q. Did you bring any documents with you 22 today? 22 (Thereupon, Gilson Deposition 23 A. I brought a binder, which was made 23 Exhibit 1, Third Amended Notice of 24 available to me by counsel. 24 Videotaped 30(b)(6) Deposition of 25 25 Do you know what's in it? the County of Cuyahoga, was marked Page 27 Page 29 1 A. Yes, I do. for purposes of identification.) 1 2 2 There is a copy of my declaration 3 with regard to Carole Rendon. There is a copy 3 Q. Okay. So this is what I think you 4 of the corrected complaint, second amended 4 probably have already, Doctor. This is just a 5 corrected complaint, with a list of the 5 copy of the notice of deposition. So as you 6 Defendants. There is information that was 6 know, there's a number of topics, and I'm going 7 generated from my office that was shared with 7 to be covering a number of them, Doctor, and my 8 counsel already. Our monthly report. This is 8 colleagues are going to be covering them. We 9 dated from June 1st, 2018. We've done 9 have a limited period of time, so I'm going to 10 subsequent reports, but certainly this was the 10 ask you to do your best to try to answer the 11 most up to date that was furnished at that time. 11 questions that I ask. Obviously if they're not 12 The other ones, if you're interested in 12 clear, you should let me know if you don't 13 understand them, but what we're going to try and 13 obtaining them, were -- recent copy are 14 available on our website, and that would be 14 do, because these are relatively targeted, is 15 going up to January of this year. This is a 15 kind of focus on these specific areas within the 16 copy of the third amended notice of a videotaped 16 limited time we have --17 deposition. And that is in regard to the topics 17 A. Sure. 18 for the deposition that I was asked to prepare 18 Q. -- just to give you a little bit of 19 for today. This is an organizational chart for 19 a roadmap. 20 Cuyahoga County for my reference. And last is a 20 I'd also like to maybe just start 21 letter to Special Master David R. Cohen, and I 21 with number -- topic 34. Do you see that? It's 22 believe this is a correspondence about the 22 listed on page 4. A. Yes. 23 interrogatories. 23 24 Q. Is that from Linda Singer? 24 Q. So of the individuals that you A. Pardon me? 25 25 mentioned, did you speak with any of them

8 (Pages 26 - 29)

1 specifically with respect to 34?

- A. If I could just take a second to
- 3 refresh myself with the topic. I did speak to
- 4 the individual from the department -- Drug
- 5 Enforcement Agency about ARCOS data.
- Q. Was that someone that you listed 7 already or somebody else?
- A. Keith Martin.
- 9 Q. Okay. And how long did you speak to
- 10 Mr. Martin for?
- A. Maybe no more than five minutes.
- 12 Q. Did you do anything else to prepare
- 13 for topic 34?
- A. I discussed it with counsel when we
- 15 were preparing.
- Q. Anything else?
- 17 A. Not that I remember, no.
- Q. So who are the individuals and
- 19 entities other than Defendants, if any, who
- 20 Cuyahoga County believes caused or contributed 20
- 21 to the opioid crisis in Cuyahoga County?
- 22 A. Cuyahoga County believes that the
- 23 opioid crisis in our county is directly
- 24 responsible to the Defendants and does not
- 25 mention any others.

Page 31

1

- 1 Q. I think that doesn't answer my 2 question.
- 3 A. There are no others.
- Q. So you -- it's Cuyahoga's testimony 4
- 5 that there are no other individuals or entities
- 6 anywhere in the world other than the Defendants
- 7 who caused or contributed to the opioid crisis?
- 8 Is that your testimony?
- 9 MR. BADALA: Objection to form.
- A. It's the testimony of Cuyahoga 10
- 11 County that there are other individuals involved
- 12 but their responsibility is ultimately referable
- 13 back to the Defendants.
- Q. And that's not answering my 14
- 15 question, Doctor.
- You spoke with --16
- 17 A. I'm sorry. I'm trying the best I
- 18 can.
- 19 Q. Okay. One of the topics was to
- 20 identify the entities and individuals, other
- 21 than Defendants, who Cuyahoga County, as a
- 22 non-expert, believes caused or contributed to
- 23 the opioid crisis in the Cuyahoga geographic
- 24 entity -- area. Excuse me. And I'm just trying
- 25 to understand, as you sit here today on behalf

Page 30 1 of Cuyahoga, if you could tell me any

- 2 individuals or entities, other than the
- 3 Defendants, that Cuyahoga County believes caused
- 4 or contributed to --
- MR. BADALA: Objection to form.
- 6 Asked and answered.
- 7 A. Cuyahoga County does not identify
- 8 any additional individuals other than the
- 9 Defendants who caused the opioid epidemic in the 10 county.
- 11 Q. What about contributed to?
- 12 A. Again, referable back to the
- 13 Defendants, so that we have not named anybody
- 14 separately other than the Defendants.
- 15 Q. Has Cuyahoga County looked at the
- 16 ARCOS data?
- A. Cuyahoga County does not have access 17
- 18 to the ARCOS data, and as such, we have never
- 19 been able to review it.
- Q. How do you know that Cuyahoga County
- 21 doesn't have access to it?
- 22 A. Based on my discussions with
- 23 Mr. Martin from the Drug Enforcement Agency, who
- 24 oversees the ARCOS data, Cuyahoga County would
- 25 not have access to that data.

Page 33

Page 32

- That includes currently today?
- 2 A. As of today.
- 3 Q. And if you had access, would you
- 4 look at it?
- A. As it was relevant to the opioid
- 6 crisis, it certainly would have been something
- 7 we would have considered looking at, sure.
- Q. If you had access to it for the last
- 9 three or four months, it's certainly something
- 10 important to Cuyahoga County to look at, right?
- MR. BADALA: Objection to form.
- 12 A. I think it's relevant in terms of --
- 13 as I understand ARCOS data, it's distribution 14 of -- quantifications of distributions of drugs
- 15 into Cuyahoga County, and I think that that
- 16 would be something that would be potentially
- 17 relevant to our efforts to address the opioid 18 crisis.
- 19 I think, you know, at this point in
- 20 the opioid crisis we're also looking at an
- 21 evolution from the original problem with opioid
- 22 pain relievers to heroin and fentanyl, but I
- 23 think the information from a county standpoint
- 24 would still be potentially helpful.
 - Q. And as you understand it, the county

Page 34 Page 36 1 hasn't had access and hasn't looked at any of 1 and I think it's still in this way referable 2 the ARCOS data even to today? 2 back to the Defendants. 3 MR. BADALA: Objection to form. 3 Q. Well, has anybody -- have you A. I am not aware of any access the 4 identified any of those, any pill mills, any 4 5 doctors who engaged in illegal conduct, any drug 5 county has to ARCOS data, and based on my 6 discussion with the Drug Enforcement 6 gang or other drug activity? 7 Administration representative with whom I spoke, 7 MR. BADALA: Objection to form. 8 8 the county does not have access to ARCOS data. A. The county has. I couldn't, as I Q. And when did you speak with 9 sit here today, give you names of those 10 Mr. Miller -- Mr. Martin? Excuse me. 10 individuals. The pill mill was something that A. I spoke with him on Friday. 11 wasn't as prevalent in this area as it was in 12 Q. Just to see if we could just make 12 the southern part of the state, but we were 13 sure that we're on the same page, Doctor, so 13 certainly aware of them and there were pain 14 it's the county's position that if a doctor 14 clinics or things like that here. 15 prescribed unlawfully a number of prescriptions 15 Q. So you're not suggesting that none 16 to patients solely for his or her economic gain, 16 of that ever happened in Cuyahoga County? 17 not for any medical purpose, would that have 17 A. Oh, no, certainly not. Certainly 18 contributed to the opioid crisis? 18 not. 19 MR. BADALA: Objection to form. 19 Q. And all of those things contributed 20 A. Yes, it would have. 20 to the opioid crisis in Cuyahoga County, 21 21 correct? Q. And if a Mexican cartel had shipped 22 illegal synthetic fentanyl into the geographic 22 A. That would be the county's opinion, 23 boundary of Cuyahoga County, would that have 23 yes. 24 contributed to the opioid crisis? 24 Q. And then the question here is, 25 Yes, it would have. 25 Doctor, identify them. Who are they? Page 35 Page 37 Q. And if a -- do you know what a pill 1 A. I would have to refer to the 1 2 mill is? 2 prosecutor, who's also a witness, in terms of 3 A. In a general sense. 3 Defendants who were identified and prosecuted. 4 Q. But I thought you just told me that 4 Q. If there was a pill mill operating 5 none of those people did cause or contribute, so 5 in Cuyahoga County, would that have contributed 6 I'm a little confused. Did they cause or 6 to the opioid crisis? 7 7 contribute or did they not? A. Just so we're on the same page, 8 because it sounded similar to your initial 8 MR. BADALA: Objection to form. 9 A. Oh, no. I'm sorry. I said that 9 question, I would define a pill mill as an 10 illegal operation with a doctor dispensing drugs 10 they -- their actions contributed, but 11 ultimately I think their actions are referable 11 without establishing a doctor/patient 12 relationship, essentially for profit, and these 12 back to the Defendants. 13 were frequently operations that would be cash 13 Q. Well, that's not my question. My 14 question is if their -- let's start with their 14 only, very few questions asked, and I think, you 15 know, they were not reputable in any sense. 15 actions. You might have a view, a personal view Q. And that's -- I would adopt that 16 as to whether it's attributable, but what we're 17 definition, Doctor. 17 trying to find out is the identification of 18 A. You can use that one. 18 those individuals. Are you prepared to tell us 19 the identification of even one of those improper 19 Q. Okay. So when I talk about a pill 20 doctors or pill mills or drug conduct? 20 mill, I'm talking about kind of people who are 21 21 doing things for non-medically appropriate uses MR. BADALA: Objection to form. A. The only one I can think of off the 22 to essentially create economic gain for 22

10 (Pages 34 - 37)

23 top of my head was an organization -- I believe

Q. So are they one of the individuals

24 it was called the Northeast Ohio Pain Clinic.

23 themselves at the expense of patients or others.

A. Yes, that would have contributed,

MR. BADALA: Objection to form.

24

25

1 or entities that caused or contributed to the 2 opioid crisis?

MR. BADALA: Objection to form.

- A. Again, I think they had a
- 5 contribution in being an illicit source of 6 opioid pain reliever, sure.
- 7 Q. And anyone else?
- 8 A. Again, I have to say I would have to
- 9 defer to the prosecutor who they identified in
- 10 prosecutions as overprescribing in their work.
- 11 We wouldn't have directly investigated some of
- 12 these things through my agency or many others
- 13 and the prosecutor would be the best source of
- 14 information there.

3

4

- 15 Q. I understand, Doctor. As we
- 16 discussed, you're here testifying on behalf of
- 17 the county, right?
- 18 A. That's right.
- 19 Q. Did you talk to the prosecutor?
- 20 A. I spoke with James Gutierrez in
- 21 the -- oh, there's another one. James Gutierrez
- 22 in the prosecutor's office.
- Q. Did you ask him to identify any of
- 24 the people that he prosecuted?
- A. I did not. I asked him in a general

Page 40

Page 41

- 1 drug addicted in Cuyahoga County ultimately took
- 2 a prescription opioid medicine?
- 3 A. No, that would not be Cuyahoga
- 4 County's position.
- 5 Q. Okay. Are there people who never 6 had prescription opioids who are addicted?
- 7 MR. BADALA: Objection to form.
 - A. As far as I know, yes.
 - Q. Can you identify any person or
- 10 prescription, or can the county, and directly
- 11 relate it to any alleged improper conduct or
- 12 omission or misrepresentation by any of the
- 13 Defendants?

8

- MR. BADALA: Objection to form.
- 15 Outside the scope.
- 16 A. Could we just reference which topic?
- Q. It's in the interrogatories, but --
- 18 MR. BADALA: Same objection.
- 19 A. The county identified claims for
- 20 opiates that were not for cancer patients, were
- 21 high dose, that is more than 120 medical
- 22 morphine equivalents, and patients who were
- 23 diagnosed with a substance use disorder, and
- 24 patients who, by definition, had been grievously
- 25 hurt by their prescription. That's in reference

Page 39

1 way the impact of the opioid crisis on

2 prosecutions.

- Q. Did you ask anyone, in sum or
- 4 substance, hey, I have to respond to topic 34
- 5 and identify entities or individuals, can you
- 6 give me some of those names?
- 7 A. As I say, I spoke with the 8 individuals I spoke with, and -- in attempting
- 9 to identify those individuals and entities, it's
- 10 the county's position that while there may have
- 11 been intermediary steps in diversion and those
- 12 kind of issues, all of the responsibility for
- 13 the opioid crisis is referable back to the
- 14 Defendants.
- 15 Q. Even if a drug cartel shipped in
- 16 illicit fentanyl from Mexico, that's the
- 17 responsibility of the Defendants?
- 18 MR. BADALA: Objection to form.
- 19 A. Yes, because there would be no need
- 20 to ship fentanyl to this area if there wasn't a
- 21 drug-addicted population, and the drug-addicted
- 21 drug-addicted population, and the drug-addicte
- population is referable back to the opioid painrelievers and the actions of the Defendants.
- Q. So is it your testimony -- is it
- 25 Cuyahoga's testimony that every person who is

1 to Exhibit 6 in my folder.

- Q. And we're going to get to Exhibit 6,
- 3 but with respect to any of those, can you
- 4 identify any specific conduct and tie it to any
- 5 specific prescription or patient? Do you have
- 6 any of that data or information here today?
- 7 MR. BADALA: Objection to form.
- 8 Outside the scope.
- 9 A. I think this is, again, in reference
- 10 to the interrogatories that were -- data was
- 11 provided to counsel, reviewed with experts, and
- 12 that was made available in response to
- 13 interrogatories. I don't have that with me
- 14 beyond that.
- 15 Q. Not my question, Doctor.
- With respect to any alleged addicted
- 17 person -- let's start with that -- do you have
- 18 any information that their addiction -- can you
- 19 identify any person -- is relatable to any
- 20 conduct, action or omission of any Defendant?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope. Asked and answered.
- A. Sorry. I missed your question. Do
- 24 I have any information --
 - Q. As to any person who you believe is

Page 42 Page 44 1 addicted in the county, that that addiction was 1 A. Yes. 2 2 caused by any specific representation, omission Q. Did you talk to anybody else? 3 They're coming to me, but I have to 3 or misrepresentation by a Defendant; if so, who 4 say --4 and what was the statement or omission. MR. BADALA: Objection to form. 5 In connection with 34. Q. 6 A. Not as I remember. 6 Outside the scope. Asked and answered. 7 7 Q. And is it your -- let me see if I A. I mean, we have people who are 8 make sure we're clear on this. Is it the 8 addicted, and going back and looking at their 9 county's testimony that even to the extent that 9 prescription drug monitoring data, had lengthy 10 there's any contribution of anybody or entity 10 records there and subsequently went on to die of 11 other than Defendants, ultimately every single 11 heroin or fentanyl overdose, and, you know, I 12 one of those instances relates back to the 12 think that they're, initially in the first wave 13 Defendants' conduct? Is that your testimony? 13 of the epidemic, in the heroin phase, that's 14 Which instances are we talking 14 approximately 80 percent or so of our 15 about? 15 population, so while I don't think everybody who Q. Well, I'm talking about 34, right? 16 is addicted to drugs in Cuyahoga County had some 16 17 antecedent effect or, you know, cause with the 17 A. Right. I -- I'm just asking the 18 identification and -- entities of individuals 18 opioid pain relievers, a substantial percentage 19 other than the Defendant who contributed or 19 had contact with opioid pain relievers. 20 Q. And you know that how? 20 caused? Is that the instances you're talking 21 A. That was based on the review of the 21 about? 22 Ohio Automated RX Reporting System, which is our 22 Q. Here's what I'm trying to 23 understand. I want to leave this but I want to 23 prescription drug monitoring program. That was 24 started in 2006 to track prescriptions of 24 make sure that we're on the same page here. 25 25 controlled substances throughout the State of Yeah. Yeah. Sure. Page 43 Page 45 1 Ohio, and we obtained access to that and 1 Q. You've told me you can't identify 2 retrospectively reviewed our heroin overdoses, 2 anybody, but you've also then said there may be 3 2012, '13, actually going forward, and we 3 some individuals or entities out there that are 4 included our fentanyl overdoses more recently to 4 somehow in the chain, if you will, but their 5 identify previous prescriptions received by 5 conduct is somehow relatable ultimately to the 6 those individuals. 6 manufacturers. Did I get that right? Q. Let's go back to 34 for a minute, 7 MR. BADALA: Objection to form. 8 Doctor. So other than the one -- you named one 8 A. Yes, you did. 9 pill mill. What was that? Q. Okay. And is there anybody out 10 A. The Northeast Ohio Pain Clinic. I 10 there in the chain whose conduct is not in some 11 don't remember its exact name, but something 11 way, in the county's view, relatable to any of 12 like that. We participated in reviewing some 12 the Defendants? 13 records for that. 13 MR. BADALA: Objection to form. 14 O. Other than that Northeast Ohio Pain A. I think ultimately the county would 15 Clinic, can you give the names of any specific 15 say no, there is not anybody out there whose 16 individual or entity in response to topic 34? 16 conduct is not referable back to the Defendants. 17 MR. BADALA: Objection to form. 17 Q. And you're not aware and you can't A. I cannot give specific names. They 18 tell me anybody in the chain, whether they were 19 are available through the county and I would 19 relatable to the Defendants' conduct or not, 20 right? 20 have to refer to the county prosecutor as a

12 (Pages 42 - 45)

MR. BADALA: Objection to form.

A. Other than the one I mentioned, I

A. I know there were prosecutions of

23 can't give you specific names, no.

Q. Are you aware of any?

21

22

24

25

22

25

24 now?

21 better source of that information.

Q. So the prosecutor has them, you're

MR. BADALA: Objection to form.

23 just not prepared to tell me what they are right

- 1 doctors who were overprescribing based on my
- 2 discussion with the prosecutor, but the names of
- 3 those individuals or entities I do not know.
 - Q. Did some of them go to jail?
- 5 A. I would hope so, but I don't know 6 for sure.
- 7 Q. Did they lose their licenses?
- 8 A. Again, I would hope so, but I don't
- 9 know the result of that. That isn't something I
- 10 have access to right now.
- Q. And you would hope so, I take it,
- 12 because your understanding of those doctors were
- 13 that they were engaging in improper conduct that
- 14 was not in the best interest of their patients,
- 15 right?

1

4

- 16 MR. BADALA: Objection to form.
- 17 Outside the scope.
- A. I would have hoped so because this
- 19 county is in the midst of a terrible crisis that
- 20 I think those actions contribute to.
- Q. "Those actions" meaning the criminal 21
- 22 conduct of doctors?
- 23 A. The overprescribing and the flooding
- 24 of our county with pain medication, yes.
- 25 Q. By doctors, right?

Page 47

- MR. BADALA: Objection to form.
- 2 A. By the prescribers, yes.
- 3 Q. And you believe those people should
- 4 be punished, I take it?
- 5 MR. BADALA: Objection to form.
- 6 Outside the scope.
- 7 A. Yes.
- 8 Q. And they should lose their licenses?
- MR. BADALA: Objection to form.
- 10 Outside the scope.
- O. Go ahead.
- 12 A. They broke the law. Yeah, I think
- 13 they should be punished for that, as anybody who
- 14 breaks the law should get some consequence.
- 15 Q. And if a doctor broke the law and
- 16 improperly prescribed, they should be punished
- 17 and perhaps lose their license and perhaps go to
- 18 jail, correct?
- 19 MR. BADALA: Objection to form.
- 20 Outside the scope.
- 21 A. I think that's a decision the county
- 22 would support.
- Q. And you believe that if they engaged
- 24 in illegal conduct such that they should lose
- 25 their license or go to jail, that somehow one of

Page 48

- 1 the Defendants is ultimately responsible for
- 2 that?
- 3 A. Yes.
- 4 Why is that?
- 5 A. These operations did not spring up
- 6 in a vacuum. The overprescribing of pain
- 7 medication in a pill mill was to address an
- 8 addicted population, and that addicted
- 9 population is the byproduct of overprescribing
- 10 and over-distribution of pain medication. So
- 11 the pill mill, while those activities are
- 12 illegal and I certainly would say contribute,
- 13 are ultimately referable back to an addicted
- 14 population that was created by the actions of
- 15 the Defendant. Q. The doctor wrote the prescription, 16
- 17 right, in a pill mill?
- 18 MR. BADALA: Objection to form.
- 19 Outside the scope.
- 20 A. The doctor in the pill mill had to
- 21 write the prescription, yes.
- 22 Q. And that's the illegal conduct,
- 23 right?
- 24 MR. BADALA: Objection to form.
- 25 Outside the scope.

- A. I think, you know, in speaking with
- 2 the prosecutor, they would say, you know, there
- 3 were, you know, some legitimate patients in the
- 4 pill mills and some illegitimate patients, and
- 5 certainly the ones who were receiving
- 6 diverted -- receiving prescriptions for
- 7 illegitimate purposes or under improper means,
- 8 those are the ones that are breaking the law.
- Q. So even in a pill mill, some of them
- 10 were legitimate, some of them were illegitimate?
- MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. That was my understanding based on
- 14 discussion with the county prosecutor's
- 15 representative, yes.
- 16 Q. And if a doctor was punished or
- 17 prosecuted, it was because he or she engaged in
- 18 knowingly willfully wrong conduct, right?
- MR. BADALA: Objection to form.
- 20 Outside the scope.
- 21 A. I would think so, yeah, sure.
- 22 Q. And are you aware of any statement,
- 23 misrepresentation and conduct that led any of
- 24 those doctors -- by the Defendants that led any
- 25 of those doctors to engage in illegal conduct?

1 MR. BADALA: Objection to form.

2 Outside the scope.

3

4

- Q. Any specifics?
- Statements by the Defendants?
- 5 Q. Right, that led to someone engaging 6 in illegal prescribing conduct.
- MR. BADALA: Objection to form. 7
- 8 Outside the scope.
- A. I think it's the misrepresentations
- 10 of the Defendants that create the addicted
- 11 population. They don't specifically recruit
- 12 people to run a pill mill, but as they create
- 13 the addicted population and that generates the
- 14 pill mill, I would say then those statements are 15 relevant.
- Q. Let's just talk about the doctors
- 17 who wrote those prescriptions. Do you have any 17 I read it. And I don't want to take up a lot of
- 18 information about any statements made to any of 18 your time. Some of this would be related to my
- 19 those doctors that caused them to engage in
- 20 illegal conduct?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope.
- 23 A. I don't believe the county does, no.
- 24 Q. And what could any of the Defendants
- 25 have done to prevent the Mexican drug cartel

1 MR. BADALA: Objection to form.

- 2 A. I think I've answered everybody I
- 3 can, sir.
- 4 Q. Let's look at topic 9, the factors
- 5 that the county as a non-expert believe affect
- 6 the prescribing practices for prescription
- 7 opioids in your community other than the conduct

Page 52

- 8 of Defendants.
- 9 Do you see that?
- 10 A. Yes.

- Q. Who did you talk to in order to be
- 12 able to testify about that?
- A. Mr. Shannon, in my office, and I
- 14 would have described that, and then based -- in
- 15 the medical examiner's office -- I'm sorry. I'm
- 16 just trying to get up to speed again with this.

- 19 discussion with Dr. Papp as well at the county 20 hospital.
- 21 Q. Okay. So let me just ask you, then,
- 22 an open-ended question that hopefully you can
- 23 help us with. What are the factors that you as
- 24 a non-expert, the county as a non-expert,
- 25 believe affected prescribing physicians for

- 1 from making and trafficking and sending illicit 2 fentanyl to the county? Are you aware of any
- 3 steps?
- 4 MR. BADALA: Objection to form.
- 5 Outside the scope.
- A. Could have avoided creating an
- 7 addicted population in the first place.
- Q. An addicted population, you've
- 9 mentioned that many times. I understand your
- 10 point on that. What I'm talking about is the
- 11 conduct of others, right, of doctors right now
- 12 and the cartel. Let's talk about that. Do you
- 13 have any information as to what any of the
- 14 Defendants could have done to prevent any of
- 15 those illegal conduct by Mexican drug cartels?
- MR. BADALA: Objection to form. 16
- 17 Asked and answered. Outside the scope.
- A. If the addicted population was not
- 19 created, there would not have been a market for 20 the Mexican drug cartel.
- 21 Q. Does the addicted population --
- 22 well, strike that.
- Other than what we've talked about,
- 24 can you identify any specific individual or
- 25 entity in connection with 34, topic 34?

- Page 53 1 prescription opioids in Cuyahoga County other
- 2 than the conduct of any Defendant?
- A. It is, again, the county's opinion
- 4 that ultimately those actions are all referable
- 5 back to the Defendants, and there's nothing --
- 6 there are intermediate steps, but ultimately
- 7 they're referable back to the Defendants.
- Q. And can you identify -- are you able 9 to parse out any conduct by any Defendant?
- 10 MR. BADALA: Objection to form.
- 11 Outside the scope.
- 12 A. Yes, I am. We are. The county, as 13 you know.
- 14 Q. So the answer essentially to 9 is
- 15 there are none?
- 16 MR. BADALA: Objection to form. 17 A. Other than the Defendant or actions
- 18 referable back to the Defendant.
- 19 Q. Well, that's not what it says. It
- 20 says -- let's not rewrite the interrogatory. It
- 21 says, "Other than the conduct of any Defendant."
- 22 Are there any factors, even one, that the county
- 23 believes affected prescribing practices for
- 24 prescription opioids other than the conduct of
- 25 any Defendant? Are there any, yes or no?

1 MR. BADALA: Objection to form.

- 2 Asked and answered.
- A. On behalf of the county, I'd have to 3
- 4 say again that there are intermediates, but
- 5 ultimately the answer to that would be no,
- 6 excepting those intermediates; that all of the
- 7 actions around the prescribing are referable
- 8 back to the Defendants.
- 9 O. So tell me all the intermediates.
- 10 MR. BADALA: Objection to form.
- 11 A. If we look at the heroin-addicted
- 12 population, again, 80 percent or so of these
- 13 individuals in Cuyahoga County, give or take --
- 14 I mean, you use national data coupled with local 14
- 15 data to say that that addicted population
- 16 started their addiction with opioid pain
- 17 relievers.
- 18 Now, if you would say does one of
- 19 the Defendants run a drug cartel in Mexico, I
- 20 think we would all agree the answer to that is
- 21 no. But at the time the opioid crisis evolved
- 22 from a more opioid pain reliever to a heroin
- 23 phase, again, with these folks having their
- 24 antecedent addiction to opioid pain relievers in
- 25 large measure, the availability of heroin at

- 1 that point was an inducement to the cartels to
- 2 start to sell that here, and because of less
- 3 availability of narcotics, potential
- 4 reformulations of the prescription pain
- 5 relievers, costs of the prescription pain
- 6 relievers, any other potential factors, heroin
- 7 started to become a crisis in our county, but
- 8 the actions of heroin, or the genesis of the
- 9 heroin addiction is referable back to the opioid
- 10 pain relievers.
- Q. I'm going to move to strike. I
- 12 asked you specifically, Doctor, what the
- 13 intermediates are. One is, in that answer I
- 14 think you just gave us, cartels; they're an
- 15 intermediary, right?
- 16 A. Sure.
- 17 O. Who else?
- A. The addicted population I guess are
- 19 intermediaries in that they are now engaged in
- 20 drug-seeking behavior.
- 21 Q. Who else?
- 22 A. In that model, I think that just
- 23 describes kind of the chain from the cartel.
- 24 You know, there's obviously distribution points
- 25 between cartel, dealer, and things like that.

1 Be specific as you could, please,

- 2 Doctor.
- 3 MR. BADALA: Objection to form.
- 4 A. Well, a cartel would basically
- 5 oversee an operation that potentially would have

Page 56

Page 57

- 6 local distribution points, regional distribution
- 7 points. A lot of our drugs, for example, could
- 8 have come through Columbus, Detroit, Chicago,
- 9 New York, there, and ultimately come down to
- 10 people distributing those drugs locally. I
- 11 guess they would be intermediate points. They
- 12 just kind of lump the cartel as the distribution
- 13 system there.

And then the sale of the heroin,

- 15 which, as I indicated, it's really not something
- 16 that is being manufactured or distributed by the
- 17 Defendants, but as we look at how this
- 18 population was initially created, that is
- 19 referable back to the actions of the Defendants.
- 20 Q. Now, I'm going to go back and we're
- 21 going to read number 9 again because I think
- 22 we've gotten a little off topic, but let me just
- 23 ask you a few questions here.

24 So the intermediaries are the people

25 in the cartel and illegal drug distribution

1 chains; is that fair?

- 2 MR. BADALA: Objection to form.
- 3 A. I think so, sure.
 - Q. And you can't tell me any of the
- 5 names of those people, right?
- A. Thankfully not, not. 6
- 7 What about doctors who engaged in Q.
- 8 illegal conduct; are they intermediaries in the
- 9 chain?

4

- 10 MR. BADALA: Objection to form.
- 11 A. The illegal conduct, as I just want
- 12 to be clear, is the pill mill type doctor?
- 13 Q. Yes.
- 14 A. Yes. I'd say they're part of the
- 15 intermediary, too.
- Q. What about healthcare policies that 16
- 17 encouraged doctors to write prescriptions for
- 18 opioids as opposed to other therapies?
 - MR. BADALA: Objection to form.

They could contribute in some way as

21 well.

19

- 22 Q. Could a lack of focus or funding or
- 23 attention by governments also contribute?
- 24 A. I'd have to say in a theoretical 25 sense, it's certainly possible.

- Q. Now let's get back to number 9. It
- 2 says, The factors that you, as an expert {sic},
- 3 believe affected prescribing practices, right?
- 4 Do you see that, prescribing practices for
- 5 prescription opioids in your community rather
- 6 than the conduct of the Defendant. Do you see 7 that?
- 8 A. Yes, I do.
- Q. I take it you would not tell me
- 10 that, in response to number 9, the drug cartels
- 11 would be one that you would list, would you?
- 12 A. No.
- 13 Q. So let's focus on number 9. What
- 14 are the factors in response to number 9?
- 15 MR. BADALA: Objection to form.
- 16 Asked and answered.
- 17 The factors that affected
- 18 prescribing practices were, in the early part of
- 19 the crisis, the advertisements that were
- 20 indicating that the opioid pain relievers were
- 21 either not addictive or had tremendously low
- 22 addiction potential with very little evidence.
- 23 The influence of regulatory policies with
- 24 lobbying efforts that were, again, referable
- 25 back to Defendants.

Page 59

1

- Q. Doctor, I'm sorry to interrupt you,
- 2 and I apologize, but it says other than the
- 3 conduct of the Defendants. Do you see that?
- 4 A. I do, you know, but --
- 5 O. So is there --
- MR. BADALA: Hold on. Let him 6
- 7 finish.

1

- 8 MR. CHEFFO: Well, I didn't ask a
- 9 question yet.
- 10 MR. BADALA: He was still talking
- 11 before moving on to the next one.
- 12 O. Go ahead.
- A. Thanks. I'm sorry if I'm not clear,
- 14 but it's the county's position that ultimately
- 15 all of the things that affect those prescribing
- 16 factors are referable back to the Defendants.
- 17 O. And if that's the case, Doctor, all
- 18 you have to tell me, then, is just I have none,
- 19 right. I don't need the whole long answer. I
- 20 want to just make sure, before I move to the
- 21 next topic, are there any -- let's make sure
- 22 we're clear on this. Are there any factors that
- 23 the county, as a non-expert, believe affected
- 24 prescribing practices for prescription opioids
- 25 in Cuyahoga County other than the conduct of any

- 1 of the Defendants?
 - MR. BADALA: Objection to form.

Page 60

- 3 Asked and answered.
- A. I guess it's hard because what I am
- 5 saying to you, and I hope I'm clear, and I'm
- 6 sorry if I'm not, it is the county's position
- 7 that everything is referable back to the
- 8 Defendants, but there are chains, there's
- 9 degrees of separation. But I would say, in
- 10 answer to your question, if you need a one-word
- 11 answer, the county says no, there are no other
- 12 folks who are ultimately responsible other than
- 13 the Defendants.
- 14 Q. And I'm not trying to limit you to a
- 15 one-word answer, but are there any factors --
- 16 this is different. Are there any factors
- 17 relatable to that affected prescribing practices
- 18 other than the conduct of Defendants?
- 19 MR. BADALA: Objection to form.
- 20 Asked and answered.
- 21 A. No.
- 22 Q. And do you know if the county
- 23 employed an economist to analyze the motivating
- 24 factors for illicit drug markets? Are you aware
- 25 of any work that was done in that regard?

Page 61

- MR. BADALA: Objection to form.
- 2 Also, I instruct you not to answer if you
- 3 learned this through counsel in any way.
- A. I'm not sure I understand the 4
- 5 question, actually.
- 6 MR. BADALA: Also, outside the
- 7 scope.
- 8 Q. Do you know when the first year the
- 9 Mexican drug cartel sent product into this
- 10 county?
- A. I don't think the county would know 11
- 12 that.
- 13 You don't know, though?
- 14 A. I don't know and I don't think the
- 15 county would. I don't think that's really
- 16 something we would be able to know given the
- 17 illegal and surreptitious nature of that kind of 18 distribution.
- 19 Q. So before we leave 9, there is no --
- 20 there are no factors that you can testify to
- 21 today, right? In fact, the county believes that
- 22 there are no other factors?
- 23 MR. BADALA: Objection. Asked and 24 answered.
- Ultimately, the county's position is 25

Page 62 Page 64 1 that the factors are all referable back to the 1 as a potential -- or not a potential; as a 2 Defendants. 2 source of the opioid epidemic. Q. That may be the county's position, Q. But with respect to taking a 4 but I want you to read 9 and tell me if there 4 position on all chronic therapies -- I'm sorry. 5 are no other factors, because it doesn't say 5 Strike that. 6 ultimately. It says, "Other than the conduct of In connection with taking a position 6 7 any Defendant." 7 about all prescriptions for opioid medicines for MR. BADALA: Objection. Asked and 8 chronic therapies, the county is not taking a 9 position on that? 9 answered. 10 A. I don't know how else to answer 10 MR. BADALA: Objection to form. 11 that. The county would say there were 11 A. No, it is not. 12 intermediate steps, but ultimately the conduct 12 Q. Let us -- you did some work in 13 of the Defendants is responsible for the 13 connection with certain interrogatory responses 14 prescribing practices. 14 in connection with preparing for today, did you 15 Q. Okay. Is the county's testimony and 15 not? 16 position that all prescriptions of opioids for 16 A. No, not that I'm aware of. I mean 17 chronic pain in Cuyahoga were written in 17 --18 reliance on misrepresentations and omissions and 18 Q. Did you look at any charts --19 wrongdoing of Defendants? A. The data was certainly available to 19 20 MR. BADALA: Objection to form. 20 everybody, but --21 21 Which topic are we looking at? Q. Did you look at any charts or 22 MR. CHEFFO: It's a general question 22 printouts of prescription drug data? 23 first. 23 A. I mean, I've reviewed the Ohio 24 MR. BADALA: Outside the scope. 24 Automated RX Recovery System in my capacity as 25 The county doesn't have an opinion 25 the medical examiner in association with the Page 63 Page 65 1 on the medical appropriateness of prescriptions 1 fatalities that were passing through our office. 2 written for opioid pain relievers in association 2 That wasn't in preparation for today 3 with all chronic pain patients. 3 specifically. 4 MR. CHEFFO: I'm sorry. Can you 4 Q. Well, the interrogatory responses to 5 read that back to me, please? 5 interrogatory 6, 7 and 10, did you look at (Record read.) 6 those? 7 Q. Does it have a position on the 7 A. No. They weren't on my scope of --8 appropriateness of opioid therapy in connection 8 or 6 was, I guess. 7 and 10 --9 with any chronic pain patients? Q. They're encompassed within the 10 MR. BADALA: Objection to form. 10 Special Master's order, but tell us what you did 11 Outside the scope. 11 for 6. 12 A. The county doesn't have an opinion 12 A. The county collected claims data 13 on appropriateness of therapy. That's, I think, 13 from third parties, such as Medical Mutual of 14 referred to experts. 14 Ohio, which was the healthcare carrier for the 15 Q. So the county has not taken a 15 county; Bureau of Workers' Compensation, which 16 position, as you know it, as to whether any 16 is the state workman's compensation board; and 17 prescription for any chronic pain patient is 17 CVS, which oversees -- CVS Pharmacy, which 18 appropriate or not? 18 oversees our prescription planning for the 19 MR. BADALA: Objection to form. 19 county, and turned that data over to its 20 Outside the scope. 20 attorneys, and the attorneys then worked with 21 A. As I understood your question, 21 experts to respond to the interrogatories. So

17 (Pages 62 - 65)

22 we furnished the claims data to attorneys, and

24 the interrogatories. I was not among the

25 experts who were consulted on that.

23 then it was reviewed with experts to respond to

22 you're asking about all prescriptions, which I

23 think the question would not offer an opinion.

24 The overprescribing in the setting of chronic

25 pain is certainly a factor the county recognizes

Page 68 1 Q. And did you see a spreadsheet that 1 A. No, I did not. 2 was produced that had 500 prescriptions on it? 2 Q. Did you review any documents? A. I'm aware that there were 500 -- I 3 3 A. No, I did not. 4 thought it was 500 patients who were identified Q. And how much time did you spend 5 who met the criteria that I mentioned 5 meeting with your lawyers in connection with 6 previously. Beyond that, that's as much as I'm 6 those topics? 7 familiar with that. 7 A. Oh. Well, we met over a couple of 8 8 days, and, I mean, topics were coming and going. 9 (Thereupon, Gilson Deposition 9 Our total meeting time I would say is probably 10 Exhibit 2, Plaintiff's The County of 10 about 10 to 12 hours. Some portion of that. I 11 Cuyahoga, Ohio and State of Ohio Ex 11 couldn't be more specific. We did not spend a 12 Rel, Prosecuting Attorney of 12 lot of time on these, as the responses to 13 Cuyahoga County, Michael C. 13 interrogatories were generated in consultation 14 O'Malley's Amended Responses to the 14 with the experts. So this was going to just 15 Manufacturer Defendants' and 15 have a reply that they were furnished and that 16 National Retail Pharmacy Defendants' 16 that was the county's response, what was in the 17 First Set of Interrogatories, with 17 interrogatories. 18 Attached Spreadsheets, was marked Q. I'm sorry. Is it your testimony you 19 for purposes of identification.) 19 don't have much to add other than what's in the 20 20 interrogatories? 21 Q. Okay. What was the criteria --21 MR. BADALA: Objection to form. 22 let's be more specific. We've marked this as 2. 22 A. That's correct. 23 This is Exhibit 2. 23 Q. Okay. Well, let's -- let's ask you MR. BADALA: Mark, we're on topic 6 24 to take a look at what we've marked as 25 but interrogatory 6? I'm just trying to keep 25 Exhibit -- it's Exhibit 2. Page 67 Page 69 1 track. 1 MR. GALLUCCI: Which one is 2? 2 2 MR. CHEFFO: No. It is a little MR. CHEFFO: It's the whole thing. 3 3 confusing. Q. Have you seen that before, Doctor? A. I have not seen this document 4 MS. ROITMAN: So we're going to be 4 5 on topic 4, 5 and 6. 5 before, no. At least I'm not --MR. BADALA: Just so it's clear. Q. So with respect to any of the names 7 Okay. 7 or prescriptions in these charts, do you have 8 Q. Are you prepared to talk about 8 any information about the criteria that was used 9 topics 4, 5 and 6, Doctor? 9 in responding to interrogatory 6? A. Just to generally state the county's 10 10 A. The claims were identified for 11 opioids that were not for cancer patients, were 11 position, yes. 12 Q. What did you do to prepare yourself 12 high dose, that is 120 medical morphine 13 for topics 4, 5 and 6? 13 equivalents or higher, which are far more A. I discussed them with counsel and 14 dangerous, and for patients with diagnosed 15 they responded to the interrogatories, which I 15 substance use disorder. 16 didn't do much preparation beyond the turning -Q. Is that for the interrogatory 6 17 the county turning over data to our attorneys 17 response or is that for more than that, or do 18 and then that being reviewed with experts to 18 you know? 19 respond to the interrogatories. 19 A. It was -- I think the criteria were 20 Q. I'm talking about your preparation, 20 spelled out in interrogatory -- or in topic 21 so one of the things you did was you met with 21 number 4, but as it related back to number 4, 22 it's the reply for number 6. 22 your lawyers, right? 23 A. Yes. Q. So those three criteria, not for 24 Q. Did you meet with anybody else in 24 cancer patients, above 20 milligrams --25 connection with those topics? 25 120.

1

1 120. Excuse me. Thank you for 2 that.

- 3 Morphine medical equivalents. A.
- So we'll just call it MME. 4
- 5 MME, yes.
- 6 Q. And then there is also a requirement
- 7 on the criteria that they are -- had been
- 8 diagnosed with an opioid abuse disorder?
- A. Diagnosed substance use disorder, 10 ves.
- 11 Q. Substance use disorder.
- 12 A. I think in some places that will
- 13 also be spelled out as substance abuse disorder.
- 14 The nomenclature is kind of in flux I think in
- 15 trying to avoid the stigmatization of addicts.
- Q. Do you know who created those
- 17 criteria?
- 18 A. I do not.
- 19 Q. So is it -- are there any other
- 20 criteria that were used?
- 21 A. That's the extent of my knowledge as
- 22 to the county of the criteria that were used to
- 23 identify the claims.
- Q. Do you know if anyone at the county
- 25 set those criteria?

Page 71

- MR. BADALA: Objection to form. 1
- 2 Outside the scope.
- 3 A. That, I do not know.
- 4 Q. And do you know what -- what
- 5 information or databases were queried in order
- 6 to generate the 500 list?
- 7 A. These criteria and then third-party
- 8 claims data was collected from Medical Mutual of
- 9 Ohio, Workman's Compensation and CVS, as they
- 10 had their relationship to the county. Beyond
- 11 that, I do not know what other entities were
- 12 queried for claims data.
- Q. Who actually did the work of
- 14 querying it? Was it the county or was it
- 15 somebody else?
- MR. BADALA: Objection to form. 16
- 17 Outside the scope.
- 18 A. I believe the county collected the
- 19 claims data, but the analysis beyond that, to
- 20 respond to the interrogatories, was with
- 21 attorneys with experts.
- 22 Q. Okay. And I think you told us you
- 23 never saw Exhibit 2 before, right?
- MR. BADALA: Objection to form.
- 25 Mischaracterizes testimony.

- Q. Did you see Exhibit 2 before?
- 2 A. I don't remember seeing this, no, I
- 3 myself. I mean, the county, I can't necessarily
- 4 say that they did not see it. Myself, I did not 5 see it.
- 6 Q. Okay. In the response to
- 7 interrogatory 6, the county identified Exhibit
- 8 A. Do you see this big document here?
- A. This one (indicating)? 9
- 10 O. Yes.
- A. Yes. 11
- 12 Q. Have you seen that exhibit before?
- 13 MR. BADALA: Objection to form.
- 14 A. Can you give me a second to not give 15 a quick off-the-cuff answer?
- 16 No, I have not seen that before.
- Q. And is it your understanding that in 17
- 18 order -- so let me strike that.
- 19 You just identified for us three
- 20 criteria, right, the one -- over 120 MME,
- 21 substance disorder, and not for cancer, right?
- 22 A. And a diagnosed substance use/abuse 23 disorder, yes.
- 24 Q. That was one of the three, right?
- 25 It was diagnosed --

Page 73

Page 72

- Oh, I'm sorry. You said that first
- 1 2 ---
- 3 Q. I may have said it backwards, but it
- 4 was not for a cancer patient, above 120 MME --
- A. Which would be considered dangerous, 5 6 and then identified substance abuse disorder.
- 7 Q. Okay. And what -- what were those
- 8 criteria used for?
- MR. BADALA: Objection to form.
- 10 Outside the scope.
- I think identification of claims
- 12 data, as I understand it.
- 13 Q. Identification of certain claims.
- 14 Did you understand it that those were the
- 15 criteria that were used to generate Exhibit A?
- A. You know, I don't know Exhibit A, so
- 17 I'm reluctant to give an answer on that. These
- 18 were the criteria that were identified to
- 19 identify the claims -- they were spelled out to
- 20 identify the claims. Being unfamiliar with this
- 21 document, if these are the claims that were
- 22 passed by the county, then these were the
- 23 criteria that were used for that. Not knowing
- 24 the document, I'm reluctant to go further than
- 25 that.

11

13

- 1 Q. What I'm just trying to understand, 2 you gave us those three criteria. What did you 3 understand those criteria were going to be used 4 for?
- A. As I understood it, there was a 6 population of 500 patients who were identified 7 to be a representative of harms that the county 8 had claimed, and then the claims data for those 9 individuals were identified using those three
- Q. So you thought that there were an 11 12 effort to identify 500 individuals and there

10 criteria.

- 13 were these criteria and those criteria generated 14 the 500 individuals?
- A. That's my understanding of that, 15 16 yes.
- 17 Q. Were you aware of any prescriptions 18 that were also identified?
- MR. BADALA: Objection to form.
- 20 Outside the scope. A. My understanding of this topic is 21
- 22 that the 500 number identified patients, not
- 23 prescriptions. I mean, prescriptions obviously
- 24 were attached to the patients, but they were
- 25 patients who were identified, not specific

1

Page 75

1 prescriptions.

- Q. And you've never seen any 3 information or list of the actual 500 patients 4 or prescriptions, have you?
- A. No, I have not.
- 6 Q. Do you understand that a list was 7 prepared?
- 8 A. Yes, I do understand that.
- Q. And is it your understanding that
- 10 every one of the patients or prescriptions on
- 11 the list meets these three criteria?
- 12 MR. BADALA: Objection to form.
- 13 Outside the scope.
- A. I mean, that's my understanding of
- 15 the criteria that were agreed to to select the 16 patients who were the 500 patients.
- 17 Q. So in order to identify the patients
- 18 or prescriptions, they had to meet all of these
- 19 three criteria; is that right?
- 20 That's my understanding, yes.
- 21 Q. Did they have to meet any other
- 22 criteria?
- 23 MR. BADALA: Objection to form.
- 24 Asked and answered.
- 25 A. Not that I'm aware of, no.

1 Q. And how was it determined that the 2 patient received opioid therapy for non-cancer 3 use?

Page 76

Page 77

4 MR. BADALA: Objection to form.

5 Outside the scope.

A. As I say, I can't give you personal 7 knowledge on that. I would think from a review 8 of medical records.

9 Q. Do you know?

MR. BADALA: Same objection. 10

- A. I don't know for certain.
- 12 Q. Do you know at all?
 - MR. BADALA: Same objections.
- 14 A. No. They were identified as not 15 being cancer patients. The criteria, how that
- 16 was arrived at, I do not know.
- 17 Q. Not how it was arrived at, but how
- 18 it was determined. Do you know how they
- 19 determined whether -- if a person or
- 20 prescription was on the list, how it was for a 21 non-cancer patient or diagnosis? Do you have
- 22 any information at all?
- 23 MR. BADALA: Objection to form.
- 24 A. No, I do not have separate
- 25 information on that.

Q. Did you talk to anybody about that?

2 A. No. I did not.

Q. Did you -- do you have any

4 information how it was determined that a

5 prescription was above 120 MME?

MR. BADALA: Objection to form.

7 Outside the scope.

- A. Other than a review of pharmacy or
- 9 medical record data, I'm giving you my best
- 10 opinion as an individual, but how the county
- 11 came to that, I do not have specific information
- 12 for it.
- Q. And I appreciate that. I don't want 13
- 14 you to guess or speculate. I think your lawyers
- 15 would agree with me. Do you have any personal
- 16 knowledge, through either your own knowledge or
- 17 from any work that you've done to prepare for
- 18 the deposition, as to how it was determined that
- 19 a prescription or patient received above 120
- 20 MME?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope.
- 23 A. Other than what I've said, you know,
- 24 a review of medical records would seem to
- 25 furnish that. I don't know.

Page 80 1 Q. Did you talk to anyone who reviewed 1 MR. BADALA: Objection to form. 2 medical records? 2 Outside the scope. 3 A. No, I did not. 3 A. No, I'm not. Q. Do you know that they reviewed 4 Q. And are you aware of any criteria 4 5 medical records? 5 that was used to identify over 120 MME? MR. BADALA: Objection to form. MR. BADALA: Objection to form. 6 7 A. No. I was just giving you my 7 Outside the scope. 8 A. I didn't understand your question. 8 best --9 Q. Guess? 9 Q. You told us one of the criteria was A. I think informed guess. There's 10 over 120 MME, I take it, per daily use; is that 10 11 only so many ways you can get this kind of 11 right? 12 information, so --12 A. Medical morphine equivalents for 13 Q. But you don't know how they did it? 13 daily use. 14 But I do not know the methodology 14 Q. For daily use. Can you be more specific about how 15 exactly. 15 Q. And you don't know what the QC 16 that was defined and how it was identified? 16 17 process was, if any, do you? MR. BADALA: Objection to form. 17 MR. BADALA: Objection to form. 18 Outside the scope. 19 Outside the scope. A. I'm aware of standard definitions 20 A. No, I do not. 20 for -- that they exist for medical morphine Q. And did -- was there -- and the 21 equivalents. What was used here, I cannot 21 22 third criteria that you said was the substance 22 honestly say I know for certain. 23 abuse disorder? 23 Q. In fact, you don't know at all, do 24 A. Yes. 24 you --25 25 Do you know how they determined if MR. BADALA: Objection to form. Page 81 Page 79 1 somebody had a substance abuse disorder? A. Don't know at all. 1 MR. BADALA: Objection to form. 2 2 Q. -- how any of these criteria were 3 Outside the scope. 3 used or developed or applied, because you didn't A. I'm aware that criteria are spelled 4 ask anybody, did you? 5 out for that diagnosis. How they came to 5 MR. BADALA: Objection to form. 6 that -- any application of this criteria, I do 6 Outside the scope. 7 not know. A. No. I was told these had been Q. Do you know what criteria they used? 8 answered in interrogatories. 9 Was it the DSM-5 criteria? Q. Did you understand that one of the 10 MR. BADALA: Objection to form. 10 topics you were going to be -- or several of the 11 Outside the scope. 11 topics was the criteria that were going to be 12 A. You're grazing into a lot of 12 used, that were used, in connection with 13 medicine I don't remember, but I don't know what 13 responding to the interrogatories? A. I was aware of the topics and these 14 criteria were used. 15 Q. I thought you told me that you did 15 are the answers that I have to give on behalf of 16 know what the criteria for substance abuse 16 the county. 17 disorder was. 17 MR. BADALA: So we're going over 18 A. I don't believe I said that. I said 18 about an hour now. Is it a good time to take a 19 there are criteria. I'm aware of the diagnosis, 19 break? 20 20 but I don't know them personally. MR. CHEFFO: Yes. Sure. 21 Q. There's a diagnosis of substance 21 THE VIDEOGRAPHER: Off the record at 22 abuse disorder? 22 10:16 a.m. 23 A. I believe so, yeah. 23 (Recess had.) 24 Q. And are you familiar what those 24 THE VIDEOGRAPHER: Back on the 25 criteria are? 25 record at 10:38 a.m.

1	Page 82	1	Page 84 Exhibit 2 Plaintiffs The City of
1	A. May I make a correction on the	1	Exhibit 3, Plaintiffs The City of
	record before we start?	2	Cleveland, County of Cuyahoga,
3	I said I had destroyed notes of	3	County of Summit and City of Akron's
	conversations with three individuals. I was	4	Supplemental Amended Responses and
	able to locate notes that I did keep and I'll	5	Objections to the Manufacturer
1	provide them to counsel.	6	Defendants' First Set of
7	MR. BADALA: We'll review them and	7	Interrogatories, Submitted Pursuant
	make sure that they don't have any	8	to Discovery Ruling No. 13, was
9	communications.	9	marked for purposes of
10	Q. Where are they?	10	identification.)
11	A. They were in a case file I have on	11	
	this.	12	Q. Let me show you Exhibit 3. Have you
13	Q. In your office?	13	,
14	A. I brought them here with me today.	14	A. No, I have not.
15	Q. So they're not in the landfill?	15	Q. Would you look at page 5, please? I
16	A. Pardon me?	16	1
17	Q. They're not in the landfill?	17	or sound familiar to you, Doctor, but let me
18	A. One might be. I can say that they	18	kind of ask you the question. The second full
1	mentioned the three individuals, Dr. Papp and	19	paragraph, do you see where it says, "Subject to
1	Vince Caraffi. I found those notes. The other		and without waiving"?
21	one, with Tamara Chapman from DCFS, I had on a	21	A. Oh, I'm sorry. I'm on 6.
22	phone list of phone numbers, was just taking	22	Q. I'm on 5.
23	messages, and I'm quite certain I threw that one	23	A. Yes.
24	away. So that might be in the landfill.	24	Q. "Subject to and without waiving the
25	I can tell you the points on that	25	foregoing objections and limitations, Bellwether
	Page 83		Page 85
1	Page 83 were that, when I spoke with her, the number of	1	Page 85 Plaintiffs contend that all prescriptions of
1	were that, when I spoke with her, the number of		Plaintiffs contend that all prescriptions of
2	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over	2	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether
2 3	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of	2 3	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the
2 3 4	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the	2 3 4	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing
2 3 4 5	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her	2 3 4	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints."
2 3 4 5 6	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid	2 3 4 5	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that?
2 3 4 5 6 7	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis.	2 3 4 5 6 7	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do.
2 3 4 5 6 7 8	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to	2 3 4 5 6 7 8	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that
2 3 4 5 6 7 8	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that.	2 3 4 5 6 7 8	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right?
2 3 4 5 6 7 8 9 10	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to	2 3 4 5 6 7 8 9	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form.
2 3 4 5 6 7 8 9 10	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that	2 3 4 5 6 7 8 9 10 11	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for
2 3 4 5 6 7 8 9 10 11 12	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I	2 3 4 5 6 7 8 9 10 11 12	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations,
2 3 4 5 6 7 8 9 10 11 12 13	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them	2 3 4 5 6 7 8 9 10 11 12 13	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for
2 3 4 5 6 7 8 9 10 11 12 13 14	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're	2 3 4 5 6 7 8 9 10 11 12 13 14	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most efficient way to deal with it.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong? A. I would say it's right.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most efficient way to deal with it. Q. So, Doctor, any other clarifications	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong? A. I would say it's right. Q. So it is Cuyahoga County's position
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most efficient way to deal with it. Q. So, Doctor, any other clarifications before we start?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong? A. I would say it's right. Q. So it is Cuyahoga County's position that all prescriptions of opioids for chronic
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most efficient way to deal with it. Q. So, Doctor, any other clarifications before we start? A. No. That's the only one. Sorry	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong? A. I would say it's right. Q. So it is Cuyahoga County's position that all prescriptions of opioids for chronic pain in Cuyahoga were written in reliance on the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most efficient way to deal with it. Q. So, Doctor, any other clarifications before we start?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong? A. I would say it's right. Q. So it is Cuyahoga County's position that all prescriptions of opioids for chronic pain in Cuyahoga were written in reliance on the misrepresentations, omissions, and wrongdoing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	were that, when I spoke with her, the number of custody cases that DCFS had seen had risen over the time of the opiate crisis, the number of toxicology positive infants had risen over the time of the opioid crisis, and that it was her impression that that was related to the opioid crisis. MR. CHEFFO: I'm going to move to strike that. MR. BADALA: We'd object to that motion to strike. MR. CHEFFO: And at the break I would call for those notes, since you have them here, produced to us, because otherwise, we're going to reserve our rights to continue this 30(b)(6) when I get the notes. So you can take it under advisement. I don't want to quibble with you, but I think that would be the most efficient way to deal with it. Q. So, Doctor, any other clarifications before we start? A. No. That's the only one. Sorry	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Plaintiffs contend that all prescriptions of opioids for chronic pain in the Bellwether jurisdictions were in reliance on the misrepresentation, omissions, and wrongdoing alleged in their complaints." Do you see that? A. Yes, I do. Q. And you testified earlier that that's not the county's position; is that right? MR. BADALA: Objection to form. A. I think the prescriptions for chronic pain were based on misrepresentations, but whether they actually were written for people with legitimate chronic pain is a separate issue, and whether they were efficacious short term for that is a separate issue. Q. Is this right or wrong? A. I would say it's right. Q. So it is Cuyahoga County's position that all prescriptions of opioids for chronic pain in Cuyahoga were written in reliance on the

888-391-3376

1

A. Yes.

2 Q. Every single one?

3 MR. BADALA: Objection to form.

4 Asked and answered.

5 A. Yes.

1

6

Q. Going back to when?

MR. BADALA: Objection to form. 7

8 Outside the scope.

A. I was told the -- for any time frame 10 that we were going back to was 1995 for the 11 litigation.

12 Q. How was chronic pain defined?

13 MR. BADALA: Objection to form.

14 Outside the scope.

A. I think in the usual way. I don't 15

16 know that I have a specific definition for it on

17 behalf of the county.

Q. How was it defined here in the

19 responses?

20 MR. BADALA: Objection to form.

A. I don't have a specific answer on 21

22 behalf of the county of the definition of that.

Q. Well, you've told me the statement

24 was true, so how do you know if it's true or not

25 if you can't define chronic pain?

Page 86 Page 88

> A. I'm sorry. Your question again? 2 Q. What steps were taken to verify that

3 every prescription written since 1995 for an

4 opioid medicine for chronic pain was done so in

5 reliance on misrepresentations, omissions, and

6 wrongdoing by the Defendants?

MR. BADALA: Objection to form. 7

8 Outside the scope.

A. The county collected the claims data 10 from the third parties and then it was turned 11 over to attorneys and experts for review.

Q. Was one of the criteria whether a 12

13 doctor was visited by a sales rep?

MR. BADALA: Objection to form.

15 Asked and answered.

A. The criteria that were applied to

17 identify the claims were that they were not for

18 cancer patients, were high dose, higher than 120

19 medical morphine equivalents, or for patients

20 diagnosed with substance abuse -- and for

21 patients diagnosed with substance abuse

22 disorder. I don't see any reference in the

23 criteria specifically to visits from

24 pharmaceutical representatives.

25 Q. Are there any criteria related to

Page 87

MR. BADALA: Objection to form. 1

2 Outside the scope.

A. The opioids were prescribed for

4 chronic pain. That's the way I read that as a

5 whole block there.

Q. And do you know what definition --7 what's your definition for chronic pain?

8 MR. BADALA: Objection to form.

9 Outside the scope.

10 A. I don't believe the county has a

11 specific definition for chronic pain. It would

12 have been referred to experts. 13 Q. Do you have one?

14 MR. BADALA: Objection to form.

15 Outside the scope.

A. Me personally? Nothing more than I

17 would say my layman's definition. I don't have

18 a specific medical definition of chronic pain.

Q. What steps were taken to verify that 20 every single prescription written in Cuyahoga

21 for chronic pain for opioids since 1995 was done 21

22 so in reliance on misrepresentations, omissions

23 and wrongdoing by the Defendants?

MR. BADALA: Objection to form.

25 Outside the scope.

Page 89 1 any conduct on behalf of any of the Defendants?

2 MR. BADALA: Objection to form.

3 Outside the scope.

A. The criteria that I enumerated here

5 are the ones that were used to identify the 6 claims.

7 Q. Do any of them relate to any conduct 8 by any Defendant?

MR. BADALA: Objection to form.

10 Outside the scope. A. Do the claims have?

11

12 O. Do the criteria?

13 MR. BADALA: Objection to form.

14 A. I'm not understanding your question. 15 I'm sorry.

16 Q. Do these relate to any criteria --

17 do any of the criteria relate to any conduct or

18 acts or omissions of any of the Defendants? MR. BADALA: Objection to form.

19 20 Outside the scope.

A. I think the criteria are clear

22 enough, and then -- I'm sorry. Your question is

23 just confusing me.

24 Q. So one of the criteria is not for

25 cancer pain, right?

A. Yes.

- Q. But you've just told me that if
- 3 there was an opioid prescription for chronic
- 4 pain for cancer patients, that was in reliance
- 5 on misrepresentations, omissions and wrongdoing
- 6 of Defendants, right?
- 7 A. Yes.
- 8 Q. So which criteria applies? Does
- 9 it --

1

- 10 A. Cancer pain is viewed separately
- 11 from chronic pain. That's terminal care,
- 12 hospice care type of pain.
- 13 Q. I'm talking about the statement on
- 14 paragraph 5, page 5, paragraph 2, that you just
- 15 told me was accurate. It doesn't carve out
- 16 cancer pain, does it?
- 17 A. No. It says, "chronic pain."
- 18 Q. So is it accurate not carving out
- 19 cancer pain?
- 20 MR. BADALA: Objection to form.
- A. Cancer pain is considered different
- 22 than chronic pain.
- 23 Q. It's your testimony that you can't
- 24 have -- a cancer patient can't have chronic
- 25 pain?

1

Page 91

- MR. BADALA: Objection to form.
- 2 Outside the scope.
- A. No. I think that, you know, they're
- 4 as eligible for chronic pain as anyone else, but
- 5 the cancer pain that they would receive opioid
- 6 pain relievers for was terminal pain and not
- 7 chronic in the conventional sense of the
- 8 understanding of that word.
- 9 Q. So you don't think pain for cancer
- 10 patients is included in the statement on page 5?
- 11 MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. That's my understanding, yes.
- 14 Q. So let's see if we can make sure
- 15 that we're on the same page. So with respect to
- 16 Exhibit 2, that was in response to
- 17 interrogatories 7 and 10; is that your
- 18 understanding?
- 19 A. This exhibit (indicating)?
- 20 O. Yes.
- A. I thought was in response to
- 22 interrogatories -- or, I'm sorry. Maybe I'm
- 23 confusing topics with interrogatories. I
- 24 thought these were generated in response to
- 25 topics 4, 5, 6 and 19.

1 Q. So that response to 4, 5 and 6 and

- 2 19, Exhibit 2, right?
- 3 A. Topics 4, 5, 6 and 19. That's my
- 4 understanding, yes.
- 5 Q. The interrogatory 6 asks Plaintiffs
- 6 to, among other things, identify and describe
- 7 500 prescriptions of opioids that were written
- 8 in Plaintiff's jurisdiction, here Cuyahoga, in
- 9 reliance on any alleged misrepresentations,
- 10 omission or other wrongdoing; is that right?
- 1 MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. I'm sorry. I don't know where
- 14 you're at.
- 15 Q. It's in Exhibit 3 on page 1. Do you
- 16 see on page 1, Identify and describe 500
- 17 prescriptions of opioids that were written in
- 18 reliance on any alleged misrepresentations or
- 19 other wrongdoing by any Defendant? Do you see
- 20 that?
- 21 A. Yes, I do.
- MR. BADALA: Just for the record,
- 23 there's more beyond that in the interrogatory.
- MR. CHEFFO: Right, and there is.
- 25 Q. And it also basically -- in addition
- Page 93

Page 92

- 1 to other things, Plaintiffs were asked to
 - 2 provide various details, including the physician
 - 3 who wrote the prescription, the specific
 - 4 misrepresentation, the specific person
 - 5 associated with Defendants who made the alleged
 - 6 misrepresentation. Do you see that?
 - 7 A. Yes, I do. That's further down on
 - 8 the page.
 - 9 Q. And in order to respond, the
 - 10 Plaintiffs referred back and the county referred
 - 11 back to Exhibit A, which is that large printout
 - 12 that I just showed you.
 - 13 A. This one here (indicating).
 - 14 Q. Right.
 - 15 A. Okay.
 - Q. And you've never seen that before
 - 17 today?
 - 18 MR. BADALA: Objection to form.
 - 19 A. No, I have not.
 - Q. And if you look at page 14 of
 - 21 Exhibit 3 -- if you look at the last paragraph
 - 22 on page 14 of Exhibit 3, in the first sentence,
 - 23 kind of midway through, it says, "Bellwether
 - 24 Plaintiffs contend that each prescription in the 25 previously-provided Exhibit A was the result of

24 (Pages 90 - 93)

1 Manufacturer Defendants' deceptive marketing."

- 2 A. I'm sorry.
- 3 Q. It's right down here, Doctor
- 4 (indicating).
- 5 A. Okay, right down at the bottom.
- 6 Okay.
- 7 Q. You've told us about three criteria?
- 8 A. Yes.
- Q. Are those the only three criteria
- 10 that you're aware of for topics 4, 5, 7 and 19
- 11 or for topics -- interrogatories 6, 7 and 10?
- MR. BADALA: I think you have them 12 13 mixed up again, Mark.
- Q. Well, irrespective of the topics or 15 the interrogatories.
- A. 4, 5, 6, 19, my understanding is
- 17 that the county collected the claims data based
- 18 on these criteria, turned them over to our
- 19 attorneys, and they were consulted with experts
- 20 and those were used to answer the
- 21 interrogatories. The county didn't have any
- 22 further involvement with the interpretation of
- 23 that.
- 24 Q. And with respect to any of the
- 25 topics that are the subject of Exhibit A, are

21

4

16

1 A. Double negatives.

> 2 MR. BADALA: Objection to form.

Q. Chronic pain was not a criteria, was

Page 96

4 it?

3

6

5 A. For selection, no.

Q. In connection with identifying any

7 of the individuals or prescriptions on Exhibit

8 A, did Cuyahoga County or anyone at its behest

9 talk to any doctors?

MR. BADALA: Objection to form. 10

11 Outside the scope.

A. The county submitted the claims data 12

13 to our attorneys and they consulted with

14 experts. I don't know the specific experts.

15 And that was the basis of the answers to the 16 interrogatories.

Q. Do you know if anyone spoke to 17 18 individual doctors or patients on Exhibit A?

MR. BADALA: Objection to form.

20 Outside the scope. Asked and answered.

A. The only expert I was aware of was

22 Rawlings, but other than that, I don't know what 23 experts were consulted.

24 Q. Doctor, my question is not that. I 25 didn't ask that question. I asked you if you're

Page 95

1 those the only three criteria, is just what I'm

- 2 trying to find out, or were there other
- 3 criteria?
- 4 MR. BADALA: Objection to form.
- 5 Asked and answered.
- A. That's my understanding, is those
- 7 are the three criteria. I am not aware of any
- 8 others that were used.
- Q. Was a requirement that a
- 10 prescription be written by a doctor who engaged 10 form the answers to the interrogatories.
- 11 in unlawful conduct or was prosecuted -- was
- 12 that one of the criteria that you were aware of?
- 13 MR. BADALA: Objection to form.
- 14 Asked and answered.
- 15 A. That criteria is not spelled out in
- 16 what I have.
- 17 Q. And it was not a criteria that a
- 18 prescription be written for something other than
- 19 chronic pain, correct?
- 20 MR. BADALA: Objection to form.
- A. It was a criteria that they were not 21
- 22 cancer patients.
- Q. So the answer to my question is yes,
- 24 the criteria was not to find prescriptions that
- 25 were not written for chronic pain?

1 aware of whether anyone, including experts or

- 2 others, spoke with any of the doctors or
- 3 patients on Exhibit A.
 - A. Oh, I'm sorry. Now I understand.
- MR. BADALA: Same objection. 5
- 6 Objection to form. Outside the scope. Asked 7 and answered.
- A. Once we turned the data over, I'm
- 9 not aware of what the experts did beyond that to
- Q. Are you aware of any -- if anyone,
- 12 experts or others, spoke to any doctors or
- 13 patients listed on Exhibit A?
- 14 MR. BADALA: Objection to form.
- 15 Outside the scope.
 - A. I am not aware of that.
- 17 Q. Are you aware of whether anyone
- 18 reviewed, as part of the criteria, any call 19 notes for sales reps in connection with the
- 20 individuals or prescriptions on Exhibit A?
- MR. BADALA: Objection to form. 21
- 22 Outside the scope.
- 23 A. The county wouldn't be aware of
- 24 that. After things were turned over to the
- 25 attorneys, they consulted with experts, and that

1 wasn't part of the county's process anymore. 2 O. So is the answer no? 3 MR. BADALA: Objection to form.

4 A. I'm not aware.

5 Q. Did you ask anyone that question? 6 MR. BADALA: Objection to form.

7 Outside the scope.

8 9 A. I don't know.

Q. You don't know if you asked?

10 A. Me personally or the county?

Q. I'm asking you, you the county, you 11

12 as the representative. In connection with your

13 work and your preparation, did you ask anyone if 13 the scope? You can say it every single time.

14 anyone had spoken to a doctor or a patient in

15 connection with the preparation of Exhibit A?

MR. BADALA: Objection to form.

17 Outside the scope. Asked and answered.

A. Again, when we finished collecting

19 claims data, it was referred over to attorneys,

20 who consulted with experts to formulate

21 responses. The process that was involved to

22 generate those responses the county does not

23 know.

24 Q. So in terms of the three criteria

25 that you talked about, do you know who came up 25 criteria.

1 Outside the scope.

2 A. How they identified that this was

Page 100

Page 101

3 not a cancer patient?

4 Q. Yes.

A. That, I do not know the criteria 5

6 that they used.

7 Q. And you don't know how they applied

8 the criteria of above 120 MME, do you?

MR. BADALA: Objection to form.

10 Outside the scope.

MR. CHEFFO: I'm not going to argue

12 with you. How could that possibly be outside

14 It doesn't make it true.

MR. BADALA: Are you asking for my 15

16 view or --

17 MR. CHEFFO: No. I'm just saying I

18 think it's becoming abusive. This is specific

19 within it. You can do it, but we'll take it up

20 with the Special Master.

21 MR. BADALA: It's just that he

22 rewrote it that it's what's the criteria, not

23 how it was applied but what is the criteria.

24 That's what it says. He's giving you the

Page 99

1 with those criteria? Was it the county or 2 somebody else?

MR. BADALA: Objection to form. 3

4 Outside the scope.

5 A. I do not know.

Q. Do you know how any of those

7 criteria were applied in practice?

8 MR. BADALA: Objection to form.

9 Outside the scope.

10 A. In the selection of claims?

11 O. Yes.

12 They were the basis for identifying

13 the claims for opiates that would be referred to

14 our attorneys.

15 Q. But do you know how they were

16 actually applied? I think we talked about this 17 a little bit earlier.

18 MR. BADALA: Objection to form.

19 Outside the scope.

20

A. They were applied -- I'm sorry.

21 Q. Let's do it again, Doctor.

You don't know how any claims 22

23 information was determined whether it was for a 23 prescribe in Cuyahoga County today over 120 MME?

24 non-cancer patient or not, do you?

25 MR. BADALA: Objection to form. 1 MR. CHEFFO: And if that's your

2 position, that that's what you think that a

3 deposition in good faith is supposed to be

4 about, I welcome that.

5 MR. BADALA: That's how Special

6 Master Cohen --

7 MR. CHEFFO: We'll take that up with

8 him very clearly, if you think that's what --

MR. BADALA: It's Exhibit B in your

10 notice. It's right there.

MR. CHEFFO: That's good. I can 11

12 read it, too.

Q. So do you know how the criteria for

14 above 120 MME was applied?

15 MR. BADALA: Objection to form.

16 Outside the scope.

17 A. 120 MME has a specific definition.

18 I would think that was what was applied. How

19 the criteria was created I do not know other

20 than that would be a dangerous level of

21 prescription opioids on a daily basis.

22 Q. Do doctors -- are they able to

MR. BADALA: Objection to form.

25 Outside the scope.

26 (Pages 98 - 101)

Page 102 Page 104 1 A. I don't honestly know the county 1 prescribe -- or you needed to use the Board of 2 would know that. 2 Pharmacy database beyond seven days. I don't 3 know if they put an MME on that. And then you 3 Q. Do you prescribe --4 were expected to check the Board of Pharmacy A. I'm not a prescriber. 4 5 MR. BADALA: Were you done with your 5 database, the Prescription Drug Monitoring 6 answer? 6 Program, every 90 days thereafter if you were 7 7 continuing to prescribe opioids. THE WITNESS: Yeah. 8 So I think they're not, as I 8 Q. So you're not a prescriber, are you? 9 9 understand it, saying it's absolutely forbidden, A. No. 10 but it is a practice that needs to be more 10 Q. You said a few times it's dangerous. 11 closely monitored. 11 Have you ever prescribed opioids? Q. Do you hold yourself out as an A. Yes, I have. 12 12 13 Q. When? 13 expert in opioids? MR. BADALA: Objection to form. 14 A. Back in my training as a surgical 15 resident. 15 Outside the scope. Q. Was that decades ago? A. In some aspects of it, sure. 16 16 A. Early 1990s. 17 Q. Which aspects? 17 MR. BADALA: Objection to form. Q. Can doctors in Cuyahoga County today 18 18 19 Outside the scope. 19 lawfully --20 A. Late 1980s. I'm sorry. 20 A. The opioid crisis. 21 Q. Are you an expert in opioid efficacy 21 Q. Can doctors lawfully prescribe 22 opioid medicines above 120 MME? 22 in prescribing? MR. BADALA: Objection to form. 23 MR. BADALA: Objection to form. 24 Outside the scope. 24 Outside the scope. 25 25 A. I believe the state has set out A. Again, as the county, I wouldn't Page 103 Page 105 1 criteria with which I am not familiar regarding 1 answer myself an expert in that. 2 prescribing of opiates. As I understand them, 2 Q. When is the last time you read a 3 as the county, those would be specifically with 3 label for an opioid product? MR. BADALA: Objection to form. 4 regard to duration, and I don't know that there 4 5 was a specific MME cap placed on them. I just 5 Outside the scope. 6 don't know. A. Me personally --6 7 Q. Yes. 7 Q. Is the answer to my question yes or 8 no? Can a doctor prescribe 120 MME or more 8 A. -- or the county? 9 9 today in Cuyahoga County lawfully? Q. No. You. 10 MR. BADALA: Objection to form. 10 A. Label for an opioid product, I don't 11 Outside the scope. 11 remember. 12 A. It's regulated by the state, so I 12 O. Was it in the last decade? 13 can't tell you that I remember the criteria, so 13 MR. BADALA: Objection to form. 14 my answer, not yes or no, is I don't know. 14 Outside the scope. 15 Q. Well, you would assume if it was 15 A. I don't remember. Might have been. 16 dangerous, then the county wouldn't allow it; 16 Q. And with respect to substance abuse 17 isn't that right? 17 disorder, do you know how that criteria was 18 MR. BADALA: Objection to form. 18 applied? 19 Outside the scope. 19 MR. BADALA: Objection to form. 20 Outside the scope. A. I think the criteria that we're 21 placed out by the Board of Pharmacy, Board of 21 A. No. Beyond the county submission of 22 Medicine and the governor were to caution about 22 the claims data, I don't know how that criteria 23 was applied. 23 the use of excessive opioids. I don't think

27 (Pages 102 - 105)

Q. Do you know if any determination was

25 made as to whether any of the individuals or

24

24 that they spelled out necessarily that it was

25 impossible to do this. They said you could not

Page 106 Page 108 1 prescriptions on Exhibit A received a medically 1 30 seconds ago? 2 unnecessary opioid prescription? MR. BADALA: Objection to form. A. The county doesn't have a position 3 3 Mischaracterizes the testimony. 4 on whether these were medically unnecessary. A. As I understood your question, you 5 Q. What about medically inappropriate? 5 were asking me separate parts of these, and the MR. BADALA: Objection to form. 6 conjunction here is "or," which means one or all 6 A. The county used these criteria to 7 of these. So the county doesn't necessarily 7 8 identify the claims that were submitted and 8 have an opinion that a specific prescription was 9 doesn't express opinions on medically 9 medically unnecessary. It may have been 10 harmful. It may have been unauthorized. 10 inappropriate or medically -- the interpretation 11 of a medical opinion. Q. But does it have a position that any Q. Can you look at Exhibit 2, please, 12 of them were -- let's start with unauthorized? 12 13 Doctor, page 5? There's not page numbers on 13 And if so, show me which ones. 14 this one. 14 MR. BADALA: Objection to form. A. I can count them. Would this be 1 15 15 Outside the scope. 16 or is this 1 here (indicating)? A. It is the position that 17 prescriptions identified in Exhibit A were 17 Q. I don't know. It's --A. That's very helpful. Okay. Just so 18 unauthorized. 19 we're literally on the same page, this page 19 Q. Which ones? 20 (indicating)? 20 A. Again, the county collected the data 21 Q. Exactly. Exactly. 21 and referred it to experts for further 22 A. Sure. 22 interpretation of it. Q. And I'm going to just direct your Q. What's the basis for that statement 24 attention to the answer section, second sentence 24 that they were unauthorized? 25 there. I'll read it to save your voice, but it MR. BADALA: Objection to form. 25 Page 109 1 says, "Bellwether Plaintiffs contend that each 1 Outside the scope. 2 prescription identified in Exhibit A" -- that's A. That they were either, you know, 3 that big chart in front of you -- was 3 prescribed to someone with a pain disorder or 4 unauthorized, medically unnecessary, ineffective 4 higher. I don't know the criteria that were 5 or harmful." 5 applied to make that decision. Do you see that? 6 Q. That wasn't one of the criteria, 6 7 A. Yes. 7 right? Q. And you just told us that the county 8 MR. BADALA: Objection to form. 9 doesn't have a position on whether something is 9 A. Pardon me? 10 medically unnecessary or unauthorized, right? 10 Q. That wasn't one of the three A. May have been ineffective or 11 criteria, right? 11 12 harmful, but --12 A. What's that? 13 Q. That something was unauthorized. Q. So the county does not have a 13 14 position about whether something is medically A. No. These are the criteria again 14 15 unnecessary or unauthorized, right? 15 for -- not for cancer patients, high dose, or MR. BADALA: Objection to form. 16 for patients with a diagnosis of substance use 16 17 A. I think what they say here is that 17 disorder. 18 the prescriptions identified there are Q. Well, let's talk about each of these 19 unauthorized, medically unnecessary, ineffective 19 then, since you told me they now -- it is the 20 or harmful. 20 policy. Q. So is that right or wrong? Does the 21 21 If -- what is the criteria for a 22 county have a position or not? 22 prescription identified as Exhibit A, 23 MR. BADALA: Objection to form. 23 unauthorized? How do we know which one is?

28 (Pages 106 - 109)

A. I don't personally know. That was

25

24 What's the criteria?

A. The county does have this position.

Q. Didn't you say exactly the opposite

24

1 collected data which was submitted to the

- 2 attorneys based on these criteria, and the
- 3 experts reviewed that for unauthorized --
- Q. Well, no. It says here that they
- 5 were unauthorized. Someone had to make -- use
- 6 certain criteria. That's what you're here to
- 7 talk about is the criteria used in connection
- 8 with these interrogatory responses, and I want
- 9 to know for each one of these what the criteria
- 10 is in order to determine whether something was
- 11 unauthorized. Do you know?
- 12 MR. BADALA: Objection to form.
- 13 Asked and answered.
- 14 A. That's not what the county was
- 15 doing. That was what was referred to the
- 16 attorneys with consultation with experts.
- 17 Q. So the answer is you don't have any 18 idea what criteria was used to determine whether 18
- 19 or not something was unauthorized, right?
- 20
- MR. BADALA: Objection to form.
- 21 A. That would have been a decision from 22 the experts' review.
- 23 Q. That's not my question, Doctor.
- 24 As you sit here today under oath,
- 25 testifying on behalf of the county, do you have

Page 112

- 1 refers us back to those -- those prescriptions,
- 2 right. And I think we've covered unauthorized.
- 3 You told me you have no idea what the criteria
- 4 is for determining whether a prescription is 5 unauthorized or not, correct?
 - MR. BADALA: Objection to form.
- 7 A. I don't know what the criteria were
- 8 that were applied to the unauthorized because
- 9 that would have been the consultation with the 10 experts.
- 11 Q. So the answer, again, is you don't
- 12 know, right? 13 MR. BADALA: Objection to form.
- 14 The county does not know.
- 15 Q. And you did not ask anybody, did 16 you?
- 17 A. We didn't ask anybody what?
 - Q. Did you ask anyone in your
- 19 preparation for your deposition today, Doctor,
- 20 hey, what are the criteria for determining
- 21 whether something is unauthorized or not? Did
- 22 that subject matter come up, yes or no?
- A. No. That was, again, a topic that
- 24 was addressed when these were referred to the
- 25 attorneys in consultation with their experts.

- 1 any idea whatsoever what criteria was used with
- 2 respect to making a determination whether a
- 3 prescription was unauthorized?
- MR. BADALA: Objection to form. 4
- A. No, I do not. The criteria that
- 6 were used for the claims that were reviewed are
- 7 what I've previously enumerated, but the
- 8 criteria that were used by the experts, I do not
- 9 have that.
- 10 Q. Do you know this is used by the
- 11 experts or this is an answer in an interrogatory
- 12 that you're supposed to testify about? That's
- 13 why I'm confused. You keep saying experts.
- 14 What experts?
- 15 A. We submitted claims data as the
- 16 county to our attorneys and they consulted with
- 17 experts to generate responses to the
- 18 interrogatories. The county did not
- 19 specifically generate those responses, though
- 20 they signed off on them.
- Q. Okay. We'll talk about that in a 21
- 22 few minutes, but your deposition here, one of
- 23 the topics is about the criteria used for the
- 24 prescriptions that are on that big chart there,
- 25 right, and in the interrogatory responses it

- Page 113
- 1 Q. And I take it if you went through 2 any of those prescriptions in that whole list,
- 3 you couldn't tell me which ones were
- 4 unauthorized because you don't know what the
- 5 criteria are; is that fair?
 - MR. BADALA: Objection to form.
 - A. I could not specifically look
- 8 through this because it wasn't my expert area to
- 9 tell you which of these were unauthorized or
- 10 medically unnecessary or ineffective or harmful.
- 11 I don't know the criteria that were applied by
- 12 the consultation -- the experts that our
- 13 attorneys consulted with.
- 14 Q. What criteria were used to determine
- 15 whether a prescription was medically
- 16 unnecessary?
- 17 MR. BADALA: Objection to form.
- 18 Q. Do you know?
- A. Again, they were referred to the 19
- 20 experts and that was their criteria. The county
- 21 did not have a separate criteria other than
- 22 their --
- 23 Q. Move to strike.
- 24 I'm going to ask you again, Doctor.
- 25 What criteria were used to determine whether it

Page 114 1 was something medically unnecessary? Do you

2 know or do you not know?

MR. BADALA: Objection to form.

A. Again, I do not know as a

5 representative of the county because those were

6 referred to counsel for consultation with

7 experts in that area.

3

4

Q. So you can't testify about the

9 criteria as you sit here today, fair?

10 MR. BADALA: Objection to form.

11 A. I cannot.

12 Q. And you didn't ask anybody about the

13 criteria for medically unnecessary prescriptions

14 before coming here to testify, did you?

15 A. No, I did not.

16 Q. And you did not ask anyone about the

17 criteria for what makes a prescription that's on

18 Exhibit A ineffective or not, what the criteria

19 are, correct?

20 A. I'm sorry. I lost my page.

21 Q. Are you with me?

22 A. I'm not because I was trying to go

23 back.

24 It's on 5. It's with those names. O.

25 My apology. I'm sorry. I just lost 1 criteria were?

2 MR. BADALA: Objection to form.

3 A. I'm only aware that the county made

4 me aware that there was a Rawlings who was used.

5 I don't know what other experts were used and I

6 did not speak to any myself personally. I am

7 not sure about other members of the county.

Q. How much time did you spend speaking 8

9 to Rawlings?

10 A. I didn't personally speak to

11 Rawlings. I just became aware that they were an

12 expert that was being used.

Q. But you knew that they were one of

14 the entities that was actually making these

15 determinations, right?

16

A. I just learned that, yes.

17 Q. And you didn't talk to them?

18 A. I just learned it this morning. I

19 don't know that I would have talked to them, but

20 I certainly didn't have the opportunity to talk

21 to them in preparation for today.

Q. And the same would be true for 22

23 harmful. You can't tell us what criteria were

24 used to determine whether a prescription that's

25 listed on Exhibit A was harmful, right?

Page 115

1 my place.

2 O. That's fine.

3 Same questions for ineffective. I 4 can do it again for you.

A. Would you, please? I'm sorry. 5

6 O. Sure.

7 You did not ask anyone what the

8 criteria was to determine whether -- criteria

9 were with respect to whether a prescription on

10 Exhibit A was ineffective, right?

A. No. That was the referral that we

12 made to the attorneys for the consultation with

13 an expert who could make a decision on that, but 13 for expert review.

14 the county did not specifically identify the

15 medically unnecessary or any of the other three

16 there.

17 Q. And not only didn't identify, you

18 can't tell me what they are, can you?

A. As the county, no, I cannot tell you

20 the criteria that were applied there.

Q. You said they referred those to the 21

22 experts?

23 A. Right.

24 Q. So can you give me a list of all the

25 experts you talked to to find out what those

Page 116

A. No. Again, these were things that

2 the county turned over to its attorneys in

3 consultation with experts who would be able to

4 address that criteria.

5 Q. Did you talk to any of the experts

6 about what was harmful?

7 A. Same answer. I mean, I'm aware only

8 of Rawlings as an expert, but I just found out

9 about that. I did not speak to any specific

10 experts. I didn't know of them. And once the

11 county made the referral in that direction, we

12 didn't pursue that further. That was a topic

14 Q. So if I asked you to look through

15 any of those -- any of those names or

16 prescriptions in Exhibit A and said tell me

17 which ones were ineffective, you couldn't do

18 that, could you?

MR. BADALA: Objection to form.

20 Outside the scope.

21 A. No, I could not.

Q. I couldn't do it either, could I?

23 MR. BADALA: Objection to form.

24 A. I would hope not. Maybe you have

25 hidden talents I don't know about. But no, I

19

1 could not.

- Q. All right. The only way we would be a able to do that is if we actually knew what 4 criteria were applied, correct?
- 5 MR. BADALA: Objection to form.
- 6 A. Right. The experts would have 7 applied their criteria.
- 8 Q. And unless we know what the criteria
- 9 is, we can't actually understand which ones are
- 10 ineffective, which ones are harmful, which ones 11 are medically unnecessary, right?
- MR. BADALA: Objection to form.
- 13 A. That's my understanding of that, 14 yes.
- 15 Q. And you don't have that information 16 for us today, do you?
- 17 MR. BADALA: Objection to form.
- 18 Mischaracterizes testimony.
- 19 A. I do not have that information.
- Q. Is it your understanding or
- 21 testimony on behalf of the county that Rawlings
- 22 is an expert?
- A. I just know of their name and that
- 24 that was a group that was reviewing it. I'd
- 25 have to say that we relied on our attorneys to

1 identify claims.

16

- Q. And they may have had other
- 3 criteria, but that was ancillary to what the 4 search criteria were; is that right?
- 5 A. They may have had other conditions,

Page 120

Page 121

- 6 I would say, but they did not have other
- 7 criteria that were being applied. These were
- 8 the three criteria used to select the -- to
- 9 identify the claims.
- 10 Q. So it wasn't -- at least in
- 11 selecting those claims, it was not part of the
- 12 process to determine whether any doctor who
- 13 wrote a prescription received information from a
- 14 manufacturer of opioids, correct?
- MR. BADALA: Objection to form.
 - A. That's not spelled out in the
- 17 criteria that were used to identify the claims.
- 18 Q. And it's not part of the criteria
- 19 that a doctor who wrote any of those
- 20 prescriptions was prosecuted or was under
- 21 investigation for improper conduct, correct?
- MR. BADALA: Objection to form.
- A. The criteria are the three that I
- 24 mentioned. Specifically whether a doctor had
- 25 visits from a representative of the

Page 119

1 identify the expert in that case.

- Q. Let me ask you this, Doctor: Tell
- 3 me everything you know about Rawlings, what you
- 4 think they are, what they do. It sounds like
- 5 you just learned about them this morning.
 - A. I just learned about them, so
- 7 honestly, I don't know really much at all about 8 them.
- 9 Q. What's the extent of your knowledge?
- 10 A. That they were an entity -- I don't
- 11 even know if it's a person, a group -- who were
- 12 consulted by our attorneys to provide expert
- 13 input into the prescriptions that were reviewed,
- 14 with the purpose of responding to the
- 15 interrogatories.
- 16 Q. So at least in terms of those
- 17 criteria that we talked about, the three, in
- 18 order to make it on the list, is it your
- 19 understanding that they had to satisfy all three
- 20 of those criteria?
- 21 A. The -- just were not a cancer
- 22 patient, high dose -- I'll summarize --
- 23 diagnosed substance use disorder?
- Q. Yes, sir.
- 25 A. Yes, that was the criteria to

- 1 pharmaceutical industry, whether they were
- 2 prosecuted, those were not independent criteria
- 3 for the identification of claims.
- Q. And I think you said this, Doctor,
- 5 but just sometimes I mishear, so let me make
- 6 sure. They actually have to satisfy all three
- 7 of those, not any one of those three criteria,
- 8 in order to make it on the list, right?
- 9 A. That's my understanding, yes.
- 10 Q. In terms of -- you said earlier that
- 11 there may have been other conditions. Am I
- 12 correct that you're just saying due to just the
- 13 way people see doctors or get conditions, they
- 14 may have had a host of different conditions or
- 14 may have had a nost of different condition
- 15 illnesses, but that wasn't a factor in
- 16 determining whether they were going to be on the
- 17 list or not other than the fact that it was not
- 18 for cancer pain, right?
- 19 MR. BADALA: Objection to form.
- 20 A. These were the criteria that were
- 21 used to identify the claims that we submitted to
- 22 our attorneys, and I think, if I remember what I
- 23 said, you know, these individuals could have had
- 24 other conditions, but these were the criteria
- 25 that were used to identify the claims we

1 submitted to our attorneys.

- Q. Okay. And just to make sure we're clear, so those are the only three criteria, fright?
- 5 A. Yes.
- 6 Q. You're not aware of how they came 7 about or who devised them, right?
- 8 A. I did not devise them and I do not 9 know who devised them, yes.
- 10 Q. And no one in the course of your 11 preparation told you who was responsible for 12 those criteria, right?
- 13 A. No, they did not.
- Q. And you don't know how they were implemented in terms of kind of matching up those criteria to actual claims and information,
- 17 right? Someone else did that work, right?
- 18 MR. BADALA: Objection to form.
- 19 Outside the scope.

1 pain, do you see that?

2

- 20 A. I -- as I tried to say earlier,
- 21 certainly in other definitions of these that
- 22 could have been applied, but the specific
- 23 application of those, I do not know for certain.
- Q. And even with respect to something that seems clear, like it says not for cancer

Page 123

1 00

16

19

- A. Not for cancer patients.
- 3 Q. Cancer patients, right. So does
- 4 that mean somebody -- do you know -- whether --
- 5 is currently having an acute problem from cancer
- 6 or do you know whether it would include people
- 7 who have cancer in remission?
- 8 MR. BADALA: Objection to form.
- 9 A. They were not cancer patients. I
- 10 don't know if it was specifically they had a
- 11 history of cancer or if it was whether they had
- 12 an active cancer. Again, I can give you my
- 13 opinion as an individual, but I don't want to
- 14 speak for the county, that it would not have
- 15 been people who had a history with cancer
- 16 because it wouldn't be an active problem.
- Q. But the point of what we're talking
- 10
- 18 about at least on this is we're trying to
- 19 understand the criteria used to generate Exhibit
- 20 A, and I think what you're telling me is you
- 21 don't know, even with respect to cancer, whether
- 22 they were trying to find people who were not
- 23 active cancer patients or whether they excluded
- 24 anyone who never had cancer? You just don't
- 25 know the answer, right?

- 1 MR. BADALA: Objection to form.
- 2 A. I don't know for certain.
- 3 Q. You couldn't go through any of the
- 4 list in front of you in Exhibit A and tell me
- 5 categorically all these people never had cancer,
- 6 could you?
- 7 A. It would be pretty good if I could
- 8 do that. I don't think so. As I would
- 9 understand, cancer patient would be an active
- 10 problem, but I can't say that for certain.
- 1 Q. In order to understand that, you
- 12 would want to see how it was defined and what
- 13 exact criteria was used, right, because then
- 14 that would help you understand how the selection
- 15 process worked?
 - MR. BADALA: Objection to form.
- 17 A. It would be helpful, yes.
- 18 Q. It would be essential, wouldn't it?
 - MR. BADALA: Objection to form.
- 20 A. As I say, I don't know that I could
- 21 tell you how the identification was made not for
- 22 cancer patients, but I do know that the claims
- 23 were identified with that criteria. I just
- 24 don't, as I sit here, have the capacity to tell
- 25 you how they ruled out the patients who did have

Page 125

Page 124

- 1 cancer.
- 2 Q. And substance abuse disorder, does
- 3 that include people who ever had a diagnosis or
- 4 is it people who are currently in treatment for
- 5 substance abuse disorder or is it people who
- 6 have a family history for substance abuse
- 7 disorder? Do you know?
- 8 MR. BADALA: Objection to form.
- 9 A. I don't know the definition. I
- 10 could give you my impression, but I don't know
- 11 that that's really representing the county.
- 12 Q. I'm only asking -- you know, you're
- 13 here to testify on behalf of the county as to
- 14 what those criteria mean. And other than what
- 14 what those criteria mean. And other than wha
- 15 you've told me, you can't tell me whether
- 16 individuals who previously had a substance abuse
- 17 disorder or currently had a substance abuse
- 18 disorder or have a family history of substance
- 19 abuse disorder are encompassed within that
- 20 criteria; is that fair?
- 21 MR. BADALA: Objection to form.
- 22 A. Fair.
- Q. And even as to the 120 MME, you
- 24 can't tell me whether that includes people who
- 25 are downwardly titrating or tapering, whether

Page 126 Page 128 1 it's used for methadone, whether it's used for 1 had conditions or diagnoses appropriately 2 some other opioid therapy to help addiction, you 2 treated with opioids or prescribing dangerously 3 just don't know, right? 3 high dosages of opioids." I won't read the list 4 MR. BADALA: Objection to form. 4 of the people who were prosecuted, but I think 5 A. It's 120 MME. I don't know what 5 that spells out the criteria that were used as 6 direction the person would have been in in their 6 medically unnecessary. 7 treatment or what specific medication would have 7 The next paragraph below the last 8 been used other than it would have a correlate 8 guy's name is the criteria that were used to say 9 that these were ineffective. The "Bellwether 9 as an MME. 10 Q. Do you know as to any of the people 10 Plaintiffs further contend that prescriptions or 11 whether the prescription was manufactured or 11 reformulated OxyContin, Hysingla ER, Opana ER, 12 distributed by one of the Defendants in this 12 Exalgo, and Xartemis XR listed in Exhibit A were 13 case? 13 ineffective in that they did not prevent 14 A. I don't know that for certain. 14 tampering, were not actually abuse-deterrent, 15 MR. CHEFFO: Can we take a short 15 and did not prevent oral abuse, despite the 16 break? 16 manufacturers' representations to the contrary." 17 17 MR. BADALA: Yes. And, lastly, "Bellwether Plaintiffs 18 THE VIDEOGRAPHER: Off the record at 18 further contend that by misrepresenting the 19 11:23. 19 risks, benefits, and superiority of opioids, 20 20 particularly for use long-term and at high (Recess had.) 21 21 doses, including, but not limited to, through 22 (Thereupon, Gilson Deposition 22 sales visits, continued medical education and 23 Exhibit 7, Handwritten Notes, was 23 speaker programs, publications and websites, and 24 marked for purposes of 24 treatment guidelines, Manufacturer Defendants 25 25 deprived prescribers and patients of the ability identification.) Page 127 Page 129 1 1 to make informed choices about whether, when and 2 (Thereupon, Gilson Deposition 2 which opioids to use -- to prescribe and use, 3 Exhibit 8, Handwritten Notes, was 3 for how long, and at what doses. Though 4 marked for purposes of 4 Defendants do not define 'unauthorized,' 5 identification.) 5 'medically unnecessary,' or 'harmful,' 6 Bellwether Plaintiffs contend that Defendants' 6 7 THE VIDEOGRAPHER: Back on the 7 misstatements regarding the benefits and very 8 record at 11:48 a.m. 8 significant risks of opioids and the A. If I could, another clarification 9 redefinition of the standard of care to include 10 into the record. 10 opioids rendered the prescriptions unauthorized, In our last area, I was looking at 11 unnecessary and harmful in that they were 12 Exhibit 2 on the break, where you had asked me 12 prescribed and taken without full and accurate 13 about how we had defined unauthorized, medically 13 information." 14 unnecessary, ineffective or harmful. And I did 14 Q. You met with the lawyers on the 15 not have a chance to review the entire page 15 break? 16 16 there, but I believe the answers to those A. Yes, I did. 17 questions are here in the continuation, and I'd 17 You know we've discussed for a few 18 like to read those into the record, that "The 18 hours now various criteria, and you told me, I 19 basis for assertion that these prescriptions 19 think, probably at least a half a dozen times, 20 were medically unnecessary is that the 20 if not more, that there are three only. Do you 21 healthcare providers listed below and in Exhibit 21 remember that testimony? 22 A were prosecuted or the subject of disciplinary 22 A. Yes, I do. 23 23 actions for their illegal or improper MR. BADALA: Objection to form. 24 prescribing of opioids, for example, without 24 Q. So is that still true? 25 examining patients or determining whether they 25 These were the criteria that were

- 1 identified -- that were used to identify the
- 2 claims, and then what I was just reading are the
- 3 bases for the contention that these were
- 4 unauthorized, medically unnecessary, et cetera,
- 5 harmful.
- 6 Q. Did you know any of that information 7 before about 20 minutes ago?
- 8 MR. BADALA: Objection to form.
- 9 I instruct you not to disclose any
- 10 conversations you might have had with the
- 11 attorneys. It's pretty clear in the deposition
- 12 protocol.
- 13 Q. You can answer.
- 14 A. I read them at the break because I
- 15 was unable to kind of read beyond that
- 16 statement, and that's when I found the terms and
- 17 just wanted to clarify them.
- 18 Q. So do all those terms apply to all
- 19 of the prescriptions and individuals?
- 20 MR. BADALA: Objection to form.
- 21 A. The terms are -- the criteria for
- 22 those terms are spelled out in the answer to the
- 23 interrogatory as it relates back to topic 6.
- Q. If I ask you questions about this,
- 25 other than what's in the interrogatory response,

Page 132

- 1 prescriptions were written by one of these
- 2 doctors listed in the exhibit; do you know?
 - 3 MR. BADALA: Objection to form.
- 4 Document speaks for itself.
- A. As I understood what I just read,
- 6 the criteria, namely, that they were
- 7 medically -- let me just go back and read it.
- 8 Give me a second.
- 9 Q. So you're only going to be able to
- 10 answer my questions by reading the
- 11 interrogatories; is that right?
- MR. BADALA: Objection to form.
- 13 A. I would like to give you a good
- 14 answer, so I'd like to read them.
- Exhibit A was unauthorized,
- 16 medically unnecessary, or ineffective or
- 17 harmful, and then the next sentence is the basis
- 18 for the assertion that these were medically
- 19 unnecessary is because of these healthcare
- 20 providers in Exhibit A being prosecuted or
- 21 disciplined.
- Q. So does that mean that every
- 23 prescription on the list was written by one of
- 24 those doctors?
- 25 A. I would --

Page 133

Page 131

- 1 do you have any personal knowledge or have you
- 2 done any preparation to respond to any of those 3 questions?
- 4 MR. BADALA: Objection to form.
- 5 Asked and answered.
- 6 A. I've reviewed a lot of, you know,
- 7 papers and forms. I can't tell you I remember
- 8 everything. As I say, I didn't remember if I
- 9 saw this before. I don't think I did, but --
- 10 Q. But, Doctor, we've spent a few hours
- 11 now and I've asked you many, many times about
- 12 criteria, so are those new criteria that we need
- 13 to go back and talk to you about, or did -- the
- 14 criteria that you've been telling me about for
- 15 two hours, do they still apply?
- MR. BADALA: Objection to form.
- 17 A. As I said when I clarified the
- 18 record, on reviewing these, I came to understand
- 19 how those terms were used. When we spoke
- 20 before, I didn't have that information, as I
- 21 hadn't read the entire page there, but I think
- 22 it clarified the questions you were asking me.
- 23 Q. Let me ask you some questions about
- 24 it then.
- Does that mean that all of the

- MR. BADALA: Objection to form.
- 2 Outside the scope.
- 3 A. I would interpret that as the
- 4 medically unnecessary ones that we talked about.
- 5 Remember, it's the OARRS, so they don't all have
- 6 to be all four, but this was the definition used
- 7 for medically unnecessary.
- 8 Q. And you can't tell me what the
- 9 criteria are as to whether something is
- 10 medically unnecessary other than you telling me
- 11 that it was written by one of these doctors,
- 12 right?
- 13 MR. BADALA: Objection to form.
- 14 A. Well, and these doctors were
- 15 prosecuted or subject to disciplinary action.
- 16 Q. Which prescriptions did they write
- 17 on the list; do you know?
- 18 A. On this list?
- 19 O. Yes.
- A. I believe the prescribers are
- 21 listed. I don't want to take up your time
- 22 trying to find each name there.
- Q. Okay. So a criteria for medically
- 24 unnecessary is that they were written by one of
- 25 these doctors?

Page 134 Page 136 A. Right. "The basis for the assertion 1 1 reading this for the first time 15 minutes ago? 2 that these prescriptions were medically 2 MR. BADALA: Objection. 3 Mischaracterizes testimony. 3 unnecessary is that the healthcare providers 4 listed below were prosecuted or the subject of A. As I said, I've read a lot of 5 disciplinary action for their illegal or 5 things. I don't remember reading this. So my 6 best answer to you is I remember reading it, you 6 improper prescribing of opioids." 7 know, within the last half hour, but I don't Q. Did you talk to anybody about any of 8 the circumstances for any of the prosecutions or 8 know if I saw that before. 9 any of the prescriptions? Q. So were all of the prescriptions 10 written on Exhibit A written by the doctors 10 MR. BADALA: Objection to form. 11 listed in this response? 11 Outside the scope. 12 MR. BADALA: Objection to form. 12 A. I spoke with a prosecutor about 13 prosecutions in general, but I did not 13 Outside the scope. 14 specifically talk about any of these individuals A. As I understand it, the ones that 15 were defined as medically unnecessary were 15 named here in the interrogatory. Q. Do you know whether all of their 16 written by these individuals. There are other 17 criteria in the topic, as I read it, which is 17 prescriptions were determined to be medically 18 unauthorized, medically unnecessary, ineffective 18 unnecessary or only certain prescriptions --19 or harmful, so I would say that the ones that MR. BADALA: Objection to form. 20 Q. -- in determining the criteria? 20 were written by these, the claim, as I A. I would just point back that they 21 understand it, is that they were medically 21 22 were prosecuted for improper prescribing of 22 unnecessary. 23 Q. Let's go then one by one. 23 opioids. 24 24 So medically unnecessary. Are there Q. But if they wrote a prescription --25 any other criteria other than they were written 25 MR. BADALA: Were you done with your Page 135 Page 137 1 answer? 1 by one of these doctors? 2 THE WITNESS: No, I was not. Could A. I have to go back to what it says, 3 I finish? 3 that the basis for the assertion they were 4 medically unnecessary is that these doctors were 4 MR. BADALA: Finish your answer. 5 prosecuted or subject to disciplinary actions A. It doesn't, as I read this, 6 specifically say every prescription, but that 6 for illegal or improper prescribing. 7 they were prosecuted for improper prescribing of 7 Q. Any other criteria? 8 opioids. It doesn't specify whether every A. Not that I'm seeing here. I mean, 9 prescription they wrote was improper or whether 9 I'm relying on this document. 10 some were. That's not how I'm reading that. Q. You didn't do any work to answer 10 Q. Well, is there any way for us to 11 that question, did you? MR. BADALA: Objection to form. 12 differentiate? 12 13 13 Mischaracterizes testimony. MR. BADALA: Objection to form. A. This would have been something our 14 Q. How would we know whether this 15 includes prescriptions before they were 15 experts would have identified as medically 16 prosecuted or after they were prosecuted? 16 unnecessary. 17 MR. BADALA: Objection to form. 17 Q. And I just want to go through each A. I think these prescriptions are the 18 one. We have limited time. 18 19 ones that they are being prosecuted for. For medically unnecessary, is it Q. Do you know? 20 your testimony the only criteria that you're 20 21 A. That's my reading of this. 21 aware of is that it was written by one of these

35 (Pages 134 - 137)

MR. BADALA: Objection to form.

Who were prosecuted or disciplined

23

25

22 doctors?

24 Mischaracterizes testimony.

Q. Do you know?

A. That's my understanding.

MR. BADALA: Objection to form.

Q. And your understanding is based on

22

23

24

Page 138 Page 140 1 for their activities. 1 of this, so I can't speak to that. O. What about ineffective? 2 Q. So if you look at Exhibit 2, there's 3 3 not doctors listed for every one. Do you know A. Ineffective I think is defined 4 that? Do you know or not, Doctor? 4 further down in the paragraph just below Jerome A. You know, this is an incredibly long 5 Yokiel, Bellwether Plaintiffs further contend 6 that prescriptions of reformulated OxyContin, 6 document, and I have to tell you I don't know. 7 Hysingla ER, Opana ER, Exalgo ER {sic} and 7 Q. Okay. A. I don't know that that's untrue. I 8 8 Xartemis ER {sic} listed in Exhibit A were 9 don't know that that's true. I haven't had the 9 ineffective in that they did not prevent 10 time to review this. And I don't want to get 10 tampering, were not actually abuse-deterrent, 11 into what I initially brought back, again, of 11 and did not prevent oral abuse despite 12 saying I reviewed a document that I didn't have 12 Manufacturers' representations to the contrary. 13 Q. Other than reading those responses, 13 the time to review and tell you that no, there's 14 not a prescriber listed for everything here. I 14 do you have any independent knowledge, based on 15 any work that you did or people that you talked 15 do not know. 16 Q. So there's a list of -- this is 16 to, in connection with the criteria used for 17 whether something was unauthorized, medically 17 Exhibit B. It's in there. Do you see this? 18 MS. ROITMAN: It's in the back of 18 unnecessary, ineffective or harmful? 19 Exhibit 2. 19 MR. BADALA: Objection to form. 20 A. I know that some of these 20 MR. BADALA: Oh, behind the big 21 formulations with which I am familiar were not 21 spreadsheet? 22 abuse-deterrent formulations. 22 MS. ROITMAN: Yes. 23 MR. BADALA: All the way back. Go 23 Q. That's not my question. 24 24 back to the 8 and a half by 11. Other than reading from that 25 25 document that you saw 15 minutes ago, do you Q. So in connection with topic 19 and Page 139 Page 141 1 interrogatory 7, you refer to this document. Do 1 have independent knowledge, based on your review 2 you know what this is? 2 as a 30(b)(6) witness, of whether prescriptions 3 were unauthorized, medically unnecessary, 3 A. I have not seen this before. 4 Q. Do you know what the criteria are 4 ineffective or harmful? 5 for any of the people who are on this list? MR. BADALA: Objection to form. A. I'm sorry. I thought I answered A. It says that they all died from an 7 overdose death so far as -- if you'll give me 7 your question in that using the criteria, that 8 time to read through to the end. 8 these were actually abuse deterrent. I am 9 Q. Do you know what substances were 9 familiar, as an individual and a representative 10 of the county, that certain formulations here 10 certified --A. I'm sorry. Just give me a second, 11 11 are not abuse-deterrent formulations. 12 Q. So if they're not abuse-deterrent 12 please. 13 formulations, what does that mean? 13 Q. Sure. 14 A. Okay. I'm sorry. A. Plaintiffs further contend that the 15 prescription of reformulated drugs were 15 Q. Do you know what substances were 16 ineffective in that they do not prevent 16 certified as the cause of death? 17 tampering, were not actually abuse-deterrent, et 17 MR. BADALA: Objection to form. 18 cetera. 18 A. For all of these? 19 Q. So if there were prescriptions on 19 O. Yes.

36 (Pages 138 - 141)

I don't know what the death

Q. Or any of them, right? You don't

A. I don't have that information, no.

Do you know whether these people had

20

22

24

25

23 know?

21 certificates read.

Q.

MR. BADALA: Objection to form.

A. I did not conduct the expert review

20 the list that were not written by any of these

22 necessary?

24 Outside the scope.

23

25

21 doctors, does that mean that they're medically

1 a diagnosis of opioid use disorder?

- 2 MR. BADALA: Objection to form.
- 3 A. Are these the claims that were
- 4 referred, because that was one of the criteria
- 5 that we used for referrals?
- 6 Q. Well, you're here to tell me,
- 7 Doctor.
- 8 A. Again, I have to say, you know, I
- 9 read a lot of documents. I don't know if these
- 10 are the names -- some of these are from Summit
- 11 County, which I don't speak for. I can't tell
- 12 you, you know, again, if all of these folks had
- 13 a diagnosis of substance use disorder and --
- Q. I guess what I'm trying to find --
- 15 this is in response to topic 19, "The criteria
- 16 used by Plaintiffs to identify individuals who
- 17 overdosed on, or became addicted to,
- 18 prescription opioids in Plaintiff's geographic
- 19 area." Do you see that?
- MR. BADALA: I think you're
- 21 referring to the depo notice.
- MR. CHEFFO: Yes.
- MR. BADALA: He's referring to this
- 24 Exhibit 1.
- 25 THE WITNESS: Okay.

- Page 143
- 1 Q. And in response to that, we received
- 2 this document, right? The first few pages talk
- 3 about Summit, but if you go to the third and
- 4 fourth page, or fifth page, it's Cuyahoga.
- 5 A. Right.
- 6 Q. So, as the topic says, could you
- 7 tell us what criteria were used to identify
- 8 these individuals?
- 9 A. The criteria that we used to
- 10 identify claims for opioids were, again, not
- 11 cancer patients, higher dose, higher than 120
- 12 MME, and patients with a diagnosed substance use
- 13 disorder.
- O. But this is different. This is --
- 15 again, you have to read the paragraph. It says,
- 16 "The criteria used by Plaintiffs to identify
- 17 individuals who overdosed on, or became addicted
- 18 to, prescription opioids." That's why there's
- 19 individual people listed here. Are you telling
- 20 me that that's the same criteria?
- 21 A. Those were the criteria used for the
- 22 response to the interrogatory.
- 23 Q. To this, B?
- A. Again, I don't recognize this list
- 25 right off the top of my head, but if this is the

Page 144

- 1 list of individuals in that 500 claims, those
- 2 were the criteria that were used, the three that
- 3 I mentioned.

6

- 4 Q. In the overdose deaths?
- 5 A. Pardon?
 - Q. Overdose deaths. Does that criteria
- 7 apply -- are those the only three criteria that
- 8 apply to the overdose deaths that are
- 9 articulated in topic 19?
- 10 A. The claims that were identified all
- 11 have those three criteria.
- 12 Q. What about the overdose deaths?
- 13 A. If they were identified as claims by
- 14 the county, then they would have met those 15 criteria.
- 16 Q. Putting aside whether they were
- 17 claims or not, what's the criteria for the
- 18 individuals who were on Exhibit B?
- MR. BADALA: Objection to form.
- 20 Asked and answered.
- Q. Do you know anything other than the
- 22 three criteria you've been telling us about this
- 23 morning?

1

- A. No. Those were the criteria that I
- 25 was told were used to identify claims.

- Q. And individuals?
- 2 A. And to identify individuals or --
- 3 yeah, individuals, I guess prescriptions or
- 4 individuals.
- 5 O. And people who overdosed?
- 6 A. I'm out in the weeds a little with
- 7 what you're saying.
- 8 Q. Really, Doctor? Maybe I'm not doing
- 9 a good job about it. What does 19 say? Can you
- 10 just read that out loud?
- 11 A. "The criteria used by Plaintiffs to
- 12 identify individuals who overdosed on, or became
- 13 addicted to, prescription opioids in the
- 14 Plaintiff's geographic area."
- 15 O. That's all I want to know is what's
- 16 the criteria.
- 17 A. How did we identify the overdose
- 18 deaths or the ones who became addicted to
- 19 prescription opioids?
- 20 O. Either.
- 21 MR. BADALA: Objection to form.
- A. The overdose deaths are, you know,
- 23 searchable in the database either in our office
- 24 or in Summit County, and those overdose deaths
- 25 would meet these criteria.

Page 146 Page 148 1 O. What criteria? A. Overdose deaths -- I mean, I don't 2 A. The three criteria we keep 2 know how Summit County works. In our office we 3 mentioning. 3 would define those as deaths with a death Q. Oh, they would? The overdose deaths 4 certificate including an opioid on it. 4 5 would all meet those criteria? Q. Is that the criteria that was used? A. If they were submitted for claims, 6 A. That, I do not know. Again, I think 7 identified claims --7 this was something that was generated by experts Q. Putting aside claims; a separate 8 in response --9 issue, overdose and addiction. What are the Q. No. Doctor, it says -- Doctor, I'm 10 criteria for determining whether someone made it 10 asking about the criteria, and if you -- let's 11 on the list that we've been looking at? Do you 11 not -- you know, if you don't know, all you have 12 know? 12 to do is just say, "I'm not prepared, I don't 13 THE WITNESS: Can I take a break? I 13 know the answer." If you do know, I'm not 14 have to tinkle really. I'll be right back, 14 asking you about experts or anybody else who 15 though. 15 looked at it. I'm just asking, I think, a very 16 THE VIDEOGRAPHER: Off the record at 16 fair question, which is, do you know what 17 criteria were used in order to determine if 17 12:08 p.m. 18 (Recess had.) 18 somebody made it on this list as an overdose 19 THE VIDEOGRAPHER: Back on the 19 death? Yes or no. Do you have personal 20 knowledge of that? 20 report at 12:11 p.m. 21 A. Much obliged. That was a necessary 21 MR. BADALA: Objection to form. 22 break. 22 Asked and answered. 23 Understood. 23 A. Right now, no, I do not. 24 24 We've talked a lot about claims data Q. Okay. And the same would be true 25 and you've told me that there are three criteria 25 for somebody who was addicted who made it on Page 147 Page 149 1 only, right? Correct? 1 this list; you do not know what criteria were 2 used, correct? 2 A. Right. Q. I'm going to put that aside. Then 3 MR. BADALA: Which list? I'm sorry. 4 Which list are you referring to? 4 there were some interrogatories and topics that 5 talked about people who overdosed and people who 5 MR. CHEFFO: On the -- the list of 6 became addicted. 6 people who were opioid addicted. 7 7 MR. BADALA: We're talking about B? A. Okay. Right. That's topic 19. 8 MR. CHEFFO: Yes. 8 Q. Is it fair to say -- you didn't do 9 9 any preparation for that topic, did you? MR. BADALA: Exhibit B. 10 MR. BADALA: Objection to form. 10 Q. Do you know, Doctor? A. Other than to familiarize myself A. Again, my information is that the 11 12 with the criteria and that they were submitted 12 500 patients who were identified, and I do not 13 know if that includes this group, were 13 to attorneys from the county for review in 14 identified with those criteria, the three 14 consultation with experts to generate lists that 15 were provided to answer these interrogatories, 15 criteria which I keep mentioning. 16 no, I did not actively participate. 16 Q. Do you know anything about people 17 Q. No. No. I'm not asking if you 17 who were identified as being addicted? 18 actively participated at all. So I'm just 18 MR. BADALA: Objection to form. 19 19 trying to find out -- you said you know the A. If they were on that list of 500, I 20 would say they had -- these criteria applied to 20 criteria. What are the criteria to determine if 21 somebody should be on a list for either being 21 them. 22 opioid addicted or an overdose death 22 Q. You're sure of that? 23 The list of 500? 23 attributable to opioids? Α.

38 (Pages 146 - 149)

That's your testimony under oath,

25 that if they were on the list of addicted, those

24

Q. Do you know?

MR. BADALA: Objection to form.

24

1 three apply? Because if it's yes, we'll move

- 2 on. Is that your testimony?3 MR. BADALA: Objection to form.
- 4 Outside the scope.
- 5 A. The claims data that was submitted 6 to the attorneys --
- 7 Q. I'm not talking about claims data.
- 8 A. -- included those three criteria.
- 9 Q. I'm talking about people who were
- 10 listed as opioid addicted. Are those the
- 11 criteria that were used to determine whether
- 12 they were opioid addicted?
- MR. BADALA: Objection to form.
- 14 A. I don't know that I understand what 15 you're asking me.
- 16 Q. What don't you understand?
- 17 A. The interrogatories spelled out --
- 18 or I was told there were criteria here, that the
- 19 county provided patients with this name -- with
- 20 the names based on whether they had -- did not
- 21 have -- were not cancer patients, had a high
- 22 dose, or -- and -- not or, and they were
- 23 diagnosed with a substance use disorder. Those
- 24 claims, which would include addicted and
- 25 overdose deaths, were referred over to our

Page 152

Page 153

- 1 addicted? You wouldn't know that either, would 2 you?
- 3 MR. BADALA: Objection to form.
- 4 A. Solely on these three criteria?
- 5 Q. Right.
- 6 A. This, again, is a basis for
- 7 selection, and that's what we refer from the
- 8 county. Beyond that, you know, you would have
- 9 to do a consultation to determine those
- 10 questions you asked.
- 11 Q. You would have to look at other 12 criteria, right?
- 13 MR. BADALA: Objection to form.
- 14 A. I don't know what went into the
- 15 experts' determinations of this.
 - Q. You don't even know if there were
- 17 experts who made these determinations, do you?
- MR. BADALA: Objection to form.
- 19 A. I was informed that when the county
- 20 turned over its list of 500 names to the
- 21 attorneys, that they would be consulting with
- 22 experts to determine claims data and share
- 23 that --
- Q. And what happened?
- A. -- and in response to the

Page 151

- 1 attorneys for consultation with experts, and
- 2 that's the basis of these responses. And I do
- 3 not know, to answer you, what criteria the
- 4 experts used, but if they were drawing that from
- 5 our claims data, these folks would have met
- 6 those three criteria.
- 7 Q. So is it your testimony there may
- 8 have been other criteria that's used?
- 9 MR. BADALA: Objection to form.
- 10 Misstates his testimony.
- 11 A. I think I've answered that before,
- 12 that these are the three criteria that were
- 13 used.
- 14 Q. That's it?
- 15 A. There may be other conditions, as I
- 16 say, but criteria were these.
- 17 Q. And you think that if they meet
- 18 those criteria, you could determine whether
- 19 someone was -- I mean, how would you even know
- 20 if they were dead based on those criteria?
- 21 MR. BADALA: Objection to form.
- A. I don't think you would.
- Q. You wouldn't, would you?
- 24 A. No.
- 25 Q. How would you know if they were

1 interrogatories.

- Q. And what happened after that, what
- 3 criteria, who was consulted, how it was applied,
- 4 you have no information, do you?
- 5 MR. BADALA: Objection to form.
- 6 Misstates testimony.
- 7 A. Unless we're going back to Exhibit
- 8 2, with the things about what constituted
- 9 medically unnecessary, harmful -- I forget the
- 10 other two -- those are spelled out in this
- 11 document.
- 12 Q. Can you tell me everything that the
- 13 Plaintiffs did, if anything, to identify whether
- 14 prescribers who wrote any of the prescriptions
- 15 on Exhibit A relied in any way on anything any
- 16 Defendant did or said?
- MR. BADALA: Objection to form.
- Are you talking about Cuyahoga
- 19 County? You said Plaintiffs.
- MR. CHEFFO: Yes, Cuyahoga County,
- 21 sure.
- A. Sorry.
- Q. Tell me everything that Cuyahoga
- 24 County did, if anything, to determine whether
- 25 prescribers who wrote the prescriptions on

Page 154 Page 156 1 Exhibit A relied in any way on anything any 1 because we were becoming concerned about the 2 Defendant ever did or said. 2 role of prescription opioids in the creation of 3 MR. BADALA: Objection to form. 3 our heroin crisis and subsequent fentanyl 4 crisis. 4 A. I don't know. I mean, I don't know 5 5 what wasn't covered in the investigation of the At those educational activities or 6 prosecutions of the medically unauthorized 6 town halls or things like that, I frequently 7 folks, so --7 spoke to physicians, who conveyed to me -- if Q. And just before we leave this, with 8 they were older, they said they were concerned 9 respect to interrogatories -- I'm sorry. With 9 about the safety of these drugs and were 10 respect to topics 19 and 4, are you aware of any 10 reassured that the addiction potential of opioid 11 other criteria that were used in order to 11 prescription pain relievers was low, less than 1 12 determine any of who those claims or individuals 12 percent. In speaking to younger physicians, 13 were or is it just the three we've been talking 13 they were told that the inadequate treatment of 14 about? 14 pain would be something they might be subject to 15 MR. BADALA: Objection to form. 15 discipline for and that they would not run the 16 risk of addicting patients to opioids if they 16 Mischaracterizes testimony. 17 17 had not controlled their pain. A. The basis for the claims were the 18 three criteria that I applied. Those were the 18 So I think those were statements 19 claims that were submitted to the attorneys for 19 that were misrepresentations of the actual harm 20 review. 20 that the opioids could potentially cause, and 21 21 those are complaints I'm hearing from Q. Topic 3 you've also been designated 22 on. I want to see if we can cover it briefly. 22 communities. That's anecdotally I realize, but 23 "Plaintiffs' knowledge of: (a) concerns or 23 it was such a consistent thing whenever I spoke 24 complaints made to them and by them about any 24 to prescribers. 25 promotion, marketing or educational activities 25 Q. I move to strike. Page 155 Page 157 1 with respect to prescription opioids within or 1 Let's see if we can just focus on 2 relating to Plaintiff's geographic area; and 2 the topic that's actually listed there, Doctor. 3 actions taken by them or others in response to 3 "Plaintiff's knowledge of concerns or complaints 4 those concerns." 4 made to them or by them about promotion, 5 marketing, or educational activities with 5 Do you see that? 6 A. Yes, I do. 6 respect to prescription opioids within or 7 Q. Are you prepared to testify about 7 related to Plaintiff's geographic area." 8 that? 8 Do you see that? 9 9 A. Um-hum. A. Yes, I am. 10 Q. Okay. What knowledge does Cuyahoga 10 Q. Giving me some level of specificity, 11 have about concerns or complaints made to it or 11 are you aware of any specific complaints or 12 by it about any promotion, marketing or 12 concerns that were raised to you or to the 13 educational activities? 13 county responding specifically to the wording of 14 MR. BADALA: Objection to form. 14 topic 3? 15 A. The county itself would not receive 15 MR. BADALA: Objection to form. 16 the complaints of physicians. They would be 16 Asked and answered. 17 more state functions, Board of Pharmacy, Board 17 A. As I said, the concerns were being 18 of Medicine. I can say that as part of our 18 expressed to me in the course of educational 19 county's response to the opioid epidemic, I 19 activities and they did relate to marketing and 20 spoke at all of our major institutions as a 20 the promotion of these drugs as being not 21 representative of the county, our hospital 21 potentially significantly addictive. 22 organizations -- there are three in Cuyahoga 22 When? When did you first hear

40 (Pages 154 - 157)

MR. BADALA: Objection to form.

23 those?

24

23 County, the Cleveland Clinic, University

24 Hospital, which is affiliated with Case Western,

25 and MetroHealth Medical Center -- about issues 25 Outside of the scope.

- 1 A. I could not give you a specific
- 2 date. I had town hall and multiple meetings in
- 3 which I believe were furnished educational
- 4 activities with physicians specifically to
- 5 address the heroin crisis, but also to start to
- 6 share information that we had gleaned from the
- 7 prescription monitoring program, OARRS, in our
- 8 state, that indicated that there was a
- 9 substantial concern that the heroin-addicted
- 10 population was progressing from an opioid pain
- 11 reliever addicted population, and that was when
- 12 I would hear the concerns because there were
- 13 concerns about overprescribing and a setup for
- 14 heroin addiction or fentanyl addiction and they
- 15 were expressed to me at those town halls.
- Q. And I'm going to move to strike and
- 17 we're going to have to ask for more time. I
- 18 asked you very specifically when and you've
- 19 given me kind of a speech.
- 20 A. 2013.
- 21 Q. Okay. Thank you.
- 22 A. That's when I started my town halls.
- 23 Q. It's very simple.
- 24 A. It would have continued to the
- 25 present.

Page 159

19

2

7

- Q. So I'm asking -- bite size pieces --
- 2 2013 is the first time that you did your town
- 3 halls and that's when you heard complaints,
- 4 fair?
- A. That's the first time I, as an agent
- 6 of the county, became aware of it, and I think
- 7 that that's the first time, you know, that I am
- 8 aware that people were expressing those concerns
- 9 about addiction.
- 10 Q. And so is the answer that the
- 11 county's first time that it had concerns or
- 12 complaints in response to topic 3 was in 2013
- 13 based on your investigation and work in
- 14 preparation for this deposition? Is that fair?
- 15 MR. BADALA: Objection to form.
- 16 A. Let me just reread that.
- 17 With the understanding that we would
- 18 not have -- I'm not representing the state, who
- 19 may have received those complaints. That's the
- 20 first I'm aware of the county understanding
- 21 that. So around 2013.
- 22 Q. There's no -- is it really your
- 23 testimony there's no ability for the county to
- 24 receive a complaint by a consumer or another
- 25 doctor or a public citizen to one of the various

Page 160 1 people in town -- in county government?

MR. BADALA: Objection to form.

2 3 A. The appropriate mechanism for those

4 investigations would be at the state level. Can

- 5 somebody from the county receive those, that's
- 6 certainly possible. Local law enforcement
- 7 could, who also are not county employees. We
- 8 have our sheriff. And they may have received
- 9 those as well, but the actual complaints and
- 10 concerns, as I know them to be a county
- 11 function, are probably the date I mentioned.
- 12 Q. Other than the individual complaints
- 13 that you heard of when you were having these
- 14 anecdotal conversations, did you identify any
- 15 database or any people who maintained those or 16 any complaints about pharmaceutical or other
- 17 Defendant conduct or marketing activities?
- 18 MR. BADALA: Objection to form.
 - A. Not as I remember the county level.
- 20 Q. And that's -- as part of your
- 21 preparation for today, you did a full and fair
- 22 analysis of whether there were any concerns or
- 23 complaints maintained by the county, fair?
- 24 Yes, I did. A.
- 25 And your testimony is you didn't

1 find any?

- A. I could not find anything within the
- 3 county that I would say were fulfilling this,
- 4 but as I say, whether there were complaints made
- 5 from the county up to the state, that, I did not
- 6 investigate.
 - Q. Now, you also were --
- 8 A. Or to federal. I guess they could
- 9 also possibly --
- 10 Q. Why didn't you investigate those?
- 11 MR. BADALA: Objection to form.
- 12 A. The regulation of medicine in the
- 13 state of Ohio is at the state level, and the
- 14 regulation of complaints about doctors'
- 15 practices and things like that would seem to be
- 16 more appropriate at the state level. The county
- 17 doesn't have a specific mechanism to investigate
- 18 those complaints to the best of my knowledge.
- 19 Q. But you just told me that the county
- 20 may have made a referral to the state or the
- 21 Feds because those are the right people, and
- 22 that's exactly what this calls for, right? It
- 23 says, "Concerns or complaints made to them or by
- 24 them," meaning Cuyahoga County. Do you see
- 25 that?

- A. Yes, I do.
- 2 Q. And the answer may be the same, but
- 3 I just want to make sure we're on the same page.
- 4 Did you do any work to identify whether the
- 5 county ever made a complaint or expressed any
- 6 concerns to any federal agency or any statewide
- 7 agency with respect to promotional, marketing or
- 8 educational activities concerning prescription
- 9 opioids?

1

- 10 A. Not that I know of.
- 11 Q. And it's your testimony that the
- 12 state is actually the agency that's best
- 13 empowered to handle those types of complaints?
- 14 A. The state would investigate
- 15 overprescribing through the Board of Pharmacy,
- 16 medical practices through the Board of Medicine.
- 17 That would be the more appropriate people to
- 18 address that.
- 19 Q. And you're not aware of whether
- 20 anybody in the entire Cuyahoga County system
- 21 made a complaint or a referral to any of those
- 22 state agencies, are you?
- 23 MR. BADALA: Objection to form.
- A. I know the prosecutor, in my
- 25 discussions with him, talked about prescribings

Page 164

- 1 regarding pharmaceutical or defense advertising
- 2 or marketing information to a state or federal
- 3 agency? Do you have any specific --
- 4 MR. BADALA: Objection. Outside the
- 5 scope.
- 6 A. Whether the county did?
- 7 Q. Yes.
- 8 A. No, I do not.
- 9 Q. And do you have any information
- 10 whether the county made any of those inquiries
- 11 or concerns and expressed them to any federal
- 12 agency?
- 13 A. Before the time we're talking about?
- 14 Q. Any time. That's what this calls
- 15 for.

16

25

- MR. BADALA: Objection to form.
- 17 A. I think when we identified, through
- 18 the Poison Death Review Committee, through our
- 19 task forces, that there was a role for the
- 20 prescription opiates in the subsequent evolution
- 21 into heroin and fentanyl addiction, there were
- 22 representatives on the task forces at the
- 23 federal level, at state level, and that
- 24 information would have been passed up to them.
 - We as a county would have -- when we

Page 163

- 1 of, you know, doctors over, you know, the time
- 2 frame for the lawsuit, and, you know, those
- 3 people could have, you know, or should have been
- 4 referred to the Board of Pharmacy or Board of
- 5 Medicine.
- 6 Q. But you'd be speculating? Do you
- 7 know?
- 8 A. What's that?
- 9 Q. Do you know whether they did or not
- 10 or are you speculating?
- 11 A. Well, I think the other piece of it,
- 12 not to evade your question, is that there would
- 13 be opportunities, based on my discussion with
- 14 the prosecutor, where information would be
- 15 filtered back to them from those state agencies
- 16 as well.
- 17 Q. I understand.18 And you understand. Doctor, tod
- And you understand, Doctor, today is

A. I think that's great and I hope I'm

- 19 just my opportunity to try and just probe for
- 20 information and get it, which I don't have.
- 22 being helpful.

- Q. So these are very simple questions.
- 24 Are you aware of any facts in which
- 25 the state made a referral or a complaint

- Page 165 1 identified people who were doctor shopping based
- 2 on that review, we went back and looked at all
- 3 of their prescribing as far as we could with our
- 4 prescription drug monitoring program for
- 5 overdose deaths. If we identified doctor
- 6 shopping, which we defined as five or more
- 7 prescribers within a one-year period, we would
- 8 refer that back to the Board of Pharmacy, "we"
- 9 being the medical examiner's office.
- I also know, based on conversations
- 11 with the Division of Child and Family Services.
- 12 there were also instances -- I don't have
- 13 specifics that I could share with you, and I
- 14 don't know if the county would have them, but
- 15 when they became aware of what looked like -- I
- 16 remember the term -- my contact used "fishy
- 17 prescriptions," they would also be referred to
- 18 the state for further investigation.
- 19 Q. Are fishy prescriptions -- do they
- 20 contribute to the opioid crisis?
- 21 MR. BADALA: Objection to form.
- 22 A. I think, sure. You know, if they're
- 23 not going to be, you know, something that's
- 24 legitimate -- you know, anything I think that 25 puts more drugs into the system, especially by

Page 168 Page 166 1 an illegal means, has the potential to 1 both of these folks participated in. If I say 2 contribute to the opioid crisis. 2 task force, this is the Board of Health task Q. And do you know whether any of those 3 force. The other one was housed in the -- or 4 chaired by the U.S. Attorney, initially Steve 4 fishy prescriptions are on the list in front of 5 you? 5 Dettelbach, then Carole Rendon, and now Justin 6 A. They were child and family services, 6 Herdman, our succession of U.S. Attorneys. 7 so I don't know really. That was an anecdotal 7 Sorry I went on. 8 Q. I'm trying not to cut you off, but 8 recollection. Q. Does doctor shopping lead to and 9 I'm asking very specific questions here. Have you ever been media trained? 10 contribute to the opioid crisis? 10 MR. BADALA: Objection to form. MR. BADALA: Objection. Outside the 11 12 Which topic are we on? 12 scope. 13 MR. CHEFFO: General questions. 13 A. No. Am I good? 14 Q. You're looking at the camera a lot. 14 Q. You can answer. A. Well, that -- I have been trained to 15 MR. BADALA: Outside the scope. 15 16 talk to the jury. 16 A. Does doctor shopping contribute to 17 the opioid crisis? 17 Q. Oh, okay. 18 You only took notes for three 18 MR. BADALA: Objection to form. 19 A. I think that that's a well 19 people? 20 recognized form of diversion of pharmaceuticals. 20 A. Yes. 21 21 Q. You presented us with some Q. And are these the complete notes 22 handwritten notes just a little while ago. Do 22 from the two that you provided or are there 23 anything missing? 23 you have a copy in front of you? 24 24 A. I do not. A. No. This is everything. 25 In fact, when you told us that these 25 MR. CHEFFO: Let's mark them. Have Page 167 Page 169 1 we marked them yet? 1 were somewhere in a landfill, they were in your 2 bag back in your room probably? 2 MR. BADALA: Yes. We have 7 and 8. 3 Q. What are these, Doctor? 3 A. Yes. One was in a landfill. 4 A. Oh, when we talked earlier, we had 4 Q. But these two, where were they? 5 said was there anybody who I had talked to about 5 A. These were in a file in my bag. 6 -- in preparation for today, and these are two 6 Q. In your bag. 7 7 of the conversations I had where I took notes When was the last time you looked at 8 actually. And I think I mentioned the third 8 them before right now? 9 one, which I'm quite confident I threw away. I A. I just wrote them I think within the 10 wasn't at the time remembering that I had kept 10 last week or two, so within the last week or 11 these. They were just preserved, so I produced 11 two. 12 them. 12 MR. CHEFFO: Okay. I think I'm just 13 But anyway, one is -- Exhibit 7 is 13 about done. Just give me about two minutes. 14 my notes when I talked to Joan Papp, who was the MR. BADALA: Yes. Do you want to go 14 15 doctor at MetroHealth Medical Center who was the 15 off the record? 16 principal founder of our Deaths Avoided With 16 MR. CHEFFO: Yes. Let's go off the 17 Naloxone program, naloxone being the antidote to 17 record for a minute. 18 potentially reverse an opioid overdose. 18 THE VIDEOGRAPHER: Off the record at And the other one was Vince Caraffi, 19 12:35 p.m. 20 and that's C-a-r-a-f-f-i, and he was -- he is 20 (Recess had.) 21 still the injury prevention program supervisor 21 THE VIDEOGRAPHER: Back on the 22 at the County Board of Health and he was also 22 record at 12:46 p.m. 23 the chair of the County Board of Health opiate 23 BY MR. CHEFFO: 24 task force. 24 Q. Before I ask you questions, Doctor,

43 (Pages 166 - 169)

25 some of this is, frankly, illegible. And I

There was a second task force which

- 1 don't want to quibble. I appreciate we have it
- 3 A. I'm a doctor. I can read it all, or
- 4 most of it I should say. Some of it I can't
- 5 even read.
- Q. At some point we may just ask you to
- 7 do it because it's just really hard to do, but
- 8 I'm not going to ask you to do it at this
- 9 minute. I'll see if we can decipher it over
- 10 lunch.
- 11 Before we leave topic 3, I did just
- 12 want to ask you -- there's a part B here. Now,
- 13 you told us that the only information -- tell me
- 14 if this is correct -- that you had of kind of
- 15 claims or complaints was some anecdotal
- 16 information that you obtained during some town
- 17 hall meetings starting in 2013. Is that fair?
- A. I'd characterize it more as these
- 19 were talks that were specifically towards the
- 20 medical communities, so they were more formal I
- 21 think than -- we did a lot of town halls, too,
- 22 but these were -- those concerns that I
- 23 expressed were more expressed to me when I was
- 24 in that forum where I was doing the grand rounds
- 25 or something like that.

- Page 171
- Q. And then the topic 3 has B. It 1
- 2 talks about the actions taken by Cuyahoga County
- 3 in response to those concerns or complaints. So
- 4 in your preparation, can you tell us all the
- 5 things -- so when you heard those things, I
- 6 assume there was a litany of things that you or
- 7 the county did.
- 8 A. Sure.
- I think, you know -- I have to
- 10 stress that at the time that I'm doing these,
- 11 you know, grand rounds, town halls, we have a
- 12 heroin epidemic and we have not really
- 13 established its link back to prescription drugs
- 14 at that point definitively. That's why we
- 15 needed to go back and do the OARRS data. I'm
- 16 sharing what I'm seeing because it's concerning
- 17 to me, but I don't think it would represent the
- 18 county to say that we had established that link.
- 19 So I am presenting data about heroin, I'm
- 20 collecting their anecdotal information and, at
- 21 the same time, in the medical examiner's office
- 22 we are going back to do reviews of the heroin
- 23 fatalities with specific things that we're
- 24 looking at in addition to demographic
- 25 information, just, you know, age, race, sex.

- 1 We're looking at things like where did the
 - 2 person live, where -- what was their level of
 - 3 education, was there anything that might have
 - 4 predisposed them in terms of a job to develop a

Page 172

- 5 heroin addiction. And the last one that I want
- 6 to stress, because it's relevant to this, is we
- 7 were looking at the role that prescription
- 8 opioids might have played in generating a heroin
- 9 crisis. We've had heroin epidemics in Cuyahoga
- 10 County before the prescription drug problem. So
- 11 we were really trying to collect good data to
- 12 make that association.
- Q. Again, Doctor, my question is really 13
- 14 a little bit different.
- 15 A. I'm sorry.
 - Q. It's just basically you told us that
- 17 you had some anecdotal information, and B says
- 18 the actions taken by the county in response to
- 19 those. I know you told me -- let me ask you a
- 20 few follow-ups.
- 21 You said you were hearing this and
- 22 collecting. Did you memorialize this? Did you
- 23 put this in a file? Did you take notes on any
- 24 of this?

16

- 25 MR. BADALA: Objection to form.
- Page 173
 - 2 them?

1

- 3 Q. Yes.
- 4 A. No. They were mostly conversations

These complaints as I'm hearing

- 5 I would have after these meetings. I have a
- 6 record in our statistical report of where I was
- 7 speaking, but the actual person who came up to
- 8 me, I didn't ask them their name. If I knew it,
- 9 I knew it. If I didn't -- and writing down any
- 10 memos about that, I didn't do that.
- 11 Q. So the answer is no, you have no
- 12 written record of any of that, right?
- 13 A. No.
- 14 Q. Have you identified any written
- 15 record of anybody in the county that
- 16 memorialized a complaint or concern about
- 17 promotion, marketing or educational activities
- 18 with respect to prescription opioids?
- 19 MR. BADALA: Objection to form.
- 20 A. Again, you know, I don't have the
- 21 access to the state data where those complaints
- 22 would have been made, but within the county we
- 23 don't have really a reporting structure like
- 24 that I'm aware of and I didn't find any 25 evidence of those complaints being filed at the

1 county level.

- Q. And with respect to those specific 3 concerns or complaints that you were told
- 4 anecdotally, are there actions that the county
- 5 took or steps taken?
- A. Not to be unresponsive, but what I 7 was saying before about --
- Q. When someone starts an answer "not
- 9 to be unresponsive," I know what's coming, so I
- 10 would kind of maybe ask you to try to be
- 11 responsive.
- 12 A. Well, what I want to say is doing
- 13 those look-backs on our heroin overdoses into
- 14 the prescription database was my way of
- 15 responding to the concerns that these folks had
- 16 about overprescribing based on misinformation
- 17 about the safety of these drugs. And, you know,
- 18 the other piece of anecdotal information that
- 19 I'm hearing, and this would be at town halls in
- 20 addition to other places, and I think there was
- 21 also a national concern that we were really one
- 22 of the first counties to recognize is that
- 23 people are going from the opioid pain relievers
- 24 to heroin, and I think the only way we could
- 25 really go back and look at that with decedent

- Page 176 A. Let me just read the question one 1
- 2 more time.
- 3 Not that I can think of. It's a
- 4 very pervasive problem, as I think you know, and
- 5 whether there were more concerns or complaints
- 6 I'm not thinking of, I don't want to shut the
- 7 door on it, but I would just say that's the best
- 8 I can think of now.
- Q. Does the county still reimburse for
- 10 opioids?

14

16

19

- 11 MR. BADALA: Objection to form.
- 12 Outside the scope.
- A. I'm not sure I understand. 13
 - Q. Does the county still reimburse for
- 15 opioid medicines for people for which it funds?
 - MR. BADALA: Objection to form.
- 17 Outside the scope.
- 18 Q. Do you know?
 - MR. BADALA: Same objections.
- 20 A. I don't know that. I would say, you
- 21 know, the jail or someplace like that, but most
- 22 of that -- I mean, we did the Medicaid expansion
- 23 in Ohio, so I would think most of that would be
- 24 reimbursed by federal. I honestly don't know.
- 25 Q. Have you seen any information or

Page 175

- Page 177 1 memoranda of any interviews with any healthcare
 - 2 providers who wrote any of the prescriptions in
 - 3 connection with Exhibit A?
 - 4 MR. BADALA: Objection to form.
 - 5 Outside the scope.
 - A. No, I have not.
 - 7 Q. And I think the last kind of
 - 8 question or area, you mentioned -- I just want
 - 9 to follow up. You testified that when you heard
 - 10 these anecdotal reports, you went back and you
 - 11 checked OARRS data, perhaps amongst others, in
 - 12 connection with your database of overdose
 - 13 deaths. Did I get that right?
 - A. Right. We were cross-checking our
 - 15 heroin overdoses against the OARRS database. We
 - 16 would also, I should say -- and I think this
 - 17 started about 2014 or '15. We were sending
 - 18 lists of our prescription opioid deaths
 - 19 quarterly to the Ohio Department of Health as
 - 20 part of a grant, but the specific checks we were
 - 21 doing in the office that I mentioned were on the
 - 22 heroin overdose population.
 - 23 Q. And you were looking for what?
 - 24 A. Well, there was, again, the
 - 25 anecdotal evidence that we may be seeing a

1 data as a county was to go back and look at our 2 decedents, our drug overdoses, and establish

- 3 that link that they had to the --
- Q. Doctor, I'm going to have to move to 5 strike. We're going to have to ask for more
- 6 time because this is not even remotely
- 7 responsive.
- MR. BADALA: That was -- he just
- 9 said that in response to that, that's what they 10 did. They started looking at the data.
- MR. CHEFFO: I'm getting an entire
- 12 speech about the heroin --
- 13 MR. BADALA: You are completely
- 14 incorrect. That is completely responsive.
- 15 Q. Is there anything that the county
- 16 did in response to any of these anecdotal 17 complaints other than what you've just told us?
- 18 A. The county hospital, after they
- 19 initiated Project DAWN, opened an office of
- 20 opioid affairs to monitor prescribing within the 21 county hospital, and that was with follow-up to
- 22 people who might have been overprescribing, and,
- 23 you know, to just look at that and potentially 24 try to steer them towards less prescribing.
- 25 Q. Anything else?

- 1 transition from prescription opiates to heroin.
- 2 We had a spike in heroin mortality, and the
- 3 function of going back to look at that was to
- 4 firm up to our satisfaction that this was, in
- 5 fact, the relationship. I think the data to
- 6 inform that was critical because, you know,
- 7 policies get into trouble when you have
- 8 inadequate data, and I think that this was
- 9 really something that we wanted to be sure we
- 10 were right on.
- 11 Q. Did the county conduct any studies
- 12 to assess the potential impact of pharmaceutical
- 13 marketing on prescribing practices in Cuyahoga? 13 don't have a DEA number, I'm not writing
- 14 A. The county itself, I don't -- not
- 15 that I know of.
- 16 Q. Any neighboring counties that you're 17 aware of?
- A. Marketing practices -- I'm sorry.
- 19 Read it one more time.
- 20 O. Sure.
- 21 Did the county conduct any studies
- 22 to assess the potential impact of pharmaceutical
- 23 marketing on prescribing practices or did a
- 24 neighboring county?
- 25 You know, I'll say no because I

Page 180

- 1 would show a prescription from a pharmacy? A. You know, our access to that
- 3 database evolved over time, so originally -- oh,
- 4 one other person I spoke to in preparation was
- 5 the head of the OARRS, Chad Garner. But our
- 6 access to this actually predated his becoming 7 the head of that.
- 8 We reached back to them because of
- 9 the concern that the prescription opioids might
- 10 be creating that drug-addicted population who
- 11 eventually move on to heroin; and when we
- 12 originally requested that access, because I
- 14 prescriptions for opioids, I could not actually
- 15 get access as a prescriber, so what they did,
- 16 and it's part of OARRS' mission, is they'll
- 17 support public health initiatives to, you know,
- 18 ultimately respond to responsible opioid
- 19 prescribing. They gave us de-identified data.
- 20 So what I could tell from that was
- 21 the overdose victim -- those were the names we
- 22 supplied, what they had been prescribed, but
- 23 what I could not see was who was doing the
- 24 prescribing. So it became hard for us to do
- 25 anything about doctor shopping or really a lot

Page 179

- 1 think there were reports that I read about, you
- 2 know, how did this opioid crisis, you know,
- 3 start, and they would point to things like, you
- 4 know, marketing practices. But the county
- 5 specifically studying that, that -- I don't know
- 6 of anything specific research-wise.
- 7 Q. If someone has an overdose death of
- 8 heroin, can you determine whether they ever had
- 9 a prescription opioid?
- MR. BADALA: Objection to form. 10
- Q. A lawful prescription opioid. 11
- 12 MR. BADALA: Outside the scope.
- 13 A. What we were doing going back into
- 14 the OARRS file was to find if they had the
- 15 prescription.
- Q. That's what you were trying to do is 16
- 17 find out if they had a lawful prescription? 18 A. Right.
- 19 Q. And for how long did you go back?
- A. Well, I shouldn't say -- I don't 20
- 21 know that they were lawful. Whether they had a 21 that ring a bell to you?
- 22 prescription for opioid pain relievers. Whether
- 23 they were diverted or, you know, pill mill, that
- 24 I couldn't tell.
- 25 So what would it show, though? It

Page 181 1 of things that would have been specific about

- 2 diversion at a prescriber level.
- In, I want to say, about June of
- 4 2013, we get law enforcement access to the
- 5 opioid -- pardon me, the OARRS, the Ohio
- 6 Automated Reporting RX System, and at that point
- 7 I can start to go back and look at physicians
- 8 specifically and prescribers.
- So initially the -- pardon me --
- 10 2012 data was just aggregated. I could tell,
- 11 geez, a lot of these folks have prescriptions,
- 12 but I couldn't really get a good handle on what
- 13 was going on at a deeper level of, you know,
- 14 where is the diversion occurring, and there were
- 15 very lengthy reports at that time.
- Q. Are you aware of any studies that
- 17 were done by either Cleveland or Summit that
- 18 showed that well over 90 percent of the doctors
- 19 who responded indicated that they were not
- 20 influenced by pharmaceutical marketing? Does
- 22 MR. BADALA: Objection to form.
- 23 A. Not a study I'm familiar with.
- 24 Q. Over 90 percent?
 - A. I'm not familiar with any study

Page 184 Page 182 1 along those lines. 1 investigation of doctors, pharmacists, Q. And the last question, I think I 2 pharmacies, clinics, 'pill mills,' or hospitals 3 in Plaintiff's geographic area for diversion of 3 promise, is, of the three criteria, the 4 prescription opioids or the improper prescribing 4 substance abuse disorder -- we talked about that 5 earlier. 5 of opioids." A. Yeah. Sure. 6 Is that one? 7 7 Q. Other than saying that's a criteria, A. Yes. 8 The next is, "Plaintiff's knowledge 8 can you tell us anything more about how that's O. 9 of and access to data concerning prescription 9 defined, whether that's used -- something from 10 the DSM-4 or 5 or something else, or is that the 10 opioid manufacturing, prescribing, distribution, 11 extent of your knowledge? 11 or dispensing." Is that one, Doctor? A. Topic 27 for me, right? 12 12 A. That's the extent of my knowledge. 13 As I think I said earlier, there's criteria for 13 Q. Correct. 14 A. Okay. Yes. 14 that diagnosis. I don't know if they were Q. The next is topic 28, "The policies 15 specifically applied in identifying that 15 16 regarding the Ohio Board of Pharmacy's OARR\$ 16 population or which criteria were. 17 database." Is that one? 17 MR. CHEFFO: Okay. Let's take a 18 A. Yes. 18 lunch break. 19 THE VIDEOGRAPHER: Off the record at 19 And then, finally, for my portion of 20 this deposition, topic number 30, "What efforts, 20 1 o'clock p.m. 21 if any, Plaintiffs made to influence the DEA's 21 22 quota-setting process; and what actions, if any, 22 (Luncheon recess had.) 23 Plaintiffs took in response to the DEA's setting 23 24 24 of quotas." Is that one of yours, Doctor? 25 Yes, it is, sir. 25 Page 183 Page 185 1 Q. Excellent. Thank you. 1 THE VIDEOGRAPHER: Back on the 2 Let me ask you a few questions about 2 record at 1:38 p.m. 3 3 the prescription drug supply chain and diversion 4 of prescription drugs. 4 AFTERNOON SESSION Do you understand or do you have an 5 EXAMINATION OF THOMAS GILSON, M.D. 6 BY MR. BORANIAN: 6 understanding of the prescription drug supply 7 7 chain? Q. Good afternoon, Dr. Gilson. I'm 8 A. In a general way. 8 Steven Boranian. 9 Q. So prescription drugs go from a You understand you're here 10 testifying as a representative of the county, 10 prescription drug manufacturer to pharmacies or 11 healthcare facilities, there's usually a 11 correct? 12 A. Yes, I do. 12 wholesaler or distributor involved, and then the 13 drugs are prescribed to patients or dispensed to Q. So I'm going to question you on some 14 patients who hold valid prescriptions, true? 14 topics different from this morning's 15 questioning, although there may be some modest 15 MR. BADALA: Objection to form. 16 overlap. I'm going to read off those topics and 16 Sorry, Steve. Is this topic 2? 17 please, Doctor, tell me if you understand that 17 MR. BORANIAN: Correct. 18 you are testifying for the county on these 18 MR. BADALA: I'm going to also 19 object to outside the scope. 19 particular topics. 20 20 A. Right. As I understand your The first is topic number 2, 21 "Diversion of prescription opioids in 21 question, they would be receiving --22 Plaintiff's geographic area." 22 Q. My question is this: Does what I A. Yes, I do. That was one of the ones 23 just said match your understanding of the 24 that I was prepared to respond to as well. 24 prescription drug supply chain? MR. BADALA: Same objections. 25 25 Q. The next is topic number 15, "The

A. Could you read it back quick?
 Q. Let me do it again for you.

3 A. Sure. Thank you.

4 Q. A prescription drug manufacturer 5 supplies prescription drugs to a pharmacy or

6 healthcare facility, there's usually a

7 distributor or wholesaler involved, and drugs

8 are then dispensed to patients who hold valid

9 prescriptions. Does that match your

10 understanding as a physician of the prescription

11 drug supply chain?

MR. BADALA: Objection to form.

13 Outside the scope.

14 A. As a physician, yes. In this

15 county, I would say yes.

Q. And are you familiar with the

17 concept known as a closed supply chain?

18 MR. BADALA: Same objection.

19 A. No, I'm not.

Q. So within that whole process, from

21 manufacturer to the patient, product should

22 neither enter nor exit the supply chain, and

23 that's what we mean by a closed supply chain.

24 Is that clear, Doctor?

MR. BADALA: Objection to form.

Page 188

1 that have been diverted?2 MR. BADALA: Objection to form.

3 Outside the scope.

4 A. I think, you know, the data I can

5 look at evolves over time. The best number I

6 can give you is from an Ohio Department of

7 Health report from 2010, which estimated, using

8 their methodology, that somewhere about 20 to 23

9 percent of the overdoses that were being seen

10 were associated with diverted prescription

11 medication.

12 I don't know that we've actually13 looked at the percentage of diversion because

14 the crisis, as it's evolved, has really gone to

15 a point where we're not talking about the

16 diversion of legal substances so much as an

17 evolution into illegal substances.

18 Q. And that's the prevalence you're

19 currently seeing with heroin and fentanyl,

20 correct?

A. Right. That's where our opioid

22 crisis is now as of -- probably since about

23 2011, 2012. It wasn't that the opioid pain

24 reliever aspect of it and mortality associated

25 with it went away. It's just that the rise in

Page 187

A. Got it. Okay.

Q. So if a product is channeled or

3 provided to someone outside the supply chain for

4 a non-legitimate medical purpose, is that known

5 as drug diversion?

1

6 A. I could see that. I usually think

7 of it as kind of the improper use of medication

8 for non-therapeutic use, but I think we're

9 saying the same thing.

10 Q. Would that be your definition of

11 drug diversion, what you just said?

12 A. It would be one I would be willing

13 to work with, sure.

14 Q. Is drug diversion a crime?

MR. BADALA: Objection to form.

16 Outside the scope.

17 A. I believe so.

Q. When a licensed manufacturer or

19 distributor ships a prescription opioid to

20 another licensed entity for legal sale, is that

21 considered drug diversion?

A. When a licensed manufacturer ships

23 it to a distributor, no, I don't think so.

Q. What percentage of prescription

25 opioid abuse in the county stems from opioids

Page 189
1 what's been driving mortality more since those

2 years I mentioned has been the illicit drugs.

Q. But it's fair to say that the aspect

4 associated with opioid pain relievers has

5 plateaued or diminished since 2011?

MR. BADALA: Objection to form.

7 Outside the scope.

8 A. It bounces around, but it appears to

9 have plateaued after rising, yes.

10 Q. In about 2011, right?

11 MR. BADALA: Objection to form.

12 Outside the scope.

18 cover?

13 A. Sure. Okay.

14 Q. Now, the Ohio Department of Health

15 report that you just referenced, is that

16 statewide data or is that -- well, strike that.

What geographic scope does that data

19 A. It was divided into regional

20 reports, so there wasn't really any

20 Teports, so there wasn't really any

21 county-specific data that I can point to in it.

22 I do know at one point around that time the Ohio

23 Department of Health identified different

24 counties that they thought were having a problem

25 with opioid pain relievers. Most of them were

1 in the southern part of the state, though

- 2 Cuyahoga County was one of those counties as 3 well.
- 4 Q. Now, you've said the county has not
- 5 really tracked the percentage related to
- 6 diverted opioids, but has the county ever
- 7 collected any information from which that
- 8 percentage could be calculated on a countywide
- 9 basis?
- 10 A. I would think that would be more at 11 a state level. I'm not aware of anything at the
- 12 county level that I could think of off the top
- 13 of my head. The prescribing information would
- 14 be more state level, so OARRS and things like
- 15 that, which would have the pharmacies
- 16 responding, would be more state -- might drill
- 17 down into the county, but I don't know that.
- 18 The county itself would not collect that data to
- 19 the best of my knowledge.
- 20 Q. Let me ask you about how diversion
- 21 occurs. When a patient gives or sells his or
- 22 her medication to someone else, that's drug
- 23 diversion, true?
- 24 A. I'd consider that, sure.
- 25 If a doctor intentionally

- Q. Do you agree that almost all
- 2 prescription drug diversion occurs after
- 3 prescription drugs have been dispensed to
- 4 patients?
- A. I wouldn't know. I mean, I am
- 6 certainly aware of instances where it has been
- 7 dispensed to the patient and instances where
- 8 somebody may overmedicate themselves or they're
- 9 selling drugs or they're potentially just having
- 10 leftover drugs that somebody has access to, but
- 11 I wouldn't know that I would say the majority
- 12 would be that. I wouldn't have an opinion on
- 13 it.
- 14 Q. So those are all examples of drug
- 15 diversion that occur?
- 16 A. At a patient level.
- 17 Q. At a patient level. Very well.
- Can you give me any examples of 18
- 19 diversion that occur before drugs have been
- 20 dispensed to patients?
- 21 A. I think the overprescribing, the
- 22 pill mill scenario, the robbery of a pharmacy,
- 23 the influx of large amounts of drugs beyond the
- 24 population density would be indications to me of
- 25 diversion.

- 1 overprescribes medication without establishing a 1
- 2 doctor/patient relationship and without a valid
- 3 medical purpose, is that drug diversion?
- 4 A. I think I would consider that the 5 same, yes.
- Q. When a drug user or consumer steals 7 prescription drugs from another patient, is that 8 drug diversion?
- A. Yes. They weren't -- they're
- 10 outside their intended recipient.
- Q. Is doctor shopping a well-known form 12 of diversion?
- 13 MR. BADALA: Objection to form.
- 14 A. I would consider that it's within
- 15 the intent to obtain multiple prescriptions.
- Q. And doctor shopping is defined as
- 17 you defined earlier today, correct?
- 18 That's the definition I use. I know
- 19 that some other individuals, when I talk, we use
- 20 slightly different variations, but that was
- 21 actually one our task force or our Poison Death
- 22 Review Committee received from the medical
- 23 director of our alcohol, drug abuse and mental
- 24 health services department, so that's the one
- 25 we've used since inception.

Page 193

Page 192

- Q. Can you identify any examples of
- 2 drugs being stolen from pharmacies in Cuyahoga
- 4 A. I am aware of that phenomenon
- 5 happening, but I don't have specifics I could
- 6 share with you.
- 7 Q. And when a doctor intentionally
- 8 overprescribes prescription drugs, the diversion
- 9 occurs after the drugs have been dispensed to a
- 10 patient in that example, true?
- A. Okay. I can see your point. 11
- 12 Q. And when a drug distributor
- 13 distributes drugs lawfully to a pharmacy and
- 14 those drugs are then dispensed to a patient and
- 15 then diverted to another, that occurs after the
- 16 product has been dispensed to patients, true?
- 17
 - A. Sure. I would say so.
- Q. Has the county ever investigated any 18
- 19 pharmaceutical distributor or manufacturer for 20 drug diversion?
- 21
 - MR. BADALA: Objection to form.
- 22 A. When we filed the lawsuit, I know
- 23 they were named as defendants.
- 24 Q. Sure.
 - Other than this lawsuit, has the

1 county ever investigated any pharmaceutical

- 2 distributor or manufacturer for drug diversion?
- 3 MR. BADALA: Objection to form.
- 4 Outside the scope.
- 5 A. Not that I know of.
- 6 Q. Had the county ever considered doing 7 that before it filed this lawsuit?
- A. I know there were concerns about
- 9 just how many opioids there were in our county.
- 10 Whether it was discussed, you know, to look at
- 11 distribution, manufacturing, marketing and
- 12 things like that -- there were a lot of
- 13 discussions with different task forces how that
- 14 could have been done, but to the best of my
- 15 knowledge, they didn't get beyond the discussion 15 law enforcement and other regulators? 16 phase.
- 17 Q. Has the county ever investigated any
- 18 of the Defendants in this case for drug
- 19 diversion other than filing this lawsuit?
- 20 MR. BADALA: Objection to form.
- 21 Outside the scope.
- 22 A. Let me just review all the
- 23 Defendants. I know we were investigating
- 24 prescribers more than the actual distribution
- 25 companies. I'd have to say prior to the filing

Page 195

- 1 of the lawsuit, I'm not aware of any specific
- 2 county initiatives to investigate the
- 3 pharmaceutical or distribution companies that 4 are mentioned here.
- Q. Are you aware of any instance where
- 6 any of the Defendants in this lawsuit sold or 7 distributed prescription opioids outside the
- 8 closed supply chain?
- MR. BADALA: Objection to form. 10 Outside the scope.
- A. Not that I'm aware of. 11
- 12 Q. Now, when a patient fills a
- 13 legitimate and valid prescription, can any of
- 14 the Defendants in this lawsuit stop that patient
- 15 from reselling their pills?
- MR. BADALA: Objection to form. 16
- 17 Outside the scope.
- 18 A. I don't see how they could.
- 19 Q. Can any of the Defendants stop that
- 20 patient from sharing his or her medication with
- 21 someone else?
- 22 MR. BADALA: Same objections.
- 23 A. Again, I don't see how they could do
- 24 that.
- 25 Q. Do any of the Defendants in this

Page 196

- 1 lawsuit have any power to arrest people engaged 2 in drug diversion?
- MR. BADALA: Objection to form. 3
- 4 Outside the scope.
 - A. I don't know of any arrests.
 - Q. So along those same lines, would any
- 7 of the Defendants have -- do any of the
- 8 Defendants have any power to revoke any
- 9 professional licenses, such as doctors or
- 10 pharmacists?

5

6

13

14

- 11 MR. BADALA: Objection to form.
- 12 Outside the scope.
 - A. Not that I know of.
 - Would those be issues addressed by
- MR. BADALA: Objection to form.
- 17 Outside the scope.
- A. They would be investigations by law 18
- 19 enforcement, I would think, and oversight by
- 20 regulatory boards, in our case in the state, not
- 21 at the county level.
- Q. Has the county ever reported doctors 22
- 23 to the State Medical Board for suspected
- 24 diversion of controlled substances?
- 25 Α. Yes.

- Q. In your office, the medical examiner 1 2 has done that, right?
- 3 A. Yes, we have. I would say they were
- 4 reported to the Board of Pharmacy under the
- 5 criteria that I mentioned this morning. If we
- 6 saw high dosages that were being given by a
- 7 doctor or if we saw that an individual had
- 8 received the doctor shopping -- met the doctor
- 9 shopping criteria, we would refer that
- 10 individual, the overdose victim, to Board of
- 11 Pharmacy.
- 12 I'm also aware that the Division of
- 13 Child and Family Services also had some similar
- 14 anecdotal things, which I do not have specifics
- 15 for, but also made reports about concerns about
- 16 diversion of drugs.
- 17 There were, obviously, prosecutions
- 18 of doctors who were diverting drugs through the
- 19 prosecutor's office.
- 20 Q. And the prosecution was at the
- 21 county level, correct?
- 22 A. No. Actually, there were
- 23 prosecutions of diversion or individuals -- you
- 24 know, in terms of county, there were federal
- 25 prosecutions, especially as the opioid crisis

- 1 evolved to the point where we were seeing more
- 2 of the heroin and fentanyl deaths. And I
- 3 specifically met with Carole Rendon about
- 4 strategies on those prosecutions. So I would
- 5 say that there were death specification
- 6 discussions that we had with the Federal
- 7 Department of Justice and, you know, those
- 8 sentencing guidelines were certainly discussed
- 9 in our U.S. Attorney's task force because they
- 10 can tend to be significantly longer sentences
- 11 for individuals.
- 12 Q. Let me ask you about the medical
- 13 examiner office's reports to the medical board
- 14 for investigation. When did the office first do
- 15 that?
- 16 A. We started to collect the data from
- 17 the Board of Pharmacy in 2012, but that was
- 18 de-identified, so we couldn't really find out
- 19 who was prescribing.
- 20 When we did our Poison Death Review
- 21 Committee in 2013, that's when we started to
- 22 identify doctor shoppers. At that point about
- 23 36 percent of our heroin overdose deaths -- and
- 24 it would have been in 2013 we would have started
- 25 those reports, and would have continued into
 - Page 199
- 1 2014 as well, and other years. I mean, we
- 2 haven't stopped some of these efforts, but that
- 3 would have been the start of that.
- Q. So you reported certain doctors to
- 5 the medical board in 2014. Have you done it in
- 6 subsequent years?
- 7 A. Yes.
- Q. And in what years have you done it
- 9 since 2014?
- 10 A. I think every year until the
- 11 present.
- 12 Q. And have any suspensions --
- A. You know, let me take that back
- 14 because with this magnitude of the crisis, we
- 15 fell behind in terms of our, you know, ability
- 16 to check OARRS data and we just finished 2016's
- 17 data. We did 2015. 2014, 2015, 2012, those
- 18 dates I would be willing to say with certainty
- 19 we did the reports, 2016 to say we just
- 20 finished. And the specific look we were doing
- 21 there was with fentanyl. Whether those have
- 22 been reported, I'm not certain enough to say
- 23 that that actually has happened. It would be
- 24 our intention to do so.
- 25 Q. And, to be clear, those are reports

1 of doctors to the medical board, true?

2 A. Board of Pharmacy, yes. The Board

- 3 of Pharmacy will oversee that aspect of the
- 4 investigation. We will refer decedents to them
- 5 for further evaluation and investigation.
- 6 Q. So have you ever referred a doctor 7 to the medical board for overprescribing or for
- 8 drug diversion?
- 9 A. Our practice would be to report to
- 10 the Board of Pharmacy. I don't know to what
- 11 extent they would coordinate with the medical 12 board.
- 13 Q. Have any suspensions or prosecutions
- 14 resulted from your reporting of particular
- 15 physicians to -- we'll just stick to the state?
 - MR. BADALA: Objection to form.
- 17 A. I'm not aware, once we referred
- 18 them, what the consequences of those
- 19 investigations were.
- 20 Q. So, to your knowledge, there have
- 21 been no consequences; is that right?
- 22 MR. BADALA: Objection to form.
- 23 A. -- be disappointed in that, but we
- 24 referred them to the appropriate investigative
- 25 agency; and as I mentioned earlier, the county
- Page 201 1 prosecutor has also participated in prosecutions
- 2 of pill mill doctors and things like that as
- 3 well.
- 4 Q. But you don't know if there's been
- 5 any result from your reporting of doctors to the
- 6 medical board or the board of pharmacy, right?
- 7 MR. BADALA: Objection to form.
- 8 Outside the scope.
- 9 A. No, I don't.
- 10 Q. Have there been other times when the
- 11 county has suspected diversion that you haven't
- 12 already described to me?
- 13 A. As I mentioned, the diversion
- 14 concerns that would be expressed with the
- 15 Division of Child and Family Services in the
- 16 course of custodial placement, investigation of
- 17 children who were born with positive toxicology,
- 18 my discussions with them were that they would
- 19 report, again, instances to the Board of
- 20 Pharmacy and that they would refer them, again,
- 21 for investigation beyond their capacity.
- 22 Q. So you've not made any reports,
- 23 then, directly to any state agency other than
- 24 the Board of Pharmacy; is that correct?
- 25 MR. BADALA: Objection to form.

Page 204 Page 202 1 A. I cannot speak for the whole county, 1 know that. 2 so I don't know where those referrals were from Q. Are you aware of any instance where 3 the Division of Child and Family Services -- the 3 the county reported a specific suspicion of drug 4 diversion to any of the Defendants in this case? 4 appropriate agency at the state level to receive 5 those complaints, as the county understands it, A. Seeing it from that perspective, I 6 is the Board of Pharmacy, but whether 6 explained how we've been trying to kind of work 7 individuals made those referrals to other 7 with our pharmacies to address the overdose 8 places, including the Board of Medicine, which 8 crisis. Those are people we have communicated 9 would certainly be somebody overseeing medical 9 with. To specifically address diversion at the 10 practitioners' conduct, may have happened. I 10 county level to any of the Defendants, including 11 don't know for certain whether it did or did 11 those pharmacies, that would not have been 12 not. 12 something we would have done. I think we may 13 Q. Are you aware of any referrals to 13 have done that further upstream through pharmacy 14 the dental board? 14 again, Board of Pharmacy. 15 A. No, I am not. 15 We did -- I take that back, too. 16 Q. Are you aware of any referrals to 16 One year we did -- for 2014 we tracked pharmacy 17 the nursing board? 17 data to see if there was specific pharmacies 18 A. No. 18 that were being identified as frequent sources 19 I should back up with the dentists. 19 or multiple sources of diversion. So if we used 20 There are certain medical dentists, doctor of 20 the same paradigm, it was kind of if we had five 21 medical dentistry, and they may have been on our 21 pharmacies that were being used by an individual 22 reports and I don't know about them, but 22 within a one-year period, we did report that to 23 specifically that I knew this was a dentist and 23 the Board of Pharmacy in addition to the doctor 24 we made a referral, that I can't say. 24 shopper prescribers. 25 Q. Have you ever reported anything or 25 Q. Were there occasions when the county Page 203 Page 205 1 has the county ever reported anything to the 1 suspected diversion but made no report to 2 veterinary medical licensing board? 2 anyone? 3 A. Not that I know of. 3 MR. BADALA: Objection to form. 4 4 Q. Has the county ever notified any of A. I don't know. None that I know of. 5 the Defendants of any suspected drug diversion? 5 O. Are there instances in which the A. I mean, we've shared things, data, 6 county is aware that drug diversion is occurring 7 and that it continues to occur today? 7 that the county has collected with folks like --8 I know CVS Pharmacy has, you know, agreed to 8 MR. BADALA: Objection to form. 9 Outside the scope. 9 sell naloxone without a prescription. We would 10 have made that effort to all of the pharmacies 10 A. I think we continue to run our OARRS 11 locally in response to the drug epidemic, which 11 reports at the medical examiner's office on our 12 is an outgrowth of the diversion I think. So 12 decedents and we have, you know, continued to 13 that would have been something. 13 find doctor shoppers up into, you know, recent 14 Q. My question is, have you ever 14 years. We, again, you know, make those 15 reported ---15 referrals and tend to make those referrals. So 16 MR. BADALA: Were you done with your 16 I would say that, you know, the number of doctor 17 answer? 17 shoppers has not gone down to zero, so we're 18 still aware of diversion and reporting it. 18 Q. I thought you were done. I'm sorry. 19 MR. BADALA: Only if you're done. 19 And one of the benefits, I would 20 A. I think that, you know, those 20 say, of, you know, the evolution of our 21 entities were probably the ones we had contact 21 prescription drug monitoring program, in

52 (Pages 202 - 205)

22 association with other states developing these

25 lines more easily to identify doctor shopping in

23 in response to diversion, is that we are now

24 able to identify people who can cross state

22 with. We did not, to the best of my knowledge,

23 reach back to the manufacturers. I don't know

24 to what extent the local task forces or anybody

25 would have spoken to distributors. I do not

- 1 that capacity, so that if they were not
- 2 necessarily doctor shopping in Cuyahoga County,
- 3 we might be able to identify them through going
- 4 to Pennsylvania or West Virginia or someplace
- 5 like that.
- Q. When did the county first becomeaware that drug diversion was occurring within
- 8 the county?
- 9 A. You know, that's a hard question to
- 10 answer because I think at some level drug
- 11 diversion has gone on for a very long time. So,
- 12 you know, there were people who would write
- 13 prescriptions for codeine back in the 1970s
- 14 during that heroin epidemic that I've been told
- 15 about. There were, you know, diversions that
- 16 were going on, you know, back in the 1980s per
- 17 the prosecutor's discussion with me. I would
- 18 say with regard to this crisis, we started back
- 19 in the opioid prescription phase to track
- 20 oxycodone in terms of mortality in the medical
- 21 examiner, then coroner's office, back in 1998.
- 22 So I would say, you know, diversion has a broad
- 23 definition, and it probably has gone on for a
- 24 very long time, whether somebody is giving
- 25 somebody a pill because they complained of

- 6 Page 208
 - 1 by its nature is somewhat clandestine, so may 2 not be able to provide solid evidence of it, but
 - 3 I think there were suspicions where the pill
 - 4 mills were more prevalent in the southern part
 - 5 of the state, that they may have contributed to
 - 6 pills coming up to our county as well.
 - 7 Q. And what is the basis for what you
 - 8 just told me? In other words, what information
 - 9 are you relying on to describe this drug
 - 10 diversion occurring outside of the county?
 - 1 A. Primarily discussions with law
 - 12 enforcement who would have been present at task
 - 13 force meetings. They would be both local law
 - 14 enforcement, state law enforcement, state
 - 15 representatives, and including our, you know,
 - 16 federal partners with regards to diversion of
 - 17 drugs into our area. Again, I'd have to point
 - 18 back to the two task forces, the Board of Health
 - 19 one with Vince Caraffi and then the U.S.
 - 20 Attorneys with Steve Dettelbach and Carole
 - 21 Rendon.

4

- Q. Does the county keep any records or
- 23 statistics of the source of diverted drugs that
- 24 have an impact within the county?
- 25 A. I'm not sure I understand your

Page 207

- 1 something. But diversion on the scale that we,
- 2 you know -- it's getting that attention in the
- 3 prosecutions, I would say the prosecutor related
- 4 to me that their prosecution stepped up in the
- 5 late 1990s and through the 2000s.
- 6 Q. Is the county aware of diversion
- 7 occurring outside the county that has an impact
- 8 within the county?
- 9 A. I would suspect that, you know, the
- 10 pill mills and other places certainly have an
- 11 impact. The fact that we see doctor shopping in
- 12 jurisdictions outside of Cuyahoga County with
- 13 individuals dying here I think would tend to
- 14 indicate that there is a diversion problem
- 15 outside of Cuyahoga County as well.
- 16 Q. And where is that occurring?
- 17 A. Where is what occurring?
- 18 Q. So if there's diversion occurring
- 19 outside of Cuyahoga County, as you've described,
- 20 that has an impact within the county, where is
- 21 that diversion occurring?
- A. Well, the doctor shopping, as I
- 23 mentioned, could be other counties. It could
- 24 be, as I mentioned, recently other states that
- 25 we've been able to look at. And the diversion

- 1 question. Do they keep a record of diverted
- 2 drugs that would produce overdoses, fatalities?
- 3 Q. Sure. So let me ask it again.
 - You've described you've heard from
- 5 law enforcement professionals in connection with
- 6 task forces that drug diversion outside the
- 7 county might be having an impact within the
- 8 county. Does the county have any record of that
- 9 happening? If I wanted to look for documents
- 10 reflecting that dynamic, what would the county
- 11 have, if anything?
- MR. BADALA: Objection to form.
- 13 Outside the scope.
- 14 A. Well, it's probably more of a local
- 15 law enforcement function, so the county wouldn't
- 16 have those records individually. They would be
- 17 a local law enforcement. That said, the
- 18 sheriff's department provides local law
- 19 enforcement for some of the smaller
- 20 municipalities in our county and they may have
- 21 that data. I am not aware of that.
- Q. Are you aware of any data tracking
- 23 the source, the geographic source of diverted
- 24 drugs that made their way into Cuyahoga County?25 MR. BADALA: Objection to form.

- 1 Outside the scope.
- 2 A. Am I aware -- sorry. I was looking
- 3 out the window, but am I aware of --
- 4 Q. Are you aware of any data which
- 5 would reflect the geographic source of diverted
- 6 drugs that have an impact within the county?
- 7 MR. BADALA: Same objections.
- 8 A. Well, sure. I mean, you know, more
- 9 recently with the fentanyl epidemic, we were
- 10 quite aware from medical examiner investigations
- 11 that some of those, you know, drugs were coming
- 12 from China. There were, you know, reports of
- 13 individuals trafficking drugs from Mexico into
- 14 this area along our interstates.
- 15 In terms of diverted drugs and the
- 16 source there, you mean the opioid prescription
- 17 pain medication. That I'm not as aware as --
- 18 having as clear identification of a source on
- 19 that.
- Q. So the examples of drugs being
- 21 imported from China and Mexico, those have to do
- 22 with the illicit shipment of drugs, correct?
- A. Which the county would maintain is
- 24 an extension of the opioid crisis. They are
- 25 illicit drugs, yes.

Page 211

- 1 Q. And so that does not fall within the 2 definition of drug diversion, does it?
- 3 MR. BADALA: Objection to form.
- 4 Q. You may think that they're related,
- 5 but those are not diverted drugs, are they?6 A. Fentanyl is a Schedule 2 drug and
- 7 it's being diverted into this country.
- 8 Q. But our definition of drug diversion
- 9 is when a drug leaves the closed supply chain
- 10 for an illegitimate medical purpose. So illicit
- 11 drugs, they're never within the closed supply
- 12 chain; the use of illicit drugs is not drug
- 13 diversion, is it?

14

- MR. BADALA: Objection to form.
- 15 A. No. I think the consequence of the
- 16 opioid pain relievers creates this climate where
- 17 we see a heroin crisis and a fentanyl crisis,
- 18 though, so I don't think it's completely a
- 10 modgii, so i don't mink it s completely t
- 19 stretch to go back and say that the diversion
- 20 and overprescribing that was done prior to the
- 21 crises is completely separate from the crisis we
- 22 deal with now.
- Q. I understand your opinion on that.
- 24 I'm not asking you now whether they're
- 25 completely separate. What I'm asking is, is the

- 1 supply of illicit fentanyl from Mexico drug 2 diversion?
- 3 MR. BADALA: Objection to form.
- 4 Asked and answered.
- 5 A. Within your definition of that
- 6 closed chain, no.
- 7 O. And the same is true for illicit
- 8 fentanyl from China, correct?
- 9 A. Within the closed chain, again,
- 10 that's true.
- 1 Q. Do you have any information or
- 12 data -- does the county have any information or
- 13 data suggesting that diverted drugs from Florida
- 14 are making their way into Ohio?
- 15 A. It would be anecdotal, talking to
- 16 law enforcement. And I believe at the time I
- 17 had those conversations. Florida had not enacted
- 18 pill mill legislation, so our pill mill
- 19 legislation in Ohio came in 2011, and I think
- 20 there were adjacent states, including Florida,
- 21 who did not enact that legislation until later,
- 22 and it was again through discussions with law
- 23 enforcement that I was made aware, as a county
- 24 agent in the medical examiner's office, as with
- 25 the task forces which have county representation
 - Page 213
- 1 as well as other partners, that there were drugs
- 2 that were being brought from other jurisdictions
- 3 into Ohio and into Cuyahoga County.
- 4 Q. And what has the county done to --
- 5 if anything, to interdict that flow of drugs
- 6 into the county?
- A. Those would be law enforcement
- 8 things. I mean, we have, as a county, designed
- 9 protocols for the investigation of drug-related
- 10 deaths, and they were shared with local law
- 11 enforcement as well as our sheriff for training,
- 12 and we would basically instruct them -- I mean,
- 13 it was developed in conjunction with law
- 14 enforcement processing a death scene, which the
- 15 medical examiner's office would notify them
- 16 about, so that should these cases come to
- 17 prosecution in the future, the evidence that
- 18 would be needed to facilitate that would be more
- 19 acceptable than if you were trying to start that
- 20 investigation as much as months afterwards when
- 21 the death was finally ruled.
- In terms of other means of, you
- 23 know, trying to minimize diversion, the county
- 24 sheriff's office instituted a drug drop box
- 25 program that would enable people who had

Page 214

1 medications in their medicine cabinets, opioid

2 pain relievers -
3 Q. Let me cut you off there, Doctor.

4 The question was what has the county done to

5 interdict drugs, the flow of drugs, from outside

6 the county, and I think you've answered the

7 question. Is there anything else you wanted to

9 A. I would like to think that -- and 10 it's your time and I really am very sensitive to 11 that, but I'd like to say that, you know, that

8 add to that?

12 diversion out of the medicine cabinets that I

13 was just mentioning about by reports that were 14 more on a national level was a very significant

15 problem. We introduced in Cuyahoga County, with

16 the support of our sheriff, who was a county

17 official, drug drop boxes, drug take-back -18 Q. Doctor, the question pending is, has

19 the county done anything to interdict the flow,

20 which the county is claiming, the flow of drugs

21 from other states. If you finished answering,

22 then I'll ask you another question.

23 A. Oh, I thought you wanted me to go on

24 about what I was talking about.

25 Q. I wanted you to answer the question.

1 law enforcement.

2 Q. Referring to the City of Cleveland,

Page 216

3 right?

4 A. Pardon me?

5 Q. Referring to cities, right, when you

6 say "local law enforcement"?

7 A. Cities, yeah. It would not be

8 necessarily a county. But I have to stress the

9 county sheriff provides that service to some of

10 the smaller counties that otherwise could not

11 afford it. So they would do some investigation.

12 Investigation would also be done at the level of

13 the prosecutor's office, though that may be

14 significantly overlapping with local law

15 enforcement.

16 Q. Which county agency or agencies are

17 responsible for investigating the

18 overprescription of opioid medicines?

19 MR. BADALA: Objection to form.

A. That would be a state function. I

21 mean, the investigation of overprescribing would

22 be a Board of Pharmacy issue and we would report

23 things there as we detected them for further

24 investigation, but beyond that, that would be

25 something that would have been more handled at a

Page 215

4

12

A. Sure.

1

Q. Okay. Thank you.

3 Has the county dealt with law

4 enforcement in other places like Florida to5 interdict the flow of drugs into the county if

6 the county is claiming that's happening?

7 A. Again, I would say a lot of that 8 might be local law enforcement the county would

9 not be aware of. With regard to task forces and

10 federal partners, I would say that we are

11 sharing information through them, Department of

12 Justice, Drug Enforcement Agency, and I would

13 say that that would be a means of, you know, a

14 more global approach than just our region.

Q. Let me ask you about theinvestigation of drug diversion, and these

17 topics somewhat overlap, Doctor.

18 A. Which topic are we on?

19 Q. We're on topic 15, but again,

20 they're not so neatly contained.

21 Which county agency or agencies are

22 responsible for investigating drug diversion?

A. Well, I think our sheriff, as a law

24 enforcement agency, would do that, but primarily

25 the investigation of diversion would be local

Page 217 1 state level -- or a federal level, I mean, if

2 you know, there was some issue of that, and

3 sharing information across multiple partners.

Q. Does the county collaborate with

5 state or federal agencies in that effort?

6 A. Our task forces have representation

7 from local, county, state and federal level

8 people, so we would be sharing that information.

Q. Is that collaboration formalized in

10 writing, in a memorandum of understanding or any

11 other writing?

MR. BADALA: Objection to form.

13 A. These committees were formed. I

14 mean, the U.S. Attorney's committee keeps

15 minutes, has monthly meetings, and would address

16 these kinds of topics. We would share things

17 like that. I had a personal meeting with Carole

18 Rendon to discuss strategies about drug

19 prosecutions and mixed intoxications. I mean,

20 some of those things we have done. Some of them

21 may not be documented as well.

Q. So you've told me about the

23 referrals that the county has made to state

24 authorities. How many cases of drug diversion

25 has the county itself investigated?

- 1 A. That may be something the prosecutor 2 could tell you better than I.
- 3 Q. Do you know how many county 4 investigations have resulted in disciplinary 5 proceedings or criminal charges?
- MR. BADALA: Objection to form. 7 Outside the scope.
- A. I'd have to say, again, you know,
- 9 the disciplinary process for pharmacies or
- 10 prescribers would have occurred outside of the
- 11 county's framework. It would be a state
- 12 function.
- 13 Q. But you mentioned the county
- 14 prosecutors. I'll ask you again. Do you know
- 15 how many county investigations have resulted in 15 in terms of identifying impacts of illegal 16 criminal charges?
- 17 MR. BADALA: Objection to form.
- A. I'd have to say again the county
- 19 prosecutor is in a better position to answer 20 that than I am.
- 21 Q. Has there been diversion occurring
- 22 that the county has not investigated?
- A. I guess there's diversions they
- 24 don't know about.
- 25 Other than not knowing, is there any

- Q. And that's a local law enforcement
 - 2 function, not a county function, true?
 - A. Exactly. Right. Cleveland is their

Page 220

- 4 biggest city, but it's not under the county's
- 5 direction.
- 6 Q. So how many cases related to the use
- 7 of illegal opioids has the county investigated,
- 8 including heroin and fentanyl?
- A. Tough question. I can tell you how
- 10 many fatalities we've had. How many overdoses
- 11 potentially --
- 12 Q. I'm --
- 13 A. -- I couldn't give a specific answer
- 14 because that's one of the challenges we faced,
- 16 opioids, is if we try to track emergency room
- 17 data, they're not always coded appropriately or
- 18 they may be coded as something different. So I
- 19 think that would be a very tough number to
- 20 actually get in terms of the impact of illegal
- 21 opioids and what might have been followed up on,
- 22 what might not have. I don't know.
- 23 Q. So the answer is in the end you
- 24 don't know, right?
- 25 A. Give me your question again. I

1 reason the county hasn't investigated diversion 2 more?

- 3 MR. BADALA: Objection to form.
- 4 A. Not that I know of.
- O. Has the county dedicated resources
- 6 specifically to the investigation of drug
- 7 diversion?
- A. Through the sheriff's office, again,
- 9 as a local law enforcement agency I'd have to
- 10 say, but again, a lot of these investigations do
- 11 not start at the county level. They start with
- 12 local law enforcement.

18 Outside the scope.

- 13 Q. And are you aware of any local law 14 enforcement, including the county sheriff,
- 15 dedicating resources specifically to the
- 16 investigation of drug diversion?
- 17 MR. BADALA: Objection to form.
- A. I don't know. I want to say that I 19
- 20 anecdotally heard that Cleveland -- the City of
- 21 Cleveland had done that, but I don't know that
- 22 for certain. They had a narcotics unit, and I
- 23 believe they were investigating diversion as
- 24 part of their duties, but it's outside the scope
- 25 of what I know for certain.

- 1 really feel like I'm not helping, but I want to.
- 2 Q. How many cases relating to illegal 3 opioids, including heroin and fentanyl and
- 4 carfentanil and others, has the county
- 5 investigated?
- 6 MR. BADALA: Objection to form.
- 7 Outside the scope.
- 8 A. I'd have to say I don't know and I
- 9 don't know if it's knowable.
- 10 Q. Do county agencies prescribe
- 11 opioids?
- 12 MR. BADALA: Objection to form.
- 13 Outside the scope.
- A. I know opioids are prescribed at the
- 15 jail as part of the medical treatment. I
- 16 believe the jail is staffed by MetroHealth
- 17 Medical Center for care. Other than that, I
- 18 don't know that they're prescribing opioids.
- Q. Do county-affiliated hospitals or
- 20 healthcare facilities prescribe opioids?
 - MR. BADALA: Same objections.
- 22 A. Our county-affiliated hospital is
- 23 the MetroHealth Medical Center, so it would be
- 24 the same one that services the jail. It's a
- 25 large hospital. They would prescribe opioids

1 for certain.

- Q. And has the county ever investigated 3 diversion that might be occurring in connection
- 4 with patients being treated by county
- 5 representatives, either in the jail or at the
- 6 hospital?
- MR. BADALA: Objection to form. 7
- 8 Outside the scope.
- A. I do know that the MetroHealth
- 10 Medical Center initiated an office of opioid
- 11 safety, and one of the functions of that would
- 12 be to investigate prescribing practices within
- 13 the county hospital, within MetroHealth Medical 13 it was never volunteered because we could not
- 14 Center, and then there would be a loop
- 15 potentially closing back on individuals who were 15
- 16 identified who might have been overprescribing 16
- 17 or felt to be overprescribing outside of the
- 18 basic, you know, metrics that they were using.
- 19 I don't know what those metrics are, but there
- 20 was definitely feedback in that office of opioid
- 21 safety to the prescribers within that system,
- 22 and they would be the prescribers in the jail as
- 23 well because they oversee the jail -- healthcare
- 24 service at the jail. They don't oversee the
- 25 whole jail. And I think, you know, that office

Page 224

- 1 Q. Has the county ever asked for ARCOS 2 data at any time?
- 3 MR. BADALA: Objection to form.
- 4 A. In my discussion with the DEA
- 5 representative, he said that that access would
- 6 never have occurred, so I don't think we ever 7 asked.
- 8 Q. That conversation occurring last
- 9 Friday, true?
- 10 A. Yeah, but, you know, I sit on the
- 11 task force with this fellow and he was certainly
- 12 aware of their database, I was aware of it, and
- 14 access it.
 - Q. So you have interfaced with DEA?
 - A. Absolutely.
- Q. And during that time have you ever 17
- 18 asked for access to ARCOS data?
 - MR. BADALA: Objection to form.
- 20 A. I guess no because we knew we
- 21 weren't going to get it.
- 22 Q. Well -- but if the county is
- 23 concerned with drug diversion and the abuse of
- 24 drugs, wouldn't that information be useful to
- 25 you?

12

19

- 1 of opioid safety would also be overseeing those
- 2 physicians as well.
- Q. Have there been any criminal charges 4 or disciplinary proceedings arising from that 5 investigation?
- A. I do not know.
- 7 Q. Are you familiar with the ARCOS
- 8 database, Doctor?
- A. In a very general way.
- Q. Are you aware that ARCOS is a 10
- 11 database through which distributors and
- 12 manufacturers report controlled substances
- 13 transactions to the DEA?
- A. Yes. 14
- 15 Q. Have you ever -- has the county ever
- 16 had access to the ARCOS data?
- 17 A. No. I know recently the county's
- 18 attorneys received information related to the
- 19 ARCOS database, but the county itself has no
- 20 direct access to that.
- 21 Q. So you're aware that the county,
- 22 through its attorneys, was granted access to
- 23 ARCOS data in 2018, but the county itself has
- 24 not seen those data; is that what you're saying?
- 25 A. That's -- that's correct.

Page 225 MR. BADALA: Objection to form.

- 1 2 A. Absolutely. Yes, it would have been
- 3 very helpful.
- Q. But you never asked DEA about it, 5 did you?
- 6 A. Because we knew that we weren't
- 7 going to have -- or they never made it any
- 8 clearer to us that it was not something we as a 9 county would have access to.
- Q. They never offered, right? 10
- A. They never offered. 11 Q. And you never asked, right?
- 13 MR. BADALA: Objection to form.
- 14 A. No. I guess because we just didn't
- 15 think that that was going to happen.
- Q. Are you familiar with the term 16
- 17 "suspicious order report"?
- 18 A. No.
- 19 Q. Is the county familiar with the
- 20 requirements that DEA registrants have for
- 21 reporting suspicious orders of controlled
- 22 substances to the DEA?
- 23 A. In a general way, yes.
- 24 Q. Has the county ever seen a
- 25 suspicious order report?

- To the best of my knowledge, no.
- 2 Has the county ever asked DEA for
- 3 information or access to suspicious order 4 reports?
- 5 A. We have not, but again, my
- 6 understanding is that that wouldn't be something
- 7 that would be granted to the county, so we
- 8 didn't ask.

1

- 9 The answer is you didn't ask, true? Q.
- 10 We did not ask.
- Q. So if the county, again, was 11
- 12 concerned or is concerned with diversion and
- 13 abuse of controlled substances, wouldn't that
- 14 information have been useful to the county?
- MR. BADALA: Objection to form. 15
- 16 A. Sure would have, yeah.
- 17 Q. Now, we've talked quite a lot
- 18 already about the OARRS database, right?
- 19 A. Yes.
- 20 Q. Let me ask you flat out, Doctor.
- 21 What is the OARRS database?
- 22 A. It's a prescription drug monitoring
- 23 program that's operated at the state level, and
- 24 in Ohio we call it OARRS. It has other names in 24 don't remember. I know that it was pharmacy
- 25 different states.

Page 227

- 1 The function of it is to provide a
- 2 database of prescribed controlled substances.
- 3 The OARRS database was formed in 2006,
- 4 legislation I think enabled it in 2005, and then
- 5 it became operational towards the end of 2006.
- 6 It was formed at least in response to Kentucky
- 7 forming a prescription drug monitoring system
- 8 and a concern that Kentucky residents were
- 9 coming to Ohio, where we were not monitoring
- 10 these things, for drug -- obtaining drugs.
- So data started to be collected, and
- 12 then, going forward, pharmacies would enter the 12 what we were trying to do at that point was to
- 13 data from prescribing information into OARRS,
- 14 and then that could be accessed by prescribers,
- 15 law enforcement, and I believe distributors at
- 16 different levels, partly if there was an active 17 investigation.
- Q. What do you base that understanding
- 19 on, that the distributors had access to the
- 20 OARRS data?
- 21 A. It's my recollection of my
- 22 conversation with the director of OARRS. Or
- 23 maybe it was at a pharmacy level. I don't
- 24 remember. I don't want to be dogmatic about
- 25 that. I don't recall.

Q. So you don't recall why you just 1

- 2 said that distributors had access to OARRS data?
- A. Well, I was thinking distributor
- 4 pharmacists, the pharmacies.
- Q. Okay. I just wanted to clear that 6 up.
- 7 A. Distributors -- I'd have to say I
- 8 don't remember that detail.
- O. So the OARRS system has information
- 10 on all outpatient prescriptions for controlled
- 11 substances and other -- a few other drugs,
- 12 right?
- 13 A. When it started, the data that was
- 14 entered was from pharmacies, and then in 2011
- 15 there were requirements to enter data from
- 16 medications that were being dispensed from
- 17 prescriber's offices, so they wouldn't
- 18 necessarily have gotten into a pharmacy.
- Q. And then drug wholesalers were also
- 20 required to submit information to the OARRS
- 21 database, true?
- 22 MR. BADALA: Objection to form.
- 23 A. I'd have to say I believe so, but I
- 25 data.

1

Page 229

- Q. OARRS has been a helpful tool in
- 2 identifying drug diversion, right?
- A. I said it. So did the prosecutor.
- 4 Yes, it has.
- 5 O. Has the county ever used OARRS data?
- A. We've used it at the medical
- 7 examiner's office extensively.
- O. Let's start with that. So how has
- 9 the medical examiner's office used OARRS data?
- 10 A. We especially used it when we became
- 11 aware of the heroin crisis in our county, and

- 13 see if what we were hearing anecdotally, that
- 14 this represented a shift from the prescription
- 15 pain medications to the illicit heroin was
- 16 referable back to the prescribing practices of
- 17 these individuals who had died of heroin
- 18 overdose. So, as I said, we started to collect
- 19 that data in a de-identified form in 2012. We
- 20 continued until we got full access in 2013, and
- 21 we continue to collect the data and have that
- 22 access with the idea of trying to stay relevant
- 23 as our crisis evolves, so that -- now heroin,
- 24 and we've evolved to fentanyl, and those still

- 1 created. They've received prescription opioids.
- Q. So we've talked a little bit about
- 3 that, the data analysis you've done. Is there
- 4 any other use of OARRS data? For example, when
- 5 you have a subject, a decedent, does the office
- 6 do anything with OARRS data in connection with
- 7 that decedent?
- A. I mean, you know, as I mentioned
- 9 before, if we see multiple prescribers, we will
- 10 start to alert investigative agencies about
- 11 that.
- 12 Q. Do you try to pull an OARRS file for
- 13 every decedent, Doctor?
- A. We have tried to pull an OARRS file
- 15 for every heroin overdose from 2012 forward and
- 16 for every fentanyl overdose, and that started
- 17 actually when the fentanyl part of the crisis
- 18 got worse, which was 2015.
- Q. Let's look through some documents
- 20 and try to nail down this a little bit, Doctor.
- 21 I'm going to mark this as the next in order.
- 22 THE WITNESS: Would this be a good
- 23 time for a break?
- 24 MR. BADALA: Yeah. We've been going
- 25 about an hour. Let's take a five-minute break.

- - Page 231
 - MR. BORANIAN: Okay.
- 2 THE VIDEOGRAPHER: Off the record at
- 3 2:33 p.m.

1

- 4 (Recess had.)
- THE VIDEOGRAPHER: Back on the
- 6 record at 2:49 p.m.
- 7 BY MR. BORANIAN:
- Q. Dr. Gilson, you've made reference a
- 9 couple of times to a task force or task forces
- 10 --
- 11 A. There are two essentially in our
- 12 county, yes.
- 13 Q. -- including one involving Attorney
- 14 Carole Rendon. Can you tell me who else is on
- 15 those two task forces?
- A. We would be, the county, the medical
- 17 examiner's office. City of Cleveland would have
- 18 their public health -- or health department
- 19 individuals, as well as police department. The
- 20 County Board of Health would have representation
- 21 there, individuals from MetroHealth Medical
- 22 Center, Dr. Papp from Project DAWN. Cleveland
- 23 Clinic would have a representative I'm certain.
- 24 There were individuals from the governor's
- 25 office and the State Attorney General's office

Page 232

- 1 who were present. I can't say they were always
- 2 at every meeting, but they certainly were
- 3 represented there. Individuals from the
- 4 treatment and recovery community sober houses
- 5 and those individuals.
- I'm sort of running around the table
- 7 in my head who might be sitting there, and I may
- 8 have overlooked somebody, but that's a good
- 9 starting list, I would guess.
- 10 Q. Have you covered both task forces
- 11 you referred to?
- 12 A. Thinking more of the U.S. Attorney's
- 13 with Carole, but I would say there was a lot of
- 14 overlap between the two, and that the health
- 15 department was more Cuyahoga County, so the City
- 16 of Cleveland's health department was not there.
- 17 There would be presentations from different
- 18 people, too, like community groups that were
- 19 trying to address, you know, interventions,
- 20 educational strategies. That would have been
- 21 more likely at the Board of Health, but there
- 22 were also, you know, individuals who were
- 23 representing education at the U.S. Attorney's
- 24 task force as well.
- 25 Q. Were there any private citizens as

- 1 members of either of those task forces?
- 2 A. I think the individuals in the
- 3 recovery community were essentially there as
- 4 private citizens. I mean, they were, you know,
- 5 representing that viewpoint, which is very
- 6 valuable to us. But in terms of just an
- 7 at-large member from the county, that I don't
- 8 think we had.
- Q. And I should have asked you this
- 10 first, but can you please name for us the two
- 12 A. I call them, and I hope this will be
- 13 clear enough -- I don't know what their formal
- 14 names are as I sit here, but the Cuyahoga County
- 15 Board of Health task force, which was in the
- 16 injury prevention program at the Board of
- 17 Health. That's Vince Caraffi, who is the one
- 18 that chaired that up until recently. He stepped
- 19 down, and April Vince is in charge of that
- 20 coordination now.
- 21 The second one was the U.S.
- 22 Attorney's task force, which I mentioned, and
- 23 that was convened with Steve Dettelbach, who was
- 24 our U.S. Attorney at the time it started, and he
- 25 had called our summit at the Cleveland Clinic at

Page 234 Page 236 1 the end of 2013. Steve Dettelbach was replaced 1 your office, true? 2 by Carole Rendon, who was our U.S. Attorney. A. We had aggregate data that was Q. I think you've answered the 3 supplied by the Board of Pharmacy through OARRS 4 for 2012. We were not granted full access to 4 question, Doctor. 5 MR. BADALA: Were you done answering 5 that data. 6 the question? Q. Well, did you -- I'm not asking 6 7 Q. The question was what were the two 7 about full access to aggregated data. I'm 8 task forces, and you've now named two task 8 asking about access to an OARRS report for a 9 subject being investigated in the medical 9 forces. 10 A. Oh, okay. 10 examiner's office. You had access to those 11 11 reports for the individuals you were 12 (Thereupon, Gilson Deposition 12 investigating even prior to 2013, right? 13 Exhibit 9, E-Mail String, Beginning 13 MR. BADALA: Objection to form. 14 14 Bates Number CUYAH_001709118 -A. We had incomplete access to those 15 Marked Confidential, was marked for 15 individuals. 16 purposes of identification.) 16 Q. If an individual died in 2010 and 17 - - - - -17 was under investigation in your office, you had 18 Q. Let me direct your attention to 18 access to that individual's OARRS report, true? 19 Exhibit 9, Dr. Gilson. Is this an e-mail 19 MR. BADALA: Objection to form. 20 exchange in February 2013 between you and 20 A. Again, I would say not the full 21 someone named Rose and an attorney at the Board 21 report, but we had access to some of their OARRS 22 of Pharmacy named Danna Droz? 22 report, yes. 23 A. Yes. 23 Q. You had access to that individual's 24 Q. If you go to the second page on the 24 prescription history, right? 25 back of the document there. Danna Droz writes in 25 MR. BADALA: Objection to form. Page 235 Page 237 1 the second paragraph, "In talking with A. We had access to the prescription 1 2 Dr. Gilson, he wants to obtain data on persons 2 history, but not to the prescriber information, 3 who died sometime in the past for research 3 yes. 4 purposes. His right to obtain identified data 4 Q. And that's true since the inception 5 is limited to persons with whom he is currently 5 of OARRS in 2006, you had that particular 6 involved. So he may request an OARRS report 6 access, right? 7 during the process of an autopsy or death 7 MR. BADALA: Objection to form. 8 investigation. He cannot request retrospective 8 A. I requested access to OARRS. I 9 data even though he could have requested it at 9 don't believe the agency, the coroner's office, 10 the time of death." 10 had that access. I don't know that they pursued 11 Is that what it says, Doctor? 11 it or if they were even aware of it. I became 12 A. That's my understanding of it, yes. 12 aware of it and that's when I started to pursue 13 Could I finish reading it just for a second? 13 it. Q. Are you finished, Doctor? 14 14 O. Whether the office was aware of it 15 A. Give me just a second. 15 prior to 2012, the office could have requested 16 Q. Just look at me when you're done. 16 and could have received an OARRS report for an 17 A. Okay. 17 individual it was investigating as early as Q. So in February of 2013 you had 18 inception of the program, true? 19 access to OARRS for any subject that was 19 MR. BADALA: Objection to form. 20 currently under investigation in your office, 20 A. I can't answer that because I had a 21 true? 21 lot of difficulty myself obtaining that access. 22 A. That's what this reads, yes. 22 Q. Well, when you asked for access, 23 Q. And that was true even before 2013, 23 they told you that you can have access for an 24 right; that is, you had access to OARRS reports 24 individual during the process of an autopsy,

60 (Pages 234 - 237)

25 right? That's what they told you, right?

25 for individuals who you were investigating in

Page 238 Page 240 1 A. That's what this says here, but --1 investigating? Q. And that access was available to you 2 MR. BADALA: Objection to form. 3 3 since the inception of the program, you just 4 Q. So you mentioned, Doctor, that you 4 never asked, right? 5 had eventually received de-identified data? MR. BADALA: Objection to form. A. I was obtaining this, you know, 6 A. Yes, I did. 7 7 trying to reach out to get this for a period of 8 8 time before this and not getting a lot of (Thereupon, Gilson Deposition 9 Exhibit 10, Article Entitled "The 9 headway with it. 10 Cuyahoga County Heroin Epidemic," 10 In 2017 the Board of Pharmacy was marked for purposes of 11 actually created a special designation based on 11 12 identification.) 12 discussions that we were having around this for 13 13 coroners and medical examiners to guarantee they 14 would have access. A lot of the coroners in 14 Q. And let me show you Exhibit 10, 15 which is an article you published in 2014, and 15 Ohio are elected physicians who are not trained, 16 this article describes de-identified data --16 like me, to be death investigators, so they 17 could access OARRS through their own DEA license 17 analysis of de-identified data for 2012 18 fatalities; is that right? 18 because they were prescribers. I could not 19 A. What page are you at? 19 because I did not have a DEA license, and as I 20 tried to go into this to obtain the access, my 20 Q. Just take a look at the abstract. 21 It says in the third paragraph, "The medical 21 recollection, as the medical examiner, an agent 22 of the county, was that that was difficult 22 examiner's office conducted a retrospective 23 analysis of 2012 fatalities to identify 23 because I was not treating people with opioids. 24 potential risk factors and intervention points." Q. You keep saying when you obtained 25 That's the de-identified data you received from 25 access, Doctor. As a matter of fact, the Page 241 1 medical examiner's office has always had access 1 OARRS, true? 2 to OARRS and to an OARRS report, including A. The OARRS data is part of that. We

3 prescribing history, for as long as OARRS has 4 been in inception; is that right? MR. BADALA: Objection to form. 5 Q. You may not have had access to 7 retrospective de-identified data before you 8 asked in 2013, but, like we said, in 2010 or 9 2008, if you had a subject you were 10 investigating, you could get that person's 11 prescription history, true? 12 MR. BADALA: Objection to form. A. I don't think that was actually my 13 14 experience in 2011 when I started the process. 15 Q. Did you ask before 2013? 16 A. Yes, I did. 17 What did you ask for before 2013? A. I wanted access to the OARRS 19 database to see if we could establish the 20 relationship between the 2000 -- pardon me, the 21 heroin epidemic and the prescribing practices of 22 those decedents before they died. 23 Q. And had you ever -- before placing

24 that request in 2012, had you ever requested an

25 OARRS report for an individual you were

3 were identifying a lot of different things in
4 terms of what we were looking at here to try to
5 see if we could identify intervention points.
6 The OARRS data at that time, as I say, was
7 de-identified and incomplete, but we mentioned
8 it as much as it was helpful and relevant to the
9 investigation, retrospective investigation of
10 these fatalities.
11 Q. So Exhibit 10 is an article that you
12 published, right?
13 A. Yes, it is.
14 Q. And it's titled "The Cuyahoga County

15 Heroin Epidemic," right?
16 A. Yes, it is.
17 Q. This article reports on your

17 Q. This article reports on your 18 analysis of 161 heroin-related deaths in 2012, 19 true?

A. Yes. We actually excluded one of them because it was a stillborn and our feeling was that that really wasn't relevant to the population we wanted to look at.

Q. And one of the observations that you

25 made was that a prescription for legal

61 (Pages 238 - 241)

Page 244 Page 242 1 controlled substances was noted in 64 percent of 1 A. We have collected and analyzed data 2 deaths associated with heroin, true? 2 on heroin overdoses through 2016. We recently A. What page are you on? It sounds 3 got a grant for an employee to finish up the 4 familiar to me. 4 work on additional OARRS examination, and we 5 Q. The abstract, the beginning of the 5 started to look retrospectively at the fentanyl 6 abstract. 6 overdose data in 2016, when it became a 7 A. I'm sorry. Yes, that's right. 7 substantially larger problem. 8 Q. And that's based on that 8 9 de-identified 2012 OARRS data, right? 9 (Thereupon, Gilson Deposition 10 A. Yes. 10 Exhibit 11, Document Entitled Q. Now, I've seen this number 64 11 11 "Overdose Deaths in Cuyahoga 12 percent in other documents that relate to you 12 County," Beginning Bates Number 13 and your office. When we see that number, 64 13 CUYAH_001397330, was marked for 14 percent who had a prescription for legal 14 purposes of identification.) 15 controlled substances, that number comes from 15 16 the analysis of the 2012 de-identified OARRS 16 Q. This is Exhibit 11, Dr. Gilson. And 17 data, right? 17 this cover sheet is merely to note the Bates 18 A. Yes. 18 number, which is Cuyahoga 001397330. The 19 Q. Now, once you started taking 19 document starts on the second page, Doctor. And 20 advantage of your access to OARRS in 2013, did 20 this appears to be a set of slides with your 21 you start gathering data prospectively for 21 name on the first page. 22 individuals who the office was investigating? 22 Doctor, what is this document? A. We would, in the death review 23 A. It looks like a -- I don't remember 24 committee, wait a period of a few months for 24 which talk it was, but a talk I put together 25 final certification of deaths, and while we were 25 to -- I don't know who the audience was for it. Page 243 Page 245 1 I didn't specify. A talk of mine, though. 1 doing that process, we would collect an OARRS 2 Q. I'm trying to figure out when you 2 file on them. So, in that sense, it's 3 did this. It might help to look at the fifth 3 retrospective, we're looking back at their 4 page of the presentation. There's a chart there 4 prescription history. 5 that reflects some 2014 data. So would it be Q. Okay. Fair enough. A. Prospectively we're recruiting 6 fair to date this in 2015? 7 MR. BADALA: Objection to form. 7 people, but we're looking retrospectively at 8 A. Probably, yes. I would not put it 8 their prescription histories. 9 any earlier than 2014, and it looks like we have Q. My question is, going forward from 10 2013, you were collecting OARRS reports for each 10 completed data for 2014, so I would say it was 11 into 2015, because you wouldn't have had that 11 of your subjects, right? 12 A. Right. And at that time, around 12 data until actually 2015. Q. If you go to the eighth page of the 13 mid-year, we did get the final access to the 13 14 presentation, that's entitled "Heroin Epidemic." 14 prescribers in addition to the drugs that were 15 being prescribed. 15 It looks like that, Doctor (indicating). Q. And have you collected that 16 A. Let me just get there. 17 information from OARRS for each of your subjects 17 Okav. 18 since 2013 up until today? Q. It refers to a 2012 retrospective 19 review, and that's the same review that we just A. We're trying. As I said before, you 20 went over in Exhibit 10, the article you wrote, 20 know, just the burden of the extent of the 21 crisis, we have fallen behind on that, so we 21 right? 22 have --22 A. This is the review that we did at 23 the medical examiner's office using only our 23 Q. And --24 A. If I could finish. 24 data, and we did not have primary sources of

25 information. That would have been in the 2013

Sure.

Q.

D 246	D 249
Page 246 1 review. So this paper mentions some things from	Page 248 1 break, but if you could indulge me, don't go
2 2013, but I think the gist of the bulk of it is	2 away, Doctor.
3 about the 2012 review that we did in the office.	3 THE VIDEOGRAPHER: Off the record at
4 Q. The paper referring to Exhibit 10,	4 3:09 p.m.
5 right?	5 (Short recess had.)
6 A. Exhibit 10, yes.	6 THE VIDEOGRAPHER: Back on the
7 Q. Okay. Fair enough.	7 record at 3:10 p.m.
8 The next bullet point there under	8 BY MR. BORANIAN:
9 the Heroin Epidemic title is "2013 prospective	9 Q. This is Exhibit 12. Oops. I marked
10 review of heroin mortality done with ME staff,"	10 the wrong one. Hang on.
11 et cetera, et cetera, right?	11
12 A. Right. We assembled people within	12 (Thereupon, Gilson Deposition
13 the room at the ME's office in a committee that	13 Exhibit 12, Document Entitled
14 I called together to review that data, and the	14 "Opioid Crisis Response: Examining
15 goal was for example, in law enforcement we	15 Overdose Deaths at Cuyahoga County
16 had the sheriffs there, a county officer. He	16 Medical Examiner's Office," with
17 had a representative who could provide	17 Attached Sheet Bates Numbered
18 information to us, partly on arrests but mostly	18 CUYAH_001684555 - Marked
19 on incarceration data, because what we were	19 Confidential, was marked for
20 trying to do in this was to identify	purposes of identification.)
21 intervention points, and one of the risk factors	21
22 for fatal overdose was somebody who was coming	22 Q. This is Exhibit 12, Dr. Gilson.
23 out of incarceration or a treatment facility.	23 This appears to be a presentation, or maybe a
24 So that was kind of the makeup of this.	24 poster, with your name on it, along with
25 Q. So if you go to the next page, we're	25 Dr. Deo. Can you tell us what this is, Doctor?
Page 247	Page 249
1 talking about a set of 194 overdose fatalities,	1 A. I'm not completely certain, but I
2 right?	2 think this was a poster that Dr. Deo, who is a
3 A. Right.	3 student at the Case Western School of Public
4 Q. And that's 2013, right?	4 Health, produced based on research he was doing
5 A. Right.	5 at our office.
6 Q. And then if you go three more pages,	6 Q. So it's entitled "Opioid Crisis
7 it says, "PDR Findings." It looks like that	7 Response: Examining Overdose Deaths at Cuyahoga
8 (indicating). 9 A. Yes.	8 County Medical Examiner's Office," with a Bates
9 A. Yes. 10 Q. It says here 73 percent of heroin	9 number noted on the second page as 001684555, 10 and if you look over at the far right column,
11 overdose victims had a file with OARRS, right?	11 Doctor, it says, "OARRS Data, Fentanyl Overdose
12 A. Right. About three-fourths.	12 Deaths February 2017," right?
13 Q. Now, we've also seen that number, 73	13 A. Right.
14 percent, in other documents associated with you	14 Q. Is this part of the analysis of
15 or your office. And when we see that, 73	15 fentanyl deaths in connection with OARRS that
16 percent of heroin overdoses who had an OARRS	
17 file, that refers to this 2013 data set, right?	17 A. Yes.
18 A. Right.	18 Q. It says, "55 fentanyl overdose
MR. BORANIAN: I'm told the phone	19 deaths in February 2017," right?
20 isn't working. I'm not sure what to do about	20 A. That was one of the worst months in
21 that.	21 Cuyahoga County, yes.
22 MR. GALLUCCI: I think that's	Q. And the fourth bullet point says
23 probably from before when we heard it right	23 that 41 out of 55 had an OARRS file, right?
24 before we took a break.	24 A. That's correct.
25 MR. BORANIAN: Okay. Let's take a	Q. That's about 80 percent, right?
	l .

63 (Pages 246 - 249)

Page 250 A. Yes.

- 2 Q. Now, you've mentioned earlier in the
- 3 deposition that same number, 80 percent. Is
- 4 this the source for your citation of the 80
- 5 percent figure?
- A. No.

1

- 7 Q. Okay. Has the medical examiner's
- 8 office done any analysis of fentanyl overdose
- 9 deaths other than what's represented here on
- 10 Exhibit 12?
- 11 A. Yes, we have.
- 12 Q. What is the source of your stated
- 13 opinion that 80 percent of fentanyl deaths have
- 14 a history of prescription medication?
- A. It's this information. I thought
- 16 you said 80 percent of our opioid deaths, heroin
- 17 deaths.
- Q. Maybe I misspoke. I'm sorry,
- 19 Doctor. I haven't looked at the transcript, but
- 20 I think you said earlier today that 80 percent
- 21 of fentanyl deaths have a recent history or a
- 22 history of a prescription drug prescription,
- 23 right?
- 24 A. No. What I said earlier today was
- 25 that approximately 80 percent of the heroin

Page 252

- 1 were as short as six months and, at the longest,
- 2 18 months. So I thought that number -- and this
- 3 was one of the reasons I wanted to continue to
- 4 collect the data -- was potentially an
- 5 underestimate.
- 6 When I saw this number, this still
- 7 actually represents, to some extent, a, you
- 8 know, initial period look-back of about two
- 9 years for virtually all of these cases in 2013.
- 10 That was a better look-back period.
- 11 Q. Let me stop you there. When you say
- 12 "this number," which number?
- 13 A. 73 percent.
 - Q. Okay. Continue.
- 15 A. Is better data, and that's really
- 16 what we were striving to get to see if we could
- 17 tie the heroin crisis back to opioid pain
- 18 relievers.

14

- 19 At the time we were collecting this
- 20 data, there was really very little, other than
- 21 anecdotal reports, to say this heroin phase of
- 22 the crisis represented a transition.
- In 2013 substance abuse and mental
- 24 health services published a bulletin, where they
- 25 had gone back and talked to actual heroin users

Page 251

- Page 253
- 1 and said, "How did you get started abusing 2 opioids," and that number was 79.5 percent, 80
 - 3 percent of those addicts said I started using
 - 4 opioid pain relievers. And when they looked the
 - 5 other direction, most of the people who were
 - 6 abusing opioid pain relievers said no, I never
 - 7 started with heroin, I'm abusing this substance.
 - So when I saw that number in
- 9 conjunction with this -- and this is again as
 - 10 more data is becoming involved -- that's where I
 - 11 draw that number of about 80 percent of our
 - 12 addicted population come from that transition.
 - 13 I can't talk to the people after they died to
 - 14 ask them how did you get started, but somebody

 - 15 did that, we didn't duplicate that effort, but
 - 16 we used this data as a support to that to say,
 - 17 listen, almost 80 percent of our overdoses have
 - 18 been using prescription opioids, some of them
 - 19 with very long track records and, in fact, you

 - 20 know, that number is very close to what's being
 - 21 quoted from the interviews with the living
 - 22 individuals who are abusing heroin currently.
 - 23 Q. The 80 percent, then, comes from a 24 bulletin that you read, right?
 - 25 A. From the substance abuse and mental

1 overdose deaths that we had in that phase of the 2 crisis had an OARRS file, and that was the 73

- 3 percent that I'm referencing here.
- Q. Okay. So that's where I'm confused
- 5 then. Okay. So what I was seeing for heroin 6 deaths is 64 percent based on the 2012
- 7 retrospective data.
- A. Sure.
- Q. I have seen 73 percent based on the
- 10 194 cases in 2013. Doctor, where do you get 80
- 11 percent of heroin-related deaths have an OARRS
- 12 file?
- 13 A. Sure.
- 14 My estimate, if I might say, is that
- 15 we estimated approximately 80 percent of the
- 16 heroin overdose victims had a history of
- 17 receiving prescription pain relievers. I take 18 that from this data, the 73 percent. And I'm
- 19 not parsing that for, you know, this is closer
- 20 to what I want.
- The 2012 data, where the 66 percent
- 22 came from, was actually limited in the time of 23 look-back because we had delay in getting access
- 24 to OARRS to do the look-back. So some of the
- 25 look-backs we did on heroin overdoses in 2012

Page 254 Page 256 1 health services. 1 go back to review the original research data. I Q. Have you reviewed the data upon 2 didn't understand you if that was what you were 3 which they base that bulletin? 3 saying. A. Yes, I did. 4 4 Q. Okay. My question was if you had 5 Q. And what form did that data take? 5 reviewed the data, so I'll ask again. A. They're interviewing heroin addicts, Did you review the original research 7 current heroin addicts, with the question that I 7 data for that bulletin? 8 said, you know, how did you get started abusing 8 MR. BADALA: Objection to form. 9 opioids, and 80 percent, 79.5 percent said that 9 Outside the scope. 10 they had started abusing prescription 10 A. No. I reviewed the bulletin and the 11 medications. 11 methods that were spelled out in it. 12 Q. Did those interviews take into 12 MR. BADALA: Do you have to take a 13 account whether those individuals had a 13 break or anything? 14 prescription for the opioid that they say they THE WITNESS: Sure. Okay. 14 15 initiated with? 15 MR. BADALA: Why don't we take a A. They talked about non-medical pain 16 five-minute break. 17 reliever use. I do not know that I remember 17 THE VIDEOGRAPHER: Off the record at 18 enough detail to say whether they had, in fact, 18 3:19 p.m. 19 obtained those legally or by diversion. 19 (Recess had.) 20 Q. So you can't tell from those data 20 THE VIDEOGRAPHER: Back on the 21 whether the use of prescription opioids was 21 record at 3:26 p.m. 22 legal or illegal for that population, true? 22 BY MR. BORANIAN: A. I don't remember exactly the -- what 23 Q. So, Dr. Gilson, we've been 24 that metric was. 24 discussing the investigation of diversion and 25 The other thing I wanted to add --25 overprescription and the use of the OARRS Page 255 Page 257 1 Q. They didn't ask about that in their 1 database. Has the county made any other uses of 2 survey, did they? 2 the OARRS database beyond what we've already 3 A. Pardon? 3 discussed? 4 MR. BADALA: Were you done? 4 MR. BADALA: Objection to form. 5 Q. They didn't ask about that in their 5 Q. Not just your office, the whole 6 survey, did they? 6 county. 7 A. Could I finish the previous thought, 7 A. We're obviously sharing our data at 8 though? 8 these task forces, including the data that we've 9 9 gleaned from OARRS -- by "we" in this case, I'm Q. Sure. A. The other thing I wanted to add 10 10 putting on my medical examiner hat -- and 11 about that study is they did a ten-year 11 impacts that could have on law enforcement, 12 look-back. Basically they wouldn't trust the 12 prosecutions, things like that. I can't 13 addict's memory beyond ten years, so they were 13 necessarily quantitate, but the collaborative 14 looking back further than we were with our data 14 effort that we created I think with this data 15 So I thought that might have explained some of 15 and pointing it back towards opioid pain 16 the smaller discrepancy, the 73 percent versus 16 relievers I think is kind of a ripple effect of 17 the 79 percent, but statistically they were very 17 using the OARRS system. 18 close. 18 Specifics in terms of using the 19 Q. In what form was that data provided 19 OARRS system, I'm aware some jurisdictions use 20 to you? 20 it to identify doctors to sign death 21 What data was that? 21 certificates. We have not done that. A. 22 Q. The data that supported the bulletin 22

65 (Pages 254 - 257)

Q. Do you know who the OARRS

23 registrants are within the county, people who

24 actually have an OARRS access set of

25 credentials?

24 data. In what form was it?

25

23 that you reviewed. You said you reviewed the

I reviewed the bulletin. I didn't

Page 260 Page 258 1 A. Within the county itself? 1 file system for county investigations of 2 Yes. 2 overprescribing of medicine? Q. 3 A. Again, at our county hospital, with 3 A. As county representatives or just 4 the office of opioid affairs that was opened, 4 the whole county? 5 they review prescribing practices with opioid Q. As representatives of the county, 6 for example, the sheriff's office or protective 6 pain relievers with the idea of addressing 7 apparent overprescribing with practitioners that 7 services or the medical examiner. A. I would know that the physicians at 8 they identify. 9 the county hospital would all have OARRS access 9 When a physician is under 10 investigation for participating in illegal 10 because that was actually part of an initiative 11 diversion, does the county take steps to stop 11 in 2015, to have all of the medical 12 the behavior during the investigation? 12 practitioners have access to OARRS, and then I 13 think the pharmacists are similar, that they 13 A. Are we talking -- I'm a little 14 confused -- pill mill scenario or something like 14 have to have access, so I would think pharmacy 15 personnel at our county hospital would have 15 that or --Q. Yeah, any doctor under 16 that; jail, by extension, as we covered that, 16 17 would have access. And we in the medical 17 investigation, whether a county employee or 18 someone running a pill mill, someone running a 18 examiner's office. The sheriff, unless it's 19 pain clinic. If that doctor is under 19 through a law enforcement, which I'm not aware 20 of -- I don't know if they do or do not. Other 20 investigation, does the county take any steps to 21 stop the illegal activity while the 21 law enforcement agencies I believe do, but 22 they're not county representatives. 22 investigation is going on? 23 Q. Does the county sheriff ever A. I mean, ultimately they would arrest 24 them, I guess, if they were founded in the 24 directly access the OARRS database? 25 A. I do not know. I don't know. As I 25 evidence collection period. I guess until you Page 259 Page 261 1 said, they have access. They can have access 1 really know that it's a crime --2 through law enforcement. 2 Q. Short of arresting somebody, is 3 Q. So other than your office, are you 3 anything done to stop the behavior that is under 4 aware of any other county office that makes 4 investigation? 5 direct access to the OARRS database? A. If I can go back to the county A. Oh, I'm sorry if I wasn't clear. 6 hospital, the example with the office of opioid 7 The county hospital has to have that access with 7 affairs there, yes, they are liaisoned with --8 its practitioners and its pharmacy. 8 through the medical staff and the practices are Q. Anyone else? Any other agencies? 9 described. And I don't think it's an immediate 10 A. Can I look at the org chart? I 10 you're doing the wrong thing so much as they 11 can't see anybody here I could say with 11 require an explanation, and if that explanation 12 certainty has access. 12 isn't satisfactory, then they're remediated to, 13 Q. Is there any database or central 13 you know, prescribing practices, maybe 14 file system for cases investigating drug 14 reacquaintance with CDC prescribing guidelines 15 diversion? 15 from 2016 or something like that as a basis.

16 MR. BADALA: Objection to form.

- 17 A. At the county level or --
- 18 Q. Yes.
- 19 A. Unless it's in the county
- 20 prosecutor's office, I'm not aware of one. I
- 21 know they have a unit who would be investigating
- 22 cases for prosecution, but otherwise, most of
- 23 the investigation of diversion and things like
- 24 that I think would be at a state level.
- Q. Is there any central database or

66 (Pages 258 - 261)

Q. Now, Doctor, I'm also going to ask

17 you about topic number 27, which is "Knowledge

18 of and access to data concerning prescription

20 or dispensing." We've already gone through

24 there other databases that the county could use

25 to gain information about the manufacturing,

19 opioid manufacturing, prescribing, distribution,

21 ARCOS and OARRS and a few others. I'm not going

So here's my question, Doctor: Are

23

22 to repeat that.

Page 262 Page 264 1 prescribing, distribution or dispensing of 1 and it's authored purportedly by the Ohio 2 opioids? 2 Department of Health. It has a number of 3 A. I just want to say, for clarity, we 3 statistics and bullet points in it. On page 12, 4 do not have access to the ARCOS database, so we 4 for example, it has numbers for unintentional 5 drug overdoses. On pages 30, 31 and 32 there's 5 could not access that. And then OARRS is really the best 6 some statistics purporting to identify how this 7 access that I know of we have for data 7 occurred. The document is entitled "Ohio's 8 concerning at least dispensing and distribution. 8 Prescription Drug Overdose Epidemic." 9 Manufacture, we don't have any independent 9 My question is, do you know where 10 access to that. And prescribing obviously does 10 these data came from? 11 come through the OARRS database. 11 A. There's a lot of data in this. 12 Q. Do you have any access to any 12 Could you be a little more specific? 13 databases from the Department of Health? 13 Q. Well, let's start with the chart A. We are in task forces with the 14 that I identified, the one on page 12, 15 Department of Health, and if I understand, 15 unintentional drug overdoses. Do you know where 16 county department of health or state department 16 these data came from? 17 of health, city department of health? 17 MR. BADALA: Objection to form. Q. Well, I was referring to the state 18 Outside the scope. 19 department of health, so let's start with that. A. They list their data sources at the 19 20 Do they have any databases that you have access 20 bottom of the page. 21 to regarding the manufacture and distribution, 21 Q. Okay. And so does the county have 22 dispensing, et cetera, of opioids? 22 access to these same data sources? A. I don't know where the Board of 23 A. I don't know if we have access to 24 Pharmacy sits, if that sits in the Department of 24 the Wonder data, or if that's pushed downward 25 Health, but we maintain that relationship with 25 towards state departments of health. That's a Page 263 Page 265 1 Department of Health through our task forces. I 1 CDC function and they tend to collaborate more 2 don't have any databases I could steer you 2 with state departments of health. I don't think 3 towards about those topics. 3 there would have been any impediment to us 4 Q. I'm going to mark this as the next 4 necessarily getting that from the Department of 5 exhibit, which is number 12. And this is a 5 Health, but it might not have come directly to 6 relatively long one, Doctor, but my question is 6 us. The Office of Vital Statistics we 7 going to be specific. This is a document that 7 contribute towards. And, again, that 8 appears to have -- we're at 13. 8 information gets tabulated. It takes a very 9 9 long time, though, for death certificate data to 10 (Thereupon, Gilson Deposition 10 get tabulated just because of an inherent lag Exhibit 13, Document Entitled "Ohio 11 11 that can be sometimes up to two years behind 12 Department of Health, Ohio's 12 real time. 13 Prescription Drug Overdose Epidemic: 13 Q. So the Office of Vital Statistics is 14 Epidemiology, Contributing Factors 14 listed as a source on many of these slides. 15 and Ongoing Prevention Efforts," 15 Just to clarify, does the county have access --16 Beginning Bates Number 16 I know you contribute to that database, but does 17 CUYAH 001547662 - Marked 17 the county have access to that database? 18 Confidential, was marked for 18 MR. BADALA: Objection to form. 19 purposes of identification.) 19 To search that database? 20 20 O. Yes. MR. BORANIAN: Can you mark that A. I don't know. I certainly would see 21 21 22 number 13, Doctor, or Sal? 22 no reason we couldn't query the Ohio Department 23 Thanks. 23 of Health for that. 24 Q. This is a document that's Bates 24 Q. Are you familiar with SAMHSA data, 25 label is 001547662. It's dated April 17, 2014 25 S-A-M-H-S-A, data?

67 (Pages 262 - 265)

- A. I had mentioned SAMHSA earlier, yes.
- 2 O. What is that data?

1

- 3 A. That's the Substance Abuse and
- 4 Mental Health Services Administration. That's a
- 5 federal entity that pretty much tracks what its
- 6 name says, substance abuse and mental health 7 services.
- 8 Q. Does the county have access to that 9 data?
- 10 MR. BADALA: Objection to form.
- 11 A. Through their publications. I don't
- 12 know -- again, I don't know if we have direct
- 13 access to their data or if we rely on their
- 14 publications and data that they might push down
- 15 toward the Department of Health. A lot of times
- 16 the federal data comes down to the Department of
- 17 Health, not down to our county level.
- 18 Q. Does the county have access to the
- 19 child and protective service database that the
- 20 state runs known as SACWIS, S-A-C-W-I-S?
- A. Which page are we on?
- Q. We're on data.
- A. Which topic?
- Q. Let me read it to you. "Plaintiff's
- 25 knowledge of and access to data concerning

Page 268

- 1 in national efforts. Informally I've certainly
- 2 reached out to colleagues in different areas,
- 3 Summit County being one; the New England states,
- 4 where I spent a decent part of my career; New
- 5 York City; participation in national
- 6 organizations around prescription drug
- 7 monitoring. I've presented at two of those
- 8 meetings in 2017 and 2018 as they were trying to
- 9 kind of formulate policies, best policies. I
- 10 kind of left both meetings with Mr. Garner, the
- 11 director of OARRS, thinking we had it probably
- 12 better than a lot of other states.
- So I'm aware of efforts by other
- 14 states, if that's answering your question.
- 15 Q. Is the county aware of any data
- 16 concerning the manufacturing, prescribing,
- 17 distribution or dispensing of opioids other than
- 18 what we've already discussed?
- 19 A. To the best of my knowledge, I've
- 20 covered everything I think I can.
- Q. Okay. Does the county have access
- 22 to any additional data that we haven't already 23 discussed?
- 24 MR. BADALA: Objection to form.
- A. Let me just read the topic.

Page 267

- 1 prescription opioid manufacturing, prescribing,
- 2 distribution, or dispensing."
- 3 A. And we're talking about child and
- 4 family service data from the state?
- 5 O. Yes.
- 6 A. I don't know if we have access to 7 that data.
- / mai data.
- 8 Q. Do you have access to any law
- 9 enforcement databases, such as the LERMs
- 10 database for the City of Cleveland?
- MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. As a county, the sheriff has access
- 14 to law enforcement databases; as an entity, law
- 15 enforcement within the county.
- 16 Q. You have access to the medical
- 17 examiner office's data, true?
- 18 A. Yes, I would hope so.
- 19 Q. Do you have access to data from
- 20 other jurisdictions, such as the federal
- 21 government, other than ARCOS, states, cities or
- 22 counties?
- 23 MR. BADALA: Objection to form.
- 24 Outside the scope.
- A. Both informally and by participation

- 1 I mean, in participation in national 2 meetings and other things like that, I would
- 3 become aware of opioid prescribing and, you
- 4 know, mortality as it impacted other areas in
- 5 the country, and colleagues, as I said, from
- 6 previous jurisdictions where I've worked or just
- 7 know, and I've had discussions with them along
- 8 those lines.
- 9 Q. Do some of the Defendants in this
- 10 lawsuit submit data to the ARCOS database?
- 11 MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. I believe that the distributors are
- 14 required to submit data to the ARCOS database
- 15 and to monitor potentially suspicious activity
- 16 with distribution. That's my very cursory
- 17 knowledge of the ARCOS database.
- Q. Does any Defendant have access to
- 19 data, to ARCOS data, other than what it itself
- 20 submitted?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope.
- A. I honestly don't know.
- Q. Do some of the Defendants in this
- 25 case submit data to ARCOS?

Page 270 1 MR. BADALA: Objection to form. 2 Outside the scope. 3 A. As I understand the ARCOS system, 4 and again, I wouldn't say I or the county would 5 be expert in that given that we have no access, 6 my understanding of how that database works 7 is --8 Q. I was asking about OARRS. Did I say ARCOS? 10 A. You said ARCOS. 11 Q. Strike that. 12 MR. BADALA: I think you keep mixing

- 13 them up. 14 MR. BORANIAN: No. Just that one
- 15 time. 16 O. Do some of the Defendants in this
- 17 case submit data to OARRS?
- 18 MR. BADALA: Same objection.
- 19 A. I think the pharmacies that I see
- 20 listed as Defendants would be submitting data to
- 21 OARRS. We previously talked about the
- 22 distributors, and I don't know to what extent
- 23 they're required to submit information to OARRS.
- 24 I just honestly don't know that. I'd have to
- 25 check that. But the pharmacies are the source

Page 272

- 1 examiner/coroner access, which no, you would not
- 2 have. What we can pull out of OARRS with that
- 3 access, I don't know how that would relate, just
- 4 not knowing what sort of access the wholesalers
- 5 or the distributors would have to OARRS.
- Q. Do any of the Defendants in this
- 7 case have access to suspicious order reports
- 8 submitted by other entities?
- 9 MR. BADALA: Objection to form.
- 10 A. The suspicious order report, as I
- 11 understand it, is a DEA reporting about quantity
- 12 of drugs that were put into an area that seemed
- 13 excessive. That's my understanding of it. And
- 14 I don't know that any entity in the county has
- 15 access to those.
- 16 Q. Do Defendants have access to
- 17 those --
- 18 A. Oh, do the Defendants?
- 19 -- other than the ones that they
- 20 themselves submitted?
- 21 A. I don't know the workings of that
- 22 system.

1

- 23 Q. Do Defendants have access to any of
- 24 the other databases we've reviewed today?
- 25 A. I don't know.

Page 271

- 1 of the information for a lot of the OARRS
- 2 database.
- Q. Does any Defendant in this case have 4 access to data other than what it submitted to 5 OARRS?
- MR. BADALA: Objection to form.
- 7 Outside the scope.
- A. I'm sorry. That's a question that's
- 9 just broad. Do they have access to what kind of 10 data.
- Q. So, for example, if my client is a
- 12 distributor. It submits wholesale data to
- 13 OARRS. Does my client have access to any data 13 I mentioned, would have to have its
- 14 in OARRS other than what itself submitted?
- 15 MR. BADALA: Objection to form.
- 16 A. I do not know what kind of access
- 17 the distributors have if they submit data to
- 18 OARRS. I'd have to say that's something the
- 19 state would be better to answer than I.
- 20 Q. Okay. Fair enough.
- 21 To your knowledge, distributors like
- 22 my client don't have access to OARRS like you
- 23 do, true?
- 24 MR. BADALA: Objection to form.
- 25 A. We have a specialized medical

Page 273 MR. BADALA: Objection to form.

- 2 A. I honestly just don't know.
- 3 Q. Doctor, topic 28 is "The policies
- 4 regarding the Ohio Board of Pharmacy's OARR\$ 5 database."
- 6 Doctor, what policies -- let's start
- 7 with written policies. What written policies
- 8 does the county have relating to the OARRS
- 9 database?
- 10 The OARRS is a state database. I
- 11 don't know that we have any specific county
- 12 policies regarding it. The county hospital, as
- 14 practitioners registered with OARRS, and to
- 15 check under specific circumstances for
- 16 prescribing pain medication, so any prescription
- 17 lasting over seven days, any continued pain
- 18 medication therapy that would extend beyond 90
- 19 days has to be revisited every 90 days. And
- 20 that would apply, again, to the medical services 21 provided in the jail.
- 22 Q. Those are state regulations, right?
- 23 A. Right. I mean, we have to comply at
- 24 the county level with the state legislations.
 - And OARRS is now mandatory, right?

- 1 A. OARRS checks, except in that setting
- 2 of like immediate post-therapy, the seven-day
- 3 window, is mandatory to be checked. And
- 4 dentists do not get an exception for that.
- 5 That's only physicians.
- Q. And that became mandatory for
- 7 physicians in 2015?
- 8 A. April 2015.
- Q. And for pharmacies in 2016, right?
- 10 A. That's my best understanding of it.
- 11 I talked with the head of OARRS and he said some
- 12 of those things are vague, but that's a fair
- 13 estimate.
- 14 Q. So it was nine to ten years before
- 15 it became mandatory?
- A. OARRS was started in 2006. The
- 17 reporting by the pharmacies about the controlled
- 18 substances was mandatory. The checks on it did
- 19 not go into place until 2015, I think we just
- 20 said, so about nine years.
- 21 Q. And for pharmacies in 2016, right?
- 22 A. Or the pharmacies.
- 23 Okay. Could that have been done Q.
- 24 sooner?
- 25 A. I think that, you know, the

- Page 276 1 that -- I believe in the emergency department at
 - 2 the MetroHealth Medical Center they did
 - 3 implement the check on OARRS for any narcotic
 - 4 prescription earlier than 2015.
 - Q. How about in law enforcement? Were
 - 6 there any policies -- are there any policies or
 - 7 procedures in the county law enforcement
 - 8 agencies that address when those employees can
 - or should access data through OARRS?
 - 10 A. Again, most of our law enforcement
 - 11 investigation of diversion, which OARRS would be
 - 12 beneficial for, would be done at a local level.
 - 13 So I don't know to what extent the sheriff has
 - 14 done that or has access to it.
 - 15 Q. How about any other agency, whether
 - 16 it's protective services or the county
 - 17 department of health; do they have written
 - 18 policies or procedures which specify when an
 - 19 employee can or should access data through
 - 20 OARRS?
 - 21 They wouldn't have access to OARRS
 - 22 because they're not prescribers, law
 - 23 enforcement, or, obviously, pharmacies. So no,
 - 24 I -- I would expect they do not because they
 - 25 don't have access to it.

Page 275

- 1 legislation regarding the practice of medicine
- 2 is always a touchy topic. And could it have
- 3 been done sooner? I guess it could have. I
- 4 wouldn't really know, you know, enough to say
- 5 how that could have been enacted.
- Q. Did the county do anything in those
- 7 intervening nine or ten years to make it
- 8 mandatory for physicians and pharmacies in the
- 9 county to report to OARRS --
- 10 MR. BADALA: Objection to form.
- 11 Outside the scope.
- 12 Q. -- or to check OARRS?
- 13 A. The county did not. Again, the
- 14 oversight of prescribing is a state function, so
- 15 it would not have really been something the
- 16 county I think would have addressed.
- 17 Q. Are you aware of any policies or
- 18 practices that specifically address when a
- 19 county agency or employee can or should access
- 20 data through OARRS?
- 21 A. I don't know the specifics regarding
- 22 the county hospital and their prescribers. I
- 23 know they have to adhere to the state
- 24 guidelines, as we mentioned, and whether they
- 25 implemented any of those guidelines earlier than 25 for the purpose of detecting and stopping drug

- Page 277 Q. And how about the medical examiner's
- 2 office; do you have policies, written policies
- 3 which address when your employees can or should
- 4 access data through OARRS?
- A. I don't know if we have them in
- 6 writing, to be honest with you, but we have used
- 7 the OARRS database for different data mining in
- 8 regard to especially our linkage of the
- 9 heroin-addicted population back to the opioid
- 10 pain relievers, and the fentanyl-addicted
- 11 population back to the opioid pain relievers as
- 12 well. But written policies, I would think that
- 13 if we had them, they should have been shared by
- 14 counsel, but I don't know that I can tell you
- 15 that for certain.
- 16 Q. And we have already covered, haven't
- 17 we, the data mining that you've done with the
- 18 OARRS database?
- 19 A. I feel like we have, but I'd
- 20 certainly be willing to help you answer any
- 21 questions you might want to ask.
- 22 Q. Now, you first requested OARRS data
- 23 in 2013. Are you aware of any effort to -- by
- 24 anyone in the county to use the OARRS database

1 diversion before 2013?

- 2 A. Using the OARRS database?
- 3 Q. Yes.
- 4 MR. BADALA: Objection to form.
- 5 A. In the course of investigations that
- 6 the prosecutor would address, I would expect --
- 7 again, this is local law enforcement, but our
- 8 prosecutor will be ultimately prosecuting those
- 9 cases. They would have accessed OARRS for that 10 purpose.
- And when I spoke with James
- 12 Gutierrez, he was also, like me, saying that
- 13 OARRS was a great tool for them in prosecutions.
- 14 Q. Did the county use OARRS for
- 15 prosecutions prior to 2013?
- 16 A. Yes.
- 17 Q. And when was the first time the
- 18 county used OARRS for prosecution?
- 19 A. I'd have to defer to the
- 20 prosecutor's office on that. I do not know the
- 21 date.
- Q. In the end, OARRS is a very useful
- 23 tool for both law enforcement and public health,
- 24 right?
- 25 MR. BADALA: Objection to form.

Page 280

- 1 Q. We're talking about policies and
- 2 procedures that relate to the OARRS database,
- 3 but I'm following up on OARRS generally. The
- 4 question is, would the investigation of drug
- 5 diversion be more difficult without the OARRS
- 6 database?

7

- MR. BADALA: Objection to form.
- 8 Q. Without access to the OARRS
- 9 database?
- MR. BADALA: Outside the scope.
- 11 A. I would say, you know, again, the
- 12 investigation of drug diversion is primarily
- 13 much more of a local law enforcement function.
- 14 Again, our sheriff could be participating in,
- 15 and certainly, as I said, our prosecutor was
- 16 able to say that the OARRS database was very
- 17 helpful in the prosecution of diversions, but
- 18 the identification of diversion, I would have to
- 19 say from a county standpoint that's probably
- 20 more something that local law enforcement is 21 doing.
- Q. Would the investigation of drug
- 23 diversion be more difficult without access to
- 24 the OARRS database?
- MR. BADALA: Objection to form.

Page 279

- 1 Outside the scope.
- 2 A. I find it very useful in my capacity
- 3 as a public health officer.
- 4 Q. And it would be more difficult to
- 5 detect and address diversion, drug diversion, if
- 6 that didn't exist, right?
- 7 MR. BADALA: Objection to form.
- 8 Outside the scope.
- 9 Q. Strike that.
- 10 It would be more difficult to detect
- 11 and address drug diversion if you didn't have
- 12 access to those data, right?
- 13 MR. BADALA: Objection to form.
- 14 Outside the scope.
- 15 A. Detect or investigate, I don't -- I
- 16 certainly would say it might be -- it's a great
- 17 tool to facilitate investigation. The detection
- 18 of it and getting started with it might be
- 19 painfully obvious in some situations.
- Q. And the investigation would be more
- 21 difficult without access to those data, right? 22 MR. BADALA: Objection to form.
- 23 Outside the scope.
- A. Which topic -- are we still on
- 25 data -- I'm sorry -- or are we back to OARRS?

- Page 281
 1 Asked and answered. Outside the scope.
- 2 A. I'd have to say it's a great tool to
- 3 do investigations on prescribing, and if we've
- 4 already mentioned those prescribing practices
- 5 that result in diversion, yes, the OARRS
- 6 database certainly would be helpful to identify
- 7 them.
- 8 Q. You're not going to answer, are you,
- 9 Doctor?

- 10 MR. BADALA: Objection.
- 11 Q. Could I ask you again?
 - A. I didn't hear what you said, sir.
- 13 Q. Forget it.
- Okay, topic 30, "What efforts, if
- 15 any, Plaintiffs made to influence the DEA's
- 16 quota-setting process; and what actions, if any,
- 17 Plaintiffs took in response to the DEA setting
- 18 of quotas."
- Doctor, is the county aware that the
- 20 DEA sets quotas with respect to Schedule 1 and 2
- 21 controlled substances?
- 22 A. I wasn't aware Schedule 1 they set
- 23 quotas on. Those are illegal drugs.
- Q. Is the county aware -- fine. Is the
- 25 county aware that the DEA sets quotas with

Page 282 Page 284 1 respect to any controlled substances? 1 federal partners. To what extent that has any A. The Schedule 2 drugs are the ones 2 influence, I have no idea, if it has any at all. 3 that are potentially addictive. Heroin is a Q. Has the county ever become aware of 4 Schedule 1, as I understand, so there better not 4 any of the quotas in any year? 5 be any quota setting by the DEA on that. A. No. Q. Is the county aware that the DEA 6 Q. And the county has not reacted to 7 sets quotas with respect to controlled 7 any of those quotas in any year? substances? 8 MR. BADALA: Objection. Outside the 9 I think in a general way they are, 9 scope. 10 yes. 10 A. Not knowing them, we could not react 11 And when did it become aware of 11 to them. 12 that? 12 MR. BORANIAN: Let's take a break. 13 A. I honestly don't know. 13 THE VIDEOGRAPHER: Off the record at 14 Q. What is -- well, strike that. 14 3:59 p.m. 15 Do you know what the aggregate 15 (Recess had.) 16 production quota is? 16 THE VIDEOGRAPHER: Back on the 17 A. No, I do not. 17 record at 4:13 p.m. 18 MR. BADALA: Objection to form. EXAMINATION OF THOMAS GILSON, M.D. 19 Q. Does the county know how the 19 BY MR. CARTER: 20 aggregate production quota is calculated? 20 Q. Good afternoon, Doctor. 21 MR. BADALA: Objection to form. 21 A. Hi, Mr. Carter. 22 Outside the scope. 22 Q. Yes. You just got my name. I'm Ed 23 A. I don't know the answer to that. 23 Carter. I've got some questions for you this 24 Q. Has the county ever made any 24 afternoon, okay? 25 comments or objections to the aggregate 25 Yeah. Sure. Page 283 Page 285 1 production quota? Q. With respect to the SAMHSA bulletin None that I'm aware of. 2 that you mentioned, what was the date of that? 3 Q. Has the county ever provided any 3 MR. BADALA: Objection to form. 4 input into that quota? 4 A. It was, I believe, August 2013. A. Again, in my discussions with our 5 Q. And SAMHSA, by its nature, was not 6 DEA liaison to the opiate task force, the 6 compiling Cuyahoga County-specific data, was it? 7 Attorney General's task force especially, that 7 It was national data, right? 8 input isn't sought from DEA and we don't 8 A. Yes, that's correct. 9 influence their quota-setting process. Q. You were also asked a question 10 Q. And that same goes for the 10 earlier whether the county ever reported 11 manufacturing quota? 11 diversion to the Defendants, and you mentioned a 12 A. If that's part of the DEA's 12 request to CVS and pharmacies to provide 13 quota-setting process, we don't influence that. 13 naloxone without a prescription. Do you recall 14 Q. And how about the procurement quota? 14 that testimony? 15 A. I'm assuming you're telling me 15 A. It came through a task force. I 16 genuine parts of that process, but we have no 16 don't remember the exact wording I said, but as 17 influence on them. 17 we were trying to blanket the community with 18 Q. No input at all, right? 18 naloxone, that was one of the interventions that A. Pardon me? 19 19 was recommended, yes. 20 No input into that at all, right? 20 O. And that's one of the interventions 21 A. I would only say, you know, as we 21 that was requested from the task force to the 22 share this data, that our office, as the medical 22 pharmacies, correct?

72 (Pages 282 - 285)

That's my understanding of that,

Q. And in response to that, the

23

25

24 yes.

23 examiner's office, and then these other task

24 force pieces of data, are being shared, that's

25 obviously something that we're sharing with

1

2

4

5

10

3 you say --

9 mortality.

11 the county?

1 pharmacies did make naloxone available without

- 2 prescription, correct?
- 3 A. Yes, they did. Or at least I know
- 4 that certain ones did, but I know that in
- 5 general that was a very positive response.
- 6 Q. Are you aware of any that refused 7 that request?
- 8 A. I don't know that I know if anybody 9 did refuse or not.
- 10 Q. I want to ask you about topic 18.
- 11 You were designated as a witness for
- 12 the county to testify on topic 18, correct?
- 13 A. Yes, I am.
- 14 Q. What did you do to prepare to
- 15 respond to questions about topic 18?
- A. I reviewed medical examiner data
- 17 with regard to overdose deaths as they related
- 18 to these medications and drugs listed here. I
- 19 also reviewed the drug chemistry data, the
- 20 seized drug data in the forensic crime
- 21 laboratory. And I think that's -- those are my
- 22 biggest pieces of that.
- Q. How far back did you review the ME
- 24 data?
- 25 A. 2006.

Q. Methamphetamine has been abused in

6 been abused in the county, correct?

12 A. We issued an alert actually earlier

A. Yes. In fact, in 2006 that was

8 actually the highest cause of drug overdose

13 in 2018, about almost a year ago, to notice that

MR. BADALA: Objection to form.

THE WITNESS: Sure. I said yes.

Q. Cocaine is one of those drugs that's

THE COURT REPORTER: I'm sorry? Did

- 14 there was an upsurge in methamphetamine. It's
- 14 there was an upsurge in methamphetamine. It s 15 not a drug we see terribly frequently in our
- 16 county, but -- there were months in 2018 where
- 17 we did, but it's really not a major player in
- 18 what gets seized, and certainly not in our death
- 19 data.
- Q. If it's not a major player, why did
- 21 the county release an alert?
- 22 A. Oh. Well, I think that was the
- 23 responsible thing to do when we saw a big uptick
- 24 in the number of seizures. Methamphetamine is
- 25 not a drug that is without its problems. It

Page 287

- 1 Q. And how far back did you review the 2 seized drug data?
- 3 A. Through 2017.
- 4 Q. So 2017 was as far back as you went?
- 5 A. Yes.
- 6 Q. Okay. Anything else to prepare on
- 7 topic 18? Did you talk to anyone specifically 8 about topic 18?
- 9 A. I discussed things with Mr. Shannon
- 10 in my office, about trends and things, as we
- 11 recalled them, and our memories were pretty
- 12 similar on those things.
- 13 Q. Anyone else?
- 14 A. Specifically on these topics, I
- 15 don't remember, but I think that's everybody.
- 16 Q. You agree --
- 17 A. That's my preparation. I should say
- 18 there's one person. That's everybody.
- 19 Q. Sure.
- You agree many illegal drugs have
- 21 been abused in Cuyahoga County?
- MR. BADALA: Objection to form.
- A. Over the course of its history?
- Q. Over the course of the time period
- 25 relevant to this lawsuit.

Page 289

- 1 certainly has issues in the southern part of
- 2 Ohio. It's not just been a big factor in the
- 3 Cuyahoga County experience.
- 4 Q. In the alert did it say anything
- 5 describing the extent to which meth was a
- 6 problem in the county? Did it say
- 7 methamphetamine is not a real problem here but
- 8 we're issuing an alert?
- 9 A. I don't remember the exact wording
- 10 of the alert, but I would certainly say,
- 11 Mr. Carter, it did not say it wasn't a problem.
- 12 Any of these drugs are problems, and the fact
- 13 that we were seeing more of it and issuing an
- 14 alert, it certainly wasn't the intention of the
- 15 medical examiner's officer or crime laboratory
- 16 to downplay that. We were issuing the alert
- 17 because we were concerned.
- 18 Q. Is marijuana an illegal drug that's
- 19 been abused in the county?
- MR. BADALA: Objection to form.
- A. Well, it's a legal substance now in
- 22 Ohio. I think the details are being worked out
- 23 now about distribution. But for the time frame
- 24 that we're talking about, most of that time it
- 25 was an illegal drug.

- 1 Q. And during that time period when it
- 2 was classified as an illegal drug was it abused3 in the county?
- 4 MR. BADALA: Objection to form.
- 5 A. Yes.
- 6 Q. What about synthetic marijuana; was 7 that abused in the county?
- 8 MR. BADALA: Objection to form.
- 9 A. You know, I saw this question, and I
- 10 would define synthetic marijuana as having a lot
- 11 of overlap with spice and bath salts, and that's
- 12 how I would answer your question, which is that
- 13 we did have spice, bath salts, synthetic
- 14 marijuana. How you described them as a problem,
- 15 probably for about a year. And we were seizing
- 16 lots of them. They were scheduled in Ohio, and
- 17 I want to say this is about 2013, and largely
- 18 vanished after that scheduling. We saw very few
- 19 of them being submitted to the laboratory.
- 20 Those numbers dropped off dramatically.
- 21 And in terms of mortality from the
- 22 synthetic cannabinoids, very, very rare. We did
- 23 research in the office and presented that on
- 24 MDPV, which I would have to look up what those
- 25 letters stand for. I think it's methyl -- I'd

Page 292

- 1 out what is just amphetamine versus
- 2 methamphetamine because of the relationship they
- 3 have in the breakdown in the body.
- 4 Q. As a result of that chemical
- 5 relationship, is it possible that the
- 6 methamphetamine overdose deaths are
- 7 underreported?

8

- A. Meaning, I guess, if I understand
- 9 you correctly, could we have something reported
- 10 as an amphetamine death and that actually being
- 11 methamphetamine --
- 12 Q. Correct.
- 13 A. -- and it would have been
- 14 misidentified? I suppose that's certainly a
- 15 possibility. I would add, too, parenthetically,
- 16 in 2017 most of our methamphetamine deaths were
- 17 in association with fentanyl and it was about 24
- 18 deaths, so the numbers aren't large, and it's
- 19 sort of one of those things I think that
- 20 fentanyl has a general trend in our county of
- 21 pulling up a lot of other drugs. So
- 22 methamphetamine, cocaine, heroin all got pulled
- 23 up in 2016 when fentanyl really took off. And
- 24 in analyzing that data, especially with cocaine
- 25 and heroin, the change wasn't due to increases

Page 291

- 1 have to look them up, but we didn't see a lot of
- 2 mortality associated with them. And in my
- 3 discussions with Dr. Papp, who's an emergency
- 4 room physician, they weren't also something that
- 5 was really dominating the picture in the
- 6 emergency rooms either. Opioids are, far and
- 7 away, dominating this picture in terms of what's
- 8 being seized and certainly what's being, you
- 9 know, a source of mortality.
- 10 Q. So lumping those together, synthetic
- 11 marijuana, spice, bath salts, those substances
- 12 were abused in the county with a focus around
- 13 2013, correct?

17

- 14 A. That's my best recollection.
- 15 Q. What about amphetamines; have
- 16 amphetamines been abused in Cuyahoga County?
 - A. I think, you know, most of that is
- 18 referable back to methamphetamine, and when
- 19 methamphetamine is broken down in the body, it
- 20 goes to amphetamine. So a lot of our toxicology
- 21 positive testing on that -- for example, in
- 22 2016, we had 15 overdose deaths with
- 23 methamphetamine -- 16 overdoses with
- 24 methamphetamine detected, 15 with amphetamine
- 25 detected, so it's a little bit harder to tease

- Page 293 1 in isolated cocaine and heroin mortality. It
- 2 was due to mixtures. Methamphetamine, being as
- 3 small as it is, we didn't do that analysis.
- Q. And the fentanyl that you referenced
- 5 pulling things up, that's illicit manufactured
- 6 fentanyl that you described earlier, correct?
- 7 A. That's -- that's our best
- 8 understanding of that, yes.
- Q. What about benzodiazepines; have
- 10 they been abused in Cuyahoga County?
- 11 A. Yes, they have.
- 12 Q. K2, has that been abused in the
- 13 county?
- 14 A. K2 is another one of the synthetic
- 15 cannabinoids, so I would sort of lump it under
- 16 the answer that I gave there.
- 17 Q. You would answer it the same way
- 18 that you did with respect to spice, bath salts?
- 19 A. Right, and the synthetic
- 20 cannabinoids, that sort of cluster, the
- 21 cathinones and other things. That was a trend
- 22 that we saw for a period of time, and mostly it
- 23 came under that heading of bath salts, but these
- 24 were other names for that.
- Q. What about hallucinogens? Has

- 1 ectasy and has LSD -- have those been abused in 2 the county?
- A. We don't see a lot of LSD in the
- 4 county, at least in the mortality data or
- 5 particularly in the seizure data. I would
- 6 hesitate to say, especially over this time
- 7 frame, that that number is zero, but again I
- 8 would emphasize it's a very small participant.
- 9 And in and of itself, LSD is not a fatal
- 10 substance in overdose. It probably would prompt
- 11 more visits to the emergency department, and,
- 12 again, based on my discussions with an emergency
- 13 room physician at one of our three healthcare
- 14 systems, it's not the player that the opioids
- 15 are.
- 16 Q. And with respect to drug abuse, the
- 17 county recognizes drug abuse that does not
- 18 result in an overdose death, correct?
- 19 MR. BADALA: Objection to form.
- 20 Q. So, for example, with LSD, you can
- 21 have people abusing the drug whether or not they
- 22 overdose and die on it, correct?
- A. Right. We don't have, for example,
- 24 a lot of deaths from marijuana. In fact, we
- 25 don't have any deaths from marijuana by itself.

Page 295

- 1 The benzodiazepines by themselves very
- 2 infrequently to vanishingly rare cause death by
- 3 themselves. Alcohol. Opioids, yes, they're
- 4 very much present there, but by themselves, not
- 5 a particularly toxic compound.
- Q. What about PCP? Has that been
- 7 abused in the county?
- A. We have a certain number of seizures
- 9 with PCP every month. It's probably similar to
- 10 oxycodone seizures, maybe about 10 to 25 a
- 11 month.
- 12 Q. Is PCP a major player?
- 13 MR. BADALA: Objection to form.
- A. I wouldn't consider it anywhere near 14
- 15 the scope of fentanyl and heroin, and I would
- 16 not, if I was handicapping the race, say in any
- 17 way that it's a major player. I wouldn't list
- 18 any of these except for the cocaine as a major
- 19 player.
- 20 Q. And every one of these drugs that we
- 21 just went through that are listed here in topic
- 22 18, cocaine, methamphetamine, marijuana, the
- 23 synthetics, amphetamines, benzodiazepine,
- 24 ectasy, LSD and PCP, every one of those has
- 25 caused addictions in the county, correct?

Page 296

- 1 MR. BADALA: Objection to form.
- 2 Outside the scope.
- A. You know, I don't want to voice an 3
- 4 opinion as to what constitutes addiction for
- 5 some of these substances because I don't know
- 6 and I don't think it's very clearly defined.
- 7 There are addictions to cocaine and
- 8 methamphetamine. Are there addictions to the
- 9 synthetic cannabinoids? I don't know how
- 10 clearly defined that is. Are there addictions
- 11 to LSD versus abuse of it? That, I don't know.
- 12 I don't think it's clear and I don't think the
- 13 county would say all of these can be potentially
- 14 addictive substances.
- 15 Q. So to put a fine point on it,
- 16 sitting here today, does the county consider
- 17 each of those substances to be an addictive
- 18 substance?
- 19 MR. BADALA: Objection to form.
- 20 Outside the scope.
- 21 A. The --
- 22 O. Hold on one second so I can cure the
- 23 objection if it's valid.
- MR. CARTER: How is that outside the
- 25 scope of the use and abuse of controlled or

- 1 regulated substances?
 - MR. BADALA: It just asked about
- 3 Plaintiff's knowledge and the actions taken.
- 4 You're taking it much further than that. You're
- 5 asking if it constitutes addiction. I don't see
- 6 the word "addiction."
- 7 MR. CARTER: So are you stipulating
- 8 for this case that abuse is not related to
- 9 addiction?
- 10 MR. BADALA: I'm reading the topics
- 11 that you wrote clearly, but you're reading
- 12 something completely different it seems like.
- 13 MR. CARTER: If the position is
- 14 abuse does not equal addiction, then that will
- 15 streamline my questions. Are you saying abuse
- 16 is not addiction?
- 17 MR. BADALA: You wrote the topics.
- 18 I'm reading exactly how you wrote it.
 - MR. CARTER: So I'll reask my
- 20 question the same way then because I'm not
- 21 worried about the objection.
- 22 Q. Does the county consider each of
- 23 those drugs on the list to be an addictive drug?
- 24 MR. BADALA: Same objections.
- 25 Outside the scope.

- 1 A. No, because abuse does not equal 2 addiction.
- 3 Q. Has the county seen reports of 4 minors using and abusing every one of these 5 substances on the list?
- A. I don't know that I could drill that 7 specifically into the data; that I know a lot of 8 the charges around these would, again, be things 9 that would be investigated by local law
- 10 enforcement, and that data wouldn't be furnished 10 wind up in our county hospital, they would also
- 11 necessarily to the county. 12 Q. From the county's perspective, is
- 13 drug abuse by minors a significant issue that 14 they're concerned in addressing and preventing? 15 MR. BADALA: Objection to form.
- 16 A. Of course. I mean, nobody wants to 17 see kids suffer. They don't like to see anybody 18 suffer from drug use and abuse, but if you were
- 19 asking me, you know, are there specific
- 20 initiatives, I believe there are. We certainly
- 21 have tried with the opioid crisis to establish a
- 22 presence in our school systems to do education
- 23 on that. I know we're not talking about the
- 24 opioids here, but -- no. I'd have to say it's
- 25 such an obvious question. Any abuse by a child

Page 300 1 would be incurring costs. We have an alcohol,

- 2 drug addiction and mental health services agency
- 3 in the county. It's separate from -- it's
- 4 legally separate from county government, but
- 5 they certainly are a group we collaborate with
- 6 on the task force and are incurring costs around 7 this.
- 8 The other thing I would say is, you
- 9 know, to the extent that these are people who
- 11 be incurring costs. Maybe they're reimbursed,
- 12 maybe they're not, but I would say they
- 13 certainly would probably cost the county money.
- 14 There hasn't been, I think, a dramatic
- 15 escalation in any of these that I am aware of
- 16 over the time frame, but at a baseline they
- 17 certainly cost the county money.
- Q. When you say there hasn't been a
- 19 dramatic escalation, what was the baseline cost
- 20 that the county incurred related to the use and
- 21 abuse of the substances in topic 18 in 2015?
- 22 MR. BADALA: Objection to form.
- 23 Outside the scope.
- 24 A. I don't have an answer to that 25 question. I did not come across that number in

Page 299

1 would be a source of concern to the county.

- Q. And given the county's concern about 3 children abusing drugs, do you understand the 4 rates or prevalence of children abusing the
- 5 drugs in this list?
- A. There's data that's collected from 7 federal groups, like the behavioral risk factor
- 8 surveys, that our County Board of Health would
- 9 be more familiar with than I. To the extent
- 10 that goes down to the county level, I would have 10 substances?
- 11 to defer to them on that. That's a somewhat
- 12 separate entity from us as the county.
- 13 Q. Of the drugs on this list, which one 14 of them is most frequently abused by minors 15 under 18?
- A. I don't think the county could give 17 you an answer on that.
- Q. Has the use and abuse of the
- 19 substances identified in topic 18 -- has every 20 one of those caused the county to incur costs?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope.
- A. To the extent, obviously, that we
- 24 have, you know, treatment programs for
- 25 individuals abusing drugs, the county certainly

- 1 my research on cost to the county on that. As I
- 2 said, some of the costs that I mentioned are 3 outside of the county, and that the ADAMHS --
- 4 that's our alcohol, drug addiction and mental
- 5 health services -- is a separate entity and
- 6 their budget is separate from the county.
- 7 Q. Is there any year from 1995 through 8 to 2018 for which you could quantify the costs 9 related to the use and abuse of the topic 18
- 11 MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. No.
- 14 Q. Given that inability, do you stand
- 15 by your testimony that those costs have not
- 16 escalated over time?
- 17 A. No. I didn't say the costs didn't
- 18 escalate. I'm sorry if I wasn't clear. The
- 19 mortality that we see with these drugs
- 20 especially, and the emergency room visits that
- 21 we see with these drugs, are not significantly
- 22 changed over time. I will make an exception
- 23 about cocaine and heroin, but in general, those
- 24 numbers haven't changed. So the treatments that
- 25 are in place for them were not, to the best of

Page 302 1 my knowledge, changing, because there wasn't an 1 Outside the scope. 2 increase in the problems these were causing with 2 A. I don't think so. 3 3 the opioid epidemic. Some of these things Q. Does Cuyahoga County have a cocaine 4 certainly would have the effect of the opioids 4 epidemic? 5 pushing a lot of things that were less prevalent 5 A. No. I mean, if I can qualify that 6 out. 6 and explain. If you look at our mortality data, 7 7 which somebody was kind enough to give me -- on So, for example, in our drug court, 8 which was started in 2007, at the time it 8 the chart this would be Exhibit 11. Cocaine is 9 started, per the presiding judge there, most of 9 shown here from 2006 to 2014, and the mortality 10 the cases they were hearing at that time were 10 hasn't changed dramatically over that period of 11 cocaine related, and over time they've evolved 11 time. I can tell you that in 2015 that was also 12 to almost exclusively opioids, to the point that 12 true, and in 2016, when we looked at that data, 13 the county had to incur the cost of setting up a 13 cocaine deaths nearly doubled in the county, 14 separate docket for drug court. 14 from about 100 to over 200. But when we 15 We had cases in place where there 15 filtered out the impact of mixtures on the 16 was a START program, which is a program that 16 cocaine data, what we saw was that, in fact, 17 brings children and parents of addicted children 17 cocaine had actually remained flat in isolation; 18 in contact with people in recovery, and that 18 in other words, cocaine without fentanyl hadn't 19 was, again, primarily driven by cocaine, but as 19 really changed, but the fentanyl had pulled that 20 the opioid crisis has worsened, the focus has 20 curve up. That was also similar for heroin.

21

25

Page 303

23 county has money to do and we have to treat as 24 many of these folks as we can. 25 MR. CARTER: I'll move to strike

1 everything after the portion of the response

21 come again towards opioids. We don't ignore the

22 cocaine population, but there's only so much the

24 laced with illicit fentanyl?

2 where it said, "in general those numbers haven't 3 changed"? 4 MR. BADALA: Just note my objection. 5 MR. CARTER: You object to my motion 6 to strike; is that what you're saying? 7 MR. BADALA: Yes. 8 MR. CARTER: Okay. Q. Do any of the Defendants in this 10 case -- have they ever made, sold, marketed or 11 distributed any of the drugs identified in topic 12 18? 13 MR. BADALA: Objection to form. 14 Outside the scope. 15 A. Many of these drugs are illegal, so 16 I wouldn't consider them controlled substances. 17 Cocaine and amphetamine and benzodiazepines are 18 legal Schedule 2 -- I think cocaine --19 medications. I do not know whether these are 20 manufactured or distributed by the Defendants. 21 Q. Does the cocaine -- excuse me. 22 Strike that. Does the county link the use and 23 abuse of the drugs in topic 18 to any specific

MR. BADALA: Objection to form.

Q. The same with respect to meth; are 2 there examples where people may have intended to 3 use meth but instead got meth that was laced 4 with other substances, such as illicit fentanyl? A. I can only say these are 6 possibilities. I can't get inside the mind of 7 what people were intending to abuse with regard 8 to your question about cocaine. Traditionally, 9 that was a drug that we saw much more prevalent 10 in the African-American community and did not 11 see a lot of fentanyl or heroin or opioid pain 12 overdoses in the community. With that rise that 13 I described, though, in 2016, we started to see 14 a rise -- actually, it went back to 2015 -- in 15 African-American fentanyl mortality, and it was 16 our concern at that time that the mixture was 17 pulling up that group. 18 On the other hand, the percentage of 19 African-American cocaine deaths relative to 20 other races declined because the mixture of 21 cocaine in the fentanyl distribution was also 22 showing up in the people intending to purchase 23 fentanyl.

So I can't be specific, especially 25 with a small subset like methamphetamine, what

Q. Is it possible that Cuyahoga County

22 residents intended to abuse cocaine and,

23 instead, ended up getting a mixture of cocaine

I think that's a true statement.

77 (Pages 302 - 305)

24

24 Defendant?

25

Page 304

- 1 they were intending to purchase and what they 2 got.
- 3 Q. How does the county define an 4 epidemic?
- 5 MR. BADALA: Objection to form.
- 6 Outside the scope.
- 7 A. With the standard definition, which
- 8 is an elevated prevalence of a disease beyond
- 9 its baseline in a community.
- Q. So when you were talking about
- 11 cocaine and the doubling of deaths between, I
- 12 think it was -- you said it was 2015 and 2016?
- 13 A. Right. Yes.
- Q. So do you consider that doubling a 14
- 15 cocaine epidemic?
- MR. BADALA: Objection to form. 16
- 17 Outside the scope.
- A. No, for the reason that I am -- that
- 19 I mentioned, which is that when you factor out
- 20 the opioid contribution to that elevation, it's
- 21 not at an increased incidence over baseline.
- 22 Q. Would you consider the number of
- 23 deaths in 2016 where cocaine was adjudicated and
- 24 certified as the cause of death, is that a
- 25 crisis for Cuyahoga County?

Page 307

- 1 MR. BADALA: Objection to form.
- 2 Outside the scope.
- A. I mean, we were in the midst of an
- 4 opioid crisis before that. Certainly there was
- 5 an acute worsening in 2016 that was driven by --
- 6 primarily by fentanyl. That's the position of
- 7 the county. The fact that cocaine was pulled
- 8 back up with that, heroin was pulled back up
- 9 with that doesn't negate the contribution of
- 10 fentanyl to that part of the crisis.
- Q. So I'm trying to understand, with
- 12 respect to cocaine specifically, does the county
- 13 consider itself to be in the middle of a cocaine
- 14 crisis?
- 15 MR. BADALA: Objection to form.
- 16 Outside the scope.
- 17 A. We're in the middle of a drug
- 18 crisis. I mean, is cocaine up from where it
- 19 was, yes, and I think the strategy is all of the
- 20 above with the drugs. But if you're asking me
- 21 is the elevation in cocaine significant relative
- 22 to the elevation of the opioids, I would say
- 23 that it's less, because what our data shows in
- 24 the mortality data is that the elevation in the
- 25 cocaine is, unfortunately, being pulled up by

1 fentanyl.

- O. So before the cocaine doubled
- 3 between '15 and '16, that previous baseline
- 4 level of cocaine abuse and death, do you
- 5 consider -- does the county consider the 2014
- 6 level of cocaine abuse and use to be a crisis in
- 7 and of itself?
- 8 MR. BADALA: Objection to form.
- 9 Outside the scope.
- A. It's an area of concern. If you're 10
- 11 asking me is it a crisis because it's acutely
- 12 worsened, the answer to that is no.
- 13 Q. So my question is if -- well, how
- 14 many deaths were there in 2014 caused by
- 15 cocaine?
- 16 A. I can check. 124.
- Q. Does Cuyahoga County consider 124 17
- 18 deaths to be a crisis?
- 19 MR. BADALA: Objection to form.
- 20 A. I'm sorry. You know, we're not
- 21 turning our back on these folks. All of these
- 22 things are sad, that these people are dying, and
- 23 I think, you know, the overshadowing of this
- 24 crisis by heroin, fentanyl is just more tragic,
- 25 but if you're asking me are these folks any less

Page 309

- 1 valuable or something, like no. That's not a
- 2 position. The county is concerned about all of
- 3 our citizens, and these 124 folks who died of a
- 4 cocaine overdose are just as much, you know,
- 5 missed by their people as the hundreds who died
- 6 of a fentanyl or heroin overdose.
- 7 Q. So from the county's perspective,
- 8 the 124 deaths in 2014, the county would
- 9 consider those to be a crisis for cocaine?
- 10 MR. BADALA: Objection to form.
- 11 Outside the scope.
- 12 A. I mean, as you use the term
- 13 "crisis," I think of that in terms of the
- 14 epidemic, and that is not part of the epidemic,
- 15 but it's a source of great concern. We don't
- 16 like to see our citizens die of any drug
- 17 overdose, but -- maybe we're parsing over words,
- 18 but, you know, the crisis is really the opioids,
- 19 it's not the cocaine here, but that doesn't mean
- 20 that it's not a source of tremendous concern.
- 21 Q. What did Cuyahoga County do in 2014
- 22 or the years that followed to address the use
- 23 and abuse of cocaine that resulted in 124 deaths
- 24 in 2014?
- 25 The county would have continued its

- 1 drug treatment services. The county would have
- 2 made available things like the START program to
- 3 those parents. It wasn't like we exclusively,
- 4 you know, excluded them. So we would connect
- 5 those parents with cocaine issues, with, you
- 6 know, a mentor in recovery. The county would
- 7 have responded to separate families where there
- 8 potentially was an issue that wasn't resolvable
- 9 with cocaine. I think the county, you know,
- 10 continued its treatment efforts. Drug court
- 11 didn't shut cocaine people out. It's just that
- 12 the docket became much more tilted towards
- 13 opioids.
- 14 Q. Is that everything you can identify
- 15 sitting here today the county did in response to
- 16 the cocaine use and abuse in 2014?
- 17 A. If I can look at our organizational
- 18 chart again.
- During that time period, around
- 20 2013, 2014, the sheriff's office instituted
- 21 strike forces. They were supposed to supplement
- 22 local law enforcement so that they could address
- 23 any multitude of issues. So it could have been
- 24 in part, you know, drug trafficking. Re-entry
- 25 programs obviously were making efforts to
- Page 311
- 1 reintegrate cocaine addicts. Workforce
- 2 development. Prosecutions of drug dealers by
- 3 our county prosecutor. The creation of drug
- 4 court for the treatment of drug addicts in lieu
- 5 of incarceration, provision of mental and
- 6 medical health services in the county jail.
- 7 Q. Does the county --
- 8 A. There's a lot of things --
- 9 Q. I'm sorry.
- 10 A. I'm sorry. I just wanted to sort of
- 11 close it.
- This problem touches so many levels
- 13 of our community, and I think, you know,
- 14 interventions for some of these things are not
- 15 necessarily just we shut the door on everything
- 16 except the opioids. We're trying to deal with
- 17 all of them, and I don't want to say that I
- 18 could be exhaustive. I think as I run through
- 19 our org chart, there's a lot of things I can see
- 20 there.
- Q. From the county's perspective, is
- 22 the use and abuse of methamphetamine at crisis
- 23 level?
- 24 MR. BADALA: Objection to form.
- 25 Outside the scope.

- 1 A. Again, you know, with what I've said
- 2 about crisis, I would say no, it hasn't really 3 escalated to the comparabilities of like being
- 4 similar to heroin or, especially now, fentanyl.
- 5 Q. Has the county done everything in
- 6 its power to combat the abuse of the illegal
- 7 drugs identified in topic 18?
- 8 A. I think the county has made
- 9 significant investments to do that. I think if
- 10 you ask me are there more things we wish we
- 11 could do, we do. But there's -- you know, as
- 12 much as we can do, I really feel, especially our
- 13 models of collaboration, cooperation -- they're
- 14 national models now, and I do feel that this has
- 15 really been a very exemplary response to this
- 16 crisis, both this one and the opioid crisis
- 17 especially.
- 18 Q. You talked earlier in the day about
- 19 Mexican cartels and China with respect to
- 20 illicit fentanyl. Do you recall that topic
- 21 generally?
- A. I remember mentioning China, and I
- 23 think the person who was asking me at the time
- 24 mentioned Mexico, and that's part of the story I
- 25 think as well.

- Page 313
- 1 Q. Do you agree that the importation of 2 heroin and illicit fentanyl from other countries
- 3 into the county could be considered an act of
- 4 terrorism?
- 5 MR. BADALA: Objection to form.
- 6 Outside the scope.
- Which topic are we on?
- 8 MR. CARTER: We're on 34.
- 9 MR. BADALA: If you could just
- 10 indicate that.
- 11 A. I think I made that statement.
- O. You've made that statement. I'm
- 13 asking does the county agree with it.
- 14 A. I wouldn't want to necessarily put
- 15 that as the county's position. It's a personal
- 16 opinion. I don't know that I have independent
- 17 confirmation to say that.
- 18 Q. Okay. In terms of the drivers of
- 19 the rapid increase in mortality in the county
- 20 from 2010 through to today, do you agree that
- 21 it's been heroin, illicit fentanyl, fentanyl
- 22 analogs and cocaine since 2010?
- MR. BADALA: Objection to form.
- A. Sure. I mean, I think that, you
- 25 know, you can look at this page from Exhibit 13.

1

- 1 which goes up to 2012. Here's our crack
- 2 cocaine. There's our prescription opioids.
- 3 Here's the heroin phase. And if you want to go
- 4 back to our own charts and graphs, the fentanyl
- 5 phase was even worse than the heroin escalation.
- 6 The analogs of fentanyl that we saw,
- 7 carfentanil, the elephant tranquilizer, those
- 8 other drugs, all caused significant rises in
- 9 mortality, and like the opioid pain relievers,
- 10 heroin, fentanyl, they are illicit opioids that
- 11 act on the same mechanism in the brain that the
- 12 opioid pain relievers do.

1 2012, 2011 onward.

- 13 Q. So I think we're on the same page,
- 14 but just to be clear then, from 2010 through to
- 15 today the primary drivers of the increase in
- 16 mortality in the county have been heroin,
- 17 illicit fentanyl, fentanyl analogs and cocaine,
- 18 true?

8

10

13

17

19

18 on that.

9 use disorder?

- A. Again, I'd have to put the caveat 19
- 20 with cocaine that, by itself, it hasn't
- 21 dramatically changed, and that the changes that
- 22 we see in cocaine can be reasonably attributed
- 23 to fentanyl, as can the changes after 2016 with
- 24 heroin, but heroin, in the time frame you
- 25 mentioned, is a significant game changer from

Q. I want to follow up on some

3 questions on topic 19. You talked about the

4 criteria. I'm not going to go through all that

5 again, but I want to focus on the criteria, the

6 third one you identified, people that have been

7 diagnosed with an opioid use disorder, okay?

A. The county identified that in

Q. So sitting here today, can you give

A. I believe we deferred to the experts

Q. Related, does the county have an 20 official working definition of addiction that it

21 used to identify individuals in response to

A. I'm not aware of a working

22 Exhibit A and Exhibit B that are part of

25 definition the county has for addiction.

11 consultation with experts beyond what I'm

14 me a scientific or a layperson definition that

16 did you defer to the experts on that?

15 the county used to define opioid use disorder or

12 prepared to talk about today.

How does the county define an opioid

- Page 316 Q. Do you agree that a diagnosis of
- 2 addiction is a medical task?
- MR. BADALA: Objection to form.
- 4 A. I mean, the addiction has a
- 5 definition in medicine.
- Q. And there are physicians who provide
- 7 medical diagnoses of addiction, correct?
- MR. BADALA: Objection to form. 8
- 9 Outside the scope.
- 10 A. I don't know if I would say
- 11 addiction versus substance use or abuse
- 12 disorder. It's an area of medicine, the
- 13 terminology of which I am not familiar and I
- 14 would not think the county would have an opinion 15 on.
- Q. Do you know whether there are ICD-10 16
- 17 codes to define a substance use disorder?
- MR. BADALA: Objection to form.
- 19 Outside the scope.
- 20 A. ICD-10?
 - O. Yes.
- 22 A. I don't think the county knows that.
- 23 I don't know it myself.
- 24 Q. Do you know what ICD codes refer to
- 25 generally?

21

Page 315

A. Sure. Sure do. I do I should say.

- 2 The county may not, but the International
- 3 Classification of Diseases. As their agent, I
- 4 would be able to inform them of that.
- Q. Do you agree that, from a medical
- 6 perspective, it's inappropriate to assume a use
- 7 disorder or an addiction, however you want to
- 8 use that term -- you would need to look at an
- 9 individual case, an individual resident story to
- 10 arrive at a conclusion of a use disorder or
- 11 addiction, right?
- 12 MR. BADALA: Objection to form.
- 13 Outside the scope.
- A. Yeah. That's a medical diagnosis 14
- 15 again and I don't think the county would express
- 16 anything about the appropriateness of
- 17 misclassifying that.
- Q. So the county has never -- well, the 18
- 19 county has never used its medical examiner data
- 20 or any other data set that it creates and
- 21 assigned classification of a use disorder or an
- 22 addiction based on looking at that data set,
- 23 correct? That's nothing the county has ever
- 24 done before?
- 25 MR. BADALA: Objection to form.

80 (Pages 314 - 317)

23 Deposition Exhibit 2?

- 1 A. The medical examiner data would not
- 2 arrive at those diagnoses. The alcohol, drug 3 addiction and mental health services of the
- 4 county would arrive at diagnoses like that. The
- 5 hospital could arrive at diagnoses like that.
- 6 Does the county itself, you know, oversee that 7 diagnosis? No.
- 8 Q. You agree that all use -- substance
- 9 use disorders can be treated, correct?
- MR. BADALA: Objection to form. 10 11 Outside the scope.
- 12 A. That's a question outside my area of 13 expertise.
- 14 Q. So you do not know whether the
- 15 county is able to treat substance use disorders
- 16 for any substance they might classify?
- MR. BADALA: Objection to form. 17
- 18 Outside the scope.
- 19 A. As I understood your question, all
- 20 substance use disorders being treatable, I don't
- 21 know that that's something that I could say the
- 22 county has an opinion on.
- Q. What about, does the county agree
- 24 that, with appropriate support, all addicted
- 25 individuals can make a recovery?

Page 319

19

- MR. BADALA: Objection to form.
- 2 Outside the scope.

1

- A. I think the county would like to
- 4 give all those addicted individuals that
- 5 opportunity. Whether or not they can recover
- 6 would be beyond really the scope of the county's
- 7 ability to predict that.
- Q. Do you agree that there are a number 9 of people who take prescription opioids and do
- 10 not develop an opioid use disorder?
- MR. BADALA: Objection to form. 11
- 12 Outside the scope.
- 13 A. Again, without having a definition
- 14 of an opioid use disorder, I could only say that
- 15 the long-term use of opioids would be expected
- 16 over time to create dependence on them and
- 17 physical withdrawal symptoms when they were
- 18 removed. Whether that moves into addiction or
- 19 not, I couldn't really say.
- Q. Do you agree there are a number of 20
- 21 people who take prescription opioids and never
- 22 go on to break the law?
- 23 MR. BADALA: Objection to form.
- 24 Outside the scope.
- 25 A. I would sure hope so.

Page 320

1 Q. Are there people who have an opioid 2 use disorder from prescription opioids who do

3 not go on to use illegal narcotics?

- MR. BADALA: Objection to form. 4 5 Outside the scope.
- 6
 - Which topic are we on?
- MR. CARTER: Topic 19, "The criteria 7
- 8 used to identify individuals who overdosed on,
- or became addicted to, prescription opioids." MR. BADALA: Objection to form. 10
- 11 Outside the scope.
- A. Now you guys made me lose the 12 13 question.
- 14 Q. Sure.
- The question was, are there people 15
- 16 who have an opioid use disorder from
- 17 prescription opioids who nonetheless do not go
- 18 on to use illegal narcotics?
 - MR. BADALA: Same objections.
- 20 A. I think national data would support
- 21 that and probably local data, that there were
- 22 people prescribed who did not go on to become 23 addicted.
- 24 Q. With respect to topic 19, has the
- 25 county itself vetted or confirmed any individual
 - Page 321
- 1 diagnosis of an opioid use disorder?
- That information was submitted to
- 3 the experts for their interpretation. The
- 4 county did not independently vet those experts.
- 5 They were referred to our attorneys and they
- 6 consulted with the experts.
- 7 Q. In connection with compiling the
- 8 individuals identified on Exhibit A, did the
- 9 county conduct any interviews of those
- 10 individuals?
- 11 A. We identified claims data with the
- 12 criteria that I've mentioned, and that was
- 13 submitted through to our attorneys, and then
- 14 they conferred with experts and responded to the
- 15 interrogatories. To my knowledge, the county
- 16 did not conduct independent interviews after
- 17 that referral.
- 18 Q. After that information was referred
- 19 to the attorneys and the experts, do you know if
- 20 the attorneys or the experts interviewed the
- 21 individuals listed on Exhibit 2, sub-Exhibit A?
- 22 It's the oversized printout.
- 23 A. It's the big one, right?
- 24
 - MR. BADALA: And I would just

25

- 1 instruct you, if you learned about any
- 2 conversations through the attorney, not to
- 3 disclose those.
- 4 Q. So it's the oversized one?
- 5 A. The big kahuna.
- 6 Q. So I'll ask a simpler question.
- 7 Sitting here today as the
- 8 representative of the county, do you know
- 9 whether anyone whose name appears on Exhibit A
- 10 has been interviewed in connection with their
- 11 identification on that chart?
- 12 A. Again, that would have been referred
- 13 to the attorneys in consultation with experts on
- 14 behalf of the county. To the best of my
- 15 knowledge, there was no follow-up interviews
- 16 conducted to the experts' opinions.
- 17 Q. To the extent the DSM-5 definition
- 18 of an opioid use disorder was employed, do you
- 19 know, for the individuals on Exhibit A,
- 20 whether -- what severity of an opioid use
- 21 disorder they were found to have had?
- A. To the extent that we're not
- 23 familiar with the criteria used, I wouldn't want
- 24 to speculate on DSM-5 criteria and whether they
- 25 were employed.

Page 323

- 1 Q. For everyone listed on Exhibit A, do 2 you know when in time they first developed any
- 3 kind of substance abuse disorder?
- 4 A. All I can say is the patients were
- 5 diagnosed with a substance use disorder. The
- 6 timing, based on the documents I have in front
- 7 of me, which were provided by our attorneys and
- 8 experts, don't specify, to my examination of
- 9 them, a date when they developed the diagnosis
- 10 -- when they developed the disorder or were
- 11 diagnosed with it. They may be two different
- 12 dates, as I'm sure you know.
- 13 Q. For any of the individuals listed on
- 14 Exhibit A, do you know whether they are
- 15 currently diagnosed with an opioid use disorder
- 16 or whether they are in some stage of remission?
- 17 MR. BADALA: Objection to form.
- 18 A. I can speak, as the county's medical
- 19 examiner, that once diagnosed with an opioid use
- 20 disorder, my understanding is that diagnosis
- 21 remains, whether it's in remission or not.
- Q. And my question is, do you know
- 23 whether any of them are in remission such that
- 24 the diagnostic code would include that modifier?
- 25 A. I don't know that the diagnostic

Page 324

- 1 code includes that modifier, so I can't answer 2 your question.
- Q. Do you know for any of the
- 4 individuals on Exhibit A what the first drug was
- 5 that they abused?
- 6 A. That may be known, but as I say, we
- 7 just identified the patients and referred them
- 8 to counsel for consultation with experts.
- 9 Whether they identified that in the course of
- 10 their investigation, I do not know if they
- 11 identified what initial drug they first used.
- 12 Q. For the individuals listed on
- 13 Exhibit A, can you identify any specific name of
- 14 a person whose first drug of abuse was a
- 15 prescription opioid?
 - MR. BADALA: Objection to form.
- 17 Outside the scope.
- 18 A. It's getting a little bit late. I'm
- 19 just getting a little fuzzy. Could you read
- 20 that back?

16

21

- Q. Sure. Happy to.
- Of the individuals listed on Exhibit
- 23 A, can you identify any individual for which
- 24 their first drug of abuse was a prescription
- 25 opioid?

- 1 MR. BADALA: Objection to form.
- 2 Outside the scope.
- A. The county cannot. We referred
- 4 these for the consultation with the experts, and
- 5 that may be something uncovered in their
- 6 consultation, but from our standpoint, we did
- 7 not go further than that to identify first drug
- 8 used or anything from the county's standpoint.
- 9 Q. Who on Exhibit A was arrested, if 10 anyone?
- 11 MR. BADALA: Objection to form.
- 12 Outside the scope.
- 13 A. I don't know who was arrested there.
- 14 We didn't really explore that when we made the
- 15 referrals. We just identified people who did
- 16 not have cancer, who were receiving high doses
- 17 of opioids, and who were diagnosed with a
- 18 substance use disorder, but we did not include
- 19 criteria for arrests.
- 20 O. Who on Exhibit A doctor shopped?
- A. Again, when the county submitted the
- 22 claims data, that was as far as we went in terms
- 23 of that investigation, and the doctor shopping
- 24 may have come to light with the consultation 25 with experts and review of records, but we are

1 not aware of that.

- Q. Who on Exhibit A pharmacy shopped?
- A. I'd have to say the same answer to 4 that.
- 5 Q. Do you know what any individual on 6 Exhibit A understood about the risks of using
- 7 prescription opioids?
 - MR. BADALA: Objection to form.
- 9 Outside the scope.
- 10 A. I don't understand your question.
- 11 Could you rephrase it?
- 12 Q. Sure.

8

- For any of the individuals listed on
- 14 Exhibit A do you know what any of them
- 15 individually understood about the health risks
- 16 associated with using prescription opioids?
- 17 A. The county would not know that.
- 18 Q. Okay. Do you know about any
- 19 conversations that any individual on Exhibit A
- 20 had with their doctor or pharmacist?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope.
- A. Again, we submitted the names, the
- 24 500 names, with the criteria that I've spelled
- 25 out, and beyond that, I really am not in a

Page 328

- 1 identified as the cause of death?
- A. We would send prescription opioid
- 3 overdose data to the Ohio Department of Health
- 4 on a quarterly basis. I believe that started in5 2014 based on grant funding. So that database
- 6 could be cross-checked with this, but as I sit
- 7 here today, I don't have that information.
- 8 Q. So sitting here today, you can't
- 9 point me to any of these individuals on page 5,
- 10 6 or 7 and tell me specifically which ones had a
- 11 prescription opioid identified as their cause of 12 death?
- 13 A. No. As I say, the information is
- 14 available based on what we, I believe, referred
- 15 to Defendants in information that was sent to
- 16 the Ohio Department of Health, but these
- 17 individuals, I can't run through the list and
- 18 pick out names and tell you this one died from
- 19 prescription opioids. I can't -- I can't do
- 20 that today.
- Q. To the extent individuals on Exhibit
- 22 B did have prescription opioids identified in
- 23 their cause of death, do you know which ones
- 24 obtained those legally pursuant to a
- 25 prescription?

Page 327

1

- 1 position to state more for the county's
- 2 involvement.
- 3 Q. Sitting here today, do you know
- 4 whether any individual on Exhibit A actually
- 5 overdosed on an opioid?
- 6 A. I do not.
- 7 Q. All right. Home stretch.
- 8 Exhibit B to Exhibit 2. It's the
- 9 one at the very back. If you turn a couple
- 10 pages in to page 5, that's where it starts with
- 11 Cuyahoga instead of Summit. Are you with me?
- 12 A. Yes, I am.
- 13 Q. So for anyone on Exhibit B, do you
- 14 know what substance was certified as their cause
- 15 of death?
- 16 A. The causes of death are not listed
- 17 on this sheet.
- 18 Q. Does the county know which of these
- 19 individuals on Exhibit B had multiple substances
- 20 certified as the cause of death?
- 21 A. As I sit here, I can't answer that
- 22 question, but that information could be
- 23 obtained.
- Q. Does the county know which of these
- 25 individuals, if any, had prescription opioids

- Page 329
 A. I don't know if that would be
- 2 knowable, so I don't -- I'd have to say the
- 3 county would say we don't know.
- 4 Q. For anyone on Exhibit B with an
- 5 overdose attributable to a prescription opioid,
- 6 can you tell me whether it was obtained legally
- 7 or illegally?
- 8 A. I thought that was the question I
- 9 just answered. I'm sorry.
- 10 Q. I just wanted to make sure I was on
- 11 the same page with you.
- So do you know -- I think I asked
- 13 you if you knew if it was legal, so I'm asking
- 14 all together, both sides, can you tell me one
- 15 way or the other whether anyone on here with a
- 16 death that was attributable to a prescription
- 17 opioid, whether that was obtained legally or
- 18 illegally?
- 19 A. I cannot tell you that. I don't
- 20 know whether these prescription opioid deaths
- 21 would have been legal or, as I said, whether we
- 22 can actually track that through our database

24 something legally in another jurisdiction that

- 23 because of the potential legal -- obtaining
- 25 we don't have access to.

- O. From the medical examiner's 2 perspective, there's no data or ability at the
- 3 medical examiner level to posthumously diagnose
- 4 an opioid use disorder, is there?
- A. We would have to rely, in the course
- 6 of a death investigation, whether the individual
- 7 came to our office with that diagnosis, but in
- 8 terms of an anatomical examination or laboratory
- 9 testing, I'm not aware of anything that
- 10 facilitates that diagnosis.
- Q. Has the county's medical examiner
- 12 ever diagnosed -- made a primary diagnosis of an
- 13 opioid use disorder in a case that it was
- 14 investigating?

1

- 15 A. We may list it as a diagnosis in our
- 16 investigation, but as I say, that would have
- 17 been uncovered in the course of a historical
- 18 review, not from the actual physical examination
- 19 of an individual.
- 20 Q. For the individuals listed on
- 21 Exhibit B, do you know which ones, if any, were
- 22 arrested?
- A. Again, I don't know if that
- 24 information is available, but I do not know it
- 25 as I sit here today.

Page 331

- 1 Q. Was anyone on Exhibit B involved in 2 doctor shopping?
- A. I would have to go back to the
- 4 database. Again, information might be
- 5 available, but I don't honestly know that I
- 6 could point to a specific name on this list and
- 7 tell you that was a doctor shopper.
- Q. Who on Exhibit B pharmacy shopped?
- A. I'd have to answer the same way.
- 10 That information may be available but I do not
- 11 have it with me today in preparation for
- 12 testimony.
- 13 Q. Who on Exhibit B diverted
- 14 prescription opioids?
- 15 A. That may be a very tough question to
- 16 answer, actually, because if they weren't
- 17 caught, nobody would probably know that, so I
- 18 couldn't -- I don't think anybody could give you
- 19 an answer to that question in completion. There
- 20 may be records of prosecutions within the county
- 21 for some of these folks diverting, but I don't
- 22 think I would be able to say whether they would
- 23 be exhaustive given the surreptitious nature of
- 24 that activity.
- 25 Q. Is the county able to say

Page 332

- 1 conclusively for every person listed on Exhibit
- 2 B that but for their use of prescription
- 3 opioids --
- 4 THE WITNESS: I'm sorry. Could we
- 5 take a break? My daughter was supposed to be
- 6 picked up at 5:30 and I want to make sure my
- 7 wife knows I won't be doing that today.
 - MR. CARTER: Sure. Absolutely. I
- 9 only have three questions left, but you can take
- 10 a break.
- 11 THE WITNESS: I'll be right back. I
- 12 just have to call her.
- 13 MR. CARTER: That's fine. We'll go
- 14 off the record.
- THE VIDEOGRAPHER: Off the record at 15
- 16 5:08 p.m.
- 17 (Short recess had.)
- 18 THE VIDEOGRAPHER: Back on the
- 19 record at 5:10 p.m.
- 20 BY MR. CARTER:
- 21 Q. Is the county prepared to say
- 22 conclusively for every person listed on Exhibit
- 23 B that but for their use of prescription
- 24 opioids, they would not have overdosed and died
- 25 when they did?

- 1 A. As I say --
- 2 MR. BADALA: Objection to form.
- 3 A. As I say, these were identified with
- 4 criteria. Not having their causes of death in
- 5 front of me, I do not know what they died from.
- 6 We do, as a county, support and state that
- 7 individuals who died from opioid pain relievers,
- 8 in addition to heroin and fentanyl, in large
- 9 measure, are referable back to the opiate pain
- 10 reliever use in this county, but I don't know
- 11 the causes of death on these individuals other
- 12 than they overdosed, and not knowing specifics
- 13 on that, I just know that they have a substance
- 14 use disorder, but I don't know the substances
- 15 and I don't think I should offer an opinion
- 16 without that information.
- 17 Q. So I asked you about every person on
- 18 the list. Let me ask any person on the list.
- 19 For any person on that list is the county able
- 20 to tell me that but for their use of
- 21 prescription opioids, they would not have
- 22 overdosed and died when they did?
- 23 MR. BADALA: Objection to form.
- 24 A. Again, lacking their cause of death,
- 25 I can only point to the criteria that were used

- 1 to select this list, but I don't know that I
- 2 could specifically answer your question beyond
- 4 Q. With respect to some of the
- 5 questions I asked you in terms of doctor
- 6 shopping arrests, pharmacy shopping, whether
- 7 they diverted, were any of those factors
- 8 considered in compiling the list of individuals
- 9 on Exhibit B?
- A. We identified the claims, as I said,
- 11 for the opioids on the basis that they did not
- 12 have -- they were not cancer patients, they were
- 13 receiving high dose, which we defined as 120
- 14 medical morphine equivalents or higher, and that
- 15 they had a diagnosis of a substance use
- 16 disorder. Beyond that, I cannot characterize
- 17 them further in terms of arrests or other
- 19 Q. With respect to the folks on Exhibit
- 20 B, who on there had a dose of over 120 MME?
- 21 MR. BADALA: Objection to form.
- 22 Outside the scope.
- A. As I understand it, these criteria
- 24 were applied to the individuals on that list of
- 25 500 that were provided, and they met all three

1 of these criteria.

- Q. So you believe everyone on Exhibit B 3 met all three of those criteria?
- A. I am not familiar enough with
- 5 Exhibit B, but if they are taken from the claims
- 6 data, then they would have met those three 7 criteria.
- Q. Does Exhibit B include all
- 9 prescription-related opioid deaths that the
- 10 county has experienced during the time frame or 10
- 11 is it some subset?
- 12 A. It's got to be a subset. There just
- 13 aren't enough names on there for all the opioid
- 14 deaths that we've had.
- 15 Q. My question was prescription opioid
- 16 related, so would you give the same answer to
- 17 that? So does Exhibit B contain all
- 18 prescription opioid deaths that the county has
- 19 experienced?
- 20 A. Give me a second to think on that.
- 21 That would be impossible given the
- 22 number here. There's more prescription opioid
- 23 deaths in the county than these names here.
- Q. Can you attribute any Cuyahoga
- 25 County resident's death to the specific conduct

1 of a specific Defendant?

2 MR. BADALA: Objection to form.

Page 336

3 Outside the scope.

- 4 A. The opioid crisis has its genesis in
- 5 the prescribing practices that were facilitated
- 6 by the Defendants, and, to that extent, the
- 7 opioid deaths, in large measure, are the
- 8 responsibility of the actions of the Defendants.
- 9 That's the position of the county.
- 10 Q. Can you link any specific conduct to 11 any individual's death?
- MR. BADALA: Objection to form. 12
- 13 Outside the scope.

14

- A. Any specific conduct --
- 15 Of the Defendants to an individual's O. 16 death.
- 17 MR. BADALA: Same objections.
- A. The misrepresentation of the 18
- 19 addiction potential of the compounds, the large
- 20 distribution of drugs into the county, the
- 21 efforts to create formulations that were not --
- 22 I shouldn't say not tamper resistant. The
- 23 efforts to create guidelines for prescribing and
- 24 lobbying efforts around those. A lot of -- I
- 25 can't think of everything necessarily in one
- Page 335

Page 337 1 swoop, but the actions of the Defendants are --

- 2 in the counties have been responsible for the
- 3 deaths -- the creation of the opioid crisis and
- 4 the deaths that we're seeing.
- O. Which individual on Exhibit B died 6 as a result of a misrepresentation of the
- 7 addictive potential of the compounds?
- 8 MR. BADALA: Objection to form.
- 9 Outside the scope.
- A. I think again I have to say that
- 11 with regard to Exhibit B, I do not have causes
- 12 of death as to substances and I wouldn't want to
- 13 hazard a guess as to what information would be
- 14 relevant to your question.
- 15 Q. Which individual on Exhibit B died
- 16 as a result of the large distribution of drugs
- 17 into the county?
- MR. BADALA: Objection to form. 18
- 19 Outside the scope.
- A. To point to a specific one, I could 20
- 21 not do.
- 22 Q. Which individual on Exhibit B died
- 23 as a result of efforts to create guidelines for
- 24 prescribing and/or lobbying efforts around
- 25 those?

Page 338 Page 340 1 MR. BADALA: Objection to form. 1 Outside the scope. 2 Outside the scope. 2 Which topic are we on? 3 MR. CARTER: Topic 34. A. I'd have to say, again, I can't 4 point to specific ones. I don't know their 4 MR. BADALA: Objection to form. 5 causes of death. And not knowing that, I can't 5 Outside the scope. 6 go further on characterizing them. A. So if I understand your question, 7 you're asking me to identify which of the Q. With respect to the 8 misrepresentation of the addictive potential of 8 Defendants we believe caused or contributed to 9 the compounds, the large distribution into the 9 the opioid crisis in our geographic area. 10 county, and the lobbying efforts, which specific Q. No. I'm asking the flip of that. 10 11 Defendants engaged in that conduct that you 11 My question is, can you identify any Defendant 12 who could have prevented Cuyahoga County's 12 believe was causal of any death? 13 MR. BADALA: Objection to form. 13 opioid crisis? 14 Outside the scope. 14 MR. BADALA: Objection to form. A. Which topic are we on now? 15 15 Outside the scope. Q. On topic 19 and 34 and 2 and 18 and A. Yes. All of them. 16 16 Q. And how could they have prevented 17 probably others. 17 18 MR. BADALA: So is it your position 18 it? 19 19 that this applies to all those topics, this MR. BADALA: Same objections. 20 question? 20 A. By not creating that culture of 21 MR. CARTER: Yes. The ones that I 21 undertreatment of pain, by not encouraging the 22 just mentioned, yes. 22 overprescribing of pain medications, by not 23 A. And one more time. I'm sorry. 23 misrepresenting the addictive potential of those 24 Q. So which Defendants, sitting here 24 medications. The things that have been spelled 25 out before I think in terms of the actions of 25 today, does the county identify as engaging in Page 339 Page 341 1 the specific conduct that you just mentioned 1 the Defendants that contributed to the opioid 2 crisis, with pain relievers initially and 2 related to the death of anyone on Exhibit B? 3 MR. BADALA: Objection to form. 3 subsequently transitioning into the opioid 4 crisis as we saw it with heroin and fentanyl and 4 Outside the scope. A. The county identifies all of the 5 the analogs of fentanyl. 6 Defendants. That was why we filed the lawsuit. Q. With respect to the mortality data 7 And the specifics of these individuals I regret 7 that you have, what was the mortality 8 I don't have, but the county's position is that 8 attributable to illegal drugs for 2017 --9 all of the Defendants are ultimately responsible 9 MR. BADALA: Objection to form. 10 for this creation of this drug-addicted 10 Q. -- or whatever year you have in 11 population. 11 front of you? In Exhibit 11, what's the last Q. So for any individual on Exhibit B, 12 year? That's the yellow one that's at the top. 13 can you link their death to any specific 13 A. The last year on here is 2014. 14 Defendant? 14 Q. Okay. Then let's do it without a 15 MR. BADALA: Objection to form. 15 specific number. What could any Defendant have 16 done to prevent the deaths in 2017 in Cuyahoga 16 Outside the scope. Asked and answered. 17 A. As I understand the individuals on 17 County that your office determined were caused 18 B, the county identified them and referred them 18 by heroin, illicit fentanyl, fentanyl analogs, 19 for -- to our attorneys for expert analysis. 19 carfentanil or cocaine? 20 The county doesn't have a position on what you 20 MR. BADALA: Objection to form. 21 had asked me. 21 You said '14 and then you said '17. 22

86 (Pages 338 - 341)

MR. CARTER: I did. So this

23 question is 2017. I was trying to give him a

24 reference point to a number. I was trying to

25 wrap up since we're at the end of the day. So

Q. And then my last question, can you

MR. BADALA: Objection to form.

23 identify any Defendant named in the lawsuit who

24 could have prevented the county's opioid crisis?

22

25

Page 342 Page 344 1 I'll ask it again to be clear. 1 record. I think we're done, but just a quick Q. I understand you don't have a 2 caucus. 3 specific number of deaths in front of you, but 3 THE VIDEOGRAPHER: Off the record at 4 there were deaths in 2017 in Cuyahoga County 4 5:22 p.m. 5 that were attributable to heroin, illicit 5 (Recess had.) 6 fentanyl, carfentanil, fentanyl analogs and 6 THE VIDEOGRAPHER: Back on the 7 cocaine. Each of those substances represented 7 record at 5:35 p.m. 8 at least one death in 2017, correct? EXAMINATION OF THOMAS GILSON, M.D. A. Yes. Illicit fentanyl, I'd sort of 9 BY MS. ROITMAN: 10 just say that our testing can't distinguish 10 Q. Good evening, Mr. Gilson, or 11 diverted fentanyl from illicitly manufactured 11 Dr. Gilson. I'm Sara Roitman from Purdue. I 12 fentanyl, but our general impression is that 12 introduced myself to you earlier. I just have a 13 most of those deaths were attributable to 13 few more questions for you. 14 14 illicitly manufactured fentanyl. MS. ROITMAN: Before we begin, I 15 O. So whatever the number was 15 think we have a housekeeping administrative 16 attributable to that combination of illegal 16 point. Exhibits 4, 5 and 6 were premarked but 17 drugs that I just mentioned, what -- can you 17 they were not introduced into the record. I 18 identify any Defendant who could have prevented 18 think that's the consensus of everyone for 19 clarity sake. Thank you. 19 those deaths in 2017? 20 MR. BADALA: Objection to form. 20 Q. Dr. Gilson, I'd like to talk about 21 Beyond the scope. 21 topic 4, and topic 4 is -- includes the criteria 22 A. Again, all the Defendants could have 22 that Plaintiffs used to identify the information 23 prevented that situation. 23 required by the interrogatories at issue in Q. So all the Defendants could have 24 discovery ruling number 5, and for your 25 prevented every single illicit drug death from 25 reference, those interrogatories at issue, the Page 343 Page 345 1 those substances I just mentioned in 2017? 1 ones I'm going to talk about, are manufacturers' A. I don't think it would be the 2 interrogatories 6, 7 and 10, specifically, the 3 county's position on every one, but most of 3 Plaintiffs' response to number 6, which was 4 them, yes. 4 marked as Exhibit 3 today. And it's -- to 5 orient you, it's the December 31st, 2018 5 O. Can you identify a percentage? 6 I'd have to look closer at that. I 6 response to interrogatory 6. 7 don't know. 7 A. I have Exhibit 3. MR. CARTER: Okay. And then just as Q. So, Dr. Gilson, to orient you, the 9 an administrative clean-up, I'd like to mark the 9 exhibit that we have been referring to today as 10 binder that the witness brought with him today 10 Exhibit 2, I believe, that giant Excel 11 as whatever the next number is. I think it's 11 spreadsheet --12 14. 12 A. This one, yes. 13 MS. RANJAN: That one has the notes 13 Q. -- that was -- Plaintiffs referred 14 to that in their response to interrogatory 6 14 on it, doesn't it? 15 THE WITNESS: This one has my notes. 15 when they were identifying 500 alleged MR. BADALA: You can mark that one. 16 16 prescriptions that were written in reliance of 17 MR. CARTER: We'll handle the 17 Manufacturer Defendants' alleged misstatement. 18 logistics of --18 I appreciate that you have testified numerous 19 19 times today that you didn't see Exhibit 2 or MR. BADALA: That's okay. 20 20 that spreadsheet prior to today, and so I'm 21 (Thereupon, Gilson Deposition 21 just --22 Exhibit 14, Binder, was marked for 22 A. I'm going to say I don't remember 23 purposes of identification.) 23 seeing them. 24 24 MR. BADALA: Object to that 25 characterization. 25 MR. CARTER: If we could go off the

87 (Pages 342 - 345)

Q. Fair enough.

What I'm going to ask you really is 3 just strictly the criteria that the county used

4 when responding to interrogatory number 6.

So did any of the criteria that the

6 county used in responding to interrogatory 6 7 include determining whether a doctor on that

8 Excel spreadsheet was ever visited by a sales

9 representative?

1

MR. BADALA: She's talking about 11 Exhibit 3.

12 A. This would be page -- I remember the 13 list was there.

Q. I can tell you it's not -- it is --

15 what I'm trying to figure out is the criteria

16 that was used for identifying the prescriptions

17 listed on that giant Excel spreadsheet, the 500

18 prescriptions.

19 A. I just want to refresh my memory.

20 So it says in Exhibit 2, on the page with the

21 doctors' names, that the "Bellwether Plaintiffs

22 further contend that, by misrepresenting the

23 risks, benefits, and superiority of opioids,

24 particularly for use long-term and at high

25 doses, including, but not limited to, through

Page 348

1 they were not cancer patients, they were high

2 dose, that is greater than 120 morphine --

3 medical morphine equivalents or higher, and 4 patients who were diagnosed with a substance

5 abuse disorder.

6 Q. And so would the answer to my 7 question be no?

8 A. But I think they were saying -- at

9 least the prescriptions identified in Exhibit A

10 was unauthorized, medically unnecessary,

11 ineffective, or harmful, and then further down

12 on that page they identify that the

13 misrepresentation was unnecessary and harmful,

14 do not -- but that the sales visits are included

15 in some of the misrepresentations.

16 Q. Doctor, I'm going to move to strike.

17 I need you to answer my question.

18 A. I'm trying to, ma'am. I'm very

19 sorry.

Q. So if you can focus on what I'm

21 asking.

22 Did the criteria that Plaintiffs

23 used to come up with the prescriptions on that

24 list, did it include determining whether or not

25 any of those doctors had been visited by a sales

Page 347

1 sales visits, continuing medical education and

2 speaker programs, publications and websites, and

3 treatment guidelines, Manufacturer Defendants

4 deprived prescribers and patients of the ability

5 to make informed choices about whether, when and

6 which opioids to prescribe and use, for how

7 long, and at what doses." So it mentions sales

8 visits in that. I don't know specifically, of

9 the doctors who were listed, which ones had a 10 sales visit.

Q. Doctor, I don't want to interrupt

12 you, but I do want you to answer my question.

13 It's getting late, and I think all of us want to

14 get out of here and get you out of here. That

15 wasn't my question. My question was, in coming

16 up with the prescriptions that are identified in

17 Exhibit 2, that big Excel spreadsheet, which was

18 provided in response to interrogatory 6, did the

19 criteria that Plaintiffs used to come up with

20 the prescriptions on that list include any

21 criteria to determine whether any of the

22 prescribers on that list had ever been visited

23 by a sales representative?

A. The criteria that I have harkened

25 back to that were used to create the list where

1 representative?

2 MR. BADALA: Objection to form.

3 Asked --

4

Q. The answer should be yes or no.

5 A. I've tried to answer it as best I

6 can from the response from the interrogatory.

7 Whether that was a separate criteria, that's not

8 my understanding.

9 Q. For the record, you're not -- the

10 response that you're reading from there is not

11 in response to interrogatory 6. It's in

12 response to interrogatory 7 or interrogatory 10.

13 My question is focused on interrogatory 6. If

14 you're not going to answer my questions, I am

15 going to have to request more time. I assure

16 you we are all trying to get out of here, so --

17 was there any separate criteria that was used

18 besides the three criteria that you've

19 identified, non-cancer, high dose opioids in

20 your words, and patients identified with an

21 opioid use disorder? Were any other criteria

22 used for coming up with the prescriptions on

23 Exhibit A?

A. That's how we identified the claims.

Q. So the rest of my questions should

25

- 1 be fairly simple for you to answer. Would any
- 2 of the criteria include whether any of those
- 3 doctors were visited by a sales representative?
 - A. These criteria do not include that.
- 5 Q. Do any of the criteria include being
- 6 visited by one of the Manufacturer Defendants' 7 sales representatives?
- A. Not the criteria that were used.
- Q. Did any of the criteria used pertain
- 10 to whether or not any of the physicians on that
- 11 list ever attended a continuing medical
- 12 education program that was sponsored by any of 12 more helpful.
- 13 the Manufacturer Defendants?
- 14 A. Not listed in my list of criteria.
- 15 O. Did the criteria include ever --
- 16 whether any of those doctors ever had attended a 16 mess up the record a little bit.
- 17 continuing medical --

4

- A. I think I finally understand where
- 19 we're differing. These are --
- 20 Q. Please let me finish my question.
- 21 A. Oh, sure. Absolutely.
- Q. Did the criteria that you used 22
- 23 include if they ever attended any sort of
- 24 continuing medical education program at all
- 25 relating to opioids?

1

Page 351

- A. No. I think what I'm saying, if I
- 2 could answer where I think we might be on
- 3 different purposes, is I think that things I was
- 4 describing were characterizations of the
- 5 prescriptions, but the claims that we submitted
- 6 to attorneys were based on these criteria.
- 7 Q. Again -- and this may be an issue
- 8 that you just have not read that response before
- 9 today and why it has been somewhat frustrating
- 10 to get accurate kind of answers to our questions
- 11 on this -- what are you referring to there isn't
- 12 the response to interrogatory number 6 that I'm
- 13 asking about. It's in response to a completely
- 14 different interrogatory, 7 and 10. So if you
- 15 could just stay with me and answer my questions,
- 16 I think we would all be grateful for it.
- 17 MR. BADALA: I think part of the
- 18 problem is you're telling him to look at 2 when
- 19 you're talking about 3.
- 20 MS. ROITMAN: No. For the record,
- 21 he's, on his own volition, reading a different
- 22 exhibit that we're not talking about.
- MR. BADALA: I get it, but you keep
- 24 saying back to the prescriptions in Exhibit 2.
- 25 Exhibit 3 is what you're talking about. So we

Page 352

- 1 can put 2 to the side and he can look at 3. I
- 2 think that's the confusion.
- MS. ROITMAN: The confusion is 3
- 4 Exhibit 2, which is that big list of -- that
- 5 huge Excel spreadsheet, that is what I'm
- 6 referring to. Plaintiffs -- you referred to
- 7 that big list when they were responding to
- 8 interrogatory 6.
- 9 MR. BADALA: So that's where I think
- 10 the confusion is. He is now looking at that.
- 11 If he can look at Exhibit 3, then I think that's
- 13 Q. So we can call it 2A if you want. I
- 14 think part of the problem is --
- 15 MR. BADALA: I think that's going to
- 17 A. -- is you have not looked at these
- 18 responses before today and you're not familiar
- 19 with them.
- 20 MR. BADALA: I'm going to object to
- 21 that characterization. That's not been his
- 22 testimony.
- 23 MS. ROITMAN: You can object all you
- 24 want.

1

25 Let's go back to my questions.

Page 353 A. Sure.

- 2 Q. Did any of the criteria that were
- 3 used to come up with the prescriptions that were
- 4 identified in that big Excel spreadsheet include
- 5 trying to figure out if any of the doctors on
- 6 there had had any specific contact with one of
- 7 the Manufacturing Defendants?
- 8 A. In coming up with a list, no.
 - Q. Any criteria -- was there any
- 10 criteria that was used for determining why any
- 11 of the doctors on that big exhibit, Excel
- 12 spreadsheet, prescribed the opioids to the
- 13 patients listed there?
- A. I think some of them were the ones
- 15 who were prosecuted, so they were identified by
- 16 that.
- 17 Q. So is that a different criteria that
- 18 you're saying you were using?
- MR. BADALA: Objection to form.
- 20 Asked and answered.
- 21 A. I am not following your question.
- 22 I'm sorry.
- Q. I'm trying to -- you've identified
- 24 the three criteria that were used. I'm trying
- 25 to figure out if there are any other criteria

	Page 354		Page 356
1	that were used to identify the people on Exhibit	1	1 age 330
1	2A.	2	(Deposition concluded at 5:48 p.m.)
3		3	
	the doctors. No. The claims for the opioids	4	
1	are the three criteria that I mentioned.	5	
6		6	
-	further questions.	7	
8	_	8	
9	MR. BADALA: Anyone else in the room	9	
1	have any questions? Anyone on the phone have	10	
1	any questions?	11	
12		12	
13	1	13	
1	record quickly?	14	
15	THE VIDEOGRAPHER: Off the record at	15	
		16	
17	5:45 p.m. (Recess had.)	17	
18		18	
	record at 5:47 p.m.	19	
20		20	
	BY MR. BADALA:	21	
$\begin{vmatrix} 21\\22\end{vmatrix}$		22	
	follow-up questions from your deposition today.	23	
24		24	
	some notes during your conversation with Tamara	25	
			Daga 257
1	Page 355 Chapman. Do you recall that?	1	Page 357 Whereupon, counsel was requested to give
2			instruction regarding the witness' review of
3			the transcript pursuant to the Civil Rules.
4		4	and transcript parsaunt to the Civil reales.
	I wrote them on a piece of paper no bigger than	5	SIGNATURE:
1	two-by-two inches, and they the points I	_	Transcript review was requested pursuant to
1	wrote down were that they were seeing an		the applicable Rules of Civil Procedure.
1	increase in the number of custody cases at DCSF,	8	the applicable Rules of Civil Flocedure.
1	which is where Ms. Chapman is employed, an	9	TRANSCRIPT DELIVERY:
1	increase in the number of positive toxicology	_	Counsel was requested to give instruction
1	bursts, and that she indicated that it was her		regarding delivery date of transcript.
1	impression that was related to opioids.	12	regarding derivery date of trumseript.
13	-	13	
	questions.	14	
15	•	15	
	2	16	
116	Č	17	
16 17			
17	, 1	18	
17 18	And I just want to note one thing	18 19	
17 18 19	And I just want to note one thing for the record. Plaintiffs did serve amended	19	
17 18 19 20	And I just want to note one thing for the record. Plaintiffs did serve amended responses and objections to the 30(b)(6)	19 20	
17 18 19 20 21	And I just want to note one thing for the record. Plaintiffs did serve amended responses and objections to the 30(b)(6) deposition. Those weren't included, but by	19 20 21	
17 18 19 20 21 22	And I just want to note one thing for the record. Plaintiffs did serve amended responses and objections to the 30(b)(6) deposition. Those weren't included, but by reference, we refer to our responses and	19 20 21 22	
17 18 19 20 21 22	And I just want to note one thing for the record. Plaintiffs did serve amended responses and objections to the 30(b)(6) deposition. Those weren't included, but by reference, we refer to our responses and objections.	19 20 21	

90 (Pages 354 - 357)

	Page 358	1 Veritext Legal Solutions	Page 360
1	REPORTER'S CERTIFICATE	1100 Superior Ave	
2	The State of Ohio,)	2 Suite 1820 Cleveland, Ohio 44114	
3) SS:	3 Phone: 216-523-1313	
4	County of Cuyahoga.)	4 January 15, 2019	
5		5	
6	I, Renee L. Pellegrino, a Notary Public	To: SALVATORE BADALA 6	
7	within and for the State of Ohio, duly	Case Name: In Re: National Prescription Opiate Litigation v.	
8	commissioned and qualified, do hereby certify	7 Veritext Reference Number: 3191875	
	that the within named witness, THOMAS GILSON, M.D.,	8	
	was by me first duly sworn to testify the truth, the	Witness: Thomas Gilson, M.D. Deposition Date: 1/14/2019	
	whole truth and nothing but the truth in the cause	10 Dear Sir/Madam:	
	aforesaid; that the testimony then given by the	The deposition transcript taken in the above-referenced	
	above referenced witness was by me reduced to	12	
	· ·	matter, with the reading and signing having not been	
	stenotypy in the presence of said witness;	expressly waived, has been completed and is available	
	afterwards transcribed, and that the foregoing is a	for review and signature. Please call our office to	
	true and correct transcription of the testimony so	15	
	given by the above referenced witness.	make arrangements for a convenient location to	
18	I do further certify that this	accomplish this or if you prefer a certified transcript	
19	deposition was taken at the time and place in the	17 can be purchased.	
20	foregoing caption specified and was completed	18	
21	without adjournment.	19 If the errata is not returned within thirty days of your 20 receipt of this letter, the reading and signing will be	
22		21 deemed waived.	
23		22 23 Sincerely,	
24		24 Production Department	
25		25 NO NOTARY REQUIRED IN CA	
	P. 250		D 261
1	Page 359		Page 361
1	I do further certify that I am not a	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS	Page 361
2	I do further certify that I am not a relative, counsel or attorney for either party,	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2	Page 361
2 3	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v.	Page 361
2 3 4	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action.	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875	Page 361
3	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil	Page 361
2 3 4	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action.	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of	Page 361
2 3 4 5 6	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony	Page 361
2 3 4 5 6	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me.	Page 361
2 3 4 5 6 7	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony as transcribed by the court reporter.	Page 361
2 3 4 5 6 7 8	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony as transcribed by the court reporter.	Page 361
2 3 4 5 6 7 8 9	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County,	Page 361
2 3 4 5 6 7 8 9 10 11	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019.	DEPOSITION REVIEW CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 3191875 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony as transcribed by the court reporter.	Page 361
2 3 4 5 6 7 8 9 10 11	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019.	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12	Page 361
2 3 4 5 6 7 8 9 10 11 12 13	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that:	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019.	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony as transcribed by the court reporter. 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony as transcribed by the court reporter. 9 Date Thomas Gilson, M.D. Sworn to and subscribed before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed.	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 thisday of	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 this day of	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 this day of	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 this day of	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 this day of, 20 17 18 Notary Public 19 Commission Expiration Date	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 4 WITNESS' NAME: Thomas Gilson, M.D. 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have made no changes to the testimony as transcribed by the court reporter. 8 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 this	Page 361
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I do further certify that I am not a relative, counsel or attorney for either party, or otherwise interested in the event of this action. IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 15th day of January, 2019. Renee L. Pellegrino, Notary Public within and for the State of Ohio	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 3191875 3 CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 1/14/2019 WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have made no changes to the testimony as transcribed by the court reporter. 9 Date Thomas Gilson, M.D. 10 Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that: 12 They have read the transcript; 13 They signed the foregoing Sworn Statement; and 14 Their execution of this Statement is of their free act and deed. 15 I have affixed my name and official seal 16 this day of, 20 17 18 Notary Public 19 Commission Expiration Date	Page 361

91 (Pages 358 - 361)

	Page 30	2
1	DEPOSITION REVIEW	
2	CERTIFICATION OF WITNESS	
2	ASSIGNMENT REFERENCE NO: 3191875	
3	CASE NAME: In Re: National Prescription Opiate Litigation v.	
	DATE OF DEPOSITION: 1/14/2019	
4 5	WITNESS' NAME: Thomas Gilson, M.D. In accordance with the Rules of Civil	
5	Procedure, I have read the entire transcript of	
	my testimony or it has been read to me.	
7	I have listed my changes on the attached	
8	Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s).	
9	I request that these changes be entered	
	as part of the record of my testimony.	
10	I have executed the Errata Sheet, as well	
11	as this Certificate, and request and authorize	
	that both be appended to the transcript of my	
	testimony and be incorporated therein.	
13	Date Thomas Gilson, M.D.	
14		
	Sworn to and subscribed before me, a	
15	Notary Public in and for the State and County, the referenced witness did personally appear	
16	and acknowledge that:	
17	They have read the transcript;	
10	They have listed all of their corrections	
18	in the appended Errata Sheet; They signed the foregoing Sworn	
19	Statement; and	
	Their execution of this Statement is of	
20 21	their free act and deed. I have affixed my name and official seal	
	this day of, 20	
23		
	Notary Public	
24		
25	Commission Projection Date	
	Commission Expiration Date	
		2
	Page 30	3
1	Page 30 ERRATA SHEET	3
1	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST	3
1 2	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019	3
1	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019	3
1 2 3	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 36 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 36 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON Date Thomas Gilson, M.D. SUBSCRIBED AND SWORN TO BEFORE ME THIS	-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON	-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 30 ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST ASSIGNMENT NO: 1/14/2019 PAGE/LINE(S) / CHANGE /REASON Date Thomas Gilson, M.D. SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20 Notary Public	

92 (Pages 362 - 363)

[**& - 19**] Page 1

	T	T	T
&	108 11:23,23	126 12:15	154 13:12,12
& 1:20 2:6,10,20	109 11:24,24	127 4:18 7:17,18	155 13:13
3:21 4:3,7,12,17	1095 3:13	129 12:15	157 13:13
5:2 18:17,20	10:16 81:22	12:08 146:17	158 13:14
0	10:38 81:25	12:11 146:20	159 13:14
	11 4:13 7:23	12:35 169:19	15th 359:7
001397330 7:24	140:24 244:10,16	12:46 169:22	16 291:23 308:3
244:13,18	304:8 341:11	13 7:16 8:7 43:3	160 13:15,15
001547662 8:10	110 11:25 12:3	84:8 263:8,11,22	161 13:16 241:18
263:17,25	1100 5:4 360:1	313:25	162 13:16
001684555 8:5	111 12:3	130 12:16,16	164 13:17,17
248:18 249:9	112 12:4,4	1300 4:8	165 13:18
001709118 7:20	113 12:5,5	131 12:17,17	166 13:18,19
234:14	114 12:6,6	132 12:18,18	168 13:19
1	116 12:7	133 12:19,19	17 1:7 263:25
1 7:5 28:23 92:15	117 12:7,8	134 12:20,20	341:21
92:16 106:15,16	118 12:8,9,9	135 12:21,21,22	173 13:20,20
142:24 156:11	11:23 126:19	136 12:22,23	176 13:21,21,22
182:20 281:20,22	11:48 127:8	137 12:23,24	177 13:22
282:4	12 8:3 68:10 248:9	138 12:24	179 13:23
1/14/2019 360:8	248:13,22 250:10	139 12:25 13:3	18 1:10 252:2
361:3 362:3 363:2	263:5 264:3,14	14 1:16 8:11 93:20	286:10,12,15
10 7:21 65:5,8	359:16	93:22 341:21	287:7,8 295:22
68:10 91:17 94:11	120 12:10,10 40:21	343:12,22	299:15,19 300:21
240:9,14 241:11	69:12,25 70:1	141 13:3	301:9 303:12,23
245:20 246:4,6	72:20 73:4 77:5	142 13:4	312:7 338:16
295:10 316:16,20	77:19 80:5,10	144 13:4	1800 3:5
345:2 349:12	88:18 100:8	145 13:5	181 13:23
351:14	101:14,17,23	147 13:5,6	1820 360:2
100 11:15,15	102:22 103:8	148 13:6	183 6:9,14
304:14	125:23 126:5	149 13:7	185 13:24,24
10017 2:4	143:11 334:13,20	14th 18:2	186 13:25 14:3,3
10036-6796 3:14	348:2	15 136:1 138:25	187 14:4,4
101 3:4 11:16	121 12:11	177:17 183:25	188 14:5
102 11:16,17	122 12:11	215:19 291:22,24	189 14:5,6
103 11:17,18	123 12:12	308:3 360:4	19 91:25 92:2,3
104 11:18,19,19	124 12:12,13,13	150 13:7,8	94:10,16 140:25
105 11:20,20,21	308:16,17 309:3,8	151 13:8,9	142:15 144:9
106 11:20,20,21	309:23	152 13:9,10,10	145:9 147:7
107 11:22,22	125 12:14,14	153 13:11,11	154:10 315:3
			320:7,24 338:16

[**191 - 278**] Page 2

191 14:6	2006 42:24 227:3,5	309:24 310:16,20	221 14:20,21,21
193 14:7	237:5 274:16	328:5 341:13	222 14:22
194 14:7,8 247:1	286:25 288:7	2015 199:17,17	2222 2:7
251:10	304:9	230:18 245:6,11	2227 359:12
195 14:8,9,9	2007 302:8	245:12 258:11	224 14:22,23
1950 1:21	2008 239:9	274:7,8,19 276:4	225 14:23,24
196 14:10,10,11	201 3:9 14:12	300:21 304:11	226 14:24
1970s 206:13	2010 188:7 236:16	305:14 306:12	228 14:25
1980s 102:20	239:8 313:20,22	2016 199:19 244:2	23 188:8
206:16	314:14	244:6 261:15	230-7676 2:4
1990s 102:17	2011 188:23 189:5	274:9,21 291:22	231-7353 4:14
207:5	189:10 212:19	292:23 304:12	234 7:19
1995 86:10 87:21	228:14 239:14	305:13 306:12,23	236 15:3,3
88:3 301:7	315:1	307:5 314:23	237 15:4,4,5
1998 206:21	2012 43:3 181:10	2016's 199:16	238 15:5
1:38 183:2	188:23 198:17	2017 238:10	239 15:6,6
1st 27:9	199:17 229:19	249:12,19 268:8	24 292:17
2	230:15 236:4	287:3,4 292:16	240 7:21 15:7
	237:15 239:24	341:8,16,23 342:4	244 7:23
2 6:3 7:7 66:10,22	240:17,23 241:18	342:8,19 343:1	245 15:7
66:23 68:25 69:1	242:9,16 245:18	2018 27:9 223:23	248 8:3
71:23 72:1 90:14	246:3 251:6,21,25	268:8 288:13,16	25 295:10
91:16 92:2 106:12	314:1 315:1	301:8 345:5	252-9060 3:10
127:12 140:2,19	2013 158:20 159:2	2019 1:16 18:2	257 15:8
153:8 183:20	159:12,21 170:17	359:7 360:4	259 15:8
185:16 211:6	181:4 198:21,24	202 3:23 14:13	26 9:3
281:20 282:2	229:20 234:1,20	2020 359:16	263 8:7
303:18 315:23	235:18,23 236:12	205 14:13,14	264 15:9
321:21 327:8	239:8,15,17	209 14:14	265 15:9
338:16 345:10,19	242:20 243:10,18	20th 4:8	266 15:10
346:20 347:17	245:25 246:2,9	210 14:15,15	267 15:10,11
351:18,24 352:1,4	247:4,17 251:10	211 14:16,16	268 15:11
20 6:8 69:24 130:7	252:9,23 277:23	212 3:14 14:17	269 15:12,12
188:8 361:16	278:1,15 285:4	216 2:8,12 4:9,19	27 184:12 261:17
362:22 363:22	290:17 291:13	5:5 14:17	270 15:13,13
200 14:11,12	310:20	216-523-1313	271 15:14,14,15
304:14	2014 177:17 199:1	360:3	272 15:15
2000 4:18 239:20	199:5,9,17 204:16	217 14:18	273 15:16
20005 3:18,22	240:15 245:5,9,10	218 14:18,19	275 15:16
2000s 207:5	263:25 304:9	219 14:19,20	278 15:17
2005 227:4	308:5,14 309:8,21	,	

[**279 - 5:48**] Page 3

279 15:17,18,18,19	308 16:11,12	352 17:11	48 9:16
28 184:15 273:3	309 16:12	353 17:12	49 9:17,17,18
280 15:19,20	31 9:3 264:5	354 6:12	4:13 284:17
2804 1:6,7	312 3:18 4:5 16:13	358 6:16	5
281 15:20,21	313 16:13,14	36 9:6 198:23	5 67:5,9,13 79:9
282 15:21,22	316 16:14,15,15	360 2:3	84:15,22 90:14,14
284 6:10 15:22	317 4:14 16:16	37 9:7,7	91:10,25 92:1,3
285 15:23	318 16:16,17,17	38 9:8	94:10,16 106:13
287 15:23	319 16:18,18,19	39 9:8	114:24 182:10
288 15:24	3191875 360:7	3:09 248:4	322:17,24 327:10
289 15:24	361:2 362:2	3:10 248:7	328:9 344:16,24
29 7:5	31st 345:5	3:19 256:18	50 3:9 9:18,19,19
290 15:25 16:3	32 9:4 264:5	3:26 256:21	500 66:2,3,4 71:6
294 16:3	320 16:19,20,20	3:59 284:14	74:6,12,14,22 75:3
295 16:4	323 16:21	4	75:16 92:7,16
296 16:4,5	324 16:21	4 29:22 67:5,9,13	144:1 149:12,19
298 16:5,6	324-1107 4:5	69:21,21 91:25	149:23 152:20
299 16:6	325 2:16 16:22,22	92:1,3 94:10,16	326:24 334:25
2:33 231:3	326 16:23,23	154:10 182:10	345:15 346:17
2:49 231:6	33 9:4	344:16,21,21	51 9:20,20
2a 352:13 354:2	330 3:10	40 9:9,9,10 22:19	52 9:21
3	333 16:24,24	41 9:10,11 249:23	53 9:21,22
3 7:12 84:1,12	334 16:25	415 2:22 3:6	54 9:22,23
92:15 93:21,22	336 17:3,3,4	42 9:11	55 1:21 2:7 249:18
154:21 157:14	337 17:4,5	43 9:12	249:23
159:12 170:11	338 17:5,6	43215-2673 2:17	56 9:23
171:1 345:4,7	339 17:6,7	434-5584 3:23	57 9:24,24,25
346:11 351:19,25	34 9:5,5 29:21	44 9:12	58 10:3
352:1,11	30:1,13 39:4 43:7	44113 2:12	591-6000 2:22
30 1:14 7:5 20:24	43:16 44:5,16	44113-1901 2:8	592-5000 5:5
28:24 83:16 108:1	51:25,25 313:8	44113-7213 5:4	5:08 332:16
139:2 184:20	338:16 340:3	44114 4:9 360:2	5:10 332:19
264:5 281:14	340 17:7,8,8,9	44114-1214 4:18	5:22 344:4
355:20	3400 3:17	44308 3:10	5:30 332:6
300 16:7	341 17:9,10	45 9:13,13,14	5:35 344:7
301 16:7	342 17:10	45090 1:10	5:45 354:16
303 16:8,8	343 8:11	46 9:14	5:47 354:19
304 16:9	344 6:11	46204-3535 4:13	5:48 355:25 356:2
306 16:9,10	349 17:11	469-3939 2:17	2110 220.23 300.2
307 16:10,11	35 3:17 9:6 22:18	47 9:15,15,16	
10.10,11		17:12	

[6 - access] Page 4

6	72 10:9,9	91 11:5,6	182:4 187:25
6 1:14 7:5 20:24	725 3:22	92 11:6	191:23 224:23
28:24 41:1,2 65:5	73 10:10 247:10,13	93 11:7	226:13 252:23
65:8,11 66:24,25	247:15 251:2,9,18	94105 3:5	253:25 266:3,6
67:5,9,13 69:9,16	252:13 255:16	94111-5356 2:21	294:16,17 296:11
69:22 72:7 83:16	74 10:10	95 11:7,8,8	296:25 297:8,14
84:21 91:25 92:1	75 10:11,11	950 2:11 5:4	297:15 298:1,13
92:3,5 94:11,16	76 10:12,12,13,13	96 11:9,9,10	298:18,25 299:18
130:23 139:2	77 4:4 10:14,14	97 11:10,11,11	300:21 301:9
328:10 344:16	78 10:15,15	98 11:12,12,13	303:23 304:22
345:2,3,6,14 346:4	79 10:16,16 255:17	99 11:13,14,14	305:7 308:4,6
346:6 347:18	79.5 253:2 254:9	9:07 1:16 18:3	309:23 310:16
349:11,13 351:12	8	a	311:22 312:6
352:8 355:20	8 7:18 127:3	a.m. 1:16 18:3	316:11 323:3
60 10:3,4	140:24 167:2	81:22,25 127:8	324:14,24 348:5
600 2:16	80 10:17,17,18	aaron 1:8	abused 287:21
60601-5094 4:4	42:14 54:12	ability 128:25	288:6,10 289:19
61 10:4	249:25 250:3,4,13	159:23 199:15	290:2,7 291:12,16
614 2:17	250:16,20,25	319:7 330:2 347:4	293:10,12 294:1
62 10:5,5	251:10,15 253:2	able 32:19 52:12	295:7 299:14
621-0200 4:19	253:11,17,23	53:8 61:16 82:5	324:5
621-7860 4:9	254:9	101:22 117:3	abusing 253:1,6,7
63 10:6,6	81 10:18,19	118:3 132:9	253:22 254:8,10
64 10:7 242:1,11	84 7:12	205:24 206:3	294:21 298:4
242:13 251:6	844 2:4	207:25 208:2	299:3,4,25
646-5857 3:18	85 10:19	280:16 317:4	abusive 100:18
659-5980 3:6	86 10:20,20,21,21	318:15 331:22,25	acceptable 213:19
66 7:7 251:21	10:22	333:19	access 24:3 26:12
68 10:7	861-0804 2:8	absolutely 104:9	32:17,21,25 33:3,8
696-4441 2:12	87 10:22,23,23	224:16 225:2	34:1,4,8 43:1
698-3814 3:14	88 10:24,24,25	332:8 350:21	46:10 173:21
7	89 11:3,3,4,4	abstract 240:20	180:2,6,12,15
-	9	242:5,6	181:4 184:9
7 6:4 7:17 65:5,8	-	abuse 70:8,13	192:10 223:16,20
91:17 94:10,11	9 6:5 7:19 52:4	72:22 73:6 78:23	223:22 224:5,14
126:23 141:1	53:14 56:21 58:1	79:1,16,22 88:20	224:18 225:9
167:2,13 328:10 345:2 349:12	58:10,13,14 61:19	88:21 105:16	226:3 227:19
	62:4 234:13,19	125:2,5,6,16,17,19	228:2 229:20,22
351:14 71 10:8 8	90 11:5 104:6	128:14,15 138:10	235:19,24 236:4,7
71 10:8,8	181:18,24 273:18	138:11,22 139:8	236:8,10,14,18,21
	273:19	139:11,12,17	236:23 237:1,6,8

[access - agencies] Page 5

237:10,21,22,23	184:22 281:16	318:24 319:4	addressed 112:24
238:2,14,17,20,25	297:3 336:8 337:1	320:9,23 339:10	196:14 275:16
239:1,6,18 242:20	340:25	addicting 156:16	addressing 260:6
243:13 251:23	active 123:12,16	addiction 41:18	298:14
257:24 258:9,12	123:23 124:9	42:1 54:16,24	adhere 275:23
258:14,17,24	227:16	55:9 58:22 126:2	adjacent 212:20
259:1,1,5,7,12	actively 147:16,18	146:9 156:10	adjournment
261:18 262:4,5,7	activities 48:11	158:14,14 159:9	358:21
262:10,12,20	138:1 154:25	164:21 172:5	adjudicated
264:22,23 265:15	155:13 156:5	296:4 297:5,6,9,14	306:23
265:17 266:8,13	157:5,19 158:4	297:16 298:2	administration
266:18,25 267:6,8	160:17 162:8	300:2 301:4	34:7 266:4
267:13,16,19	173:17	315:20,25 316:2,4	administrative
268:21 269:18	activity 36:6	316:7,11 317:7,11	343:9 344:15
270:5 271:4,9,13	260:21 269:15	317:22 318:3	administrator
271:16,22 272:1,3	331:24	319:18 336:19	24:9
272:4,7,15,16,23	acts 89:18	addictions 295:25	adopt 35:16
275:19 276:9,14	actual 75:3 122:16	296:7,8,10	advantage 242:20
276:19,21,25	156:19 160:9	addictive 58:21	advertisements
277:4 279:12,21	173:7 194:24	157:21 282:3	58:19
280:8,23 329:25	252:25 330:18	296:14,17 297:23	advertising 164:1
accessed 227:14	acute 123:5 307:5	337:7 338:8	advisement 83:17
278:9	acutely 308:11	340:23	affairs 175:20
accomplish 360:16	adamhs 301:3	addicts 70:15	260:4 261:7
account 254:13	add 25:4 68:19	253:3 254:6,7	affect 52:5 59:15
accurate 90:15,18	214:8 254:25	311:1,4	affiliated 155:24
129:12 351:10	255:10 292:15	addition 24:12	221:19,22
acknowledge	addict's 255:13	92:25 171:24	affixed 359:6
361:11 362:16	addicted 39:21,21	174:20 204:23	361:15 362:21
act 313:3 314:11	40:1,6 41:16 42:1	243:14 333:8	afford 216:11
361:14 362:20	42:8,16 48:8,8,13	additional 32:8	aforesaid 358:12
action 41:20	50:10,13 51:7,8,18	244:4 268:22	african 305:10,15
133:15 134:5	51:21 54:11,15	address 33:17	305:19
359:4	55:18 142:17	48:7 117:4 158:5	afternoon 6:14
actions 37:10,11	143:17 145:13,18	162:18 204:7,9	183:4,7 284:20,24
37:15 39:23 46:20	147:6,22 148:25	217:15 232:19	age 20:11 171:25
46:21 48:14 53:4	149:6,17,25	275:18 276:8	agencies 21:22
53:17 54:7 55:8	150:10,12,24	277:3 278:6 279:5	162:22 163:15
56:19 127:23	152:1 158:9,11	279:11 309:22	215:21 216:16
137:5 155:3 171:2	180:10 253:12	310:22	217:5 221:10
172:18 174:4	277:9,10 302:17	320.22	230:10 258:21
	,1000.11		

[agencies - appear]

250 0 276 0	-111 40 11	174 10 175 16	50 0 54 0 50 16
259:9 276:8	alleged 40:11	174:18 175:16	52:2 54:2 58:16
agency 24:17 30:5	41:16 85:5,24	177:10,25 197:14	60:3,20 61:24
32:23 38:12 162:6	92:9,18 93:5	212:15 252:21	62:9 75:24 81:8
162:7,12 164:3,12	345:15,17	anecdotally	86:4 88:15 95:5
200:25 201:23	allow 103:16	156:22 174:4	95:14 96:20 97:7
202:4 215:12,21	alyse 4:3 19:17	219:20 229:13	98:17 110:13
215:24 216:16	alyse.fischer 4:5	answer 22:13	131:5 139:6
219:9 237:9	amend 25:1	29:10 31:1 53:14	144:20 148:22
275:19 276:15	amended 7:5,9,14	54:5,20 55:13	151:11 157:16
300:2	27:4,16 28:23	59:19 60:10,11,15	212:4 214:6 234:3
agent 159:5	66:14 84:4 355:19	61:2 62:10 72:15	281:1 329:9
212:24 238:21	american 305:10	73:17 86:21 94:20	339:16 353:20
317:3	305:15,19	95:23 98:2 102:6	answering 31:14
aggregate 236:2	americas 3:13	103:7,14 105:1	214:21 234:5
282:15,20,25	amerisourceberg	106:24 110:17	268:14
aggregated 181:10	3:2 19:3,5,20	111:11 112:11	answers 81:15
236:7	ami 2:11 18:14	117:7 123:25	96:15 97:10
ago 22:6,12 102:16	amounts 192:23	130:13,22 132:10	127:16 351:10
108:1 130:7 136:1	amphetamine	132:14 135:1,4	antecedent 42:17
138:25 166:22	291:20,24 292:1	136:6 137:10	54:24
288:13	292:10 303:17	147:15 148:13	antidote 167:17
agree 54:20 77:15	amphetamines	151:3 159:10	anybody 19:23
192:1 287:16,20	291:15,16 295:23	162:2 166:14	32:13 36:3 44:2
313:1,13,20 316:1	analogs 313:22	173:11 174:8	44:10 45:2,9,15,18
317:5 318:8,23	314:6,17 341:5,18	203:17 206:10	47:13 67:24 77:1
319:8,20	342:6	214:25 218:19	81:4 112:15,17
agreed 75:15	analysis 71:19	220:13,23 226:9	114:12 134:7
203:8	160:22 230:3	237:20 271:19	148:14 162:20
ahead 47:11 59:12	240:17,23 241:18	277:20 281:8	167:5 173:15
ajp 2:13	242:16 249:14	282:23 290:12	203:24 259:11
akeyes 3:23	250:8 293:3	293:16,17 299:17	286:8 298:17
akron 3:10	339:19	300:24 308:12	331:18
akron's 7:14 84:3	analyze 60:23	324:1 326:3	anymore 26:6,13
al 1:10	analyzed 244:1	327:21 331:9,16	98:1
alcohol 191:23	analyzing 292:24	331:19 334:2	anyway 167:13
295:3 300:1 301:4	anatomical 330:8	335:16 347:12	apadukone 2:22
318:2	ancillary 120:3	348:6,17 349:4,5	apologize 59:2
alert 230:10	andrew 3:21 19:15	349:14 350:1	apology 114:25
288:12,21 289:4,8	anecdotal 160:14	351:2,15	apparent 260:7
289:10,14,16	166:7 170:15	answered 32:6	appear 361:11
	171:20 172:17	41:22 42:6 51:17	362:15

$[appearances \hbox{--} attorney's]$

	I		I
appearances 2:1	april 233:19	articles 28:16	asks 92:5
3:1 4:1 5:1 6:3	263:25 274:8	articulated 144:9	aspect 188:24
18:9 19:11	arcos 30:5 32:16	aseem 2:20 18:19	189:3 200:3
appears 189:8	32:18,24 33:13	aside 144:16 146:8	aspects 104:16,17
244:20 248:23	34:2,5,8 223:7,10	147:3	assembled 246:12
263:8 322:9	223:16,19,23	asked 26:1,2 27:18	assertion 127:19
appended 362:11	224:1,18 261:21	32:6 35:14 38:25	132:18 134:1
362:18	262:4 267:21	41:22 42:6 51:17	137:3
applicable 357:7	269:10,14,17,19	54:2 55:12 58:16	assess 178:12,22
application 79:6	269:25 270:3,9,10	60:3,20 61:23	assigned 317:21
122:23	area 24:19 31:24	62:8 75:24 84:16	assignment 361:2
applied 81:3 88:16	36:11 39:20 113:8	86:4 88:15 93:1	362:2 363:2
99:7,16,20 100:7	114:7 127:11	95:5,14 96:20,25	associated 93:5
100:23 101:14,18	142:19 145:14	97:6 98:9,17	188:10,24 189:4
105:18,23 109:5	155:2 157:7 177:8	110:13 117:14	242:2 247:14
112:8 113:11	183:22 184:3	127:12 131:5,11	291:2 326:16
115:20 118:4,7	208:17 210:14	144:20 148:22	association 23:2
120:7 122:22	272:12 308:10	152:10 157:16	63:2 64:25 172:12
149:20 153:3	316:12 318:12	158:18 212:4	205:22 292:17
154:18 182:15	340:9	224:1,7,18 225:4	assume 20:2
334:24	areas 29:15 268:2	225:12 226:2	103:15 171:6
applies 90:8	269:4	233:9 237:22	317:6
338:19	argue 100:11	238:4 239:8 281:1	assuming 283:15
apply 130:18	arising 223:4	285:9 297:2	assure 349:15
131:15 144:7,8	arrangements	329:12 333:17	attached 7:11 8:5
150:1 273:20	360:15	334:5 339:16,21	66:18 74:24
appreciate 77:13	arrest 196:1	349:3 353:20	248:17 362:7
170:1 345:18	260:23	asking 44:17	attempting 39:8
approach 215:14	arrested 325:9,13	63:22 98:11	attended 350:11
appropriate 25:1	330:22	100:15 108:5	350:16,23
35:21 63:18 160:3	arresting 261:2	125:12 131:22	attention 57:23
161:16 162:17	arrests 196:5	147:17 148:10,14	106:24 207:2
200:24 202:4	246:18 325:19	148:15 150:15	234:18
318:24	334:6,17	159:1 168:9	attorney 7:8 66:12
appropriately	arrive 317:10	211:24,25 236:6,8	168:4 231:13,25
128:1 220:17	318:2,4,5	270:8 297:5	233:24 234:2,21
appropriateness	arrived 76:16,17	298:19 307:20	283:7 322:2 359:2
63:1,8,13 317:16	article 7:21 240:9	308:11,25 312:23	attorney's 198:9
approximately	240:15,16 241:11	313:13 329:13	217:14 232:12,23
42:14 250:25	241:17 245:20	340:7,10 348:21	233:22
251:15		351:13	

[attorneys - badala]

ottomore 21.12.14	ave 360:1	•	204:15 206:13,16
attorneys 21:13,14		b	·
65:20,20,22 67:17 71:21 88:11 94:19	avenue 2:3,11 3:13 5:4	b 1:14 7:5 20:24	206:18,21 208:18 211:19 214:17
96:13 97:25 98:19	avoid 70:15	28:24 83:16 101:9	222:15 229:16
99:14 110:2,16	avoided 25:13	139:2 140:17	231:5 234:25
111:16 112:25	51:6 167:16	143:23 144:18	243:3 248:6
113:13 115:12	aware 34:4 36:13	149:7,9 170:12	251:23,24 252:8
117:2 118:25	45:17,24 49:22	171:1 172:17	251.23,24 232.8 252:10,17,25
117.2 118.23	51:2 60:24 64:16	315:22 327:8,13	252:10,17,25
122:1 130:11	66:3 74:17 75:25	327:19 328:22	256:20 257:15
147:13 150:11	79:4,19 80:4,19	329:4 330:21	261:5 277:9,11
151:1 152:21	81:14 94:10 95:7	331:1,8,13 332:2	279:25 284:16
154:19 168:6	95:12 96:21 97:1	332:23 334:9,20	
		335:2,5,8,17 337:5	286:23 287:1,4 291:18 305:14
208:20 223:18,22 321:5,13,19,20	97:9,11,16,17,23 98:4 116:3,4,11	337:11,15,22	307:8,8 308:21
322:13 323:7	, ,	339:2,12,18	, ,
339:19 351:6	117:7 122:6 137:21 154:10	355:20	314:4 324:20 327:9 331:3
		back 28:8 31:13	
attributable 37:16	157:11 159:6,8,20	32:12 36:2 37:12	332:11,18 333:9
147:23 329:5,16	162:19 163:24	39:13,22 42:8	344:6 347:25
341:8 342:5,13,16	165:15 173:24	43:7 44:12 45:16	351:24 352:25
attribute 335:24	178:17 181:16	48:13 53:5,7,18	354:18
attributed 314:22	190:11 192:6	54:8 55:9 56:19	backs 174:13
audience 244:25	193:4 195:1,5,11	56:20 58:1,25	251:25
august 285:4	197:12 200:17	59:16 60:7 62:1	backwards 73:3
authored 264:1	202:13,16 204:2	63:5 69:21 81:24	badala 2:3 6:12
authorities 217:24	205:6,18 206:7	86:6,10 93:10,11	18:10,10 20:1,9
authorize 362:11	207:6 209:21,22	102:14 112:1	26:9 31:9 32:5
automated 42:22	210:2,3,4,10,17	114:23 127:7	33:11 34:3,19
64:24 181:6	212:23 215:9	130:23 131:13	35:24 36:7 37:8
autopsy 235:7	219:13 223:10,21	132:7 134:21	37:21 38:3 39:18
237:24	224:12,12 229:11	137:2 140:11,18	40:7,14,18 41:7,21
availability 54:25	237:11,12,14	140:23,24 146:14	42:5 43:17,25
55:3	257:19 258:19	146:19 153:7	45:7,13,21 46:16
available 23:4,15	259:4,20 268:13	163:15 165:2,8	47:1,5,9,19 48:18
23:18 26:24 27:14	268:15 269:3	169:2,21 171:13	48:24 49:11,19
28:12,19 41:12	275:17 277:23	171:15,22 174:25	50:1,7,21 51:4,16
43:19 64:19 238:2	281:19,22,24,25	175:1 177:10	52:1 53:10,16
286:1 310:2	282:6,11 283:2	178:3 179:13,19	54:1,10 56:3 57:2
328:14 330:24	284:3 286:6	180:8 181:7 183:1	57:10,19 58:15
331:5,10 360:13	300:15 315:24	186:1 199:13	59:6,10 60:2,19
	326:1 330:9	202:19 203:23	61:1,6,23 62:8,20

[badala - bates] Page 9

(2.24.62.10.10	127 22 120 10	245 7 255 4 256 2	255 12 17 260 5
62:24 63:10,19	137:23 138:19	245:7 255:4 256:8	355:13,17 360:5
64:10 66:24 67:6	139:5,23 140:20	256:12,15 257:4	bag 169:2,5,6
68:21 71:1,16,24	140:23 141:17	259:16 264:17	baker 4:17 18:22
72:13 73:9 74:19	142:2,20,23	265:18 266:10	20:5
75:12,23 76:4,10	144:19 145:21	267:11,23 268:24	bakerlaw.com
76:13,23 77:6,21	147:10,24 148:21	269:11,21 270:1	4:19
78:6,18 79:2,10	149:3,7,9,18 150:3	270:12,18 271:6	balraj 24:8
80:1,6,17,25 81:5	150:13 151:9,21	271:15,24 272:9	barnes 4:12
81:17 82:7 83:10	152:3,13,18 153:5	273:1 275:10	base 227:18 254:3
85:10,25 86:3,7,13	153:17 154:3,15	278:4,25 279:7,13	based 32:22 34:5
86:20 87:1,8,14,24	155:14 157:15,24	279:22 280:7,10	42:21 46:1 49:13
88:7,14 89:2,9,13	159:15 160:2,18	280:25 281:10	52:14 85:12 94:17
89:19 90:20 91:1	161:11 162:23	282:18,21 284:8	110:2 135:25
91:11 92:11,22	164:4,16 165:21	285:3 287:22	138:14 139:1
93:18 94:12 95:4	166:11,15,18	288:1 289:20	150:20 151:20
95:13,20 96:2,10	167:2 168:11	290:4,8 294:19	159:13 163:13
96:19 97:5,14,21	169:14 172:25	295:13 296:1,19	165:1,10 174:16
98:3,6,16 99:3,8	173:19 175:8,13	297:2,10,17,24	238:11 242:8
99:18,25 100:9,15	176:11,16,19	298:15 299:21	249:4 251:6,9
100:21 101:5,9,15	177:4 179:10,12	300:22 301:11	294:12 317:22
101:24 102:5,23	181:22 185:15,18	303:4,7,13,25	323:6 328:5,14
103:10,18 104:14	185:25 186:12,18	306:5,16 307:1,15	351:6
104:18,23 105:4	186:25 187:15	308:8,19 309:10	baseline 300:16,19
105:13,19 106:6	188:2 189:6,11	311:24 313:5,9,23	306:9,21 308:3
107:16,23 108:2	191:13 193:21	316:3,8,18 317:12	bases 130:3
108:14,25 109:8	194:3,20 195:9,16	317:25 318:10,17	basic 222:18
110:12,20 111:4	195:22 196:3,11	319:1,11,23 320:4	basically 56:4
112:6,13 113:6,17	196:16 200:16,22	320:10,19 321:25	92:25 172:16
114:3,10 116:2	201:7,25 203:16	323:17 324:16	213:12 255:12
117:19,23 118:5	203:19 205:3,8	325:1,11 326:8,21	basis 96:15 99:12
118:12,17 120:15	209:12,25 210:7	333:2,23 334:21	101:21 108:23
120:22 121:19	211:3,14 212:3	336:2,12,17 337:8	127:19 132:17
122:18 123:8	216:19 217:12	337:18 338:1,13	134:1 137:3 151:2
124:1,16,19 125:8	218:6,17 219:3,17	338:18 339:3,15	152:6 154:17
125:21 126:4,17	221:6,12,21 222:7	339:25 340:4,14	190:9 208:7
129:23 130:8,20	224:3,19 225:1,13	340:19 341:9,20	261:15 328:4
131:4,16 132:3,12	226:15 228:22	342:20 343:16,19	334:11
133:1,13 134:10	230:24 234:5	345:24 346:10	bates 7:19,24 8:5
134:19,25 135:4	236:13,19,25	349:2 351:17,23	8:10 234:14
135:13,17,23	237:7,19 238:5	352:9,15,20	244:12,17 248:17
136:2,12 137:12	239:5,12 240:2	353:19 354:9,21	249:8 263:16,24

[bath - brought] Page 10

	I	I	T.
bath 290:11,13	believes 30:20,22	319:6 326:25	bockius 4:3
291:11 293:18,23	31:22 32:3 53:23	334:2,16 342:21	body 291:19 292:3
becoming 100:18	61:21	big 72:8 107:3	boranian 3:3 6:9
156:1 180:6	bell 181:21	111:24 140:20	19:4,4 183:6,8
253:10	bellwether 84:25	288:23 289:2	185:17 231:1,7
beginning 7:19,24	85:2 93:23 107:1	321:23 322:5	247:19,25 248:8
8:9 28:4 234:13	128:9,17 129:6	347:17 352:4,7	256:22 263:21
242:5 244:12	138:5 346:21	353:4,11	270:14 284:12
263:16	beneficial 276:12	bigger 355:5	355:16
behalf 2:2,10,14	benefits 128:19	biggest 220:4	born 201:17
2:19 3:2,12,20 4:2	129:7 205:19	286:22	bottom 94:5
4:6,11,15 5:2	346:23	bill 19:13	264:20
18:20,23,25 19:3,7	benzodiazepine	binder 8:11 26:23	boulevard 2:16
19:13,15,18,20,22	295:23	343:10,22	bounces 189:8
21:3 28:14 31:25	benzodiazepines	bit 29:18 99:17	boundary 34:23
38:16 54:3 81:15	293:9 295:1	172:14 230:2,20	box 213:24
86:17,22 89:1	303:17	291:25 324:18	boxes 214:17
110:25 118:21	best 23:16 29:10	352:16	brain 314:11
125:13 322:14	31:17 38:13 46:14	bite 159:1	brandy 2:15 18:24
behavior 55:20	77:9 78:8 136:6	blanket 285:17	branjan 2:18
260:12 261:3	161:18 162:12	block 87:5	break 81:19 83:12
behavioral 299:7	176:7 188:5	board 25:6,9	126:16 127:12
behest 96:8	190:19 194:14	65:16 103:21,21	129:15 130:14
believe 27:22	203:22 226:1	104:1,4 155:17,17	146:13,22 182:18
28:19 37:23 41:25	262:6 268:9,19	162:15,16 163:4,4	230:23,25 247:24
47:3,23 50:23	274:10 291:14	165:8 167:22,23	248:1 256:13,16
52:5,25 58:3	293:7 301:25	168:2 184:16	284:12 319:22
59:23 71:18 79:18	322:14 349:5	196:23 197:4,10	332:5,10
79:23 87:10	better 43:21 218:2	198:13,17 199:5	breakdown 292:3
102:25 127:16	218:19 252:10,15	200:1,2,2,7,10,12	breaking 49:8
133:20 158:3	268:12 271:19	201:6,6,19,24	breaks 47:14
187:17 212:16	282:4	202:6,8,14,17	briefly 154:22
219:23 221:16	beyond 41:14 66:6	203:2 204:14,23	bring 26:21
227:15 228:23	67:16 71:10,19	208:18 216:22	brings 302:17
237:9 258:21	92:23 97:9 104:2	231:20 232:21	broad 206:22
269:13 276:1	105:21 130:15	233:15,16 234:21	271:9
285:4 298:20	152:8 192:23	236:3 238:10	broke 47:12,15
315:17 328:4,14	194:15 201:21	262:23 273:4	broken 291:19
335:2 338:12	216:24 255:13	299:8	brought 26:23
340:8 345:10	257:2 273:18	boards 196:20	82:14 140:11
	306:8 315:11		213:2 343:10
Veritant Legal Solutions			

[bryant - certainly]

bryant 3:13	121:18 122:25	284:23 289:11	caused 30:20 31:7
btlaw.com 4:14	123:2,3,5,7,9,11	296:24 297:7,13	31:22 32:3,9 38:1
budget 301:6	123:12,15,21,23	297:19 302:25	42:2 44:20 50:19
bulk 246:2	123:24 124:5,9,22	303:5,8 313:8	295:25 299:20
bullet 246:8	125:1 143:11	320:7 332:8,13,20	308:14 314:8
249:22 264:3	150:21 325:16	338:21 340:3	340:8 341:17
bulletin 252:24	334:12 348:1	341:22 343:8,17	causes 327:16
253:24 254:3	349:19	343:25 355:15	333:4,11 337:11
255:22,25 256:7	cannabinoids	carve 90:15	338:5
256:10 285:1	290:22 293:15,20	carving 90:18	causing 302:2
burden 243:20	296:9	case 1:7,10 21:15	caution 103:22
bureau 65:15	cap 103:5	21:16 22:23 59:17	caveat 314:19
burling 2:20 18:20	capacity 64:24	82:11 119:1	cavitch 4:7 19:21
bursts 355:11	124:24 201:21	126:13 155:24	cavitch.com 4:10
byproduct 48:9	206:1 279:2	194:18 196:20	cdc 261:14 265:1
c	caption 358:20	204:4 249:3 257:9	center 25:11
_	caraffi 25:5 26:18	269:25 270:17	155:25 167:15
c 7:8 66:13 167:20 266:20	82:20 167:19	271:3 272:7 297:8	221:17,23 222:10
ca 360:25	208:19 233:17	303:10 317:9	222:14 231:22
	cardinal 3:20	330:13 360:6	276:2
cabinets 214:1,12	19:16	361:3 362:3	central 259:13,25
calculated 190:8 282:20	care 90:11,12	cases 83:2 213:16	certain 26:7 64:13
california 2:21 3:5	129:9 221:17	217:24 220:6	73:13 76:11 80:22
call 20:24 70:4	career 268:4	221:2 251:10	82:23 110:6
83:13 97:18	carfentanil 221:4	252:9 259:14,22	122:23 124:2,10
226:24 233:12	314:7 341:19	278:9 302:10,15	126:14 134:18
332:12 352:13	342:6	355:8	139:10 199:4,22
360:14	carole 27:3 168:5	cash 35:13	202:11,20 219:22
called 20:11 37:24	198:3 208:20	categorically	219:25 222:1
233:25 246:14	217:17 231:14	124:5	231:23 249:1
calls 26:15 161:22	232:13 234:2	cathinones 293:21	277:15 286:4
164:14	carrier 65:14	caucus 344:2	295:8
camera 168:14	cartel 34:21 39:15	caught 331:17	certainly 27:10
cancer 40:20	50:25 51:12,20	causal 338:12	33:6,9 36:13,17,17
69:11,24 72:21	54:19 55:23,25	cause 37:5,6 42:17	48:12 49:5 57:25
73:4 76:2,15,21	56:4,12,25 61:9	141:16 156:20	63:25 64:19
88:18 89:25 90:4	cartels 51:15 55:1	288:8 295:2	116:20 122:21
90:10,16,19,21,24	55:14 58:10	306:24 327:14,20	160:6 192:6 198:8
91:5,9 95:22	312:19	328:1,11,23	202:9 207:10
99:24 100:3	carter 2:15 6:10	333:24 358:11	224:11 232:2
109:15 119:21	19:1,1 284:19,21		265:21 268:1
107.13 117.21			

[certainly - clarified]

277:20 279:16	changed 301:22	83:8,12 92:24	city 2:10 7:12,13
280:15 281:6	301:24 303:3	100:11,17 101:1,7	18:15 84:1,3
288:18 289:1,10	304:10,19 314:21	101:11 126:15	216:2 219:20
289:14 291:8	changer 314:25	142:22 149:5,8	220:4 231:17
292:14 298:20	changes 314:21,23	153:20 166:13,25	232:15 262:17
299:25 300:5,13	361:7 362:7,9	169:12,16,23	267:10 268:5
300:17 302:4	changing 302:1	175:11 182:17	civil 20:12 357:3,7
307:4	channeled 187:2	chemical 292:4	361:5 362:5
certainty 199:18	chapman 24:11	chemistry 286:19	claim 136:20
259:12	82:21 355:1,9	chicago 3:18 4:4	claimed 74:8
certificate 6:16	characterization	56:8	claiming 214:20
148:4 265:9 358:1	345:25 352:21	chief 24:10	215:6
362:11	characterizations	child 21:17 23:6	claims 40:19 65:12
certificates 141:21	351:4	24:11 26:17	65:22 69:10 70:23
257:21	characterize	165:11 166:6	71:8,12,19 73:11
certification	170:18 334:16	197:13 201:15	73:13,19,20,21
242:25 361:1	characterizing	202:3 266:19	74:8 88:9,17 89:6
362:1	338:6	267:3 298:25	89:11 94:17 96:12
certified 20:14	charge 233:19	children 201:17	98:19 99:10,13,22
141:10,16 306:24	charges 218:5,16	299:3,4 302:17,17	105:22 106:8
327:14,20 360:16	223:3 298:8	china 210:12,21	111:6,15 120:1,9
certify 358:8,18	chart 27:19 107:3	212:8 312:19,22	120:11,17 121:3
359:1	111:24 245:4	chip 4:8 19:21	121:21,25 122:16
cetera 130:4	259:10 264:13	choices 129:1	124:22 130:2
139:18 246:11,11	304:8 310:18	347:5	142:3 143:10
262:22	311:19 322:11	chronic 62:17 63:3	144:1,10,13,17,25
chad 180:5	charts 64:18,21	63:9,17,24 64:4,8	146:6,7,8,24 150:5
chain 45:4,10,18	69:7 314:4	85:2,12,14,21	150:7,24 151:5
55:23 57:9 185:3	check 104:4	86:12,25 87:4,7,11	152:22 154:12,17
185:7,24 186:11	199:16 270:25	87:18,21 88:4	154:19 170:15
186:17,22,23	273:15 275:12	90:3,11,17,22,24	321:11 325:22
187:3 195:8 211:9	276:3 308:16	91:4,7 95:19,25	334:10 335:5
211:12 212:6,9	checked 177:11	96:3	349:24 351:5
chains 57:1 60:8	274:3 328:6	circumstances	354:4
chair 167:23	checking 177:14	134:8 273:15	clandestine 208:1
chaired 168:4	checks 177:20	citation 250:4	clarification 127:9
233:18	274:1,18	cities 216:5,7	clarifications
challenges 220:14	cheffo 3:13 6:8	267:21	83:20
chance 127:15	19:8,8,23 20:16	citizen 159:25	clarified 131:17
change 292:25	59:8 62:22 63:4	citizens 232:25	131:22
362:8 363:3	67:2 69:2 81:20	233:4 309:3,16	

[clarify - complaints]

clarify 130:17	close 253:20	collect 172:11	commissioned
265:15	255:18 311:11	190:18 198:16	358:8
clarity 262:3	closed 186:17,23	229:18,21 243:1	committee 164:18
344:19	195:8 211:9,11	252:4	191:22 198:21
classification	212:6,9	collected 65:12	217:14 242:24
317:3,21	closely 104:11	71:8,18 88:9	246:13
classified 290:2	closer 22:18	94:17 108:20	committees
classify 318:16	251:19 343:6	110:1 190:7 203:7	217:13
clean 343:9	closing 222:15	227:11 243:16	communicated
clear 29:12 44:8	clr 1:25	244:1 299:6	204:8
57:12 59:13,22	cluster 293:20	collecting 98:18	communications
60:5 67:6 89:21	cocaine 288:5	171:20 172:22	82:9
122:3,25 130:11	292:22,24 293:1	243:10 252:19	communities
186:24 199:25	295:18,22 296:7	collection 260:25	156:22 170:20
210:18 228:5	301:23 302:11,19	columbus 2:17	community 52:7
233:13 259:6	302:22 303:17,18	56:8	58:5 232:4,18
296:12 301:18	303:21 304:3,8,13	column 249:10	233:3 285:17
314:14 342:1	304:16,17,18,22	combat 312:6	305:10,12 306:9
clearer 225:8	304:23 305:8,19	combination	311:13
clearly 101:8	305:21 306:11,15	342:16	companies 4:16
296:6,10 297:11	306:23 307:7,12	come 28:8 56:8,9	194:25 195:3
cleveland 1:22 2:8	307:13,18,21,25	112:22 213:16	comparabilities
2:10,12 4:9,18 5:4	308:2,4,6,15 309:4	253:12 262:11	312:3
7:13 18:15 24:15	309:9,19,23 310:5	265:5 300:25	compensation
26:11 84:2 155:23	310:9,11,16 311:1	302:21 325:24	65:15,16 71:9
181:17 216:2	313:22 314:2,17	347:19 348:23	compiling 285:6
219:20,21 220:3	314:20,22 341:19	353:3	321:7 334:8
231:17,22 233:25	342:7	comes 242:15	complained
267:10 359:7	code 323:24 324:1	253:23 266:16	206:25
360:2	coded 220:17,18	coming 24:20 44:3	complaint 27:4,5
cleveland's 232:16	codeine 206:13	68:8 114:14 174:9	85:24 159:24
client 20:7 271:11	codes 316:17,24	208:6 210:11	162:5,21 163:25
271:13,22	cohen 27:21 101:6	227:9 246:22	173:16
climaco 1:20	collaborate 217:4	347:15 349:22	complaints 85:5
climate 211:16	265:1 300:5	353:8	154:24 155:11,16
clinic 37:24 43:10	collaboration	commander 24:14	156:21 157:3,11
43:15 155:23	217:9 312:13	comments 282:25	159:3,12,19 160:9
231:23 233:25	collaborative	commission	160:12,16,23
260:19	257:13	359:16 361:19	161:4,14,18,23
clinics 36:14 184:2	colleagues 29:8	362:25 363:25	162:13 170:15
	268:2 269:5		171:3 173:1,21,25

[complaints - contrary]

174:3 175:17	conclusion 317:10	conjunction 108:6	consulted 65:25
176:5 202:5	conclusively 332:1	213:13 253:9	94:19 96:13,23
complete 168:21	332:22	connect 310:4	97:25 98:20
completed 245:10	conditions 120:5	connection 21:7	111:16 113:13
358:20 360:13	121:11,13,14,24	22:25 24:5 44:5	119:12 153:3
completely 175:13	128:1 151:15	51:25 63:8 64:6	321:6
175:14 211:18,21	conduct 36:5	64:13,14 67:25	consulting 152:21
211:25 249:1	37:20 40:11 41:4	68:5 81:12 96:6	consumer 159:24
297:12 351:13	41:20 44:13 45:5	97:19 98:12,15	191:6
completion 331:19	45:10,16,19 46:13	110:7 138:16	cont'd 3:1 4:1 5:1
comply 273:23	46:22 47:24 48:22	140:25 177:3,12	8:1 10:1 11:1 12:1
compound 295:5	49:18,23,25 50:6	209:5 222:3 230:6	13:1 14:1 15:1
compounds	50:20 51:11,15	249:15 321:7	16:1 17:1
336:19 337:7	52:7 53:2,9,21,24	322:10	contact 42:19
338:9	57:8,11 58:6 59:3	connolly 3:21	165:16 203:21
concept 186:17	59:25 60:18 62:6	consensus 344:18	302:18 353:6
concern 158:9	62:12 89:1,7,17	consequence	contain 335:17
173:16 174:21	95:11 120:21	47:14 211:15	contained 215:20
180:9 227:8 299:1	139:25 160:17	consequences	contend 85:1
299:2 305:16	178:11,21 202:10	200:18,21	93:24 107:1
308:10 309:15,20	321:9,16 335:25	consider 190:24	128:10,18 129:6
concerned 156:1,8	336:10,14 338:11	191:4,14 295:14	138:5 139:14
224:23 226:12,12	339:1	296:16 297:22	346:22
289:17 298:14	conducted 240:22	303:16 306:14,22	contention 130:3
309:2	322:16	307:13 308:5,5,17	continuation
concerning 162:8	conferred 321:14	309:9	127:17
171:16 184:9	confident 167:9	considered 33:7	continue 83:15
261:18 262:8	confidential 7:20	73:5 90:21 187:21	205:10 229:21
266:25 268:16	8:6,10 234:15	194:6 313:3 334:8	252:3,14
concerns 154:23	248:19 263:18	consistent 156:23	continued 128:22
155:4,11 157:3,12	confirmation	constituted 153:8	158:24 198:25
157:17 158:12,13	313:17	constitutes 296:4	205:12 229:20
159:8,11 160:10	confirmed 320:25	297:5	273:17 309:25
160:22 161:23	confused 37:6	consultation 68:13	310:10
162:6 164:11	111:13 251:4	110:16 112:9,25	continues 205:7
170:22 171:3	260:14	113:12 114:6	continuing 104:7
174:3,15 176:5	confusing 67:3	115:12 117:3	347:1 350:11,17
194:8 197:15	89:23 91:23	147:14 151:1	350:24
201:14	confusion 352:2,3	152:9 315:11	contrary 128:16
concluded 356:2	352:10	322:13 324:8	138:12
		325:4,6,24	

[contribute - county]

4 11 4 27 5 7	1. 4.	4 200 12 17 10	CF 10 15 10 CC 10
contribute 37:5,7	coordination	cost 300:13,17,19	65:12,15,19 66:10
46:20 48:12 57:20	233:20	301:1 302:13	66:13 67:17 70:22
57:23 165:20	copies 23:11	costs 55:5 299:20	70:24 71:10,14,18
166:2,10,16 265:7	copy 27:2,3,13,16	300:1,6,11 301:2,8	72:3,7 73:22 74:7
265:16	29:5 166:23	301:15,17	77:10 81:16 84:2
contributed 30:20	coroner 21:19	counsel 18:8 19:10	84:3 86:17,22
31:7,22 32:4,11	22:24 24:8 272:1	20:7 26:24 27:8	87:10 88:9 93:10
34:18,24 35:5,25	coroner's 206:21	30:14 41:11 61:3	94:17,21 96:8,12
36:19 37:10 38:1	237:9	67:14 82:6 114:6	97:23 98:10,11,22
44:19 208:5 340:8	coroners 238:13	277:14 324:8	99:1 101:23 102:1
341:1	238:14	357:1,10 359:2	102:18 103:3,9,16
contributing 8:9	corporate 20:25	count 106:15	104:25 105:8,21
263:14	22:10	counties 174:22	106:3,7 107:8,13
contribution 38:5	corporation 2:19	178:16 189:24	107:22,24 108:7
44:10 306:20	3:2 18:21	190:2 207:23	108:20 110:14,25
307:9	correct 36:21	216:10 267:22	111:16,18 112:14
controlled 42:25	47:18 68:22 95:19	337:2	113:20 114:5
156:17 196:24	112:5 114:19	countries 313:2	115:14,19 116:3,7
223:12 225:21	118:4 120:14,21	country 211:7	117:2,11 118:21
226:13 227:2	121:12 147:1	269:5	123:14 125:11,13
228:10 242:1,15	149:2 170:14	county 1:9 2:2 7:6	139:10 142:11
274:17 281:21	183:11 184:13	7:7,8,13,13,22,23	144:14 145:24
282:1,7 296:25	185:17 188:20	8:4 18:11,13 21:3	147:13 148:2
303:16	191:17 197:21	21:4,20 25:7,8,11	150:19 152:8,19
convened 233:23	201:24 210:22	27:20 28:25 30:20	153:19,20,24
convenient 360:15	212:8 223:25	30:21,22,23 31:11	155:15,21,23
conventional 91:7	249:24 285:8,22	31:21 32:3,7,10,15	157:13 159:6,20
conversation	286:2,12 288:6	32:17,20,24 33:10	159:23 160:1,5,7
224:8 227:22	291:13 292:12	33:15,23,25 34:5,8	160:10,19,23
354:25 355:4	293:6 294:18,22	34:23 35:5 36:8	161:3,5,16,19,24
conversations	295:25 316:7	36:16,20 38:17	162:5,20 164:6,10
21:9 25:18 82:4	317:23 318:9	40:1,10,19 42:1,16	164:25 165:14
130:10 160:14	342:8 358:16	43:19,20 45:14	167:22,23 171:2,7
165:10 167:7	corrected 27:4,5	46:19,24 47:21	171:18 172:10,18
173:4 212:17	correction 82:1	49:14 50:23 51:2	173:15,22 174:1,4
322:2 326:19	corrections 362:17	52:5,19,24 53:1,12	175:1,15,18,21
conveyed 156:7	correctly 292:9	53:22 54:3,13	176:9,14 178:11
cooperation	correlate 126:8	55:7 59:23,25	178:14,21,24
312:13	correspondence	60:11,22 61:10,11	179:4 183:10,18
coordinate 200:11	27:22	61:15,21 62:11,25	186:15 187:25
		63:12,15,25 64:8	189:21 190:2,4,6

[county - crisis] Page 16

		I	1
190:12,17,18	267:13,15 268:3	335:23,25 336:9	258:16 268:20
193:3,18 194:1,6,9	268:15,21 270:4	336:20 337:17	277:16
194:17 195:2	272:14 273:8,11	338:10,25 339:5	covering 29:7,8
196:21,22 197:21	273:12,24 275:6,9	339:18,20 341:17	covington 2:20
197:24 200:25	275:13,16,19,22	342:4 346:3,6	18:20
201:11 202:1,5	276:7,16 277:24	358:4 361:10	crack 314:1
203:1,4,7 204:3,10	278:14,18 280:19	362:15	create 35:22 50:10
204:25 205:6	281:19,24,25	county's 34:14	50:12 319:16
206:2,6,8 207:6,7	282:6,19,24 283:3	36:22 39:10 40:4	336:21,23 337:23
207:8,12,15,19,20	284:3,6 285:6,10	44:9 45:11 53:3	347:25
208:6,10,22,24	286:12 287:21	59:14 60:6 61:25	created 48:14
209:7,8,8,10,15,20	288:6,11,16,21	62:3,15 67:10	51:19 56:18 70:16
209:24 210:6,23	289:3,6,19 290:3,7	68:16 85:9,20	101:19 230:1
212:12,23,25	291:12,16 292:20	98:1 155:19	238:11 257:14
213:3,4,6,8,23	293:10,13 294:2,4	159:11 218:11	creates 211:16
214:4,6,15,16,19	294:17 295:7,25	220:4 223:17	317:20
214:20 215:3,5,6,8	296:13,16 297:22	298:12 299:2	creating 51:6
215:21 216:8,9,16	298:3,11 299:1,8	309:7 311:21	180:10 340:20
217:4,7,23,25	299:10,12,16,20	313:15 319:6	creation 156:2
218:3,13,15,18,22	299:25 300:3,4,10	323:18 325:8	311:3 337:3
219:1,5,11,14	300:13,17,20	327:1 330:11	339:10
220:2,7 221:4,10	301:1,3,6 302:13	339:8,24 340:12	credentials 257:25
221:19,22 222:2,4	302:23 303:22	343:3	crime 187:14
222:13 223:15,19	304:3,13,21 306:3	countywide 190:8	261:1 286:20
223:21,23 224:1	306:25 307:7,12	couple 68:7 231:9	289:15
224:22 225:9,19	308:5,17 309:2,8	327:9 354:22	criminal 46:21
225:24 226:2,7,11	309:21,25 310:1,6	coupled 54:14	218:5,16 223:3
226:14 229:5,11	310:9,15 311:3,6,7	course 24:24	crises 211:21
231:12,16,20	312:5,8 313:3,13	122:10 157:18	crisis 8:3 21:21,23
232:15 233:7,14	313:19 314:16	201:16 278:5	30:21,23 31:7,23
238:22 240:10	315:8,10,15,19,25	287:23,24 298:16	33:6,18,20 34:18
241:14 244:12	316:14,22 317:2	324:9 330:5,17	34:24 35:6 36:20
246:16 248:15	317:15,18,19,23	court 1:1 6:18	38:2 39:1,13
249:8,21 257:1,6	318:4,6,15,22,23	18:6 19:24 288:2	46:19 54:21 55:7
257:23 258:1,3,4,5	319:3 320:25	302:7,14 310:10	58:19 83:3,5,7
258:9,15,22,23	321:4,9,15 322:8	311:4 361:7	104:20 156:3,4
259:4,7,17,19	322:14 325:3,21	cov.com 2:22	158:5 165:20
260:1,3,11,17,20	326:17 327:18,24	cover 154:22	166:2,10,17 172:9
261:5,24 262:16	329:3 331:20,25	189:18 244:17	179:2 188:14,22
264:21 265:15,17	332:21 333:6,10	covered 112:2	197:25 199:14
266:8,17,18	333:19 335:10,18	154:5 232:10	204:8 206:18

[crisis - data] Page 17

210:24 211:17,17	115:20 116:1,23	354:5	171:2 172:9
211:21 229:11,23	117:4 118:4,7,8	critical 178:6	178:13 190:2
230:17 243:21	119:17,20,25	cross 177:14	193:2 206:2
248:14 249:6	120:3,4,7,8,17,18	205:24 328:6	207:12,15,19
251:2 252:17,22	120:23 121:2,7,20	crum 5:7	209:24 213:3
298:21 302:20	121:24 122:3,12	cuff 72:15	214:15 232:15
306:25 307:4,10	122:16 123:19	culture 340:20	233:14 240:10
307:14,18 308:6	124:13,23 125:14	cure 296:22	241:14 244:11,18
308:11,18,24	125:20 128:5,8	current 254:7	248:15 249:7,21
309:9,13,18	129:18,25 130:21	currently 33:1	285:6 287:21
311:22 312:2,16	131:12,12,14	123:5 125:4,17	289:3 291:16
312:16 336:4	132:6 133:9,23	188:19 235:5,20	293:10 304:3,21
337:3 339:24	134:20 136:17,25	253:22 323:15	306:25 308:17
340:9,13 341:2,4	137:7,20 138:16	cursory 269:16	309:21 327:11
criteria 66:5,21	139:7 141:4 142:4	curve 304:20	335:24 340:12
69:8,19,23 70:7,17	142:15 143:7,9,16	custodial 201:16	341:16 342:4
70:20,22,25 71:7	143:20,21 144:2,6	custody 6:18 83:2	358:4
72:20 73:8,15,18	144:7,11,15,17,22	355:8	cuyahoga's 31:4
73:23 74:2,3,10,13	144:24 145:11,16	cut 168:8 214:3	39:25
74:13 75:11,15,19	145:25 146:1,2,5	cuyah 7:20,24 8:5	cvs 65:17,17 71:9
75:22 76:15 78:22	146:10,25 147:12	8:10 234:14	203:8 285:12
79:4,6,8,9,14,16	147:20,20 148:5	244:13 248:18	d
79:19,25 80:4,9	148:10,17 149:1	263:17	d 3:16
81:2,11 88:12,16	149:14,15,20	cuyahoga 1:9 2:2	d.c. 3:22
88:23,25 89:4,12	150:8,11,18 151:3	7:6,7,8,13,21,23	daily 80:10,13,14
89:16,17,21,24	151:6,8,12,16,18	8:4 18:11,13 21:4	101:21
90:8 94:7,9,18	151:20 152:4,12	25:7 27:20 28:15	dan 1:8
95:1,3,7,12,15,17	153:3 154:11,18	28:25 30:20,21,22	
95:21,24 96:3	182:3,7,13,16	31:10,21,23 32:1,3	dangerous 69:14 73:5 101:20
97:18 98:24 99:1	197:5,9 315:4,5	32:7,15,17,20,24	102:10 103:16
99:7 100:5,8,22,23	320:7 321:12	33:10,15 34:23	dangerously 128:2
100:25 101:13,19	322:23,24 325:19	35:5 36:16,20	danna 234:22,25
103:1,13,20	326:24 333:4,25	40:1,3 42:16 53:1	data 30:5 32:16,18
105:17,22 106:7	334:23 335:1,3,7	54:13 59:25 62:17	32:24,25 33:13
109:4,6,11,14,21	344:21 346:3,5,15	66:11,13 84:2	34:2,5,8 41:6,10
109:24 110:2,6,7,9	347:19,21,24	85:20,22 87:20	42:9 54:14,15
110:18 111:1,5,8	348:22 349:7,17	92:8 96:8 101:23	64:19,22 65:12,19
111:23 112:3,7,20	349:18,21 350:2,4	102:18 103:9	65:22 67:17 71:8
113:5,11,14,20,21	350:5,8,9,14,15,22	143:4 153:18,20	71:12,19 73:12
113:25 114:9,13	351:6 353:2,9,10	153:23 155:10,22	74:8 77:9 88:9
114:17,18 115:8,8	353:17,24,25	161:24 162:20	94:17 96:12 97:8
			74.11 70.12 71.0

[data - deaths] Page 18

00.10 105.22	260.25 270.17 20	245.6 279.21	J 1: 21.22
98:19 105:22	269:25 270:17,20	245:6 278:21	dealing 21:23
108:20 110:1	271:4,10,12,13,17	285:2 323:9	dealt 215:3
111:15 146:24	275:20 276:9,19	357:11 360:8	dear 360:10
150:5,7 151:5	277:4,7,17,22	361:3,9,19 362:3	death 141:7,16,20
152:22 171:15,19	279:12,21,25	362:13,25 363:20	147:22 148:3,19
172:11 173:21	283:22,24 285:6,7	363:25	164:18 179:7
175:1,10 177:11	286:16,19,20,24	dated 27:9 263:25	191:21 198:5,20
178:5,8 180:19	287:2 288:19	dates 199:18	213:14,21 235:7
181:10 184:9	292:24 294:4,5	323:12	235:10 238:16
188:4 189:16,17	298:7,10 299:6	daughter 332:5	242:23 257:20
189:21 190:18	304:6,12,16	david 24:12 27:21	265:9 288:18
198:16 199:16,17	307:23,24 317:19	dawn 25:13,15,16	292:10 294:18
203:6 204:17	317:20,22 318:1	175:19 231:22	295:2 306:24
209:21,22 210:4	320:20,21 321:11	day 2:14 18:25	308:4 327:15,16
212:12,13 220:17	325:22 328:3	274:2 312:18	327:20 328:1,12
223:16,23,24	330:2 335:6 341:6	341:25 359:7	328:23 329:16
224:2,18 227:11	database 104:2,5	361:16 362:22	330:6 333:4,11,24
227:13,20 228:2	145:23 160:15	363:22	335:25 336:11,16
228:13,15,25	174:14 177:12,15	days 68:8 104:2,6	337:12 338:5,12
229:5,9,19,21	180:3 184:17	273:17,19,19	339:2,13 342:8,25
230:3,4,6 235:2,4	223:8,11,19	360:19	deaths 7:23 8:4
235:9 236:2,5,7	224:12 226:18,21	dcfs 82:21 83:2	25:13 144:4,6,8,12
239:7 240:5,16,17	227:2,3 228:21	dcsf 355:8	145:18,22,24
240:25 241:2,6	239:19 257:1,2	de 180:19 198:18	146:4 148:1,3
242:9,17,21 244:1	258:24 259:5,13	229:19 239:7	150:25 165:5
244:6 245:5,10,12	259:25 262:4,11	240:5,16,17,25	167:16 177:13,18
245:24 246:14,19	265:16,17,19	241:7 242:9,16	198:2,23 213:10
247:17 249:11	266:19 267:10	dea 180:13 223:13	241:18 242:2,25
251:7,18,21 252:4	269:10,14,17	224:4,15 225:4,20	244:11 248:15
252:15,20 253:10	270:6 271:2 273:5	225:22 226:2	249:7,12,15,19
253:16 254:2,5,20	273:9,10 277:7,18	238:17,19 272:11	250:9,13,16,17,21
255:14,19,21,22	277:24 278:2	281:17,20,25	251:1,6,11 286:17
255:24 256:1,5,7	280:2,6,9,16,24	282:5,6 283:6,8	291:22 292:6,16
257:7,8,14 261:18	281:6 328:5	dea's 184:21,23	292:18 294:24,25
262:7 264:10,11	329:22 331:4	281:15 283:12	304:13 305:19
264:16,19,22,24	databases 71:5	dead 151:20	306:11,23 308:14
265:9,24,25 266:2	261:24 262:13,20	deal 83:19 211:22	308:18 309:8,23
266:9,13,14,16,22	263:2 267:9,14	311:16	329:20 335:9,14
266:25 267:4,7,17	272:24	dealer 55:25	335:18,23 336:7
267:19 268:15,22	date 18:1 27:11	dealers 311:2	337:3,4 341:16
269:10,14,19,19	158:2 160:11		342:3,4,13,19

[decade - designated]

decade 105:12	37:3,12 39:14,17	definitely 222:20	departments
decades 102:16	39:23 40:13 44:11	definition 35:17	264:25 265:2
decedent 174:25	44:13 45:12,16,19	40:24 86:16,22	dependence
230:5,7,13	48:1 49:24 50:4	87:6,7,11,17,18	319:16
decedents 175:2	50:10,24 51:14	101:17 125:9	depo 142:21
200:4 205:12	52:8 53:5,7 54:8	133:6 187:10	deposed 20:14,21
239:22	54:19 56:17,19	191:18 206:23	22:6
december 345:5	58:25 59:3,16	211:2,8 212:5	deposition 1:13
decent 268:4	60:1,8,13,18 62:2	306:7 315:14,20	7:5 18:3 22:2,11
deceptive 94:1	62:13,19 66:15,16	315:25 316:5	23:1 24:24 27:17
dechert 3:12,16	84:6 87:23 88:6	319:13 322:17	27:18 28:22,24
19:7,9	89:1,18 90:6 93:5	definitions 80:19	29:5 66:9 77:18
dechert.com 3:15	94:1 126:12	122:21	83:25 101:3
decipher 170:9	128:24 129:4,6	definitively	111:22 112:19
decision 47:21	193:23 194:18,23	171:14	126:22 127:2
109:5 110:21	195:6,14,19,25	degrees 60:9	130:11 159:14
115:13	196:7,8 203:5	delay 251:23	184:20 234:12
declaration 27:2	204:4,10 269:9,24	delivery 357:9,11	240:8 244:9
declined 305:20	270:16,20 272:6	demographic	248:12 250:3
dedicated 219:5	272:16,18,23	171:24	263:10 315:23
dedicating 219:15	285:11 303:9,20	density 192:24	343:21 354:23
deed 361:14	328:15 336:6,8,15	dental 202:14	355:21 356:2
362:20	337:1 338:11,24	dentist 202:23	358:19 360:8,11
deemed 360:21	339:6,9 340:8	dentistry 202:21	361:1,3 362:1,3
deeper 181:13	341:1 342:22,24	dentists 202:19,20	deprived 128:25
defendant 19:5,14	345:17 347:3	274:4	347:4
41:20 42:3 44:19	350:6,13 353:7	deo 248:25 249:2	derek 24:17
48:15 53:2,9,17,18	defense 164:1	department 8:7	describe 92:6,16
53:21,25 58:6	defer 38:9 278:19	24:11,15 30:4	208:9 355:3
62:7 89:8 92:19	299:11 315:16	177:19 188:6	described 52:14
153:16 154:2	deferred 315:17	189:14,23 191:24	201:12 207:19
160:17 269:18	define 35:9 86:25	198:7 209:18	209:4 249:16
271:3 303:24	129:4 148:3	215:11 231:18,19	261:9 290:14
336:1 339:14,23	290:10 306:3	232:15,16 262:13	293:6 305:13
340:11 341:15	315:8,15 316:17	262:15,16,16,17	describes 55:23
342:18	defined 80:16	262:19,24 263:1	240:16
defendants 7:9,10	86:12,18 124:12	263:12 264:2	describing 289:5
7:15 18:23 19:18	127:13 136:15	265:4,22 266:15	351:4
20:7 27:6 30:19	138:3 165:6 182:9	266:16 276:1,17	description 7:3
30:24 31:6,13,21	191:16,17 296:6	294:11 328:3,16	designated 20:24
32:3,9,13,14 36:2	296:10 334:13	360:24	154:21 286:11

[designation - disorder]

_			_
designation	139:11,12,17	332:24 333:5,7,22	disciplined 132:21
238:11	detroit 56:8	337:5,15,22	137:25
designed 213:8	dettelbach 168:5	different 60:16	disclose 130:9
designee 20:25	208:20 233:23	90:21 121:14	322:3
22:10	234:1	143:14 172:14	discount 4:6 19:22
despite 128:15	develop 172:4	183:14 189:23	discovery 7:16
138:11	319:10	191:20 194:13	84:8 344:24
destroyed 26:8	developed 81:3	220:18 226:25	discrepancy
82:3	213:13 323:2,9,10	227:16 232:17	255:16
detail 228:8	developing 205:22	241:3 268:2 277:7	discuss 217:18
254:18	development	297:12 323:11	discussed 21:18,19
details 93:2	311:2	351:3,14,21	30:14 38:16 67:14
289:22	devise 122:8	353:17	129:17 194:10
detect 279:5,10,15	devised 122:7,9	differentiate	198:8 257:3
detected 216:23	diagnose 330:3	135:12	268:18,23 287:9
291:24,25	diagnosed 40:23	differing 350:19	discussing 256:24
detecting 277:25	69:14 70:8,9	difficult 238:22	discussion 34:6
detection 279:17	72:22,25 88:20,21	279:4,10,21 280:5	46:2 49:14 52:19
determination	119:23 143:12	280:23	163:13 194:15
105:24 111:2	150:23 315:7	difficulty 237:21	206:17 224:4
determinations	323:5,11,15,19	diminished 189:5	discussions 32:22
116:15 152:15,17	325:17 330:12	direct 106:23	162:25 194:13
determine 110:10	348:4	223:20 234:18	198:6 201:18
110:18 113:14,25	diagnoses 128:1	259:5 266:12	208:11 212:22
115:8 116:24	316:7 318:2,4,5	direction 117:11	238:12 269:7
120:12 147:20	diagnosis 76:21	126:6 220:5 253:5	283:5 291:3
148:17 150:11	79:5,19,21 109:16	directly 30:23	294:12
151:18 152:9,22	125:3 142:1,13	38:11 40:10	disease 306:8
153:24 154:12	182:14 316:1	201:23 258:24	diseases 317:3
179:8 347:21	317:14 318:7	265:5	disorder 40:23
determined 76:1	321:1 323:9,20	director 24:13,18	69:15 70:8,9,11,13
76:18,19 77:4,18	330:7,10,12,15	25:12 191:23	72:21,23 73:6
78:25 99:23	334:15	227:22 268:11	78:23 79:1,17,22
134:17 341:17	diagnostic 323:24	disappointed	88:22 105:17
determining 112:4	323:25	200:23	109:3,17 119:23
112:20 121:16	die 42:10 294:22	disciplinary	125:2,5,7,17,18,19
127:25 134:20	309:16	127:22 133:15	142:1,13 143:13
146:10 346:7	died 141:6 229:17	134:5 137:5 218:4	150:23 182:4
348:24 353:10	235:3 236:16	218:9 223:4	315:7,9,15 316:12
deterrent 128:14	239:22 253:13	discipline 156:15	316:17 317:7,10
138:10,22 139:8	309:3,5 328:18		317:21 319:10,14

[disorder - document]

320:2,16 321:1	269:13 270:22	212:13 331:13	200:6 202:20
322:18,21 323:3,5	271:17,21 272:5	334:7 342:11	204:23 205:13,16
323:10,15,20	district 1:1,2 18:6	diverting 197:18	205:25 206:2
325:18 330:4,13	18:6	331:21	207:11,22 214:3
333:14 334:16	diversion 39:11	divided 189:19	214:18 215:17
348:5 349:21	166:20 181:2,14	division 1:3 18:7	223:8 226:20
disorders 318:9,15	183:21 184:3	21:17 23:6 26:17	230:13,20 234:4
318:20	185:3 187:5,11,14	165:11 197:12	235:11,14 238:25
dispensed 185:13	187:21 188:13,16	201:15 202:3	240:4 244:19,22
186:8 192:3,7,20	190:20,23 191:3,8	divisions 22:24	245:15 248:2,25
193:9,14,16	191:12 192:2,15	docket 302:14	249:11 250:19
228:16	192:19,25 193:8	310:12	251:10 260:16,19
dispensing 35:10	193:20 194:2,19	doctor 20:17 23:9	261:16,23 263:6
184:11 261:20	196:2,24 197:16	28:10 29:4,7	263:22 273:3,6
262:1,8,22 267:2	197:23 200:8	31:15 34:13,14	281:9,19 284:20
268:17	201:11,13 203:5	35:10,11,17 36:25	325:20,23 326:20
distinguish 342:10	203:12 204:4,9,19	38:15 41:15 43:8	331:2,7 334:5
distributed 56:16	205:1,6,18,23	47:15 48:16,20	346:7 347:11
126:12 195:7	206:7,11,22 207:1	49:16 55:12 56:2	348:16
303:11,20	207:6,14,18,21,25	57:12 59:1,17	doctors 36:5 37:20
distributes 193:13	208:10,16 209:6	67:9 69:3 83:20	46:1,12,22,25
distributing 56:10	211:2,8,13,19	84:13,17 88:13	49:24,25 50:16,19
distribution 33:13	212:2 213:23	94:3 95:10 96:24	51:11 57:7,17
48:10 55:24 56:6	214:12 215:16,22	98:14 99:21 103:8	96:9,18 97:2,12
56:6,12,25 61:18	215:25 217:24	106:13 110:23	101:22 102:18,21
184:10 194:11,24	218:21 219:1,7,16	112:19 113:24	121:13 132:2,24
195:3 261:19	219:23 222:3	119:2 120:12,19	133:11,14,25
262:1,8,21 267:2	224:23 226:12	120:24 121:4	136:10 137:1,4,22
268:17 269:16	229:2 254:19	131:10 140:4	139:21 140:3
289:23 305:21	256:24 259:15,23	142:7 145:8 148:9	161:14 163:1
336:20 337:16	260:11 276:11	148:9 149:10	181:18 184:1
338:9	278:1 279:5,5,11	157:2 159:25	196:9,22 197:18
distributions	280:5,12,18,23	163:18 165:1,5	199:4 200:1 201:2
33:14	281:5 285:11	166:9,16 167:3,15	201:5 257:20
distributor 185:12	diversions 206:15	169:24 170:3	346:21 347:9
186:7 187:19,23	218:23 280:17	172:13 175:4	348:25 350:3,16
193:12,19 194:2	diverted 49:6	180:25 183:17	353:5,11 354:4
228:3 271:12	179:23 188:1,10	184:11,24 186:24	document 1:8 7:23
distributors	190:6 193:15	190:25 191:2,11	8:3,7 69:4 72:8
203:25 223:11	208:23 209:1,23	191:16 193:7	73:21,24 84:13
227:15,19 228:2,7	210:5,15 211:5,7	197:7,8,8 198:22	132:4 137:9

[document - dynamic]

138:25 140:6,12	downplay 289:16	172:10 175:2	185:4,9,13 186:5,7
141:1 143:2	downward 264:24	180:10 185:3,6,10	189:2 191:7 192:3
153:11 234:25	downwardly	185:24 186:4,11	192:9,10,19,23
244:10,19,22	125:25	187:5,11,14,21	193:2,8,9,13,14
248:13 263:7,11	dozen 129:19	190:22 191:3,6,8	197:16,18 208:17
263:24 264:7	dr 24:7 25:9 26:18	191:23 192:2,14	208:23 209:2,24
documented	52:19 82:19 183:7	193:12,20 194:2	210:6,11,13,15,20
217:21	231:8,22 234:19	194:18 196:2	210:22,25 211:5
documents 22:22	235:2 244:16	200:8 203:5,11	211:11,12 212:13
26:21 68:2 142:9	248:22,25 249:2	204:3 205:6,21	213:1,5 214:5,5,20
209:9 230:19	256:23 291:3	206:7,10 208:9	215:5 224:24
242:12 247:14	344:11,20 345:8	209:6 211:2,6,8,9	227:10 228:11
323:6	354:22	211:12 212:1	243:14 272:12
dogmatic 227:24	dramatic 300:14	213:9,24 214:17	281:23 282:2
doing 35:21	300:19	214:17 215:12,16	286:18 287:20
110:15 145:8	dramatically	215:22 217:18,24	288:5 289:12
170:24 171:10	290:20 304:10	219:6,16 224:23	292:21 295:20
174:12 177:21	314:21	226:22 227:7,10	297:23 299:3,5,13
179:13 180:23	draw 253:11	228:19 229:2	299:25 301:19,21
194:6 199:20	drawing 151:4	250:22 259:14	303:11,15,23
243:1 249:4	drill 190:16 298:6	263:13 264:5,8,15	307:20 312:7
261:10 280:21	drive 3:17 4:4	268:6 277:25	314:8 336:20
332:7	driven 302:19	279:5,11 280:4,12	337:16 341:8
dominating 291:5	307:5	280:22 286:19,20	342:17
291:7	drivers 313:18	287:2 288:8,15,25	dsm 79:9 182:10
door 176:7 311:15	314:15	289:18,25 290:2	322:17,24
dosages 128:3	driving 189:1	294:16,17,21	due 121:12 292:25
197:6	drop 213:24	297:23 298:13,18	293:2
dose 40:21 69:12	214:17	300:2 301:4 302:7	duly 20:13 358:7
88:18 109:15	dropped 290:20	302:14 305:9	358:10
119:22 143:11	droz 234:22,25	307:17 309:16	dump 26:11
150:22 334:13,20	drug 3:2 4:6 8:8	310:1,10,24 311:2	duplicate 253:15
348:2 349:19	19:22 24:17,19	311:3,4 318:2	duration 103:4
doses 128:21	30:4 32:23 34:6	324:4,11,14,24	durkin 4:7
129:3 325:16	36:5,6 37:20	325:7 339:10	duties 219:24
346:25 347:7	39:15,21,21 40:1	342:25	dying 207:13
double 96:1	42:9,23 50:25	drugs 33:14 35:10	308:22
doubled 304:13	51:15,20 54:19	42:16 56:7,10	dynamic 209:10
308:2	55:20 56:25 58:10	139:15 156:9	
doubling 306:11	60:24 61:9 64:22	157:20 165:25	
306:14	104:5 165:4	171:13 174:17	

[e - equal] Page 23

	252.15 257.14	ama at 212.21	andanad 220.14
e	253:15 257:14	enact 212:21	entered 228:14
e 7:19 234:13,19	277:23	enacted 212:17	362:9
earlier 84:16 85:8	efforts 8:9 33:17	275:5	entire 127:15
99:17 121:10	58:24 184:20	encompassed 65:9	
122:20 167:4	199:2 263:15	125:19	175:11 361:5
182:5,13 191:17	268:1,13 281:14	encouraged 57:17	362:5
200:25 245:9	310:10,25 336:21	encouraging	entities 30:19 31:5
250:2,20,24 266:1	336:23,24 337:23	340:21	31:20 32:2 38:1
275:25 276:4	337:24 338:10	ended 52:22	39:5,9 44:18 45:3
285:10 288:12	eighth 245:13	304:23	46:3 71:11 116:14
293:6 312:18	either 58:21 77:16	endo 4:15,15	203:21 272:8
344:12 354:24	109:2 117:22	18:23 20:6	entitled 7:21,23
early 58:18 102:17	145:20,23 147:21	enforcement	8:3,7 240:9
237:17	152:1 181:17	24:17 30:5 32:23	244:10 245:14
easily 205:25	222:5 233:1 291:6	34:6 160:6 181:4	248:13 249:6
east 4:8	359:2	196:15,19 208:12	263:11 264:7
eastern 1:3 18:7	elected 238:15	208:14,14 209:5	entity 31:24 43:16
ecarter 2:18	elephant 314:7	209:15,17,19	44:10 51:25
economic 34:16	elevated 306:8	212:16,23 213:7	119:10 187:20
35:22	elevation 306:20	213:11,14 215:4,8	266:5 267:14
economist 60:23	307:21,22,24	215:12,24 216:1,6	272:14 299:12
ectasy 294:1	eligible 91:4	216:15 219:9,12	301:5
295:24	elizabeth 24:7	219:14 220:1	entry 310:24
ed 19:1 284:22	ellis 5:3 18:17	227:15 246:15	enumerated 89:4
education 128:22	emergency 25:10	257:11 258:19,21	111:7
172:3 232:23	220:16 276:1	259:2 267:9,14,15	epidemic 7:22 8:8
298:22 347:1	291:3,6 294:11,12	276:5,7,10,23	32:9 42:13 64:2
350:12,24	301:20	278:7,23 280:13	155:19 171:12
educational	emphasize 294:8	280:20 298:10	203:11 206:14
154:25 155:13	employed 60:23	310:22	210:9 239:21
156:5 157:5,18	322:18,25 355:9	engage 49:25	240:10 241:15
158:3 162:8	employee 244:3	50:19	245:14 246:9
173:17 232:20	260:17 275:19	engaged 36:5	263:13 264:8
edward 2:15	276:19	47:23 49:17 55:19	302:3 304:4 306:4
effect 42:17	employees 160:7	57:7 95:10 196:1	306:15 309:14,14
257:16 302:4	276:8 277:3	338:11	epidemics 172:9
efficacious 85:16	empowered	engaging 46:13	epidemiology 8:8
efficacy 104:21	162:13	50:5 338:25	263:14
efficient 83:19	enable 213:25	england 268:3	equal 297:14
effort 74:12	enabled 227:4	enter 186:22	298:1
203:10 217:5		227:12 228:15	
203.10 217.3			

[equivalents - exhibit]

equivalents 40:22	et 1:10 130:4	examiner 64:25	excessive 103:23
69:13 70:3 80:12	139:17 246:11,11	197:1 198:13	272:13
80:21 88:19	262:22	206:21 210:10	exchange 234:20
334:14 348:3	evade 163:12	238:21 257:10	excluded 123:23
er 128:11,11 138:7	evaluation 200:5	258:7 267:17	241:20 310:4
138:7,7,8	evening 344:10	272:1 286:16	exclusively 302:12
erb 4:8 19:21,21	event 359:3	317:19 318:1	310:3
erica 5:3 18:16	eventually 180:11	323:19 330:3,11	excuse 31:24
erica.james 5:5	240:5	examiner's 8:4	34:10 70:1 303:21
errata 360:19	everybody 42:15	21:16 23:3 52:15	executed 362:10
362:7,10,18 363:1	52:2 64:20 287:15	165:9 171:21	execution 361:14
escalate 301:18	287:18	205:11 212:24	362:19
escalated 301:16	evidence 58:22	213:15 229:7,9	exemplary 312:15
312:3	173:25 177:25	231:17 236:10	exhaustive 311:18
escalation 300:15	208:2 213:17	239:1 240:22	331:23
300:19 314:5	260:25	245:23 248:16	exhibit 6:18 7:5,7
especially 165:25	evolution 33:21	249:8 250:7	7:12,17,18,19,21
197:25 229:10	164:20 188:17	258:18 277:1	7:23 8:3,7,11
277:8 283:7	205:20	283:23 289:15	28:23 41:1,2
292:24 294:6	evolved 54:21	330:1	66:10,23 68:25,25
301:20 305:24	180:3 188:14	examiners 238:13	71:23 72:1,7,12
312:4,12,17	198:1 229:24	examining 8:3	73:15,16 84:1,12
esq 2:3,6,11,15,15	302:11	127:25 248:14	91:16,19 92:2,15
2:20 3:3,3,8,13,16	evolves 188:5	249:7	93:11,21,22,25
3:21 4:3,8,12,17	229:23	example 56:7	94:25 96:7,18
5:3	ex 7:8 66:11	127:24 193:10	97:3,13,20 98:15
essential 124:18	exact 22:13 43:11	230:4 246:15	101:9 106:1,12
essentially 35:12	124:13 285:16	258:6 261:6 264:4	107:2 108:17
35:22 53:14	289:9	271:11 291:21	109:22 114:18
231:11 233:3	exactly 78:15	294:20,23 302:7	115:10 116:25
establish 175:2	106:21,21 107:25	examples 192:14	117:16 123:19
239:19 298:21	161:22 220:3	192:18 193:1	124:4 126:23
established 171:13	254:23 297:18	210:20 305:2	127:3,12,21
171:18	exalgo 128:12	excel 345:10 346:8	128:12 132:2,15
establishing 35:11	138:7	346:17 347:17	132:20 136:10
191:1	examination 6:7	352:5 353:4,11	138:8 140:2,17,19
estimate 251:14	20:11,15 183:5	excellent 185:1	142:24 144:18
274:13	244:4 284:18	excepting 54:6	149:9 153:7,15
estimated 188:7	323:8 330:8,18	exception 274:4	154:1 167:13
251:15	344:8 354:20	301:22	177:3 234:13,19
			240:9,14 241:11

[exhibit - fatal] Page 25

244:10,16 245:20	104:13,21 105:1	201:14	61:22 62:1,5
246:4,6 248:9,13	113:8 115:13	expressing 159:8	240:24 246:21
248:22 250:10	116:12 117:8,13	expressly 360:13	263:14 334:7
263:5,11 304:8	118:22 119:1,12	extend 273:18	facts 163:24
313:25 315:22,22	139:25 270:5	extension 210:24	fair 57:1 113:5
315:23 321:8,21	339:19	258:16	114:9 125:20,22
321:21 322:9,19	expertise 318:13	extensively 229:7	147:8 148:16
323:1,14 324:4,13	experts 41:11	extent 44:9 70:21	159:4,14 160:21
324:22 325:9,20	63:14 65:21,23,25	119:9 182:11,12	160:23 170:17
326:2,6,14,19	67:18 68:14 71:21	200:11 203:24	189:3 243:5 245:6
327:4,8,8,13,19	87:12 88:11 94:19	243:20 252:7	246:7 271:20
328:21 329:4	96:14,14,23 97:1,9	270:22 276:13	274:12 346:1
330:21 331:1,8,13	97:12,25 98:20	284:1 289:5 299:9	fairly 350:1
332:1,22 334:9,19	108:21 110:3,16	299:23 300:9	faith 101:3
335:2,5,8,17 337:5	110:22 111:8,11	322:17,22 328:21	fall 211:1
337:11,15,22	111:13,14,17	336:6	fallen 243:21
339:2,12 341:11	112:10,25 113:12	f	familiar 66:7
343:22 345:4,7,9	113:20 114:7	f 167:20,20	79:24 84:17 103:1
345:10,19 346:11	115:22,25 116:5	faced 220:14	138:21 139:9
346:20 347:17	117:3,5,10 118:6	facilitate 213:18	181:23,25 186:16
348:9 349:23	137:15 147:14	279:17	223:7 225:16,19
351:22,24,25	148:7,14 151:1,4	facilitated 336:5	242:4 265:24
352:4,11 353:11	152:15,17,22	facilitates 330:10	299:9 316:13
354:1	315:11,16,17	facilities 185:11	322:23 335:4
exhibits 6:4 7:1	321:3,4,6,14,19,20	221:20	352:18
8:1 344:16	322:13,16 323:8	facility 186:6	familiarize 147:11
exist 80:20 279:6	324:8 325:4,25	246:23	families 310:7
exit 186:22	expiration 361:19	fact 61:21 80:23	familo 4:7
expansion 176:22	362:25 363:25	121:17 168:25	family 21:18 23:6
expect 276:24	expires 359:16	178:5 207:11	24:12 26:18 125:6
278:6	explain 304:6	238:25 253:19	125:18 165:11
expected 104:4	explained 204:6	254:18 288:7	166:6 197:13
319:15	255:15	289:12 294:24	201:15 202:3
expense 35:23	explanation	304:16 307:7	267:4
experience 24:22	261:11,11	factor 63:25	far 40:8 69:13
239:14 289:3	explore 325:14	121:15 289:2	141:7 165:3
experienced	express 106:9	299:7 306:19	249:10 286:23
335:10,19	317:15	factors 8:9 52:4,23	287:1,4 291:6
expert 31:22 52:5	expressed 157:18	53:22 55:6 58:2	325:22
52:24,24 58:2	158:15 162:5	58:14,17 59:16,22	fatal 246:22 294:9
59:23 96:21	164:11 170:23,23	60:15,16,24 61:20	
		00.13,10,24 01:20	

[fatalities - forget] Page 26

fatalities 65:1	313:2,21,21 314:4	350:20	folks 26:17 28:10
171:23 209:2	314:6,10,17,17,23	finished 98:18	54:23 60:12
220:10 240:18,23	333:8 341:4,5,18	199:16,20 214:21	142:12 151:5
241:10 247:1	341:18 342:6,6,9	235:14	154:7 168:1
february 234:20	342:11,12,14	firm 178:4	174:15 181:11
235:18 249:12,19	fgallucci 2:9	first 7:10,15 20:13	203:7 302:24
federal 20:12	fifth 143:4 245:3	22:9 42:12 51:7	308:21,25 309:3
161:8 162:6 164:2	figure 245:2 250:5	61:8 62:23 66:17	331:21 334:19
164:11,23 176:24	346:15 353:5,25	73:1 84:6 93:22	follow 172:20
197:24 198:6	file 82:11 169:5	136:1 143:2	175:21 177:9
208:16 215:10	172:23 179:14	157:22 159:2,5,7	315:2 322:15
217:1,5,7 266:5,16	230:12,14 243:2	159:11,20 174:22	354:23
267:20 284:1	247:11,17 249:23	183:20 198:14	followed 220:21
299:7	251:2,12 259:14	206:6 233:10	309:22
feds 161:21	260:1	244:21 277:22	following 280:3
feedback 222:20	filed 173:25	278:17 323:2	353:21
feel 26:6 221:1	193:22 194:7	324:4,11,14,24	follows 20:14
277:19 312:12,14	339:6	325:7 358:10	forbidden 104:9
feeling 241:21	files 229:25	fischer 4:3 19:17	force 25:8 167:24
fell 199:15	filing 194:19,25	19:17	167:25 168:2,3
fellow 224:11	fills 195:12	fishy 165:16,19	191:21 198:9
felt 222:17	filtered 163:15	166:4	208:13 224:11
fentanyl 33:22	304:15	five 22:17 30:11	231:9 232:24
34:22 39:16,20	final 242:25	165:6 204:20	233:15,22 283:6,7
42:11 43:4 51:2	243:13	230:25 256:16	283:24 285:15,21
156:3 158:14	finally 184:19	flat 226:20 304:17	300:6
164:21 188:19	213:21 350:18	flip 340:10	forces 23:4 164:19
198:2 199:21	find 23:9 37:17	flooding 46:23	164:22 194:13
210:9 211:6,17	95:2,24 115:25	floor 2:11 4:8	203:24 208:18
212:1,8 220:8	123:22 133:22	florida 212:13,17	209:6 212:25
221:3 229:24	142:14 147:19	212:20 215:4	215:9 217:6 231:9
230:16,17 244:5	161:1,2 173:24	flow 213:5 214:5	231:15 232:10
249:11,15,18	179:14,17 198:18	214:19,20 215:5	233:1,11 234:8,9
250:8,13,21	205:13 279:2	flux 70:14	257:8 262:14
277:10 292:17,20	findings 247:7	focus 29:15 57:22	263:1 310:21
292:23 293:4,6	fine 20:9 115:2	58:13 157:1	foregoing 84:25
295:15 304:18,19	281:24 296:15	291:12 302:20	358:15,20 361:13
304:24 305:4,11	332:13	315:5 348:20	362:18
305:15,21,23	finish 59:7 135:3,4	focused 349:13	forensic 286:20
307:6,10 308:1,24	235:13 243:24	folder 41:1	forget 153:9
309:6 312:4,20	244:3 255:7		281:13

[form - fulfilling] Page 27

form 26:9 31:9	118:12,17 120:15	229:19 236:13,19	forming 227:7
32:5 33:11 34:3	120:22 121:19	236:25 237:7,19	forms 131:7
34:19 35:24 36:7	122:18 123:8	238:5 239:5,12	formulate 98:20
37:8,21 38:3	124:1,16,19 125:8	240:2 245:7 254:5	268:9
39:18 40:7,14	125:21 126:4	255:19,24 256:8	formulations
41:7,21 42:5	129:23 130:8,20	257:4 259:16	138:21,22 139:10
43:17,25 45:7,13	131:4,16 132:3,12	264:17 265:18	139:11,13 336:21
45:21 46:16 47:1	133:1,13 134:10	266:10 267:11,23	forum 170:24
47:5,9,19 48:18,24	134:19 135:13,17	268:24 269:11,21	forward 43:3
49:11,19 50:1,7,21	135:23 136:12	270:1 271:6,15,24	227:12 230:15
51:4,16 52:1	137:12,23 138:19	272:9 273:1	243:9
53:10,16 54:1,10	139:5,23 141:17	275:10 278:4,25	found 82:20 117:8
56:3 57:2,10,19	142:2 144:19	279:7,13,22 280:7	130:16 322:21
58:15 60:2,19	145:21 147:10,24	280:25 282:18,21	founded 260:24
61:1 62:20 63:10	148:21 149:18	285:3 287:22	founder 167:16
63:19 64:10 68:21	150:3,13 151:9,21	288:1 289:20	four 33:9 133:6
71:1,16,24 72:13	152:3,13,18 153:5	290:4,8 294:19	fourth 2:11 143:4
73:9 74:19 75:12	153:17 154:3,15	295:13 296:1,19	249:22
75:23 76:4,23	155:14 157:15,24	298:15 299:21	fourths 247:12
77:6,21 78:6,18	159:15 160:2,18	300:22 301:11	frame 86:9 163:2
79:2,10 80:1,6,17	161:11 162:23	303:13,25 306:5	289:23 294:7
80:25 81:5 85:10	164:16 165:21	306:16 307:1,15	300:16 314:24
85:25 86:3,7,13,20	166:11,18,20	308:8,19 309:10	335:10
87:1,8,14,24 88:7	172:25 173:19	311:24 313:5,23	framework
88:14 89:2,9,13,19	176:11,16 177:4	316:3,8,18 317:12	218:11
90:20 91:1,11	179:10 181:22	317:25 318:10,17	francisco 2:21 3:5
92:11 93:18 95:4	185:15 186:12,25	319:1,11,23 320:4	frank 2:6 18:12
95:13,20 96:2,10	187:15 188:2	320:10 323:17	frankly 169:25
96:19 97:6,10,14	189:6,11 191:11	324:16 325:1,11	free 361:14 362:20
97:21 98:3,6,16	191:13 193:21	326:8,21 333:2,23	frequent 204:18
99:3,8,18,25 100:9	194:3,20 195:9,16	334:21 336:2,12	frequently 35:13
101:15,24 102:23	196:3,11,16	337:8,18 338:1,13	156:6 288:15
103:10,18 104:14	200:16,22 201:7	339:3,15,25 340:4	299:14
104:18,23 105:4	201:25 205:3,8	340:14 341:9,20	friday 34:11 224:9
105:13,19 106:6	209:12,25 211:3	342:20 349:2	front 2:21 107:3
107:16,23 108:2	211:14 212:3	353:19	124:4 166:4,23
108:14,25 109:8	216:19 217:12	formal 170:20	323:6 333:5
110:12,20 111:4	218:6,17 219:3,17	233:13	341:11 342:3
112:6,13 113:6,17	221:6,12 222:7	formalized 217:9	frustrating 351:9
114:3,10 116:2	224:3,19 225:1,13	formed 217:13	fulfilling 161:3
117:19,23 118:5	226:15 228:22	227:3,6	

[full - going] Page 28

full 84:18 129:12	garner 180:5	giant 345:10	gleaned 158:6
160:21 229:20	268:10	346:17	257:9
236:4,7,20	garofoli 1:20	gilson 1:13 6:7	global 215:14
function 160:11	gathering 242:21	18:4 20:10,15	go 43:7 46:4 47:11
178:3 209:15	geez 181:11	28:22 66:9 83:25	47:17,25 56:20
216:20 218:12	general 21:23 35:3	126:22 127:2	59:12 73:24
220:2,2 227:1	38:25 62:22	183:5,7 231:8	114:22 124:3
265:1 275:14	134:13 166:13	234:12,19 235:2	131:13 132:7
280:13	185:8 223:9	240:8 244:9,16	136:23 137:2,17
functions 155:17	225:23 282:9	248:12,22 256:23	140:23 143:3
222:11	286:5 292:20	263:10 284:18	169:14,16 171:15
·	301:23 303:2	343:21 344:8,10	174:25 175:1
funding 57:22 328:5	342:12	· · · · · · · · · · · · · · · · · · ·	174.23 173.1
funds 176:15		344:11,20 345:8 354:20,22 358:9	185:9 211:19
furnish 77:25	general's 231:25 283:7	360:8 361:4,9	214:23 234:24
furnished 27:11 65:22 68:15 158:3	generally 67:10 280:3 312:21	362:4,13 363:20	238:20 245:13 246:25 247:6
298:10	316:25	gingell 24:14	248:1 256:1 261:5
further 73:24 93:7		gist 246:2 give 22:13 29:18	274:19 314:3
94:22 108:21	generate 71:6 73:15 98:22	36:9 39:6 43:15	315:4 319:22
		43:18 45:23 54:13	
117:12 128:10,18	111:17,19 123:19		320:3,17,22 325:7
138:4,5 139:14	147:14	72:14,14 73:17	331:3 332:13
165:18 200:5	generated 27:7	76:6 81:15 115:24	338:6 343:25
204:13 216:23	68:13 74:13 91:24	123:12 125:10	352:25 354:13
255:14 297:4	148:7	132:8,13 141:7,11	goal 246:15
325:7 334:17	generates 50:13	158:1 169:13	goes 283:10
338:6 346:22	generating 172:8	188:6 192:18	291:20 299:10
348:11 354:7	genesis 55:8 336:4	220:13,25 235:15	314:1
355:13,15 358:18	genuine 283:16	299:16 304:7	going 22:6,10 24:6
359:1	geographic 31:23	315:13 319:4	27:15 29:6,8,9,13
future 213:17	34:22 142:18	331:18 335:16,20	41:2 42:8 43:3
fuzzy 324:19	145:14 155:2	341:23 357:1,10	55:11 56:20,21
g	157:7 183:22	given 61:16	67:4 68:8,14 74:3
gain 34:16 35:22	184:3 189:17	158:19 197:6	81:10,11,17 83:8
261:25	209:23 210:5	270:5 299:2	83:15 86:6,10
gallucci 2:6,6	340:9	301:14 331:23	100:11 106:23
18:12,12 69:1	getting 175:11	335:21 358:12,17	113:24 121:16
247:22	207:2 238:8	gives 190:21	132:9 147:3 153:7
game 314:25	251:23 265:4	giving 28:14 77:9	158:16,17 165:23
gang 36:6	279:18 304:23	78:7 100:24	170:8 171:22
	324:18,19 347:13	157:10 206:24	174:23 175:4,5

[going - helpful] Page 29

178:3 179:13	grievously 40:24	handled 216:25	168:2 177:19
181:13 183:13,16	group 118:24	handwritten 7:17	180:17 188:7
185:18 206:3,16	119:11 149:13	7:18 28:3 126:23	189:14,23 191:24
224:21 225:7,15	300:5 305:17	127:3 166:22	208:18 231:18,18
227:12 230:21,24	groups 232:18	hang 248:10	231:20 232:14,16
243:9 260:22	299:7	happen 25:2	232:21 233:15,17
261:16,21 263:4,7	guarantee 238:13	225:15	249:4 252:24
281:8 315:4 345:1	guess 23:8 26:12	happened 36:16	254:1 262:13,15
345:22 346:2	55:18 56:11 60:4	152:24 153:2	262:16,17,17,19
348:16 349:14,15	65:8 77:14 78:9	199:23 202:10	262:25 263:1,12
352:15,20	78:10 142:14	happening 193:5	264:2,25 265:2,5
good 20:17 21:6	145:3 161:8	209:9 215:6	265:23 266:4,6,15
24:22 81:18 101:3	218:23 224:20	happy 324:21	266:17 276:17
101:11 124:7	225:14 232:9	hard 60:4 170:7	278:23 279:3
132:13 145:9	260:24,25 275:3	180:24 206:9	299:8 300:2 301:5
168:13 172:11	292:8 337:13	harder 291:25	311:6 318:3
181:12 183:7	guidelines 128:24	harkened 347:24	326:15 328:3,16
230:22 232:8	198:8 261:14	harm 156:19	healthcare 57:16
284:20 344:10	275:24,25 336:23	harmful 107:5,12	65:14 127:21
gotten 26:5 56:22	337:23 347:3	107:20 108:10	132:19 134:3
228:18	gutierrez 38:20,21	113:10 116:23,25	177:1 185:11
government 160:1	278:12	117:6 118:10	186:6 221:20
267:21 300:4	guy's 128:8	127:14 129:5,11	222:23 294:13
governments	guys 320:12	130:5 132:17	hear 157:22
57:23	h	136:19 138:18	158:12 281:12
governor 103:22	h 2:15,16 265:25	139:4 153:9	heard 159:3
governor's 231:24	h.d. 4:11 19:14	348:11,13	160:13 171:5
grand 170:24	half 129:19 136:7	harms 74:7	177:9 209:4
171:11	140:24	hartman 4:17	219:20 247:23
grant 177:20	hall 158:2 170:17	18:22,22 20:6	hearing 156:21
244:3 328:5	halls 156:6 158:15	hat 257:10	172:21 173:1
granted 223:22	158:22 159:3	hazard 337:13	174:19 229:13
226:7 236:4	170:21 171:11	head 25:6,8 26:6	302:10
graphs 314:4	174:19	37:23 143:25	help 23:9 52:23
grateful 351:16	hallucinogens	180:5,7 190:13	124:14 126:2
grazing 79:12	293:25	232:7 274:11	245:3 277:20
great 21:5 163:21	hand 305:18 359:6	heading 293:23	helpful 33:24
278:13 279:16	handicapping	headway 238:9	106:18 124:17
281:2 309:15	295:16	health 3:20 4:16	163:22 225:3
greater 348:2	handle 162:13	8:7 19:16 24:13	229:1 241:8
	181:12 343:17	25:7,9 167:22,23	280:17 281:6
	101.12 373.17		

[helpful - identify]

352:12	hi 284:21	hospital 25:11	234:16 240:12
helping 221:1	hidden 117:25	52:20 155:21,24	244:14 248:20
herdman 168:6	high 24:18 40:21	175:18,21 221:22	263:19 280:18
hereinafter 20:13	69:12 88:18	221:25 222:6,13	322:11 343:23
hereunto 359:5	109:15 119:22	258:9,15 259:7	identified 28:11
heroin 7:22 33:22	128:3,20 150:21	260:3 261:6	36:4 37:3 38:9
42:11,13 43:2	197:6 229:25	273:12 275:22	40:19 66:4 69:10
54:11,22,25 55:6,8	325:16 334:13	300:10 318:5	72:7,19 73:6,18
55:9 56:14 156:3	346:24 348:1	hospitals 184:2	74:6,9,18,22,25
158:5,9,14 164:21	349:19	221:19	76:14 80:16 100:2
171:12,19,22	higher 69:13	host 121:14	107:2,18 108:17
172:5,8,9 174:13	88:18 109:4	hostetler 4:17	109:22 124:23
174:24 175:12	143:11,11 334:14	18:23 20:5	130:1 137:15
177:15,22 178:1,2	348:3	hour 81:18 136:7	144:10,13 146:7
179:8 180:11	highest 288:8	230:25	149:12,14,17
188:19 198:2,23	historical 330:17	hours 22:1,13	164:17 165:1,5
206:14 211:17	histories 243:8	68:10 129:18	173:14 180:19
220:8 221:3	history 123:11,15	131:10,15	189:23 198:18
229:11,15,17,23	125:6,18 236:24	housed 168:3	204:18 222:16
230:15 239:21	237:2 239:3,11	housekeeping	229:19 235:4
240:10 241:15,18	243:4 250:14,21	344:15	239:7 240:5,16,17
242:2 244:2	250:22 251:16	houses 232:4	240:25 241:7
245:14 246:9,10	287:23	huge 352:5	242:9,16 264:14
247:10,16 250:16	hold 59:6 104:12	hugh 24:9	299:19 303:11
250:25 251:5,11	185:14 186:8	hum 157:9	312:7 315:6,10
251:16,25 252:17	296:22	human 24:13	321:8,11 324:7,9
252:21,25 253:7	home 327:7	hundreds 309:5	324:11 325:15
253:22 254:6,7	honest 277:6	hurt 40:25	328:1,11,22 333:3
277:9 282:3	honestly 80:22	hysingla 128:11	334:10 339:18
292:22,25 293:1	102:1 119:7	138:7	347:16 348:9
295:15 301:23	176:24 269:23	i	349:19,20,24
304:20 305:11	270:24 273:2	icd 316:16,20,24	353:4,15,23
307:8 308:24	282:13 331:5	idea 110:18 111:1	identifies 339:5
309:6 312:4 313:2	hope 22:8 46:5,8	112:3 229:22	identify 31:20
313:21 314:3,5,10	46:11 60:5 117:24	260:6 284:2	32:7 36:25 38:23
314:16,24,24	163:21 233:12	identification 29:1	39:5,9 40:9 41:4
333:8 341:4,18	267:18 319:25	37:17,19 44:18	41:19 43:5 45:1
342:5	hoped 46:18	66:19 73:11,13	51:24 53:8 70:23
hesitate 294:6	hopefully 52:22	84:10 121:3	73:19,20 74:12
hey 39:4 112:20	hospice 90:12	124:21 126:25	75:17 80:5 88:17
		127:5 210:18	89:5 92:6,16
		127.3 210.10	

[identify - individual]

106:8 115:14,17	illegally 329:7,18	134:6,22 135:7,9	incorrect 175:14
119:1 120:1,9,17	illegible 169:25	137:6 184:4 187:7	increase 302:2
121:21,25 130:1	illegitimate 49:4,7	improperly 47:16	313:19 314:15
142:16 143:7,10	49:10 211:10	inability 301:14	355:8,10
143:16 144:25	illicit 38:5 39:16	inadequate 156:13	increased 306:21
145:2,12,17	51:1 60:24 189:2	178:8	increases 292:25
153:13 160:14	210:22,25 211:10	inappropriate	incredibly 140:5
162:4 193:1	211:12 212:1,7	106:5,10 317:6	incur 299:20
198:22 205:24,25	229:15 293:5	incarceration	302:13
206:3 240:23	304:24 305:4	246:19,23 311:5	incurred 300:20
241:5 246:20	312:20 313:2,21	inception 191:25	incurring 300:1,6
257:20 260:8	314:10,17 341:18	237:4,18 238:3	300:11
264:6 281:6	342:5,9,25	239:4	independent 121:2
310:14 315:21	illicitly 342:11,14	inches 355:6	138:14 139:1
320:8 324:13,23	illinois 3:18 4:4	incidence 306:21	262:9 313:16
325:7 338:25	illnesses 121:15	include 123:6	321:16
339:23 340:7,11	immediate 261:9	125:3 129:9	independently
342:18 343:5	274:2	150:24 323:24	321:4
344:22 348:12	impact 21:21 39:1	325:18 335:8	index 6:1,4,5 7:1
354:1	178:12,22 207:7	346:7 347:20	8:1 9:1 10:1 11:1
identifying 96:6	207:11,20 208:24	348:24 350:2,4,5	12:1 13:1 14:1
99:12 182:15	209:7 210:6	350:15,23 353:4	15:1 16:1 17:1
220:15 229:2	220:20 304:15	included 43:4	indiana 4:13
241:3 345:15	impacted 269:4	91:10 150:8	indianapolis 4:13
346:16	impacts 220:15	348:14 355:21	indicate 207:14
ignore 302:21	257:11	includes 33:1	313:10
illegal 34:22 35:10	impediment 265:3	125:24 135:15	indicated 56:15
36:5 47:24 48:12	implement 276:3	149:13 324:1	158:8 181:19
48:22 49:25 50:6	implemented	344:21	355:11
50:20 51:15 56:25	122:15 275:25	including 93:2	indicating 58:20
57:8,11 61:17	important 33:10	97:1 128:21 148:4	72:9 91:19 93:13
127:23 134:5	importation 313:1	202:8 204:10	94:4 106:16,20
137:6 166:1	imported 210:21	208:15 212:20	245:15 247:8
188:17 220:7,15	impossible 103:25	219:14 220:8	indications 192:24
220:20 221:2	335:21	221:3 231:13	indirect 21:25
254:22 260:10,21	impression 83:6	239:2 257:8	individual 30:4
281:23 287:20	125:10 342:12	346:25	43:16 51:24 77:10
289:18,25 290:2	355:12	incomplete 236:14	96:18 123:13
303:15 312:6	improper 37:19	241:7	139:9 143:19
320:3,18 341:8	40:11 46:13 49:7	incorporated	160:12 197:7,10
342:16	120:21 127:23	362:12	204:21 236:16

[individual - interrogatories]

237:17,24 239:25	334:8,24 339:7,17	217:3,8 223:18	instituted 213:24
317:9,9 320:25	inducement 55:1	224:24 226:3,14	310:20
324:23 326:5,19	indulge 248:1	227:13 228:9,20	institutions 155:20
327:4 330:6,19	industry 121:1	237:2 243:17	instruct 61:2
337:5,15,22	ineffective 107:4	245:25 246:18	130:9 213:12
339:12	107:11,19 113:10	250:15 261:25	322:1
individual's	114:18 115:3,10	265:8 270:23	instruction 357:2
236:18,23 336:11	117:17 118:10	271:1 321:2,18	357:10
336:15	127:14 128:9,13	327:22 328:7,13	intended 191:10
individually	132:16 136:18	328:15 330:24	304:22 305:2
209:16 326:15	138:2,3,9,18 139:4	331:4,10 333:16	intending 305:7
individuals 29:24	139:16 348:11	337:13 344:22	305:22 306:1
30:18 31:5,11,20	infants 83:4	informed 78:10	intensity 24:19
32:2,8 36:10	influence 58:23	129:1 152:19	intent 191:15
37:18,25 39:5,8,9	184:21 281:15	347:5	intention 199:24
43:6 44:18 45:3	283:9,13,17 284:2	infrequently	289:14
46:3 54:13 74:9	influenced 181:20	295:2	intentionally
74:12,14 82:4,19	influx 192:23	inherent 265:10	190:25 193:7
96:7 97:20 105:25	inform 178:6	initial 35:8 252:8	interdict 213:5
121:23 125:16	317:4	324:11	214:5,19 215:5
130:19 134:14	informally 267:25	initially 42:12	interest 46:14
136:16 142:16	268:1	56:18 140:11	interested 27:12
143:8,17 144:1,18	information 21:18	168:4 181:9 341:2	359:3
145:1,2,3,4,12	21:20 22:24 27:6	initiated 175:19	interfaced 224:15
154:12 191:19	28:12 33:23 38:14	222:10 254:15	intermediaries
197:23 198:11	41:6,18,24 43:21	initiative 258:10	55:19 56:24 57:8
202:7 207:13	50:18 51:13 69:8	initiatives 180:17	intermediary
210:13 222:15	71:5 75:3 76:22	195:2 298:20	39:11 55:15 57:15
229:17 231:19,21	76:25 77:4,11	injury 25:6 167:21	intermediate 53:6
231:24 232:3,5,22	78:12 99:23	233:16	56:11 62:12
233:2 235:25	118:15,19 120:13	input 119:13	intermediates
236:11,15 242:22	122:16 129:13	283:4,8,18,20	54:4,6,9 55:13
253:22 254:13	130:6 131:20	inquiries 164:10	international
299:25 315:21	141:24 149:11	inside 305:6	317:2
318:25 319:4	153:4 158:6	instance 195:5	internet 23:7
320:8 321:8,10,21	163:14,20 164:2,9	204:2	interpret 133:3
322:19 323:13	164:24 170:13,16	instances 44:12,14	interpretation
324:4,12,22	171:20,25 172:17	44:20 165:12	94:22 106:10
326:13 327:19,25	174:18 176:25	192:6,7 201:19	108:22 321:3
328:9,17,21	190:7,13 208:8	205:5	interrogatories
330:20 333:7,11	212:11,12 215:11		7:11,15 27:23

[interrogatories - kept]

40:17 41:10,13	322:15	200:19 210:10	james 5:3 18:16,16
65:21,24 66:17	intoxications	218:4,15 219:10	38:20,21 278:11
67:15,19 68:13,17	217:19	260:1 278:5 281:3	janssen 5:2 18:17
68:20 71:20 81:8	introduced 214:15	investigative	january 1:16 18:2
81:13 84:7 91:17	344:12,17	200:24 230:10	27:15 359:7 360:4
91:22,23 94:11,15	investigate 161:6	investigators	jerome 138:4
94:21 96:16 97:10	161:10,17 162:14	238:16	joan 25:9 167:14
111:18 119:15	195:2 222:12	investments 312:9	job 145:9 172:4
132:11 147:4,15	279:15	involved 31:11	john 2:16
150:17 153:1	investigated 38:11	98:21 185:12	johnson 5:2,2
154:9 321:15	193:18 194:1,17	186:7 235:6	18:17,18
344:23,25 345:2	217:25 218:22	253:10 331:1	jones 2:14 18:25
interrogatory	219:1 220:7 221:5	involvement 94:22	jonesday.com
53:20 64:13 65:4	222:2 236:9 298:9	327:2	2:18,18
65:5 66:25 69:9	investigating	involving 231:13	judge 1:8 302:9
69:16,20 72:7	194:23 215:22	irrespective 94:14	june 27:9 181:3
92:5,23 110:8	216:17 219:23	isolated 293:1	jurisdiction 92:8
111:11,25 130:23	235:25 236:12	isolation 304:17	329:24
130:25 134:15	237:17 239:10	issue 85:15,17	jurisdictions 85:3
141:1 143:22	240:1 242:22	146:9 216:22	207:12 213:2
345:6,14 346:4,6	259:14,21 330:14	217:2 298:13	257:19 267:20
347:18 349:6,11	investigation	310:8 344:23,25	269:6
349:12,12,13	120:21 154:5	351:7	jury 168:16
351:12,14 352:8	159:13 165:18	issued 288:12	justice 198:7
interrupt 59:1	184:1 198:14	issues 39:12	215:12
347:11	200:4,5 201:16,21	155:25 196:14	justin 168:5
interstates 210:14	213:9,20 215:16	289:1 310:5,23	k
intervening 275:7	215:25 216:11,12	issuing 289:8,13	k 3:8
intervention	216:21,24 219:6	289:16	k2 293:12,14
240:24 241:5	219:16 223:5	j	kahuna 322:5
246:21	227:17 235:8,20	j 2:11 3:3,21	keep 23:10 66:25
interventions	236:17 241:9,9	jackson 3:8 19:3	82:5 111:13 146:2
232:19 285:18,20	256:24 259:23	jacksonkelly.com	149:15 208:22
311:14	260:10,12,17,20	3:11	209:1 238:24
interviewed	260:22 261:4	jail 46:4 47:18,25	270:12 351:23
321:20 322:10	276:11 279:17,20	176:21 221:15,16	keeps 217:14
interviewing	280:4,12,22	221:24 222:5,22	keith 24:16 30:8
254:6	324:10 325:23	222:23,24,25	kelly 3:8 19:3
interviews 25:18	330:6,16	258:16 273:21	kentucky 227:6,8
177:1 253:21	investigations	311:6	kept 167:10
254:12 321:9,16	160:4 196:18	311.0	Sept 107.10

[keyes - knowledge]

keyes 3:21 19:15	99:22 100:5,7	176:20,21,24	273:2,11 274:25
19:15	101:13,19 102:1,2	178:6,15,25 179:2	275:4,4,21,23
kids 298:17	103:4,6,14 104:3	179:2,4,5,21,23	276:13 277:5,14
kind 29:15 35:20	105:17,22,24	180:2,17 181:13	278:20 280:11
39:12 55:23 56:12	106:17 109:2,4,23	182:14 188:4,12	282:13,15,19,23
61:17 70:14 78:11	109:25 110:9,11	189:22 190:17	283:21 286:3,4,8,8
84:18 93:23	111:10 112:7,12	191:18 192:5,11	290:9 291:9,17
122:15 130:15	112:14 113:4,11	193:22 194:5,8,10	296:3,5,9,11 298:6
158:19 170:14	113:18 114:2,2,4	194:23 196:5,13	298:7,19,23
174:10 177:7	116:5,19 117:10	197:24 198:7	299:24 300:9
187:7 204:6,20	117:25 118:8,23	199:13,15 200:10	303:19 308:20,23
246:24 257:16	119:3,7,11 121:23	201:4 202:2,11,22	309:4,18 310:4,6,9
268:9,10 271:9,16	122:9,14,23 123:4	203:3,8,8,20,23	310:24 311:13
304:7 323:3	123:6,10,21,25	204:1 205:4,4,12	312:1,11 313:16
351:10	124:2,20,22 125:7	205:13,14,16,20	313:25 316:10,16
kinds 217:16	125:9,10,12 126:3	206:9,12,15,16,22	316:23,24 318:6
knew 116:13	126:5,10,14	207:2,9 208:15	318:14,21 321:19
118:3 173:8,9	129:17 130:6	210:8,11,12	322:8,19 323:2,12
202:23 224:20	131:6 132:2	213:23 214:11	323:14,22,25
225:6 329:13	133:17 134:16	215:13 217:2	324:3,10 325:13
know 20:6,8 22:5	135:14,20,22	218:3,8,14,24	326:5,14,17,18
24:21 25:2 26:10	136:7,8 138:20	219:4,19,21,25	327:3,14,18,24
26:25 29:6,12	140:3,4,5,6,8,9,15	220:22,24 221:8,9	328:23 329:1,3,12
32:20 33:19 35:1	141:2,4,9,15,20,23	221:14,18 222:9	329:20 330:21,23
35:15 40:8 42:11	141:25 142:8,9,12	222:18,19,25	330:24 331:5,17
42:17,20 45:25	144:21 145:15,22	223:6,17 224:10	333:5,10,13,14
46:3,5,9 49:1,2,3	146:12 147:19,25	228:24 230:8	334:1 338:4 343:7
53:13 55:24 59:4	148:2,6,11,11,13	232:19,22 233:4	347:8
60:22 61:8,11,13	148:13,16 149:1	233:13 237:10	knowable 221:9
61:14,16 62:10	149:10,13,16	238:6 243:20	329:2
63:16 69:18 70:16	150:14 151:3,19	244:25 251:19	knowing 73:23
70:24 71:3,4,11	151:25 152:1,8,14	252:8 253:20	218:25 272:4
73:16,16 76:9,11	152:16 154:4,4	254:8,17 257:22	284:10 333:12
76:12,16,18 77:23	159:7 160:10	258:8,20,25,25	338:5
77:25 78:4,13,14	162:10,24 163:1,1	259:21 261:1,13	knowingly 49:18
78:16,25 79:7,8,13	163:2,3,7,9 165:10	262:7,23 264:9,15	knowledge 23:16
79:16,20 80:22,23	165:14,22,23,24	264:23 265:16,21	70:21 76:7 77:16
81:1 86:16,24	166:3,7 171:9,11	266:12,12 267:6	77:16 119:9 131:1
87:6 91:3 92:13	171:25 172:19	269:4,7,23 270:22	138:14 139:1
96:14,17,22 98:8,9	173:20 174:9,17	270:24 271:16	148:20 154:23
98:23,25 99:5,6,15	175:23 176:4,18	272:3,14,21,25	155:10 157:3

[knowledge - list] Page 35

161.10 100.11 10	J 47.10 14 15	1.64	1 4.2 10.10
161:18 182:11,12	law 47:12,14,15	leftover 192:10	lewis 4:3 19:18
184:8 190:19	49:8 160:6 181:4	legal 187:20	lexington 2:3
194:15 200:20	196:15,18 208:11	188:16 241:25	liaison 283:6
203:22 226:1	208:13,14 209:5	242:14 254:22	liaisoned 261:7
261:17 266:25	209:15,17,18	289:21 303:18	license 47:17,25
268:19 269:17	212:16,22 213:7	329:13,21,23	238:17,19
271:21 297:3	213:10,13 215:3,8	360:1 363:1	licensed 187:18,20
302:1 321:15	215:23 216:1,6,14	legally 254:19	187:22
322:15	219:9,12,13 220:1	300:4 328:24	licenses 46:7 47:8
known 186:17	227:15 246:15	329:6,17,24	196:9
187:4 191:11	257:11 258:19,21	legislation 212:18	licensing 203:2
266:20 324:6	259:2 267:8,14,14	212:19,21 227:4	lieu 311:4
knows 316:22	276:5,7,10,22	275:1	light 325:24
332:7	278:7,23 280:13	legislations 273:24	limit 60:14
l	280:20 298:9	legitimate 49:3,10	limitations 84:25
l 1:25 358:6	310:22 319:22	85:14 165:24	limited 29:9,16
359:13	lawful 20:10	187:4 195:13	128:21 137:18
l.p. 1:10 3:12	179:11,17,21	lengthy 42:9	235:5 251:22
label 105:3,10	lawfully 102:19,21	181:15	346:25
263:25	103:9 193:13	lerms 267:9	linda 27:24 28:1,2
laboratory 286:21	lawsuit 163:2	letter 27:21 28:1	line 362:7 363:3
289:15 290:19	193:22,25 194:7	360:20	lines 182:1 196:6
330:8	194:19 195:1,6,14	letters 290:25	205:25 269:8
laced 304:24 305:3	196:1 269:10	level 101:20	link 171:13,18
lack 57:22	287:25 339:6,23	157:10 160:4,19	175:3 303:22
lacking 333:24	lawyers 21:9,10	161:13,16 164:23	336:10 339:13
lag 265:10	24:22 28:13 67:22	164:23 172:2	linkage 277:8
landfill 82:15,17	68:5 77:14 129:14	174:1 181:2,13	list 27:5 58:11
82:24 169:1,3	layman's 87:17	190:11,12,14	71:6 75:3,6,11
large 54:25 93:11	layperson 315:14	192:16,17 196:21	76:20 82:22 113:2
192:23 221:25	lead 166:9	197:21 202:4	115:24 119:18
233:7 292:18	learn 22:9	204:10 206:10	121:8,17 124:4
333:8 336:7,19	learned 61:3	214:14 216:12	128:3 132:23
337:16 338:9	116:16,18 119:5,6	217:1,1,7 219:11	133:17,18 139:20
largely 290:17	322:1	226:23 227:23	140:16 141:5
larger 244:7	leave 44:23 61:19	259:17,24 266:17	143:24 144:1
lasting 273:17	154:8 170:11	273:24 276:12	146:11 147:21
lastly 128:17	leaves 211:9	299:10 308:4,6	148:18 149:1,3,4,5
late 102:20 207:5	led 49:23,24 50:5	311:23 330:3	149:19,23,25
324:18 347:13	left 268:10 332:9	levels 227:16	152:20 166:4
324.10 347.13		311:12	232:9 264:19

[list - major] Page 36

295:17 297:23	352:16	194:10 199:20	237:21 238:8,14
298:5 299:5,13	live 172:2	207:25 209:9	241:3 264:11
328:17 330:15	living 253:21	230:19 235:16	266:15 268:12
331:6 333:18,18	llp 2:20 3:2,12,16	240:20 241:23	271:1 290:10
333:19 334:1,8,24	3:21 4:3 5:3	244:5 245:3	291:1,20 292:21
346:13 347:20,22	lobbying 58:24	249:10 251:23,24	294:3,24 298:7
347:25 348:24	336:24 337:24	251:25 252:8,10	302:5 305:11
350:11,14 352:4,7	338:10	255:12 259:10	311:8,19 336:24
353:8	local 54:14 56:6	290:24 291:1	lots 290:16
listed 29:22 30:6	160:6 203:24	304:6 310:17	loud 145:10
97:13 116:25	208:13 209:14,17	313:25 317:8	low 58:21 156:11
127:21 128:12	209:18 213:10	343:6 351:18	lporter 3:7
132:2 133:21	215:8,25 216:6,14	352:1,11	lsd 294:1,3,9,20
134:4 136:11	217:7 219:9,12,13	looked 28:11	295:24 296:11
138:8 140:3,14	220:1 276:12	32:15 34:1 148:15	luke 3:3 19:19
143:19 150:10	278:7 280:13,20	165:2,15 169:7	lump 56:12 293:15
157:2 265:14	298:9 310:22	188:13 250:19	lumping 291:10
270:20 286:18	320:21	253:4 304:12	lunch 170:10
295:21 321:21	locally 56:10	352:17	182:18
323:1,13 324:12	203:11	looking 33:7,20	luncheon 182:22
324:22 326:13	locate 82:5	42:8 62:21 127:11	lwerb 4:10
327:16 330:20	location 360:15	146:11 168:14	m
332:1,22 346:17	logistics 343:18	171:24 172:1,7	m 2:15 5:3 265:25
347:9 350:14	long 30:9 59:19	175:10 177:23	m.d. 1:13 6:7
353:13 362:7,17	128:20 129:3	210:2 241:4 243:3	20:10,15 183:5
listen 253:17	140:5 179:19	243:7 255:14	284:18 344:8
listing 362:7	206:11,24 239:3	317:22 352:10	354:20 358:9
lists 147:14 177:18	253:19 263:6	looks 244:23 245:9	360:8 361:4,9
litany 171:6	265:9 319:15	245:15 247:7	362:4,13 363:20
literally 106:19	346:24 347:7	loop 222:14	ma'am 348:18
literature 23:7	longer 198:10	lose 46:7 47:8,17	madam 360:10
litigation 1:6 18:5	longest 252:1	47:24 320:12	magnitude 199:14
86:11 360:6 361:3	look 33:4,10 52:4	lost 114:20,25	mail 7:19 234:13
362:3	54:11 56:17 64:18	lot 21:24 52:17	234:19
little 23:9 29:18	64:21 65:5 68:24	56:7 68:12 79:12	main 2:11 3:9 5:4
37:6 56:22 58:22	84:15,16 93:20,21	131:6 136:4 142:9	maintain 210:23
		1460416014	
67:2 99:17 145:6	106:12 113:7	146:24 168:14	262:25
166:22 172:14	117:14 140:2	170:21 180:25	262:25 maintained
166:22 172:14 230:2,20 252:20	117:14 140:2 152:11 174:13,25	170:21 180:25 181:11 194:12	maintained
166:22 172:14 230:2,20 252:20 260:13 264:12	117:14 140:2 152:11 174:13,25 175:1,23 178:3	170:21 180:25 181:11 194:12 215:7 219:10	maintained 160:15,23
166:22 172:14 230:2,20 252:20	117:14 140:2 152:11 174:13,25	170:21 180:25 181:11 194:12	maintained

[major - medically]

295:17,18	mark.cheffo 3:15	mdpv 290:24	106:11 128:22
majority 192:11	marked 7:3,20 8:5	me's 246:13	155:25 162:16
makeup 246:24	8:10 28:25 66:18	mean 24:2 26:11	165:9 167:15
making 51:1 111:2	66:22 68:24 84:9	42:7 54:14 64:16	170:20 171:21
116:14 212:14	126:24 127:4	64:23 68:8 72:3	187:4 191:3,22
310:25	167:1 234:15,15	74:23 75:14 117:7	196:23 197:1
mandatory 273:25	240:11 244:13	123:4 125:14	198:12,13 199:5
274:3,6,15,18	248:9,18,19	131:25 132:22	200:1,7,11 201:6
275:8	263:17,18 343:22	137:8 139:13,21	202:9,20,21 203:2
manufacture	345:4	148:1 151:19	205:11 206:20
262:9,21	market 51:19	154:4 176:22	210:10 211:10
manufactured	marketed 303:10	186:23 192:5	212:24 213:15
56:16 126:11	marketing 94:1	199:1 203:6 210:8	221:15,17,23
293:5 303:20	154:25 155:12	210:16 213:8,12	222:10,13 229:6,9
342:11,14	157:5,19 160:17	216:21 217:1,14	231:16,21 236:9
manufacturer 7:9	162:7 164:2	217:19 230:8	238:13,21 239:1
7:15 66:15 84:5	173:17 178:13,18	233:4 260:23	240:21 245:23
94:1 120:14	178:23 179:4	269:1 273:23	248:16 249:8
128:24 185:10	181:20 194:11	298:16 304:5	250:7 254:16
186:4,21 187:18	markets 60:24	307:3,18 309:12	257:10 258:7,11
187:22 193:19	mart 4:6 19:22	309:19 313:24	258:17 261:8
194:2 345:17	martin 24:16 30:8	316:4	267:16 271:25
347:3 350:6,13	30:10 32:23 34:10	meaning 46:21	273:20 276:2
manufacturers	master 27:21	161:24 292:8	277:1 283:22
45:6 128:16	100:20 101:6	means 21:2 49:7	286:16 289:15
138:12 203:23	master's 65:10	108:6 166:1	311:6 316:2,7
223:12 345:1	match 185:23	213:22 215:13	317:5,14,19 318:1
manufacturing	186:9	measure 54:25	323:18 330:1,3,11
184:10 194:11	matching 122:15	333:9 336:7	334:14 347:1
261:19,25 267:1	material 21:15,17	mechanism 160:3	348:3 350:11,17
268:16 283:11	materials 22:23	161:17 314:11	350:24
353:7	23:2	media 168:10	medically 35:21
marijuana 289:18	matter 18:4 20:4	medicaid 176:22	106:1,4,5,9,10
290:6,10,14	112:22 238:25	medical 8:4 21:15	107:4,10,14,19
291:11 294:24,25	360:12	23:3,6 25:11,12	108:9 113:10,15
295:22	mcconnell 2:16	34:17 40:21 52:15	114:1,13 115:15
mark 3:13 19:8	mckesson 2:19	63:1 64:25 65:13	118:11 127:13,20
66:24 94:13	18:20	69:12 70:3 71:8	128:6 129:5 130:4
166:25 230:21	md 1:7	76:8 77:9,24 78:2	132:7,16,18 133:4
263:4,21 343:9,16	mdl 1:6	78:5 80:12,20	133:7,10,23 134:2
		87:18 88:19	134:17 136:15,18

$[medically\ \hbox{-}\ misrepresentation]$

136:21,24 137:4	memorialize	mess 352:16	midway 93:23
137:15,19 138:17	172:22	messages 82:23	midwest 363:1
139:3,21 153:9	memorialized	met 21:10,14	mill 35:2,4,9,20
154:6 348:10	173:16	28:12 66:5 67:21	36:10 43:9 48:7
medication 46:24	memories 287:11	68:7 129:14	48:11,17,20 49:9
48:7,10 126:7	memory 26:5	144:14 151:5	50:12,14 57:12
187:7 188:11	255:13 346:19	197:8 198:3	179:23 192:22
190:22 191:1	memos 173:10	334:25 335:3,6	201:2 212:18,18
195:20 210:17	mental 191:23	meth 289:5 305:1	260:14,18
250:14 273:16,18	252:23 253:25	305:3,3	miller 34:10
medications 214:1	266:4,6 300:2	methadone 126:1	milligrams 69:24
228:16 229:15	301:4 311:5 318:3	methamphetamine	mills 36:4 37:20
254:11 286:18	mention 30:25	288:10,14,24	49:4 184:2 207:10
303:19 340:22,24	mentioned 23:5	289:7 291:18,19	208:4
medicine 40:2	29:25 45:22 51:9	291:23,24 292:2,6	mind 24:20,25
79:13 88:4 103:22	66:5 82:19 120:24	292:11,16,22	305:6
155:18 161:12	144:3 160:11	293:2 295:22	mine 245:1
162:16 163:5	167:8 177:8,21	296:8 305:25	minimize 213:23
202:8 214:1,12	189:2 195:4 197:5	311:22	mining 277:7,17
260:2 275:1 316:5	200:25 201:13	methodology	minors 298:4,13
316:12	207:23,24 218:13	78:14 188:8	299:14
medicines 64:7	230:8 233:22	methods 256:11	minute 43:7
102:22 176:15	240:4 241:7 250:2	methyl 290:25	169:17 170:9
216:18	266:1 273:13	metric 254:24	230:25 256:16
meet 21:13 67:24	275:24 281:4	metrics 222:18,19	minutes 30:11
75:18,21 145:25	285:2,11 301:2	metrohealth 25:11	111:22 130:7
146:5 151:17	306:19 312:24	155:25 167:15	136:1 138:25
meeting 68:5,9	314:25 321:12	221:16,23 222:9	169:13 217:15
217:17 232:2	338:22 339:1	222:13 231:21	mischaracterizes
meetings 158:2	342:17 343:1	276:2	71:25 108:3
170:17 173:5	354:5,24	mexican 34:21	118:18 136:3
208:13 217:15	mentioning 146:3	50:25 51:15,20	137:13,24 154:16
268:8,10 269:2	149:15 214:13	61:9 312:19	misclassifying
meets 75:11	312:22	mexico 39:16	317:17
member 233:7	mentions 246:1	54:19 210:13,21	mishear 121:5
members 116:7	347:7	212:1 312:24	misidentified
233:1	mentor 310:6	michael 7:8 66:13	292:14
memoranda 177:1	merely 244:17	mid 243:13	misinformation
memorandum	meridian 4:13	middle 307:13,17	174:16
217:10	merriman 24:12	midst 46:19 307:3	misrepresentation
			40:12 42:3 49:23

[misrepresentation - negate]

85:4 93:4,6	modifier 323:24	motion 83:11	142:10 150:20
336:18 337:6	324:1	303:5	152:20 180:21
338:8 348:13	money 300:13,17	motivating 60:23	226:24 233:14
misrepresentatio	302:23	move 55:11 59:20	293:24 326:23,24
50:9 62:18 85:12	monitor 175:20	83:8 113:23 150:1	328:18 335:13,23
85:23 87:22 88:5	269:15	156:25 158:16	346:21
90:5 92:9,18	monitored 104:11	175:4 180:11	napoli 2:2
156:19 348:15	monitoring 42:9	302:25 348:16	napoli 2.2 napolilaw.com 2:5
misrepresenting	42:23 104:5 158:7	moves 319:18	narcotic 276:3
128:18 340:23	165:4 205:21	moving 59:11	narcotics 55:3
346:22	226:22 227:7,9	multiple 158:2	219:22 320:3,18
missed 41:23	268:7	191:15 204:19	national 1:6 7:10
309:5	month 295:9,11	217:3 230:9	18:4 54:14 66:16
missing 168:23	monthly 27:8	327:19	174:21 214:14
missing 100.25 mission 180:16	217:15	multitude 310:23	268:1,5 269:1
misspoke 250:18	months 22:12 33:9	municipalities	285:7 312:14
misstatement	213:20 242:24	209:20	320:20 360:6
345:17	249:20 252:1,2	mutual 65:13 71:8	361:3 362:3
misstatements	288:16		nature 61:17
129:7		n	208:1 285:5
misstates 151:10	morgan 4:3 19:17	nail 230:20	331:23
153:6	morganlewis.com 4:5	naloxone 25:13	near 295:14
mixed 94:13	morning 20:17	167:17,17 203:9	nearly 304:13
217:19	116:18 119:5	285:13,18 286:1	
	144:23 197:5	name 43:11	neatly 215:20
mixing 270:12 mixture 304:23	morning's 183:14	118:23 128:8	necessarily 72:3 103:24 108:7
	morning 8 105.14	100 00 150 10	103:24 108:7
	_	133:22 150:19	206.2 216.0
305:16,20	morphine 40:22	133:22 150:19 173:8 233:10	206:2 216:8
mixtures 293:2	morphine 40:22 69:12 70:3 80:12		228:18 257:13
mixtures 293:2 304:15	morphine 40:22 69:12 70:3 80:12 80:20 88:19	173:8 233:10	228:18 257:13 265:4 298:11
mixtures 293:2 304:15 mme 70:4,5 72:20	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3	173:8 233:10 244:21 248:24	228:18 257:13 265:4 298:11 311:15 313:14
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2	173:8 233:10 244:21 248:24 266:6 284:22	228:18 257:13 265:4 298:11 311:15 313:14 336:25
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23 126:5,9 143:12	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9 293:1 294:4	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21 named 32:13 43:8	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12 317:8 348:17
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23 126:5,9 143:12 334:20	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9 293:1 294:4 301:19 304:6,9	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21 named 32:13 43:8 134:15 193:23	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12 317:8 348:17 needed 26:6 104:1
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23 126:5,9 143:12 334:20 model 55:22	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9 293:1 294:4 301:19 304:6,9 305:15 307:24	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21 named 32:13 43:8 134:15 193:23 234:8,21,22	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12 317:8 348:17 needed 26:6 104:1 171:15 213:18
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23 126:5,9 143:12 334:20 model 55:22 models 312:13,14	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9 293:1 294:4 301:19 304:6,9 305:15 307:24 313:19 314:9,16	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21 named 32:13 43:8 134:15 193:23 234:8,21,22 339:23 358:9	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12 317:8 348:17 needed 26:6 104:1 171:15 213:18 needs 104:10
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23 126:5,9 143:12 334:20 model 55:22	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9 293:1 294:4 301:19 304:6,9 305:15 307:24	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21 named 32:13 43:8 134:15 193:23 234:8,21,22 339:23 358:9 names 36:9 39:6	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12 317:8 348:17 needed 26:6 104:1 171:15 213:18
mixtures 293:2 304:15 mme 70:4,5 72:20 73:4 77:5,20 80:5 80:10 100:8 101:14,17,23 102:22 103:5,8 104:3 125:23 126:5,9 143:12 334:20 model 55:22 models 312:13,14	morphine 40:22 69:12 70:3 80:12 80:20 88:19 334:14 348:2,3 mortality 178:2 188:24 189:1 206:20 246:10 269:4 288:9 290:21 291:2,9 293:1 294:4 301:19 304:6,9 305:15 307:24 313:19 314:9,16	173:8 233:10 244:21 248:24 266:6 284:22 322:9 324:13 331:6 360:6 361:3 361:4,15 362:3,4 362:21 named 32:13 43:8 134:15 193:23 234:8,21,22 339:23 358:9 names 36:9 39:6 43:15,18 45:23	228:18 257:13 265:4 298:11 311:15 313:14 336:25 necessary 139:22 146:21 need 39:19 59:19 60:10 131:12 317:8 348:17 needed 26:6 104:1 171:15 213:18 needs 104:10

[negatives - objection]

nagativas 06.1	168:21 172:23	nuncing 202.17	200.2 2 5 0 16 24
negatives 96:1 neighboring	343:13,15 354:25	nursing 202:17 nw 3:22	280:2,3,5,8,16,24 281:5
178:16,24	355:3	11W 3.22	oath 20:18 110:24
neither 186:22	notice 7:5 27:16	0	149:24
never 32:18 40:5	28:23 29:5 101:10	o'clock 182:20	object 83:10
71:23 75:2 93:16	142:21 288:13	o'malley's 7:9	185:19 303:5
123:24 124:5		66:14	
211:11 224:6,13	notified 203:4	oarrs 133:5 158:7	345:24 352:20,23
′	notify 213:15	171:15 177:11,15	objection 9:3,3,4,4
225:4,7,10,11,12 238:4 253:6	number 7:3,20,24 8:10 21:24 29:6,7	179:14 180:5,16	9:5,5,6,6,7,7,8,8,9
317:18,19 319:21	29:21 34:15 56:21	181:5 184:16	9:9,10,10,11,11,12
*		190:14 199:16	9:12,13,13,14,14
new 2:4,4 3:14,14	58:1,10,13,14 69:21,21,22 74:22	205:10 226:18,21	9:15,15,16,16,17
56:9 131:12 268:3 268:4	83:1,3 180:13	226:24 227:3,13	9:17,18,18,19,19
nine 274:14,20	183:20,25 184:20	227:20,22 228:2,9	9:20,20,21,21,22 9:22,23,23,24,24
275:7	188:5 205:16	228:20 229:1,5,9	
ninth 4:8	220:19 234:14	229:25 230:4,6,12	9:25 10:3,3,4,4,5,5 10:6,6,7,7,8,8,9,9
nomenclature	242:11,13,15	230:14 235:6,19	10:10,10,11,11,12
70:14	244:12,18 247:13	235:24 236:3,8,18	10:10,10,11,11,12
non 31:22 35:21	249:9 250:3 252:2	236:21 237:5,8,16	10:12,13,13,14,14
52:5,24,24 59:23	252:6,12,12 253:2	238:17 239:2,2,3	10:17,18,18,19,19
76:2,21 99:24	253:8,11,20	239:18,25 241:1,2	10:20,20,21,21,22
187:4,8 254:16	261:17 263:5,16	241:6 242:9,16,20	10:20,20,21,21,22
349:19	263:22 264:2	243:1,10,17 244:4	10:25,23,23,24,24
northeast 37:24	288:24 294:7	247:11,16 249:11	11:5,6,6,7,7,8,8,9
43:10,14	295:8 300:25	249:15,23 251:2	11:9,10,10,11,11
northern 1:2 18:6	306:22 319:8,20	251:11,24 256:25	11:12,12,13,13,14
notary 358:6	335:22 341:15,24	257:2,9,17,19,22	11:14,15,15,16,16
359:13 360:25	342:3,15 343:11	257:24 258:9,12	11:17,17,18,18,19
361:10,18 362:15	344:24 345:3	258:24 259:5	11:19,20,20,21,21
362:23 363:23	346:4 351:12	261:21 262:6,11	11:22,22,23,23,24
note 244:17 303:4	355:8,10 360:7	268:11 270:8,17	11:24,25 12:3,3,4
355:18	numbered 8:5	270:21,23 271:1,5	12:4,5,5,6,6,7,7,8
noted 242:1 249:9	248:17	271:13,14,18,22	12:8,9,9,10,10,11
notes 7:17,18	numbers 82:22	272:2,5 273:4,8,10	12:11,12,12,13,13
25:17,20 26:8,14	106:13 264:4	273:14,25 274:1	12:14,14,15,15,16
26:16,19 28:4,6,7	290:20 292:18	274:11,16 275:9	12:16,17,17,18,18
82:3,5,20 83:13,16	301:24 303:2	275:12,20 276:3,9 276:11,20,21	12:19,19,20,20,21
97:19 126:23	362:7	277:4,7,18,22,24	12:21,22,22,23,23
127:3 166:22	numerous 345:18	278:2,9,13,14,18	12:24,24,25 13:3,3
167:7,14 168:18		278:2,9,13,14,18	13:4,4,5,5,6,6,7,7
		210.22 219:23	

[objection - objections]

Page 41

			_
13:8,8,9,9,10,10	45:21 46:16 47:1	133:1,13 134:10	269:11,21 270:1
13:11,11,12,12,13	47:5,9,19 48:18,24	134:19 135:13,17	270:18 271:6,15
13:13,14,14,15,15	49:11,19 50:1,7,21	135:23 136:2,12	271:24 272:9
13:16,16,17,17,18	51:4,16 52:1	137:12,23 138:19	273:1 275:10
13:18,19,19,20,20	53:10,16 54:1,10	139:5,23 141:17	278:4,25 279:7,13
13:21,21,22,22,23	56:3 57:2,10,19	142:2 144:19	279:22 280:7,25
13:23,24,24,25	58:15 60:2,19	145:21 147:10,24	281:10 282:18,21
14:3,3,4,4,5,5,6,6	61:1,23 62:8,20	148:21 149:18	284:8 285:3
14:7,7,8,8,9,9,10	63:10,19 64:10	150:3,13 151:9,21	287:22 288:1
14:10,11,11,12,12	68:21 71:1,16,24	152:3,13,18 153:5	289:20 290:4,8
14:13,13,14,14,15	72:13 73:9 74:19	153:17 154:3,15	294:19 295:13
14:15,16,16,17,17	75:12,23 76:4,10	155:14 157:15,24	296:1,19,23
14:18,18,19,19,20	76:23 77:6,21	159:15 160:2,18	297:21 298:15
14:20,21,21,22,22	78:6,18 79:2,10	161:11 162:23	299:21 300:22
14:23,23,24,24,25	80:1,6,17,25 81:5	164:4,16 165:21	301:11 303:4,13
15:3,3,4,4,5,5,6,6	85:10,25 86:3,7,13	166:11,18 168:11	303:25 306:5,16
15:7,7,8,8,9,9,10	86:20 87:1,8,14,24	172:25 173:19	307:1,15 308:8,19
15:10,11,11,12,12	88:7,14 89:2,9,13	176:11,16 177:4	309:10 311:24
15:13,13,14,14,15	89:19 90:20 91:1	179:10 181:22	313:5,23 316:3,8
15:15,16,16,17,17	91:11 92:11 93:18	185:15 186:12,18	316:18 317:12,25
15:18,18,19,19,20	95:4,13,20 96:2,10	186:25 187:15	318:10,17 319:1
15:20,21,21,22,22	96:19 97:5,6,14,21	188:2 189:6,11	319:11,23 320:4
15:23,23,24,24,25	98:3,6,16 99:3,8	191:13 193:21	320:10 323:17
16:3,3,4,4,5,5,6,6	99:18,25 100:9	194:3,20 195:9,16	324:16 325:1,11
16:7,7,8,8,9,9,10	101:15,24 102:23	196:3,11,16	326:8,21 333:2,23
16:10,11,11,12,12	103:10,18 104:14	200:16,22 201:7	334:21 336:2,12
16:13,13,14,14,15	104:18,23 105:4	201:25 205:3,8	337:8,18 338:1,13
16:15,16,16,17,17	105:13,19 106:6	209:12,25 211:3	339:3,15,25 340:4
16:18,18,19,19,20	107:16,23 108:2	211:14 212:3	340:14 341:9,20
16:20,21,21,22,22	108:14,25 109:8	216:19 217:12	342:20 349:2
16:23,23,24,24,25	110:12,20 111:4	218:6,17 219:3,17	353:19
17:3,3,4,4,5,5,6,6	112:6,13 113:6,17	221:6,12 222:7	objections 6:5
17:7,7,8,8,9,9,10	114:3,10 116:2	224:3,19 225:1,13	7:14 9:1 10:1 11:1
17:10,11,11,12,12	117:19,23 118:5	226:15 228:22	12:1 13:1 14:1
20:3,8 26:9 31:9	118:12,17 120:15	236:13,19,25	15:1 16:1 17:1
32:5 33:11 34:3	120:22 121:19	237:7,19 238:5	76:13 84:5,25
34:19 35:24 36:7	122:18 123:8	239:5,12 240:2	176:19 185:25
37:8,21 38:3	124:1,16,19 125:8	245:7 256:8 257:4	195:22 210:7
39:18 40:7,14,18	125:21 126:4	259:16 264:17	221:21 282:25
41:7,21 42:5	129:23 130:8,20	265:18 266:10	297:24 320:19
43:17,25 45:7,13	131:4,16 132:3,12	267:11,23 268:24	336:17 340:19

Veritext Legal Solutions

www.veritext.com 888-391-3376

[objections - opened]

355:20,23	171:21 175:19	ohio 1:2,22 2:8,12	252:14 256:4,14
obliged 146:21	177:21 197:1,19	2:17 3:10 4:9,18	264:21 268:21
observations	198:14 205:11	5:4 7:7,7 8:7 18:7	271:20 274:23
241:24	206:21 212:24	24:19 37:24 42:22	281:14 284:24
obtain 191:15	213:15,24 216:13	43:1,10,14 64:23	287:6 303:8
235:2,4 238:20	219:8 222:10,20	65:14 66:11,11	313:18 315:7
obtained 43:1	222:25 229:7,9	71:9 161:13	326:18 341:14
170:16 238:24	230:5 231:17,25	176:23 177:19	343:8,19
254:19 327:23	231:25 235:20	181:5 184:16	older 156:8
328:24 329:6,17	236:1,10,17 237:9	188:6 189:14,22	omission 40:12
obtaining 27:13	237:14,15 239:1	212:14,19 213:3	41:20 42:2,4
227:10 237:21	240:22 242:13,22	226:24 227:9	92:10
238:6 329:23	245:23 246:3,13	238:15 263:11	omissions 62:18
obvious 279:19	247:15 248:16	264:1 265:22	85:4,23 87:22
298:25	249:5,8 250:8	273:4 289:2,22	88:5 89:18 90:5
obviously 29:11	257:5 258:6,18	290:16 328:3,16	once 26:5 97:8
55:24 74:23	259:3,4,20 260:4	358:2,7 359:7,14	117:10 200:17
197:17 257:7	261:6 265:6,13	360:2	242:19 323:19
262:10 276:23	277:2 278:20	ohio's 8:7 263:12	ones 26:19 27:12
283:25 299:23	283:22,23 287:10	264:7	49:5,8 89:5
310:25	290:23 310:20	okay 24:21 28:3,8	108:13,19 113:3
occasions 204:25	330:7 341:17	29:3 30:9 31:19	117:17 118:9,10
occur 192:15,19	359:6 360:14	35:19 40:5 45:9	118:10 133:4
205:7	office's 198:13	52:21 62:15 66:21	135:19 136:14,19
occurred 218:10	267:17	67:7 68:23 71:22	145:18 183:23
224:6 264:7	officer 246:16	72:6 73:7 93:15	203:21 272:19
occurring 181:14	279:3 289:15	94:5,6 106:18	282:2 286:4
205:6 206:7 207:7	offices 228:17	111:21 122:2	328:10,23 330:21
207:16,17,18,21	official 214:17	133:23 140:7	338:4,21 345:1
208:10 218:21	315:20 361:15	141:14 142:25	347:9 353:14
222:3 224:8	362:21	147:7 148:24	ongoing 8:9
occurs 190:21	officials 21:20	155:10 158:21	263:15
192:2 193:9,15	oh 24:25 25:4	168:17 169:12	online 24:1,2,3
october 359:16	36:17 37:9 38:21	182:17 184:14	onward 315:1
offer 63:23 333:15	68:7 73:1 84:21	187:1 189:13	oops 248:9
offered 225:10,11	97:4 140:20 146:4	193:11 215:2	op 1:10
office 8:4 21:16	167:4 168:17	228:5 231:1	opana 128:11
24:10 27:7 38:22	180:3 214:23	234:10 235:17	138:7
52:13,15 65:1	234:10 259:6	243:5 245:17	open 52:22
82:13 145:23	272:18 288:22	246:7 247:25	opened 175:19
148:2 165:9	350:21 354:3	250:7 251:4,5	260:4

[operated - outside]

operated 226:23	155:19 156:10	103:23 104:7,13	oral 128:15 138:11
operating 35:4	158:10 165:20	120:14 127:24	order 52:11 65:10
operation 35:10	166:2,10,17	128:2,3,19 129:2,8	71:5 72:18 75:17
56:5	167:18 174:23	129:10 134:6,23	93:9 110:10
operational 227:5	175:20 176:15	135:8 142:18	119:18 121:8
operations 24:10	177:18 179:2,9,11	143:10,18 145:13	124:11 148:17
35:13 48:5	179:22 180:18	145:19 147:23	154:11 225:17,25
opiate 1:6 18:5	181:5 184:10	155:1 156:2,16,20	226:3 230:21
25:8 83:3 167:23	187:19,25 188:21	157:6 162:9 172:8	272:7,10
283:6 333:9 360:6	188:23 189:4,25	173:18 176:10	orders 225:21
361:3 362:3	197:25 206:19	180:9,14 183:21	org 259:10 311:19
opiates 40:20	210:16,24 211:16	184:4,5 187:25	organization
99:13 103:2	214:1 216:18	190:6 194:9 195:7	37:23
164:20 178:1	222:10,20 223:1	220:7,16,21 221:3	organizational
opinion 36:22 53:3	248:14 249:6	221:11,14,18,20	27:19 310:17
62:25 63:12,23	250:16 252:17	221:25 230:1	organizations
77:10 106:11	253:4,6 254:14	238:23 253:2,18	155:22 268:6
108:8 123:13	257:15 260:4,5	254:9,21 262:2,22	orient 345:5,8
192:12 211:23	261:6,19 267:1	268:17 291:6	original 33:21
250:13 296:4	269:3 277:9,11	294:14 295:3	256:1,6
313:16 316:14	298:21 302:3,20	298:24 302:4,12	originally 180:3
318:22 333:15	305:11 306:20	302:21 307:22	180:12
opinions 106:9	307:4 312:16	309:18 310:13	outgrowth 203:12
322:16	314:9,12 315:7,8	311:16 314:2,10	outpatient 228:10
opioid 8:3 21:21	315:15 319:10,14	319:9,15,21 320:2	outside 40:15 41:8
30:21,23 31:7,23	320:1,16 321:1	320:9,17 325:17	41:22 42:6 46:17
32:9 33:5,17,20,21	322:18,20 323:15	326:7,16 327:25	47:6,10,20 48:19
34:18,24 35:6	323:19 324:15,25	328:19,22 331:14	48:25 49:12,20
36:20 38:2,6 39:1	327:5 328:2,11	332:3,24 333:21	50:2,8,22 51:5,17
39:13,22 40:2	329:5,17,20 330:4	334:11 346:23	53:11 61:6 62:24
42:18,19 54:16,21	330:13 333:7	347:6 349:19	63:11,20 71:2,17
54:22,24 55:9	335:9,13,15,18,22	350:25 353:12	73:10 74:20 75:13
58:20 63:2,8 64:2	336:4,7 337:3	354:4 355:12	76:5 77:7,22
64:7 70:8 76:2	339:24 340:9,13	opportunities	78:19 79:3,11
83:5,6 88:4 90:3	341:1,3 349:21	163:13	80:2,7,18 81:6
91:5 102:22	opioids 40:6 52:7	opportunity	86:8,14 87:2,9,15
104:20,21 105:3	53:1,24 57:18	116:20 163:19	87:25 88:8 89:3
105:10 106:2	58:5 59:24 62:16	319:5	89:10,20 91:2,12
126:2 142:1	69:11 85:2,21	opposed 57:18	92:12 96:11,20
147:22 148:4	87:3,21 92:7,17	opposite 107:25	97:6,15,22 98:7,17
149:6 150:10,12	101:21 102:11		99:4,9,19 100:1,10

[outside - pain] Page 44

	I	I	
100:12 101:16,25	320:11 324:17	overlapping	354:16,19 355:25
102:24 103:11,19	325:2,12 326:9,22	216:14	356:2
104:15,19,24	334:22 336:3,13	overlooked 232:8	padgett 4:12 19:13
105:5,14,20	337:9,19 338:2,14	overmedicate	19:13
108:15 109:1	339:4,16 340:1,5	192:8	pads 25:23
117:20 122:19	340:15	overprescribes	padukone 2:20
133:2 134:11	overdose 7:23 8:3	191:1 193:8	18:19,19
136:13 139:24	8:8 42:11 141:7	overprescribing	page 29:22 34:13
150:4 157:25	144:4,6,8,12	38:10 46:1,23	35:7 44:24 84:15
164:4 166:15	145:17,22,24	48:6,9 63:24	90:14 91:10,15
168:11 176:12,17	146:4,9 147:22	158:13 162:15	92:15,16 93:8,20
177:5 179:12	148:1,18 150:25	174:16 175:22	93:22 106:13,13
185:19 186:13	165:5 167:18	192:21 200:7	106:19,19 114:20
187:3,16 188:3	177:12,22 179:7	211:20 216:21	127:15 131:21
189:7,12 191:10	180:21 197:10	222:16,17 260:2,7	143:4,4 162:3
194:4,21 195:7,10	198:23 204:7	340:22	234:24 240:19
195:17 196:4,12	229:18 230:15,16	overprescription	242:3 244:19,21
196:17 201:8	244:6,11 246:22	216:18 256:25	245:4,13 246:25
205:9 207:7,12,15	247:1,11 248:15	oversee 56:5 200:3	249:9 264:3,14,20
207:19 208:10	249:7,11,18 250:8	222:23,24 318:6	266:21 313:25
209:6,13 210:1	251:1,16 263:13	overseeing 202:9	314:13 327:10
214:5 218:7,10	264:8 286:17	223:1	328:9 329:11
219:18,24 221:7	288:8 291:22	oversees 32:24	346:12,20 348:12
221:13 222:8,17	292:6 294:10,18	65:17,18	362:7 363:3
256:9 264:18	294:22 309:4,6,17	overshadowing	pages 143:2 247:6
267:12,24 269:12	328:3 329:5	308:23	264:5 327:10
269:22 270:2	overdosed 142:17	oversight 196:19	pain 33:22 36:13
271:7 275:11	143:17 145:5,12	275:14	37:24 38:6 39:22
279:1,8,14,23	147:5 320:8 327:5	oversized 321:22	42:18,19 43:10,14
280:10 281:1	332:24 333:12,22	322:4	46:24 48:6,10
282:22 284:8	overdoses 43:2,4	oxycodone 206:20	54:16,22,24 55:4,5
296:2,20,24	174:13 175:2	295:10	55:10 58:20 62:17
297:25 299:22	177:15 188:9	oxycontin 128:11	63:2,3,9,17,25
300:23 301:3,12	209:2 220:10	138:6	85:2,12,14,22
303:14 304:1	244:2 247:16	р	86:12,25 87:4,7,11
306:6,17 307:2,16	251:25 253:17	p.m. 146:17,20	87:18,21 88:4
308:9 309:11	264:5,15 291:23	169:19,22 182:20	89:25 90:4,10,11
311:25 313:6	305:12	183:2 231:3,6	90:12,16,17,19,21
316:9,19 317:13	overlap 183:16	248:4,7 256:18,21	90:22,25 91:4,5,6
318:11,12,18	215:17 232:14	284:14,17 332:16	91:6,9 95:19,25
319:2,12,24 320:5	290:11	332:19 344:4,7	96:3 109:3 121:18
		334.17 344.4,/	

[pain - percent] Page 45

123:1 156:11,14	part 36:12 57:14	passing 65:1	people 25:5 35:20
156:17 158:10	58:18 97:18 98:1	patel 2:11 18:14	37:5 38:24 40:5
174:23 179:22	120:11,18 155:18	18:14	42:7 47:3 50:12
188:23 189:4,25	160:20 170:12	patient 35:11 41:5	56:10,24 57:5
210:17 211:16	177:20 180:16	63:17 73:4 76:2	85:14 121:13
214:2 229:15	190:1 208:4	76:21 77:19 90:24	123:6,15,22 124:5
251:17 252:17	219:24 221:15	98:14 99:24 100:3	125:3,4,5,24
253:4,6 254:16	230:17 241:2	119:22 124:9	126:10 128:4
257:15 260:6,19	249:14 258:10	186:21 190:21	138:15 141:5,25
273:16,17 277:10	268:4 283:12	191:2,7 192:7,16	143:19 145:5
277:11 305:11	289:1 307:10	192:17 193:10,14	147:5,5 149:6,16
314:9,12 333:7,9	309:14 310:24	195:12,14,20	150:9 159:8 160:1
340:21,22 341:2	312:24 315:22	patients 34:16	160:15 161:21
painfully 279:19	351:17 352:14	35:23 40:20,22,24	162:17 163:3
paper 246:1,4	362:9	46:14 49:3,4 63:3	165:1 168:19
355:5	participant 294:8	63:9 66:4 69:11	174:23 175:22
papers 131:7	participate 147:16	69:14,24 74:6,22	176:15 196:1
papp 25:10 26:18	participated 43:12	74:24,25 75:3,10	204:8 205:24
52:19 82:19	147:18 168:1	75:16,16,17 76:15	206:12 213:25
167:14 231:22	201:1	88:18,19,21 90:4	217:8 232:18
291:3	participating	91:10 95:22 96:18	238:23 243:7
par 4:16,16	260:10 280:14	97:3,13 109:15,16	246:12 253:5,13
paradigm 204:20	participation 20:4	123:2,3,9,23	257:23 294:21
paragraph 84:19	267:25 268:5	124:22,25 127:25	300:9 302:18
90:14,14 93:21	269:1	128:25 143:11,12	305:2,7,22 308:22
128:7 138:4	particular 183:19	149:12 150:19,21	309:5 310:11
143:15 235:1	200:14 237:5	156:16 185:13,14	315:6 319:9,21
240:21	particularly	186:8 192:4,20	320:1,15,22
pardon 21:14	128:20 294:5	193:16 222:4	325:15 354:1
27:25 82:16 109:9	295:5 346:24	323:4 324:7	percent 42:14
144:5 181:5,9	parties 65:13	334:12 347:4	54:12 156:12
216:4 239:20	88:10	348:1,4 349:20	181:18,24 188:9
255:3 283:19	partly 227:16	353:13	198:23 242:1,12
parenthetically	246:18	pcp 295:6,9,12,24	242:14 247:10,14
292:15	partners 208:16	pdr 247:7	247:16 249:25
parents 302:17	213:1 215:10	peca 1:20	250:3,5,13,16,20
310:3,5	217:3 284:1	pellegrino 1:25	250:25 251:3,6,9
park 3:13	parts 108:5 283:16	358:6 359:13	251:11,15,18,21
parse 53:9	party 71:7 359:2	pending 214:18	252:13 253:2,3,11
parsing 251:19	passed 73:22	pennsylvania	253:17,23 254:9,9
309:17	164:24	206:4	255:16,17

[percentage - pllc]

percentage 42:18	193:19 194:1	314:3,5	placed 103:5,21
187:24 188:13	195:3	phenomenon	placement 201:16
190:5,8 305:18	pharmaceuticals	193:4	places 70:12
343:5	4:2,15,16 5:2	phone 19:11 20:2	174:20 202:8
perfectly 25:1	18:17 166:20	82:22,22 247:19	207:10 215:4
period 29:9 165:7	pharmacies 184:2	354:10 355:4,17	placing 239:23
204:22 238:7	185:10 190:15	360:3	plaintiff 18:11,13
242:24 252:8,10	193:2 203:10	physical 319:17	18:15
260:25 287:24	204:7,11,17,21	330:18	plaintiff's 7:7
290:1 293:22	218:9 227:12	physician 25:10	66:10 92:8 142:18
304:10 310:19	228:4,14 270:19	93:2 186:10,14	145:14 155:2
person 39:25 40:9	270:25 274:9,17	260:9 291:4	157:3,7 183:22
41:17,19,25 76:19	274:21,22 275:8	294:13	184:3,8 266:24
93:4 119:11 126:6	276:23 285:12,22	physicians 52:25	297:3
172:2 173:7 180:4	286:1	155:16 156:7,12	plaintiffs 7:12
287:18 312:23	pharmacist	158:4 181:7	84:1 85:1 92:5
324:14 332:1,22	326:20	200:15 223:2	93:1,10,24 107:1
333:17,18,19	pharmacists 184:1	238:15 258:8	128:10,17 129:6
person's 239:10	196:10 228:4	274:5,7 275:8	138:5 139:14
personal 37:15	258:13	316:6 350:10	142:16 143:16
76:6 77:15 131:1	pharmacy 7:10	pick 328:18	145:11 153:13,19
148:19 217:17	65:17 66:16 77:8	picked 332:6	154:23 184:21,23
313:15	103:21 104:2,4	picture 291:5,7	281:15,17 344:22
personally 79:20	155:17 162:15	piece 163:11	345:3,13 346:21
87:16 98:10 105:6	163:4 165:8 180:1	174:18 355:5	347:19 348:22
109:25 116:6,10	186:5 192:22	pieces 159:1	352:6 355:19
361:11 362:15	193:13 197:4,11	283:24 286:22	planning 65:18
personnel 258:15	198:17 200:2,3,10	pill 35:1,4,9,19	plateaued 189:5,9
persons 235:2,5	201:6,20,24 202:6	36:4,10 37:20	played 172:8
perspective 204:5	203:8 204:13,14	43:9 48:7,11,17,20	player 288:17,20
298:12 309:7	204:16,23 216:22	49:4,9 50:12,14	294:14 295:12,17
311:21 317:6	227:23 228:18,24	57:12 179:23	295:19
330:2	234:22 236:3	184:2 192:22	please 18:8 19:11
pertain 350:9	238:10 258:14	201:2 206:25	19:25 56:1 63:5
pervasive 176:4	259:8 262:24	207:10 208:3	84:15 106:12
pglawyer.com 2:9	326:2 331:8 334:6	212:18,18 260:14	115:5 141:12
pharma 1:10 3:12	pharmacy's	260:18	183:17 233:10
pharmaceutical	184:16 273:4	pills 195:15 208:6	350:20 360:14
4:16 88:24 121:1	phase 42:13 54:23	place 51:7 115:1	plevin 2:6
160:16 164:1	194:16 206:19	274:19 301:25	pllc 2:2 3:8
178:12,22 181:20	251:1 252:21	302:15 358:19	

[point - prescribing]

[bount breserroung]			rage 17
point 33:19 51:10	254:22 277:9,11	potentially 33:16	prepare 27:18
55:1 123:17	302:22 339:11	33:24 56:5 156:20	28:14 30:12 67:12
134:21 170:6	porter 3:3 19:19	157:21 167:18	77:17 286:14
171:14 179:3	19:19	175:23 192:9	287:6
181:6 188:15	portion 68:10	220:11 222:15	prepared 37:18
189:21,22 193:11	184:19 303:1	252:4 269:15	43:23 67:8 75:7
198:1,22 208:17	position 34:14	282:3 296:13	148:12 155:7
229:12 246:8	39:10 40:4 59:14	310:8	183:24 315:12
249:22 296:15	60:6 61:25 62:3	power 196:1,8	332:21
302:12 328:9	62:16 63:7,16	312:6	preparing 22:2,25
331:6 333:25	64:4,6,9 67:11	practice 99:7	30:15 64:14
337:20 338:4	85:9,20 101:2	104:10 200:9	prescribe 101:23
341:24 344:16	106:3 107:9,14,22	275:1	102:3,21 103:8
pointing 257:15	107:24 108:11,16	practices 52:6	104:1,7 129:2
points 55:24 56:6	218:19 297:13	53:23 58:3,4,18	221:10,20,25
56:7,11 82:25	307:6 309:2	59:24 60:17 62:14	347:6
240:24 241:5	313:15 327:1	161:15 162:16	prescribed 34:15
246:21 264:3	336:9 338:18	178:13,18,23	47:16 87:3 102:11
355:6	339:8,20 343:3	179:4 222:12	109:3 129:12
poison 164:18	positive 83:4	229:16 239:21	180:22 185:13
191:21 198:20	201:17 286:5	260:5 261:8,13	221:14 227:2
police 24:15	291:21 355:10	275:18 281:4	243:15 320:22
231:19	possibilities 305:6	336:5	353:12
policies 57:16	possibility 292:15	practitioners	prescriber 102:4,8
58:23 178:7	possible 57:25	202:10 258:12	140:14 180:15
184:15 268:9,9	160:6 292:5	259:8 260:7	181:2 237:2
273:3,6,7,7,12	304:21	273:14	prescriber's
275:17 276:6,6,18	possibly 100:12	predated 180:6	228:17
277:2,2,12 280:1	161:9	predict 319:7	prescribers 47:2
policy 109:20	post 274:2	predisposed 172:4	128:25 133:20
polster 1:8	poster 248:24	prefer 360:16	153:14,25 156:24
pops 24:24	249:2	premarked 344:16	165:7 181:8
population 39:21	posthumously	preparation 21:7	194:24 204:24
39:22 42:15 48:8	330:3	21:22,25 24:5,15	218:10 222:21,22
48:9,14 50:11,13	potential 55:3,6	65:2 67:16,20	227:14 230:9
51:7,8,18,21 54:12	58:22 64:1,1	98:13,15 112:19	238:18 243:14
54:15 55:18 56:18	156:10 166:1	116:21 122:11	275:22 276:22
74:6 158:10,11	178:12,22 240:24	131:2 147:9	347:4,22
177:22 180:10	329:23 336:19	159:14 160:21	prescribing 50:6
182:16 192:24	337:7 338:8	167:6 171:4 180:4	52:6,25 53:23
241:23 253:12	340:23	287:17 331:11	54:7 58:3,4,18

[prescribing - probably]

59:15,24 60:17	164:20 165:4	74:17,23,23 75:1,4	287:11
62:14 103:2	171:13 172:7,10	75:10,18 85:1,11	prevalence 188:18
104:22 127:24	173:18 174:14	85:21 92:7,17	299:4 306:8
128:2 134:6,22	177:18 178:1	95:24 96:7 97:20	prevalent 36:11
135:7 137:6 165:3	179:9,11,15,17,22	106:1 107:18	208:4 302:5 305:9
175:20,24 178:13	180:1,9 183:21	108:17 111:24	prevent 50:25
178:23 180:19,24	184:4,9 185:3,4,6	112:1 113:2	51:14 128:13,15
184:4,10 190:13	185:9,10,24 186:4	114:13 117:16	138:9,11 139:16
198:19 221:18	186:5,10 187:19	119:13 120:20	341:16
222:12 227:13	187:24 188:10	127:19 128:10	prevented 339:24
229:16 239:3,21	191:7 192:2,3	129:10 130:19	340:12,17 342:18
260:5 261:13,14	193:8 195:7,13	132:1 133:16	342:23,25
261:19 262:1,10	203:9 205:21	134:2,9,17,18	preventing 298:14
267:1 268:16	206:19 210:16	135:15,18 136:9	prevention 8:9
269:3 273:16	226:22 227:7	138:6 139:2,19	25:6 167:21
275:14 281:3,4	229:14 230:1	145:3 153:14,25	233:16 263:15
336:5,23 337:24	236:24 237:1	165:17,19 166:4	previous 21:19
prescribings	239:11 241:25	177:2 180:14	24:8 43:5 255:7
162:25	242:14 243:4,8	181:11 185:14	269:6 308:3
prescription 1:6	250:14,22,22	186:9 191:15	previously 66:6
8:8 18:5 40:2,6,10	251:17 253:18	206:13 228:10	93:25 111:7
40:25 41:5 42:9	254:10,14,21	345:16 346:16,18	125:16 270:21
42:23 48:16,21	261:18 263:13	347:16,20 348:9	primarily 23:22
52:6 53:1,24 55:4	264:8 267:1 268:6	348:23 349:22	208:11 215:24
55:5 58:5 59:24	273:16 276:4	351:5,24 353:3	280:12 302:19
63:17 64:22 65:18	285:13 286:2	presence 298:22	307:6
76:20 77:5,19	314:2 319:9,21	358:14	primary 245:24
87:20 88:3 90:3	320:2,9,17 324:15	present 5:7 158:25	314:15 330:12
93:3,24 95:10,18	324:24 326:7,16	199:11 208:12	principal 167:16
101:21 104:5	327:25 328:2,11	232:1 295:4	print 23:25
106:2 107:2 108:8	328:19,22,25	presentation	printout 93:11
109:22 111:3	329:5,16,20	245:4,14 248:23	321:22
112:4 113:15	331:14 332:2,23	presentations	printouts 64:22
114:17 115:9	333:21 335:9,15	28:18 232:17	prior 21:14 194:25
116:24 120:13	335:18,22 360:6	presented 166:21	211:20 236:12
126:11 132:23	361:3 362:3	268:7 290:23	237:15 278:15
134:24 135:6,9	prescriptions	presenting 171:19	345:20
139:15 142:18	34:15 42:24 43:5	preserved 167:11	private 232:25
143:18 145:13,19	49:6 50:17 57:17	presiding 302:9	233:4
155:1 156:2,11	62:16 63:1,22	pretty 124:7	probably 22:18
157:6 158:7 162:8	64:7 66:2 69:7	130:11 266:5	24:21 29:4 68:9

[probably - purporting]

129:19 160:11	product 61:9	prosecution	150:19 168:22
169:2 188:22	105:3,10 186:21	197:20 207:4	187:3 255:19
203:21 206:23	187:2 193:16	213:17 259:22	273:21 283:3
209:14 245:8	production 282:16	278:18 280:17	323:7 334:25
247:23 268:11	282:20 283:1	prosecutions	347:18
280:19 290:15	360:24	38:10 39:2 45:25	providers 127:21
294:10 295:9	professional 196:9	134:8,13 154:6	132:20 134:3
300:13 320:21	professionals	197:17,23,25	177:2
331:17 338:17	209:5	198:4 200:13	provides 209:18
probe 163:19	profit 35:12	201:1 207:3	216:9
problem 33:21	program 25:6,13	217:19 257:12	provision 311:5
123:5,16 124:10	42:23 104:6 158:7	278:13,15 311:2	public 1:21 2:7
172:10 176:4	165:4 167:17,21	331:20	4:18 159:25
189:24 207:14	205:21 213:25	prosecutor 37:2	180:17 231:18
214:15 244:7	226:23 233:16	38:9,13,19 43:20	249:3 278:23
289:6,7,11 290:14	237:18 238:3	43:22 46:2 49:2	279:3 358:6
311:12 351:18	302:16,16 310:2	134:12 162:24	359:13 361:10,18
352:14	350:12,24	163:14 201:1	362:15,23 363:23
problems 288:25	programs 128:23	207:3 218:1,19	publications
289:12 302:2	299:24 310:25	229:3 278:6,8	128:23 266:11,14
procedure 20:12	347:2	280:15 311:3	347:2
357:7 361:5 362:5	progressing	prosecutor's 38:22	publicly 23:15,17
procedures 276:7	158:10	49:14 197:19	28:12
276:18 280:2	project 25:12,14	206:17 216:13	published 240:15
proceedings 218:5	175:19 231:22	259:20 278:20	241:12 252:24
223:4	promise 182:3	prosecutors	pull 230:12,14
process 78:17 98:1	promotion 154:25	218:14	272:2
98:21 120:12	155:12 157:4,20	prospective 246:9	pulled 292:22
124:15 184:22	173:17	prospectively	304:19 307:7,8,25
186:20 218:9	promotional 162:7	242:21 243:6	pulling 292:21
235:7 237:24	prompt 294:10	protective 258:6	293:5 305:17
239:14 243:1	prosecuted 37:3	266:19 276:16	punished 47:4,13
281:16 283:9,13	38:24 49:17 95:11	protocol 130:12	47:16 49:16
283:16	120:20 121:2	protocols 213:9	purchase 305:22
processing 213:14	127:22 128:4	provide 82:6 93:2	306:1
procurement	132:20 133:15	119:12 208:2	purchased 360:17
283:14	134:4,22 135:7,16	227:1 246:17	purdue 1:9 3:12
produce 209:2	135:16,19 137:5	285:12 316:6	19:7,9 344:11
produced 66:2	137:25 353:15	provided 20:11	purportedly 264:1
83:14 167:11	prosecuting 7:8	23:21,23 41:11	purporting 264:6
249:4	66:12 278:8	93:25 147:15	

[purpose - real] Page 50

	T	T	T
purpose 34:17	query 265:22	questioning	rapid 313:19
119:14 187:4	querying 71:14	183:15	rare 290:22 295:2
191:3 211:10	question 31:2,15	questions 29:11	rates 229:25 299:4
277:25 278:10	35:9 36:24 37:13	35:14 56:23 115:3	rawlings 96:22
purposes 29:1	37:14 41:15,23	127:17 130:24	116:4,9,11 117:8
49:7 66:19 84:9	52:22 59:9 60:10	131:3,22,23	118:21 119:3
126:24 127:4	61:5 62:22 63:21	132:10 152:10	reach 203:23
234:16 235:4	63:23 80:8 84:16	163:23 166:13	238:7
240:11 244:14	84:18 88:1 89:14	168:9 169:24	reached 180:8
248:20 263:19	89:22 95:23 96:24	185:2 277:21	268:2
343:23 351:3	96:25 98:5 103:7	284:23 286:15	reacquaintance
pursuant 7:16	108:4 110:23	297:15 315:3	261:14
84:7 328:24 357:3	137:11 138:23	332:9 334:5	react 284:10
357:6	139:7 148:16	344:13 349:14,25	reacted 284:6
pursue 117:12	163:12 172:13	351:10,15 352:25	read 52:17 56:21
237:12	176:1 177:8 182:2	354:7,10,11,12,23	62:4 63:5,6 87:4
pursued 237:10	183:13 185:21,22	355:14	101:12 105:2
push 266:14	203:14 206:9	quibble 83:17	106:25 127:18
pushed 264:24	209:1 214:4,7,18	170:1	128:3 130:14,15
pushing 302:5	214:22,25 220:9	quick 72:15 186:1	131:21 132:5,7,14
put 104:3 147:3	220:25 234:4,6,7	344:1	135:5 136:4,17
172:23 244:24	243:9 254:7 256:4	quickly 354:14	141:8,21 142:9
245:8 272:12	261:23 263:6	quite 82:23 167:9	143:15 145:10
296:15 313:14	264:9 268:14	210:10 226:17	170:3,5 176:1
314:19 352:1	271:8 280:4 285:9	quota 184:22	178:19 179:1
puts 165:25	290:9,12 297:20	281:16 282:5,16	183:16 186:1
putting 144:16	298:25 300:25	282:20 283:1,4,9	253:24 266:24
146:8 257:10	305:8 308:13	283:11,13,14	268:25 324:19
q	318:12,19 320:13	quotas 184:24	351:8 361:5,6,12
qc 78:16	320:15 322:6	281:18,20,23,25	362:5,6,17
qualified 358:8	323:22 324:2	282:7 284:4,7	reading 130:2
qualify 304:5	326:10 327:22	quoted 253:21	132:10 135:10,21
quantifications	329:8 331:15,19	r	136:1,5,6 138:13
33:14	334:2 335:15	r 27:21 167:20	138:24 235:13
quantify 301:8	337:14 338:20	race 171:25	297:10,11,18
quantity 301.8 quantitate 257:13	339:22 340:6,11	295:16	349:10 351:21
quantity 272:11	341:23 347:12,15	races 305:20	360:12,20
quantity 272.11 quarterly 177:19	347:15 348:7,17	raised 157:12	reads 235:22
328:4	349:13 350:20	ranjan 2:15 18:24	ready 21:25
queried 71:5,12	353:21	18:24 343:13	real 265:12 289:7
querieu /1.3,12		10.24 343.13	

[realize - refresh] Page 51

realize 156:22	191:22 197:8	records 42:10	referencing 251:3
really 26:4 56:15	223:18 230:1	43:13 76:8 77:24	referral 115:11
61:15 119:7	237:16 240:5,25	78:2,5 208:22	117:11 161:20
125:11 145:8	receiving 49:5,6	209:16 253:19	162:21 163:25
146:14 159:22	185:21 251:17	325:25 331:20	202:24 321:17
166:7 170:7	325:16 334:13	recover 319:5	referrals 142:5
171:12 172:11,13	recess 81:23	recovery 64:24	202:2,7,13,16
173:23 174:21,25	126:20 146:18	232:4 233:3	205:15,15 217:23
178:9 180:25	169:20 182:22	302:18 310:6	325:15
181:12 188:14	231:4 248:5	318:25	referred 63:14
189:20 190:5	256:19 284:15	recruit 50:11	87:12 93:10,10
198:18 214:10	332:17 344:5	recruiting 243:6	98:19 99:13
221:1 241:22	354:17	redefinition 129:9	108:21 110:15
252:15,20 261:1	recipient 191:10	reduced 358:13	112:24 113:19
262:6 275:4,15	recognize 143:24	reed 3:2 19:5,19	114:6 115:21
288:17 291:5	174:22	reedsmith.com	142:4 150:25
292:23 304:19	recognized 166:20	3:6,7	163:4 165:17
309:18 312:2,12	recognizes 63:25	refer 37:1 43:20	200:6,17,24
312:15 319:6,19	294:17	141:1 152:7 165:8	232:11 321:5,18
325:14 326:25	recollection 166:8	197:9 200:4	322:12 324:7
346:2	227:21 238:21	201:20 316:24	325:3 328:14
reask 297:19	291:14	355:22	339:18 345:13
reason 219:1	recommended	referable 31:12	352:6
265:22 306:18	285:19	32:12 36:1 37:11	referring 142:21
362:8 363:3	record 18:2,9	39:13,22 45:16	142:23 149:4
reasonably 314:22	19:12 63:6 77:9	48:13 53:4,7,18	216:2,5 246:4
reasons 252:3	81:21,25 82:2	54:7 55:9 56:19	262:18 345:9
reassured 156:10	92:22 126:18	58:24 59:16 60:7	351:11 352:6
recall 26:16	127:8,10,18	62:1 229:16	refers 112:1
227:25 228:1	131:18 146:16	291:18 333:9	245:18 247:17
285:13 312:20	169:15,17,18,22	reference 27:20	reflect 210:5
355:1	173:6,12,15	40:16,25 41:9	reflecting 209:10
recalled 287:11	182:19 183:2	88:22 231:8	reflects 245:5
receipt 360:20	209:1,8 231:2,6	341:24 344:25	reformulated
receive 91:5	248:3,7 256:17,21	355:22 360:7	128:11 138:6
155:15 159:24	284:13,17 332:14	361:2 362:2	139:15
160:5 202:4	332:15,19 344:1,3	referenced 189:15	reformulations
received 43:5 76:2	344:7,17 349:9	293:4 358:13,17	55:4
77:19 106:1	351:20 352:16	360:11 361:11	refresh 26:5 30:3
120:13 143:1	354:14,15,19	362:15	346:19
159:19 160:8	355:19,24 362:9		

[refuse - reports] Page 52

c 2000	1 4 1 70 10	50.00.62.001.6	1 1 20 4	
refuse 286:9	related 52:18	58:20 63:2 91:6	rendon's 20:4	
refused 286:6	69:21 83:6 88:25	156:11 174:23	renee 1:25 358:6	
regard 21:17,21	157:7 190:5 207:3	179:22 189:4,25	359:13	
27:3,17 60:25	211:4 213:9 220:6	211:16 214:2	rep 88:13	
103:4 206:18	223:18 241:18	251:17 252:18	repeat 261:22	
215:9 277:8	251:11 286:17	253:4,6 257:16	rephrase 326:11	
286:17 305:7	297:8 300:20	260:6 277:10,11	replaced 234:1	
337:11	301:9 302:11	314:9,12 333:7	reply 68:15 69:22	
regarding 103:1	315:19 335:9,16	341:2	report 27:8 146:20	
129:7 164:1	339:2 355:12	reluctant 73:17,24	173:6 188:7	
184:16 262:21	relates 1:8 44:12	rely 266:13 330:5	189:15 200:9	
273:4,12 275:1,21	130:23	relying 137:9	201:19 204:22	
357:2,11	relating 155:2	208:9	205:1 216:22	
regards 208:16	221:2 273:8	remained 304:17	223:12 225:17,25	
region 215:14	350:25	remains 323:21	235:6 236:8,18,21	
regional 56:6	relationship 35:12	remediated	236:22 237:16	
189:19	71:10 178:5 191:2	261:12	239:2,25 272:10	
registered 273:14	239:20 262:25	remember 24:25	275:9	
registrants 225:20	292:2,5	26:19 30:17 43:11	reported 196:22	
257:23	relative 305:19	44:6 72:2 79:13	197:4 199:4,22	
regret 339:7	307:21 359:2	103:13 105:11,15	202:25 203:1,15	
regulated 103:12	relatively 29:14	121:22 129:21	204:3 285:10	
297:1	263:6	131:7,8 133:5	292:9	
regulation 161:12	release 288:21	136:5,6 160:19	reporter 6:18	
161:14	relevant 33:5,12	165:16 227:24	19:25 288:2 361:7	
regulations 273:22	33:17 50:15 172:6	228:8,24 244:23	reporter's 6:16	
regulators 196:15	229:22 241:8,22	254:17,23 285:16	358:1	
regulatory 58:23	287:25 337:14	287:15 289:9	reporting 42:22	
196:20	reliance 62:18	312:22 345:22	173:23 181:6	
reimburse 176:9	85:3,22 87:22	346:12	200:14 201:5	
176:14	88:5 90:4 92:9,18	remembering	205:18 225:21	
reimbursed	345:16	167:10	272:11 274:17	
176:24 300:11	relied 118:25	remission 123:7	reports 27:10	
reintegrate 311:1	153:15 154:1	323:16,21,23	177:10 179:1	
rel 7:8 66:12	reliever 38:6	remotely 175:6	181:15 189:20	
relatable 41:19	54:22 158:11	removed 319:18	197:15 198:13,25	
45:5,11,19 60:17	188:24 254:17	rendered 129:10	199:19,25 201:22	
relate 40:11 89:7	333:10	rendon 20:2 27:3	202:22 205:11	
89:16,17 157:19	relievers 33:22	168:5 198:3	210:12 214:13	
242:12 272:3	39:23 42:18,19	208:21 217:18	226:4 235:24	
280:2	54:17,24 55:5,6,10	231:14 234:2	236:11 241:17	

[reports - review] Page 53

243:10 252:21	required 228:20	286:15	122:11 180:18
272:7 298:3	269:14 270:23	responded 67:15	215:22 216:17
represent 171:17	344:23 360:25	181:19 310:7	288:23 337:2
representation	requirement 70:6	321:14	339:9
42:2 212:25 217:6	95:9	responding 69:9	responsive 174:11
231:20	requirements	81:13 119:14	175:7,14
representations	225:20 228:15	157:13 174:15	rest 349:25
128:16 138:12	reread 159:16	190:16 346:4,6	result 46:9 93:25
representative	research 179:6	352:7	201:5 281:5 292:4
34:7 49:15 74:7	235:3 249:4 256:1	response 8:3 25:2	294:18 337:6,16
98:12 114:5	256:6 290:23	41:12 43:16 58:10	337:23
120:25 139:9	301:1	58:14 68:16 69:17	resulted 200:14
155:21 183:10	reselling 195:15	72:6 91:16,21,24	218:4,15 309:23
224:5 231:23	reserve 83:15	92:1 130:25	retail 7:10 66:16
246:17 322:8	resident 102:15	136:11 142:15	retain 26:1,2
346:9 347:23	317:9	143:1,22 148:8	retained 6:18
349:1 350:3	resident's 335:25	152:25 155:3,19	25:19
representatives	residents 227:8	159:12 171:3	retrospective
88:24 164:22	304:22	172:18 175:9,16	235:8 239:7
208:15 222:5	resistant 336:22	184:23 203:11	240:22 241:9
258:3,5,22 350:7	resolvable 310:8	205:23 227:6	243:3 245:18
represented	resources 219:5	248:14 249:7	251:7
229:14 232:3	219:15	281:17 285:25	retrospectively
250:9 252:22	respect 30:1 41:3	286:5 303:1	43:2 243:7 244:5
342:7	41:16 64:3 69:6	310:15 312:15	returned 360:19
representing	91:15 94:24	315:21 345:3,6,14	reverse 167:18
125:11 159:18	105:16 111:2	347:18 349:6,10	review 22:23 24:1
232:23 233:5	115:9 122:24	349:11,12 351:8	32:19 42:21 68:2
represents 252:7	123:21 154:9,10	351:12,13	76:7 77:8,24 82:7
reps 97:19	155:1 157:6 162:7	responses 7:9,14	88:11 110:22
reputable 35:15	173:18 174:2	64:13 65:4 66:14	117:13 127:15
request 235:6,8	281:20 282:1,7	68:12 84:4 86:19	139:1,25 140:10
239:24 285:12	285:1 293:18	98:21,22 110:8	140:13 147:13
286:7 349:15	294:16 305:1	111:17,19,25	154:20 164:18
362:9,11	307:12 312:19	138:13 151:2	165:2 191:22
requested 180:12	320:24 334:4,19	352:18 355:20,22	194:22 198:20
235:9 237:8,15	338:7 341:6	responsibility	242:23 245:19,19
239:24 277:22	respond 39:4	31:12 39:12,17	245:22 246:1,3,10
285:21 357:1,6,10	65:21,23 67:19	336:8	246:14 256:1,6
require 261:11	71:20 93:9 131:2	responsible 30:24	260:5 286:23
	180:18 183:24	48:1 60:12 62:13	287:1 325:25

[review - saw] Page 54

		I	T
330:18 357:2,6	118:2,6,11 120:4	ring 181:21	runs 266:20
360:14 361:1	121:8,18 122:4,7	ripple 257:16	ruth 4:17 18:22
362:1	122:12,17,17	rise 188:25 305:12	rx 42:22 64:24
reviewed 21:11,15	123:3,25 124:13	305:14	181:6
21:16 23:2,5,12,14	126:3 132:11	risen 83:2,4	S
23:17,19 28:16	133:12 134:1	rises 314:8	s 3:13 265:25,25
41:11 43:2 64:23	141:22 143:2,5,25	rising 189:9	266:20,20 362:8,8
65:23 67:18 78:1	146:14 147:1,2,7	risk 156:16 240:24	363:3
78:4 97:18 110:3	148:23 152:5,12	246:21 299:7	sacwis 266:20
111:6 119:13	161:21,22 169:8	risks 128:19 129:8	sad 308:22
131:6 140:12	173:12 177:13,14	326:6,15 346:23	safety 156:9
254:2 255:23,23	178:10 179:18	roadmap 29:19	174:17 222:11,21
255:25 256:5,10	184:12 185:20	robbery 192:22	223:1
272:24 286:16,19	188:21 189:10	roitman 3:16 6:11	sake 344:19
reviewing 43:12	197:2 200:21	19:6,6 67:4	sake 344:19 sal 263:22
118:24 131:18	201:6 216:3,5	140:18,22 344:9	sal 263:22 sale 56:14 187:20
reviews 171:22	220:3,24 225:10	344:11,14 351:20	
revisited 273:19	225:12 226:18	352:3,23 354:6,13	sales 88:13 97:19
revoke 196:8	228:12 229:2	role 156:2 164:19	128:22 346:8
rewrite 53:20	235:4,24 236:12	172:7	347:1,7,10,23
rewrote 100:22	236:24 237:6,25	room 25:10 169:2	348:14,25 350:3,7
rhartman 4:19	237:25 238:4	220:16 246:13	salts 290:11,13
rich 2:10	239:4 240:18	291:4 294:13	291:11 293:18,23
right 33:10 38:17	241:12,15 242:7,9	301:20 354:9	salvatore 2:3
38:18 43:23 44:16	242:17 243:11,12	rooms 291:6	18:10 360:5
44:17 45:6,20	245:21 246:5,11	rose 234:21	samhsa 265:24
46:10,15,25 48:17	246:12 247:2,3,4,5	rounds 170:24	266:1 285:1,5
48:23 49:18 50:5	247:11,12,17,18	171:11	san 2:21 3:5
51:11,11 55:15	247:23 249:10,12	rpr 1:25	sandra 3:8
57:5 58:3 59:19	249:13,19,23,25	ruled 124:25	sandy 19:2
61:21 67:22 71:23	250:23 253:24	213:21	sara 3:16 19:6
72:20,21,24 75:19	273:22,23,25	rules 20:12 357:3	344:11
80:11 85:9,18,19	274:9,21 278:24	357:7 361:5 362:5	sara.roitman 3:19
89:25 90:6 92:2	279:6,12,21	ruling 7:16 84:8	satisfaction 178:4
92:10,24 93:14	283:18,20 285:7	344:24	satisfactory
94:3,5 101:10	293:19 294:23	run 50:12 54:19	261:12
103:17 107:10,15	306:13 317:11	156:15 205:10	satisfy 119:19
107:21 109:7,11	321:23 327:7	311:18 328:17	121:6
110:19 111:25	332:11	running 232:6	save 106:25
112:2,12 115:10	rights 83:15	260:18,18	saw 71:23 131:9
115:23 116:15,25	1181165 03.13	200.10,10	136:8 138:25
113.23 110.13,23			197:6,7 252:6

[saw - seizing] Page 55

253:8 288:23 scope 40:15 41:8 271:7 275:11 85:6 88:22 290:9,18 293:22 41:22 42:6 46:17 279:1,8,14,23 92:16,19 93 304:16 305:9 47:6,10,20 48:19 280:10 281:1 107:6 121:1 314:6 341:4 48:25 49:12,20 282:22 284:9 123:1 124:1 saying 60:5 100:17 50:2,8,22 51:5,17 295:15 296:2,20 140:17 142 104:0 111:13 53:11 61:7 62:24 206:25 207-25 154:22 155	3:6 13
304:16 305:9 47:6,10,20 48:19 280:10 281:1 107:6 121:1 314:6 341:4 48:25 49:12,20 282:22 284:9 123:1 124:1 saying 60:5 100:17 50:2,8,22 51:5,17 295:15 296:2,20 140:17 142	13
314:6 341:4 48:25 49:12,20 282:22 284:9 123:1 124:1 saying 60:5 100:17 50:2,8,22 51:5,17 295:15 296:2,20 140:17 142	
saying 60:5 100:17 50:2,8,22 51:5,17 295:15 296:2,20 140:17 142	12
104011110	:19
104:9 111:13 53:11 61:7 62:24 296:25 297:25 154:22 155	:5
121:12 140:12 63:11,20 65:7 299:22 300:23 157:1,8 161	1:24
145:7 174:7 182:7 71:2,17 73:10 301:12 303:14 170:9 180:2	23
187:9 223:24 74:20 75:13 76:5 304:1 306:6,17 187:6 193:1	11
238:24 256:3 77:7,22 78:19 307:2,16 308:9 195:18,23 2	204:17
278:12 297:15	:17
303:6 348:8 351:1 81:6 86:8,14 87:2 313:6 316:9,19 229:13 230	:9
351:24 353:18 87:9,15,25 88:8 317:13 318:11,18 239:19 241	:5
says 53:19,20,21 89:3,10,20 91:2,12 319:2,6,12,24 242:13 247	:15
58:2 59:2 60:11 92:12 96:11,20 320:5,11 324:17 252:16 259	:11
62:6 84:19 90:17 97:6,15,22 98:7,17 325:2,12 326:9,22 265:21 270	:19
93:23 100:24 99:4,9,19 100:1,10 334:22 336:3,13 288:15 291	:1
107:1 110:4 100:13 101:16,25 337:9,19 338:2,14 294:3 297:5	5
122:25 137:2 102:24 103:11,19 339:4,16 340:1,5 298:17,17 3	301:19
141:6 143:6,15	:11,13
148:9 161:23 105:5,14,20 scribbled 25:22 309:16 311	:19
172:17 235:11 108:15 109:1 seal 359:6 361:15 314:22 345	:19
238:1 240:21 117:20 122:19 362:21 seeing 72:2	137:8
247:7,10 249:11 133:2 134:11 search 120:4 171:16 177	:25
249:18,22 266:6	:1
346:20 150:4 157:25 searchable 145:23 204:5 251:5	5
sbadala 2:5	:4
sboranian 3:6 168:12 176:12,17 second 3:4 27:4 345:23 355	:7
scale 207:1 177:5 179:12 30:2 72:14 84:18 seeking 55:	20
scenario 192:22 185:19 186:13 106:24 132:8 seen 69:3,4	72:12
260:14 187:16 188:3 141:11 167:25 72:16 75:2	83:2
scene 213:14 189:7,12,17 194:4 233:21 234:24 84:13 93:10	5 141:3
schedule 211:6 194:21 195:10,17 235:1,13,15 176:25 188	:9
281:20,22 282:2,4 196:4,12,17 201:8 244:19 249:9 223:24 225	:24
303:18 205:9 209:13 296:22 335:20 242:11 247	:13
scheduled 290:16 210:1 218:7 seconds 108:1 251:9 298:3	3
scheduling 290:18 219:18,24 221:7 section 106:24 seized 286:2	20
school 249:3	18
298:22 256:9 264:18 34:12 44:7 52:9 291:8	
scientific 315:14 267:12,24 269:12 58:4,6 59:3 66:1 seizing 290:	15
269:22 270:2 72:1,4,5,8 84:19	

[seizure - sit] Page 56

seizure 294:5	197:13 201:15	sheriff 160:8	shut 176:6 310:11	
seizures 288:24	202:3 221:24	213:11 214:16	311:15	
295:8,10	252:24 254:1	215:23 216:9	sic 58:2 138:7,8	
select 75:15 120:8	258:7 266:4,7	219:14 258:18,23	side 352:1	
334:1	273:20 276:16	267:13 276:13	sides 329:14	
selecting 120:11	300:2 301:5 310:1	280:14	siegel 24:18	
selection 96:5	311:6 318:3	sheriff's 209:18	sign 257:20	
99:10 124:14	session 6:14 183:4	213:24 219:8	signature 357:5	
152:7	set 7:10,15 66:17	258:6 310:20	359:12 360:14	
sell 55:2 203:9	70:25 84:6 102:25	sheriffs 246:16	signed 111:20	
selling 192:9	244:20 247:1,17	shift 229:14	361:13 362:18	
sells 190:21	257:24 281:22	ship 39:20	significant 129:8	
send 328:2	317:20,22 359:5	shipment 210:22	214:14 298:13	
sending 51:1	sets 281:20,25	shipped 34:21	307:21 312:9	
177:17	282:7	39:15	314:8,25	
sense 35:3,15	setting 63:24	ships 187:19,22	significantly	
57:25 91:7 243:2	184:22,23 274:1	shkolnik 2:2	157:21 198:10	
sensitive 214:10	281:16,17 282:5	shopped 325:20	216:14 301:21	
sent 61:9 328:15	283:9,13 302:13	326:2 331:8	signing 360:12,20	
sentence 93:22	setup 158:13	shopper 204:24	similar 35:8	
106:24 132:17	seven 22:4,6 104:2	331:7	197:13 258:13	
sentences 198:10	273:17 274:2	shoppers 198:22	287:12 295:9	
sentencing 198:8	severity 322:20	205:13,17	304:20 312:4	
separate 76:24	sex 171:25	shopping 165:1,6	simple 158:23	
85:15,16 108:5	shannon 24:9	166:9,16 180:25	163:23 350:1	
113:21 146:8	52:13 287:9	191:11,16 197:8,9	simpler 322:6	
211:21,25 299:12	share 152:22	205:25 206:2	sincerely 360:23	
300:3,4 301:5,6	158:6 165:13	207:11,22 325:23	singer 27:24 28:1	
302:14 310:7	193:6 217:16	331:2 334:6,6	28:2	
349:7,17	283:22	short 85:16 126:15	single 44:11 86:2	
separately 23:24	shared 27:7 203:6	248:5 252:1 261:2	87:20 100:13	
32:14 90:10	213:10 277:13	332:17	342:25	
separation 60:9	283:24	show 84:12 108:13	sir 52:3 119:24	
serve 355:19	sharing 171:16	179:25 180:1	184:25 281:12	
service 216:9	195:20 215:11	240:14	360:10	
222:24 266:19	217:3,8 257:7	showed 93:12	sit 31:25 36:9	
267:4	283:25	181:18	110:24 114:9	
services 21:18	shaun 5:7	showing 305:22	124:24 224:10	
23:6 24:12,14	sheet 8:5 244:17	shown 304:9	233:14 327:21	
26:18 165:11	248:17 327:17	shows 307:23	328:6 330:25	
166:6 191:24	362:7,10,18 363:1			
100.0 171.21				
Varitant Lagal Colutions				

[sits - speed] Page 57

sits 262:24,24	sorry 20:1 25:4	south 3:9 4:13	335:25 336:1,10
sitting 232:7	31:17 37:9 41:23	southern 36:12	336:14 337:20
296:16 310:15	52:15 59:1,13	190:1 208:4 289:1	338:4,10 339:1,13
315:13 322:7	60:6 63:4 64:4	speak 29:25 30:3,9	341:15 342:3
327:3 328:8	68:18 73:1 83:22	34:9 116:6,10	353:6
338:24	84:21 88:1 89:15	117:9 123:14	specifically 23:13
situation 342:23	89:22 91:22 92:13	140:1 142:11	30:1 50:11 55:12
situations 279:19	94:2 97:4 99:20	202:1 323:18	65:3 88:23 103:3
six 252:1	102:20 114:20,25	speaker 128:23	111:19 113:7
size 159:1	115:5 139:6	347:2	115:14 120:24
skzerussen 3:11	141:11,14 149:3	speaking 24:25	123:10 134:14
slides 244:20	153:22 154:9	49:1 116:8 156:12	135:6 157:13
265:14	168:7 172:15	173:7	158:4,18 170:19
slightly 191:20	178:18 185:16	speaks 132:4	179:5 181:8
small 293:3 294:8	203:18 210:2	special 27:21	182:15 198:3
305:25	242:7 250:18	65:10 100:20	202:23 204:9
smaller 209:19	259:6 271:8	101:5 238:11	219:6,15 275:18
216:10 255:16	279:25 288:2	specialized 271:25	287:7,14 298:7
smith 3:2 4:11	301:18 308:20	specific 22:22	307:12 328:10
19:5,14,20	311:9,10 329:9	29:15 41:4,5 42:2	334:2 345:2 347:8
sober 232:4	332:4 338:23	43:15,18 45:23	specification
sold 195:6 303:10	348:19 353:22	51:24 56:1 66:22	198:5
solely 34:16 152:4	sort 232:6 272:4	68:11 74:25 77:11	specificity 23:10
solid 208:2	292:19 293:15,20	80:15 86:16,21	157:10
solutions 4:16	311:10 342:9	87:11,18 93:3,4	specifics 50:3
360:1 363:1	350:23	96:14 100:18	165:13 193:5
somebody 30:7	sought 283:8	101:17 103:5	197:14 257:18
71:15 79:1 99:2	sound 84:17	108:8 117:9	275:21 333:12
123:4 147:21	sounded 35:8	122:22 126:7	339:7
148:18,25 160:5	sounds 119:4	157:11 158:1	specified 358:20
192:8,10 202:9	242:3	161:17 164:3	specify 135:8
206:24,25 232:8	source 38:5,13	168:9 171:23	245:1 276:18
246:22 253:14	43:21 64:2 208:23	174:2 177:20	323:8
261:2 304:7	209:23,23 210:5	179:6 181:1	speculate 77:14
someplace 176:21	210:16,18 250:4	189:21 195:1	322:24
206:4	250:12 265:14	199:20 204:3,17	speculating 163:6
somewhat 208:1	270:25 291:9	220:13 263:7	163:10
215:17 299:11	299:1 309:15,20	264:12 273:11,15	speech 158:19
351:9	sources 204:18,19	285:6 298:19	175:12
sooner 274:24	245:24 264:19,22	303:23 305:24	speed 52:16
275:3		324:13 331:6	

[spelled - strike] Page 58

11 1 60 20	1 1 00 10	1610016710	101.6
spelled 69:20	standard 80:19	164:23 165:18	steals 191:6
70:13 73:19 79:4	129:9 306:7	173:21 190:1,11	steer 175:24 263:2
95:15 103:24	standing 20:3	190:14,16 196:20	stems 187:25
120:16 130:22	standpoint 33:23	196:23 200:15	stenotypy 358:14
150:17 153:10	280:19 325:6,8	201:23 202:4	stepped 207:4
256:11 326:24	start 29:20 37:14	205:24 208:5,14	233:18
340:24	41:17 55:2 82:2	208:14 216:20	steps 39:11 51:3
spells 128:5	83:21 108:12	217:1,5,7,23	53:6 62:12 87:19
spend 22:2 68:4,11	158:5 179:3 181:7	218:11 226:23	88:2 174:5 260:11
116:8	199:3 213:19	231:25 259:24	260:20
spent 131:10	219:11,11 229:8	262:16,18 264:25	steve 168:4 185:16
268:4	230:10 242:21	265:2 266:20	208:20 233:23
spice 290:11,13	262:19 264:13	267:4 271:19	234:1
291:11 293:18	273:6 302:16	273:10,22,24	steven 3:3 19:4
spike 178:2	310:2	275:14,23 327:1	183:8
spoke 24:8,10,14	started 42:24	333:6 358:2,7	stick 200:15
24:16,17 25:5,9	54:16 55:7 158:22	359:14 361:10	stigmatization
31:16 34:7,11	175:10 177:17	362:15	70:15
38:20 39:7,8 83:1	198:16,21,24	stated 250:12	stillborn 241:21
96:17 97:2,12	206:18 227:11	statement 42:4	stipulating 297:7
131:19 134:12	228:13 229:18	49:22 86:23 90:13	stolen 193:2
155:20 156:7,23	230:16 233:24	91:10 108:23	stop 195:14,19
180:4 278:11	237:12 239:14	130:16 304:25	252:11 260:11,21
spoken 24:7 28:10	242:19 244:5	313:11,12 361:13	261:3
98:14 203:25	253:1,3,7,14 254:8	361:14 362:19,19	stopped 199:2
sponsored 350:12	254:10 274:16	statements 50:4	stopping 277:25
spreadsheet 66:1	279:18 302:8,9	50:14,18 156:18	story 312:24 317:9
140:21 345:11,20	305:13 328:4	states 1:1 18:6	strategies 198:4
346:8,17 347:17	starting 170:17	205:22 207:24	217:18 232:20
352:5 353:4,12	232:9	212:20 214:21	strategy 307:19
spreadsheets 7:11	starts 174:8	226:25 267:21	stream 3:4
66:18	244:19 327:10	268:3,12,14	streamline 297:15
spring 48:5	state 7:7 18:8	statewide 162:6	street 2:21 3:4,9
square 1:21 2:7	19:11 36:12 42:25	189:16	3:22 4:8,13
4:18	65:16 66:11 67:10	statistical 173:6	stress 171:10
ss 358:3	102:25 103:12	statistically	172:6 216:8
staff 246:10 261:8	155:17 158:8	255:17	stretch 211:19
staffed 221:16	159:18 160:4	statistics 208:23	327:7
stage 323:16	161:5,13,13,16,20	264:3,6 265:6,13	strictly 346:3
stand 290:25	162:12,14,22	stay 229:22 351:15	strike 51:22 55:11
301:14	163:15,25 164:2		64:5 72:18 83:9
	,		

[strike - suspected] Page 59

83:11 113:23	submitting 270:20	337:12 342:7	suppose 292:14
156:25 158:16	subscribed 361:10	343:1	supposed 101:3
175:5 189:16	362:14 363:21	substantial 42:18	111:12 310:21
270:11 279:9	subsequent 27:10	158:9	332:5
282:14 302:25	156:3 164:20	substantially	sure 24:23 25:3
303:6,22 310:21	199:6	244:7	29:17 33:7 34:13
348:16	subsequently	succession 168:6	38:6 44:8,24,25
string 7:19 234:13	42:10 341:3	suffer 298:17,18	46:6 49:21 55:16
striving 252:16	subset 305:25	suggesting 36:15	57:3 59:20,21
structure 173:23	335:11,12	212:13	61:4 81:20 82:8
student 249:3	substance 39:4	suite 1:21 2:7,16	91:14 104:16
studies 178:11,21	40:23 69:15 70:9	3:5,9,17 4:18 5:4	106:22 115:6
181:16	70:11,13 72:21,22	360:2	116:7 121:6 122:2
study 181:23,25	73:6 78:22 79:1	sum 39:3	141:13 149:22
255:11	79:16,21 88:20,21	summarize 119:22	153:21 162:3
studying 179:5	105:16 109:16	summit 7:13 84:3	165:22 171:8
sub 321:21	119:23 125:2,5,6	142:10 143:3	176:13 178:9,20
subject 84:19,24	125:16,17,18	145:24 148:2	182:6 186:3
94:25 112:22	142:13 143:12	181:17 233:25	187:13 189:13
127:22 133:15	150:23 182:4	268:3 327:11	190:24 193:17,24
134:4 137:5	252:23 253:7,25	superior 360:1	208:25 209:3
156:14 230:5	266:3,6 289:21	superiority 128:19	210:8 215:1
235:19 236:9	294:10 296:18	346:23	226:16 243:25
239:9	316:11,17 318:8	supervisor 167:21	247:20 251:8,13
subjects 243:11,17	318:15,16,20	supplement	255:9 256:14
submission 105:21	323:3,5 325:18	310:21	284:25 287:19
submit 228:20	327:14 333:13	supplemental 7:14	288:4 313:24
269:10,14,25	334:15 348:4	84:4	317:1,1 319:25
270:17,23 271:17	substances 42:25	supplied 180:22	320:14 323:12
submits 271:12	141:9,15 188:16	236:3	324:21 326:12
submitted 7:16	188:17 196:24	supplies 186:5	329:10 332:6,8
84:7 96:12 106:8	223:12 225:22	supply 185:3,6,24	350:21 353:1
110:1 111:15	226:13 227:2	186:11,17,22,23	surgical 102:14
121:21 122:1	228:11 242:1,15	187:3 195:8 211:9	surreptitious
146:6 147:12	274:18 281:21	211:11 212:1	61:17 331:23
150:5 154:19	282:1,8 291:11	support 47:22	survey 255:2,6
269:20 271:4,14	296:5,14,17 297:1	180:17 214:16	surveys 299:8
272:8,20 290:19	298:5 299:19	253:16 318:24	suspect 207:9
321:2,13 325:21	300:21 301:10	320:20 333:6	suspected 196:23
326:23 351:5	303:16 305:4	supported 255:22	201:11 203:5
	327:19 333:14		205:1

[suspensions - terms]

suspensions	214:17 230:25	90:13 123:17	82:25 103:13
199:12 200:13	240:20 247:25	149:7 150:7,9	113:3,9 115:18,19
suspicion 204:3	251:17 254:5,12	153:18 154:13	116:23 117:16
suspicions 208:3	256:12,15 260:11	164:13 188:15	119:2 124:4,21,24
suspicious 225:17	260:20 284:12	212:15 214:24	125:15,24 131:7
225:21,25 226:3	319:9,21 332:5,9	235:1 247:1	133:8 140:6,13
269:15 272:7,10	taken 1:19 63:15	260:13 267:3	142:6,11 143:7
swear 19:25	87:19 88:2 129:12	280:1 289:24	153:12,23 170:13
swear 19.23 swoop 337:1	155:3 171:2	298:23 306:10	171:4 179:24
swoop 337.1 sworn 20:13	172:18 174:5	346:10 351:19,22	180:20 181:10
358:10 361:10,13	297:3 335:5	351:25 354:3	182:8 183:17
362:14,18 363:21	358:19 360:11	talks 170:19 171:2	218:2 220:9
symptoms 319:17	takes 265:8	tamara 24:11	231:14 248:25
		82:21 354:25	251:14 246:25
synthetic 34:22 290:6,10,13,22	talents 117:25 talk 24:4 35:19		304:11 328:10,18
, , ,		tamper 336:22	1
291:10 293:14,19 296:9	38:19 44:2 50:16	tampering 128:14 138:10 139:17	329:6,14,19 331:7 333:20 346:14
_,	51:12 52:11 67:8		
synthetics 295:23	77:1 78:1 96:9	tapering 125:25	telling 123:20
system 42:22	109:18 110:7	targeted 29:14	131:14 133:10
56:13 64:24	111:21 116:17,20	task 23:4 25:8	143:19 144:22
162:20 165:25	117:5 131:13	164:19,22 167:24	283:15 351:18
181:6 222:21	134:7,14 143:2	167:25 168:2,2	ten 22:17 255:11
227:7 228:9	168:16 191:19	191:21 194:13	255:13 274:14
257:17,19 259:14	244:24,24 245:1	198:9 203:24	275:7
260:1 270:3	253:13 287:7	208:12,18 209:6	tend 198:10
272:22	315:12 344:20	212:25 215:9	205:15 207:13
systems 294:14	345:1	217:6 224:11	265:1
298:22	talked 51:23 98:25	231:9,9,15 232:10	term 85:16 128:20
t	99:16 115:25	232:24 233:1,11	165:16 225:16
table 232:6	116:19 119:17	233:15,22 234:8,8	309:12 317:8
tabulated 265:8	133:4 138:15	257:8 262:14	319:15 346:24
265:10	146:24 147:5	263:1 283:6,7,23	terminal 90:11
take 25:17,20 30:2	162:25 167:4,5,14	285:15,21 300:6	91:6
46:11 47:4 52:17	182:4 226:17	316:2	terminology
54:13 58:9 68:24	230:2 252:25	tease 291:25	316:13
80:10 81:18 83:16	254:16 270:21	telephone 3:3,20	terms 33:12 37:2
100:19 101:7	274:11 312:18	4:2,7,11	98:24 119:16
113:1 126:15	315:3	tell 21:6,8,10 32:1	121:10 122:15
133:21 146:13	talking 26:17	37:18 43:23 45:18	130:16,18,21,22
172:23 182:17	35:20 44:14,16,20	54:9 57:4 58:9	131:19 172:4
199:13 204:15	51:10 59:10 67:20	59:18 62:4 65:10	197:24 199:15

[terms - thinking] Page 61

	I		
206:20 210:15	186:3 215:2	340:24 351:3	206:10 207:13
213:22 220:15,20	344:19 354:6	think 23:23 28:16	208:3 211:4,15,18
233:6 241:4	thankfully 57:6	29:3 31:1 33:12	212:19 214:6,9
257:18 290:21	thanks 59:13	33:15,19,23 35:14	215:23 220:19
291:7 309:13	263:23 354:8	36:1 37:11,22	222:25 224:6
313:18 325:22	theoretical 57:24	38:4 41:9 42:12	225:15 227:4
330:8 334:5,17	therapeutic 187:8	42:15 45:14 46:20	233:2,8 234:3
340:25	therapies 57:18	47:12,21 49:1,21	239:13 246:2
terrible 46:19	64:4,8	50:9 52:2 54:20	247:22 249:2
terribly 288:15	therapy 63:8,13	55:14,22 56:21	250:20 257:14,16
terrorism 313:4	76:2 126:2 273:18	57:3 61:11,14,15	258:13,14 259:24
testified 85:8	274:2	63:13,23 69:19	261:9 265:2
177:9 345:18	thing 69:2 156:23	70:12,14 71:22	268:20 270:12,19
testify 24:6 52:12	187:9 254:25	73:11 76:7 77:14	274:19,25 275:16
61:20 111:12	255:10 261:10	78:10 83:18 85:11	277:12 282:9
114:8,14 125:13	288:23 300:8	86:15 89:21 91:3	286:21 287:15
155:7 286:12	355:18	91:9 94:12 99:16	288:22 289:22
358:10	things 23:4,5,19	100:18 101:2,8,18	290:25 291:17
testifying 21:3	23:22 24:3 25:22	103:20,23 104:8	292:19 296:6,12
38:16 110:25	26:4,5 28:18	107:17 112:2	296:12 299:16
183:10,18	35:21 36:14,19	119:4 121:4,22	300:14 303:18
testimony 28:14	38:12 55:25 59:15	123:20 124:8	304:2,25 306:12
31:4,8,10 39:24,25	67:21 92:6 93:1	128:4 129:19	307:19 308:23
44:9,13 62:15	97:24 117:1 136:5	131:9,21 135:18	309:13 310:9
68:18 71:25 90:23	153:8 156:6	138:3 142:20	311:13,18 312:8,9
108:3 118:18,21	161:15 171:5,5,6	148:6,15 151:11	312:23,25 313:11
129:21 136:3	171:23 172:1	151:17,22 156:18	313:24 314:13
137:13,20,24	179:3 181:1	159:6 163:11,21	316:14,22 317:15
149:24 150:2	190:14 194:12	164:17 165:22,24	319:3 320:20
151:7,10 153:6	197:14 201:2	166:19 167:8	329:12 331:18,22
154:16 159:23	203:6 213:8	169:9,12 170:21	333:15 335:20
160:25 162:11	216:23 217:16,20	171:9,17 174:20	336:25 337:10
285:14 301:15	227:10 241:3	174:24 176:3,4,8	340:25 343:2,11
331:12 352:22	246:1 257:12	176:23 177:7,16	344:1,15,18
358:12,16 361:6,7	259:23 269:2	178:5,8 179:1	347:13 348:8
362:6,9,12	274:12 287:9,10	182:2,13 187:6,8	350:18 351:1,2,3
testing 291:21	287:12 292:19	187:23 188:4	351:16,17 352:2,9
330:9 342:10	293:5,21 298:8	190:10,12 191:4	352:11,14,15
teva 4:2 19:18	302:3,5 308:22	192:21 196:19	353:14
thank 21:5 70:1	310:2 311:8,14,19	199:10 203:12,20	thinking 176:6
158:21 185:1	312:10 334:18	204:12 205:10	228:3 232:12

[thinking - topics] Page 62

- G • -			C
268:11	threw 25:25 82:23	266:15 345:19	174:3 175:17
third 7:5 27:16	167:9	timing 323:6	206:14 208:8
28:23 65:13 71:7	throw 26:3	tinkle 146:14	217:22 237:23,25
78:22 88:10 143:3	tie 41:4 252:17	title 246:9	247:19
167:8 240:21	tilted 310:12	titled 241:14	tool 229:1 278:13
315:6	time 25:21 27:11	titrating 125:25	278:23 279:17
thirty 360:19	29:9,16 52:18	today 20:19,24	281:2
thomas 1:13 6:7	54:21 68:4,9,12	21:8,13,14,25 22:3	top 37:23 143:25
18:3 20:10,15	81:18 83:3,5 86:9	22:6 23:1 24:6,16	190:12 341:12
183:5 284:18	100:13 105:2	26:22 27:19 31:25	topic 29:21 30:3
344:8 354:20	116:8 133:21	33:1,2 34:2 36:9	30:13 39:4 40:16
358:9 360:8 361:4	136:1 137:18	41:6 61:21 64:14	43:16 51:25 52:4
361:9 362:4,13	140:10,13 141:8	65:2 82:14 93:17	56:22 59:21 62:21
363:20	158:17 159:2,5,7	101:23 102:18	66:24 67:5 69:20
thornburg 4:12	159:11 163:1	103:9 110:24	74:21 112:23
thought 37:4 66:4	164:13,14 167:10	112:19 114:9	117:12 130:23
74:11 79:15 91:21	169:7 171:10,21	116:21 118:16	136:17 140:25
91:24 139:6	175:6 176:2	160:21 163:18	142:15 143:6
189:24 203:18	178:19 180:3	167:6 191:17	144:9 147:7,9
214:23 250:15	181:15 188:5	205:7 243:18	154:21 157:2,14
252:2 255:7,15	189:22 206:11,24	250:20,24 272:24	159:12 166:12
329:8 354:3	212:16 214:10	296:16 310:15	170:11 171:1
three 3:13 33:9	224:2,17 230:23	313:20 314:15	183:20,25 184:12
69:23 72:19,24	233:24 235:10	315:12,13 322:7	184:15,20 185:16
74:2,9 75:11,19	238:8 241:6	327:3 328:7,8,20	215:18,19 261:17
82:4,19 94:7,9	243:12 251:22	330:25 331:11	266:23 268:25
95:1,7 98:24	252:19 265:9,12	332:7 338:25	273:3 275:2
109:10 115:15	270:15 278:17	343:10 345:4,9,19	279:24 281:14
119:17,19 120:8	287:24 289:23,24	345:20 351:9	286:10,12,15
120:23 121:6,7	290:1 293:22	352:18 354:23	287:7,8 295:21
122:3 129:20	294:6 300:16	told 24:23 28:10	299:19 300:21
144:2,7,11,22	301:16,22 302:8	37:4 45:1 71:22	301:9 303:11,23
146:2,25 149:14	302:10,11 304:11	79:15 80:9 81:7	312:7,20 313:7
150:1,8 151:6,12	305:16 310:19	86:9,23 90:2,15	315:3 320:6,7,24
152:4 154:13,18	312:23 314:24	94:7 107:8 109:19	338:15,16 340:2,3
155:22 168:18	319:16 323:2	112:3 122:11	344:21,21
182:3 247:6,12	335:10 338:23	125:15 129:18	topics 22:3,20,21
294:13 332:9	349:15 358:19	144:25 146:25	24:6 27:17 29:6
334:25 335:3,6	times 51:9 102:10	150:18 156:13	31:19 67:9,13,25
349:18 353:24	129:19 131:11	161:19 168:25	68:6,8 81:10,11,14
354:5	201:10 231:9	170:13 172:16,19	91:23,25 92:3

$[topics \hbox{-} unauthorized]$

	I	I	I
94:10,11,14,25	transcribed	148:24 185:14	152:20
111:23 147:4	358:15 361:7	190:23 193:10,16	turning 67:16,17
154:10 183:14,16	transcript 6:1	200:1 212:7,10	308:21
183:19 215:17	250:19 357:3,6,9	220:2 224:9 226:9	twelfth 3:22
217:16 263:3	357:11 360:11,16	228:21 235:21,23	two 25:4 131:15
287:14 297:10,17	361:5,12 362:5,11	236:1,18 237:4,18	153:10 167:6
338:19	362:17	239:11 241:1,19	168:22 169:4,10
total 68:9	transcription	242:2 254:22	169:11,13 208:18
touches 311:12	358:16	267:17 271:23	231:11,15 232:14
touchy 275:2	transition 178:1	304:12,25 314:18	233:10 234:7,8
tough 220:9,19	252:22 253:12	358:16	252:8 265:11
331:15	transitioning	trust 255:12	268:7 323:11
town 156:6 158:2	341:3	truth 358:10,11,11	355:6,6
158:15,22 159:2	trash 26:11	try 29:10,13	type 57:12 90:12
160:1 170:16,21	treat 302:23	163:19 174:10	types 162:13
171:11 174:19	318:15	175:24 220:16	u
toxic 295:5	treatable 318:20	230:12,20 241:4	u.s. 168:4,6 198:9
toxicology 83:4	treated 128:2	trying 23:8 31:17	208:19 217:14
201:17 291:20	222:4 318:9	31:24 37:17 44:22	232:12,23 233:21
355:10	treating 238:23	52:16 60:14 66:25	233:24 234:2
track 23:10 42:24	treatment 125:4	70:15 74:1 95:2	ultimately 31:12
67:1 206:19	126:7 128:24	114:22 123:18,22	37:11 40:1 44:11
220:16 253:19	156:13 221:15	133:22 142:14	45:5,14 48:1,13
329:22	232:4 246:23	147:19 168:8	53:4,6 54:5 56:9
tracked 190:5	299:24 310:1,10	172:11 179:16	59:14 60:12 61:25
204:16	311:4 347:3	204:6 213:19,23	62:6,12 180:18
tracking 209:22	treatments 301:24	229:12,22 232:19	260:23 278:8
tracks 266:5	tremendous	238:7 243:19	339:9
traditionally	309:20	245:2 246:20	um 157:9
305:8	tremendously	268:8 285:17	unable 130:15
trafficking 24:19	58:21	307:11 311:16	unauthorized
51:1 210:13	trend 292:20	341:23,24 346:15	107:4,10,15,19
310:24	293:21	348:18 349:16	108:10,12,18,24
tragic 308:24	trends 287:10	353:5,23,24	109:13,23 110:3,5
trained 168:10,15	tried 122:20	tucker 5:3 18:16	110:11,19 111:3
238:15	230:14 238:20	tuckerellis.com	112:2,5,8,21 113:4
training 102:14	298:21 349:5	5:5	113:9 127:13
213:11	trouble 178:7	turn 327:9	129:4,10 130:4
tranquilizer 314:7	true 86:24,24	turned 65:19	132:15 136:18
transactions	100:14 116:22	88:10 94:18 97:8	138:17 139:3
223:13	129:24 140:9	97:24 117:2	154:6 348:10
	X7 T		131.03 10.10

[uncovered - videographer]

•	0.51.10.505.55		
uncovered 325:5	274:10 285:23	uptick 288:23	usually 185:11
330:17	293:8 323:20	use 35:18 40:23	186:6 187:6
underestimate	349:8	54:14 69:15 70:9	V
252:5	understands 202:5	70:11 72:22 76:3	v 1:9 360:6 361:3
underreported	understood 63:21	80:10,13,14	362:3
292:7	74:5 108:4 132:5	103:23 104:1	vacuum 48:6
understand 20:18	146:23 318:19	109:16 110:5	vague 274:12
20:23 21:2 29:13	326:6,15	119:23 128:20	valid 185:14 186:8
31:25 33:13,25	undertreatment	129:2,2 142:1,13	191:2 195:13
38:15 44:23 51:9	340:21	143:12 150:23	296:23
61:4 73:12,14	unfamiliar 73:20	187:7,8 191:18,19	valuable 233:6
74:1,3 75:6,8 80:8	unfortunately	211:12 220:6	309:1
81:9 97:4 103:2	307:25	230:4 254:17,21	vanished 290:18
104:9 118:9	unintentional	256:25 257:19	vanishingly 295:2
123:19 124:9,11	264:4,15	261:24 277:24	variations 191:20
124:14 131:18	unit 219:22 259:21	278:14 296:25	various 22:23 24:5
136:14,21 150:14	united 1:1 18:5	298:18 299:18	93:2 129:18
150:16 163:17,18	university 155:23	300:20 301:9	159:25
176:13 183:9,17	unlawful 95:11	303:22 305:3	verify 87:19 88:2
185:5,20 208:25	unlawfully 34:15	308:6 309:12,22	veritext 3:3 360:1
211:23 256:2	unnecessary 106:2	310:16 311:22	360:7 363:1
262:15 270:3	106:4 107:4,10,15	315:7,9,15 316:11	versus 255:16
272:11 282:4	107:19 108:9	316:17 317:6,8,10	292:1 296:11
292:8 299:3	113:10,16 114:1	317:21 318:8,9,15	316:11
307:11 326:10	114:13 115:15	318:20 319:10,14	vet 321:4
334:23 339:17	118:11 127:14,20	319:15 320:2,3,16	vet 321.4 veterinary 203:2
340:6 342:2	128:6 129:5,11	320:18 321:1	vetted 320:25
350:18	130:4 132:16,19	322:18,20 323:5	victim 180:21
understanding	133:4,7,10,24	323:15,19 325:18	197:10
46:12 49:13 72:17	134:3,18 136:15	330:4,13 332:2,23	victims 247:11
74:15,21 75:9,14	136:18,22,24	333:10,14,20	
75:20 89:14 91:8	137:4,16,19	334:15 346:24	251:16
91:13,18 92:4	138:18 139:3	347:6 349:21	videographer 5:7
94:16 95:6 118:13	153:9 348:10,13	useful 224:24	18:1 19:10,24
118:20 119:19	unresponsive	226:14 278:22	81:21,24 126:18 127:7 146:16,19
121:9 135:24,25	174:6,9	279:2	/
159:17,20 185:6	untrue 140:8	user 191:6	169:18,21 182:19
185:23 186:10	ups 172:20	users 252:25	183:1 231:2,5
217:10 226:6	upstream 204:13	uses 35:21 257:1	248:3,6 256:17,20
227:18 235:12	upsurge 288:14	usual 86:15	284:13,16 332:15
270:6 272:13			332:18 344:3,6
			354:15,18 355:24

[videotaped - work]

videotaped 1:13	154:22 162:3	we've 21:23 27:9	willfully 49:18
7:5 27:16 28:24	169:14 170:1,12	51:23 56:22 66:22	william 4:12
view 37:15,15	172:5 174:12	68:24 112:2	william.padgett
45:11 100:16	176:6 177:8 181:3	129:17 131:10	4:14
viewed 90:10	219:19 221:1	146:11,24 154:13	williams 3:21
viewpoint 233:5	227:24 251:20	172:9 188:12	willing 187:12
vince 25:5 82:20	262:3 277:21	191:25 203:6	199:18 277:20
167:19 208:19	286:10 290:17	204:6 207:25	wind 300:10
233:17,19	296:3 311:17	220:10 226:17	window 210:3
virginia 206:4	313:14 314:3	229:6,24 230:2,24	274:3
virtual 3:4	315:2,5 317:7	247:13 256:23	wise 179:6
virtually 252:9	322:23 332:6	257:2,8 261:20	wish 312:10
visit 347:10	337:12 346:19	268:18 272:24	withdrawal
visited 88:13	347:11,12,13	281:3 335:14	319:17
346:8 347:22	352:13,24 355:18	website 23:3 24:2	witness 19:25 37:2
348:25 350:3,6	wanted 130:17	27:14	102:7 135:2 139:2
visits 88:23 120:25	178:9 209:9 214:7	websites 128:23	142:25 146:13
128:22 294:11	214:23,25 228:5	347:2	230:22 256:14
301:20 347:1,8	239:18 241:23	weeds 145:6	286:11 288:4
348:14	252:3 254:25	week 169:10,10	332:4,11 343:10
vital 265:6,13	255:10 311:10	welcome 101:4	343:15 354:8
voice 106:25 296:3	329:10	went 42:10 113:1	357:2 358:9,13,14
volition 23:20,22	wants 235:2	152:14 165:2	358:17 359:5
351:21	298:16	168:7 177:10	360:8 361:1,4,11
volunteered	washington 3:22	188:25 245:20	362:1,4,15
224:13	wave 42:12	287:4 295:21	wonder 264:24
W	way 21:25 36:1	305:14 325:22	word 60:10,15
w 266:20	39:1 45:11 57:20	west 3:17 4:4	91:8 297:6
wacker 3:17 4:4	61:3 83:19 86:15	206:4	wording 157:13
wait 242:24	87:4 118:2 121:13	western 155:24	285:16 289:9
waived 360:13,21	135:11 140:23	249:3	words 208:8
waiving 84:20,24	153:15 154:1	whatsoever 111:1	304:18 309:17
walmart 2:14	174:14,24 185:8	whereof 359:5	349:20
18:25 19:1	209:24 212:14	wholesale 271:12	work 38:10 60:25
want 20:7 21:8	223:9 225:23	wholesaler 185:12	64:12 71:13 77:17
44:23,23 52:17	282:9 293:17	186:7	98:13 122:17
57:11 59:20 62:4	295:17 297:20	wholesalers	137:10 138:15
77:13 83:17 110:8	329:15 331:9	228:19 272:4	159:13 162:4
123:13 124:12	ways 78:11	wife 332:7	187:13 204:6
133:21 137:17	wc.com 3:19,23	wilcox 1:20	244:4
140:10 145:15			
1.0.10 1.0.10			

[worked - zrlaw.com]

		,
worked 65:20	wrongdoing 62:19	younger 156:12
124:15 269:6	85:4,23 87:23	Z
289:22	88:6 90:5 92:10	zashin 2:10
workers 65:15	92:19	zero 205:17 294:7
workforce 311:1	wrote 48:16 50:17	zerrusen 3:8 19:2
working 247:20	93:3 120:13,19	19:2
315:20,24	134:24 135:9	zrlaw.com 2:13
workings 272:21	153:14,25 169:9	Zitawicom 2.13
workman's 65:16	177:2 245:20	
71:9	297:11,17,18	
works 148:2 270:6	355:5,7	
world 31:6	X	
worried 297:21	xartemis 128:12	
worse 230:18	138:8	
314:5	xr 128:12	
worsened 302:20		
308:12	<u>y</u>	
worsening 307:5	yeah 44:25,25	
worst 249:20	47:12 49:21 79:23	
wrap 341:25	102:7 145:3 182:6	
write 48:21 57:17	216:7 224:10	
133:16 206:12	226:16 230:24	
writes 234:25	260:16 284:25	
writing 173:9	317:14	
180:13 217:10,11	year 27:15 61:8	
277:6	165:7 199:10	
written 28:17	204:16,22 243:13	
62:17 63:2 85:13	255:11 284:4,7	
85:22 87:20 88:3	288:13 290:15	
92:7,17 95:10,18	301:7 341:10,12	
95:25 132:1,23	341:13	
133:11,24 136:10	years 21:24 22:4,6	
136:10,16,20,25	189:2 199:1,6,8	
137:21 139:20	205:14 252:9	
173:12,14 273:7,7	255:13 265:11	
276:17 277:2,12	274:14,20 275:7	
345:16	309:22	
wrong 49:18 85:18	yellow 341:12	
107:21 248:10	yokiel 138:5	
261:10	york 2:4,4 3:14,14	
	56:9 268:5	
		ral Solutions

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF SEPTEMBER 1,

2016. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.